ingredient,drug_b,severity,side_effects,mechanism,clinical_action,confidence,created_at
domperidone,ketoconazole,Major,Increased risk of QT prolongation and serious cardiac arrhythmias.,"Ketoconazole inhibits CYP3A4, which metabolizes domperidone, leading to increased domperidone levels.","Avoid co-administration; if necessary, monitor ECG closely and consider alternative antiemetic.",1,2026-05-13
domperidone,erythromycin,Major,Increased risk of QT prolongation and serious cardiac arrhythmias.,"Erythromycin inhibits CYP3A4, which metabolizes domperidone, leading to increased domperidone levels.","Avoid co-administration; if necessary, monitor ECG closely and consider alternative antiemetic.",1,2026-05-13
domperidone,clarithromycin,Major,Increased risk of QT prolongation and serious cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, which metabolizes domperidone, leading to increased domperidone levels.","Avoid co-administration; if necessary, monitor ECG closely and consider alternative antiemetic.",1,2026-05-13
domperidone,itraconazole,Major,Increased risk of QT prolongation and serious cardiac arrhythmias.,"Itraconazole inhibits CYP3A4, which metabolizes domperidone, leading to increased domperidone levels.","Avoid co-administration; if necessary, monitor ECG closely and consider alternative antiemetic.",1,2026-05-13
domperidone,verapamil,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Verapamil can inhibit CYP3A4, potentially increasing domperidone levels.",Use with caution and monitor ECG for signs of QT prolongation.,1,2026-05-13
domperidone,diltiazem,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Diltiazem can inhibit CYP3A4, potentially increasing domperidone levels.",Use with caution and monitor ECG for signs of QT prolongation.,1,2026-05-13
domperidone,risperidone,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs can prolong the QT interval; additive effect.,"Use with caution, monitor ECG, and consider alternatives if risk is high.",1,2026-05-13
domperidone,haloperidol,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs can prolong the QT interval; additive effect.,"Use with caution, monitor ECG, and consider alternatives if risk is high.",1,2026-05-13
domperidone,amiodarone,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs can prolong the QT interval; additive effect.,"Use with caution, monitor ECG, and consider alternatives if risk is high.",1,2026-05-13
domperidone,quinidine,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs can prolong the QT interval; additive effect.,"Use with caution, monitor ECG, and consider alternatives if risk is high.",1,2026-05-13
aceclofenac,warfarin,Major,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and gastric mucosal defense, potentiating the anticoagulant effect of warfarin.",Monitor INR closely; consider alternative analgesic or reduce warfarin dose.,1,2026-05-13
aceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulceration.,Additive effect on gastrointestinal mucosal damage and platelet inhibition.,Use with caution; consider gastroprotective agent or alternative NSAID.,1,2026-05-13
aceclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulceration.,Additive effect on gastrointestinal mucosal damage.,Use with caution; consider gastroprotective agent or alternative NSAID.,1,2026-05-13
aceclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of ACE inhibitors.",Monitor blood pressure and renal function; use with caution.,1,2026-05-13
aceclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of ARBs.",Monitor blood pressure and renal function; use with caution.,1,2026-05-13
aceclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of loop diuretics.",Monitor for edema and renal function; use with caution.,1,2026-05-13
aceclofenac,spironolactone,Minor,Slightly increased risk of hyperkalemia and renal impairment.,"NSAIDs can decrease renal blood flow, potentially exacerbating hyperkalemia with potassium-sparing diuretics.",Monitor potassium levels and renal function if used together.,1,2026-05-13
aceclofenac,metformin,Minor,Increased risk of lactic acidosis and renal impairment.,"NSAIDs can impair renal function, increasing the risk of metformin accumulation and lactic acidosis.",Monitor renal function closely; use with caution.,1,2026-05-13
methylcobalamin,,,,,,1,2026-05-13
serratiopeptidase,warfarin,Moderate,Increased risk of bleeding.,"Serratiopeptidase may have fibrinolytic and anticoagulant properties, potentially potentiating warfarin's effect.",Monitor INR closely and monitor for signs of bleeding.,1,2026-05-13
serratiopeptidase,clopidogrel,Moderate,Increased risk of bleeding.,"Serratiopeptidase may have fibrinolytic and antiplatelet properties, potentially potentiating clopidogrel's effect.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
serratiopeptidase,aspirin,Moderate,Increased risk of bleeding.,"Serratiopeptidase may have fibrinolytic and antiplatelet properties, potentially potentiating aspirin's effect.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
guaifenesin,,,,,,1,2026-05-13
ambroxol,,,,,,1,2026-05-13
ornidazole,warfarin,Major,Increased risk of bleeding.,"Ornidazole, like other nitroimidazoles, may inhibit the metabolism of warfarin, increasing its anticoagulant effect.",Monitor INR closely and monitor for signs of bleeding. Adjust warfarin dose if necessary.,1,2026-05-13
ornidazole,phenytoin,Moderate,Reduced efficacy of phenytoin.,"Ornidazole may induce hepatic enzymes, increasing the metabolism of phenytoin.",Monitor phenytoin levels and efficacy; adjust dose if necessary.,1,2026-05-13
ornidazole,carbamazepine,Moderate,Reduced efficacy of carbamazepine.,"Ornidazole may induce hepatic enzymes, increasing the metabolism of carbamazepine.",Monitor carbamazepine levels and efficacy; adjust dose if necessary.,1,2026-05-13
ornidazole,phenobarbital,Moderate,Reduced efficacy of phenobarbital.,"Ornidazole may induce hepatic enzymes, increasing the metabolism of phenobarbital.",Monitor phenobarbital levels and efficacy; adjust dose if necessary.,1,2026-05-13
ornidazole,lithium,Minor,Increased risk of lithium toxicity.,"Ornidazole may impair renal excretion of lithium, leading to increased serum lithium levels.",Monitor lithium levels and signs of toxicity.,1,2026-05-13
nimesulide,warfarin,Major,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and gastric mucosal defense, potentiating the anticoagulant effect of warfarin.",Monitor INR closely; consider alternative analgesic or reduce warfarin dose.,1,2026-05-13
nimesulide,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulceration.,Additive effect on gastrointestinal mucosal damage and platelet inhibition.,Use with caution; consider gastroprotective agent or alternative NSAID.,1,2026-05-13
nimesulide,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulceration.,Additive effect on gastrointestinal mucosal damage.,Use with caution; consider gastroprotective agent or alternative NSAID.,1,2026-05-13
nimesulide,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of ACE inhibitors.",Monitor blood pressure and renal function; use with caution.,1,2026-05-13
nimesulide,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of ARBs.",Monitor blood pressure and renal function; use with caution.,1,2026-05-13
nimesulide,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow, counteracting the effects of loop diuretics.",Monitor for edema and renal function; use with caution.,1,2026-05-13
nimesulide,metformin,Minor,Increased risk of lactic acidosis and renal impairment.,"NSAIDs can impair renal function, increasing the risk of metformin accumulation and lactic acidosis.",Monitor renal function closely; use with caution.,1,2026-05-13
sulbactam,aminoglycosides,Minor,No clinically significant interaction noted.,No significant pharmacological interaction.,No specific action required.,1,2026-05-13
sulbactam,probenecid,Minor,May increase serum concentrations of sulbactam.,Probenecid inhibits renal tubular secretion of sulbactam.,"Monitor for potential increase in sulbactam levels, though usually not clinically significant.",1,2026-05-13
lactobacillus,antibiotics,Minor,Reduced efficacy of lactobacillus.,"Antibiotics can kill beneficial bacteria, including lactobacilli.",Administer lactobacillus several hours apart from antibiotics.,1,2026-05-13
lactobacillus,immunosuppressants,Moderate,Increased risk of infection in immunocompromised individuals.,Lactobacillus is a live organism and may pose a risk in severely immunocompromised patients.,Use with caution in severely immunocompromised patients; consult with physician.,1,2026-05-13
thiocolchicoside,diazepam,Moderate,Increased sedation and muscle relaxation.,"Both agents have muscle relaxant and sedative properties, leading to additive effects.",Monitor for excessive sedation and respiratory depression; consider dose reduction of one or both agents.,1,2026-05-13
thiocolchicoside,lorazepam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased somnolence and impaired cognitive function; consider dose adjustment.,1,2026-05-13
thiocolchicoside,alprazolam,Moderate,Enhanced central nervous system depressant effects.,"Both agents can cause CNS depression, leading to additive effects.",Monitor for increased drowsiness and impaired coordination; potentially reduce dose.,1,2026-05-13
thiocolchicoside,clonazepam,Moderate,Potentially increased sedation and muscle relaxation.,"Both drugs can cause CNS depression and muscle relaxation, leading to additive effects.",Observe patient for signs of excessive sedation; consider dose adjustment.,1,2026-05-13
thiocolchicoside,midazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for profound sedation and respiratory depression; caution with use.,1,2026-05-13
thiocolchicoside,zolpidem,Moderate,Increased sedation and impairment of motor function.,"Both agents can cause CNS depression, leading to additive effects.",Monitor for enhanced somnolence and reduced coordination; consider dose adjustment.,1,2026-05-13
menthol,,,,,,1,2026-05-13
etoricoxib,warfarin,Moderate,Increased risk of bleeding.,COX-2 inhibitors may interfere with the anticoagulant effect of warfarin.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
etoricoxib,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium retention and blunting of ACE inhibitor efficacy.",Monitor blood pressure and renal function; consider alternative analgesic or dose adjustment of ramipril.,1,2026-05-13
etoricoxib,losartan,Moderate,Decreased antihypertensive effect and increased risk of kidney damage.,NSAIDs can reduce the effectiveness of ARBs by inhibiting renal prostaglandin synthesis.,Monitor blood pressure and renal function; consider alternative pain management.,1,2026-05-13
etoricoxib,atenolol,Moderate,Reduced antihypertensive effect.,NSAIDs can antagonize the effects of beta-blockers by causing sodium and water retention.,Monitor blood pressure; consider alternative analgesic or dose adjustment of atenolol.,1,2026-05-13
etoricoxib,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, reducing the efficacy of beta-blockers.",Monitor blood pressure and consider alternative pain relief if needed.,1,2026-05-13
etoricoxib,amlodipine,Moderate,Reduced antihypertensive effect.,NSAIDs can diminish the effects of calcium channel blockers through sodium retention.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
etoricoxib,furosemide,Moderate,"Reduced diuretic and antihypertensive effect, increased risk of renal impairment.","NSAIDs inhibit renal prostaglandin synthesis, leading to sodium and water retention.",Monitor for edema and renal function; ensure adequate hydration.,1,2026-05-13
etoricoxib,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,"Both drugs can inhibit COX enzymes, leading to additive gastrointestinal toxicity.","Avoid concomitant use; if necessary, use low-dose aspirin for cardioprotection with caution and monitor for GI symptoms.",1,2026-05-13
etoricoxib,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal impairment.,"Both are NSAIDs, leading to additive gastrointestinal and renal toxicity.","Avoid concurrent use; if necessary, monitor for GI symptoms and renal function.",1,2026-05-13
etoricoxib,clopidogrel,Moderate,Increased risk of bleeding.,NSAIDs can inhibit platelet aggregation and increase the risk of GI bleeding when combined with antiplatelet agents.,Monitor for signs of bleeding and adjust doses if necessary; use with caution.,1,2026-05-13
levosulpiride,tramadol,Moderate,Increased risk of seizures.,Both drugs can lower the seizure threshold.,Use with caution and monitor for seizure activity.,1,2026-05-13
levosulpiride,codeine,Moderate,Increased risk of seizures.,Both drugs can lower the seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
levosulpiride,morphine,Moderate,Increased risk of seizures.,Both drugs can lower the seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
levosulpiride,haloperidol,Major,Increased risk of extrapyramidal symptoms (EPS) and QT prolongation.,Both drugs can affect dopamine receptors and have the potential to prolong QT interval.,Monitor for EPS and cardiac arrhythmias; use with extreme caution and consider alternatives.,1,2026-05-13
levosulpiride,clozapine,Major,Increased risk of seizures and agranulocytosis.,Both drugs can lower the seizure threshold and affect hematological parameters.,Monitor for seizure activity and blood counts; use with extreme caution.,1,2026-05-13
levosulpiride,olanzapine,Moderate,Increased risk of seizures.,Both drugs can lower the seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
levosulpiride,metoclopramide,Major,Increased risk of extrapyramidal symptoms and tardive dyskinesia.,Both are dopamine antagonists that can cause similar side effects.,Avoid concomitant use or monitor closely for EPS.,1,2026-05-13
voglibose,metformin,Minor,Increased risk of gastrointestinal side effects.,Both agents can cause GI disturbances; additive effects possible.,Monitor for gastrointestinal upset; advise patient on potential side effects.,1,2026-05-13
voglibose,insulin,Moderate,Increased risk of hypoglycemia.,Both drugs lower blood glucose levels; additive effect.,Monitor blood glucose closely and adjust insulin dose if necessary.,1,2026-05-13
voglibose,furosemide,Minor,Potential for altered glycemic control.,Diuretics can sometimes affect glucose metabolism.,Monitor blood glucose levels regularly.,1,2026-05-13
voglibose,prednisolone,Moderate,Reduced glycemic control.,"Corticosteroids can increase blood glucose levels, counteracting the effect of voglibose.",Monitor blood glucose levels closely and adjust voglibose or insulin dose.,1,2026-05-13
voglibose,dexamethasone,Moderate,Reduced glycemic control.,"Corticosteroids can increase blood glucose levels, counteracting the effect of voglibose.",Monitor blood glucose levels closely and adjust voglibose or insulin dose.,1,2026-05-13
nandrolone decanoate,warfarin,Moderate,Increased anticoagulant effect of warfarin.,Anabolic steroids can inhibit the metabolism of warfarin.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
nandrolone decanoate,insulin,Moderate,Altered glycemic control; potential for hypoglycemia or hyperglycemia.,Anabolic steroids can affect insulin sensitivity and glucose metabolism.,Monitor blood glucose levels closely and adjust insulin dose as needed.,1,2026-05-13
nandrolone decanoate,atorvastatin,Moderate,Increased risk of hepatotoxicity and altered lipid profiles.,Both can affect liver function and lipid metabolism; potential for additive effects.,Monitor liver function tests and lipid profiles; use with caution.,1,2026-05-13
nandrolone decanoate,rosuvastatin,Moderate,Increased risk of hepatotoxicity and altered lipid profiles.,Both can affect liver function and lipid metabolism; potential for additive effects.,Monitor liver function tests and lipid profiles; use with caution.,1,2026-05-13
drotaverine,levodopa,Moderate,Reduced antiparkinsonian effect of levodopa.,Drotaverine's smooth muscle relaxant properties may antagonize levodopa's effects.,Monitor for worsening parkinsonian symptoms; consider alternative antispasmodic.,1,2026-05-13
drotaverine,atenolol,Minor,Potential for additive hypotensive effects.,Both can have vasodilatory effects.,Monitor blood pressure.,1,2026-05-13
drotaverine,metoprolol,Minor,Potential for additive hypotensive effects.,Both can have vasodilatory effects.,Monitor blood pressure.,1,2026-05-13
drotaverine,amlodipine,Minor,Potential for additive hypotensive effects.,Both can have vasodilatory effects.,Monitor blood pressure.,1,2026-05-13
drotaverine,ramipril,Minor,Potential for additive hypotensive effects.,Both can have vasodilatory effects.,Monitor blood pressure.,1,2026-05-13
drotaverine,losartan,Minor,Potential for additive hypotensive effects.,Both can have vasodilatory effects.,Monitor blood pressure.,1,2026-05-13
rutoside,,,,,,1,2026-05-13
bromelain,warfarin,Moderate,Increased risk of bleeding.,"Bromelain may have antiplatelet effects, increasing the risk of bleeding when combined with anticoagulants.",Monitor for signs of bleeding; use with caution and consider dose adjustment of warfarin.,1,2026-05-13
bromelain,clopidogrel,Moderate,Increased risk of bleeding.,"Bromelain may inhibit platelet aggregation, enhancing the effect of clopidogrel.",Monitor for bleeding and bruising; use with caution.,1,2026-05-13
bromelain,aspirin,Moderate,Increased risk of bleeding.,"Bromelain may have antiplatelet effects, increasing the risk of bleeding when combined with antiplatelet agents.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
trypsin,warfarin,Moderate,Increased risk of bleeding.,Proteolytic enzymes may potentially enhance the anticoagulant effect of warfarin.,Monitor INR closely and watch for signs of bleeding.,1,2026-05-13
trypsin,clopidogrel,Moderate,Increased risk of bleeding.,"Proteolytic enzymes may have mild antiplatelet effects, potentially increasing bleeding risk.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
trypsin,aspirin,Moderate,Increased risk of bleeding.,"Proteolytic enzymes may have mild antiplatelet effects, potentially increasing bleeding risk.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
olmesartan medoxomil,atenolol,Moderate,Increased risk of hypotension and dizziness.,Additive pharmacodynamic effect on blood pressure lowering.,Monitor blood pressure closely; consider dose adjustment.,1,2026-05-13
olmesartan medoxomil,metoprolol,Moderate,Increased risk of hypotension and dizziness.,Additive pharmacodynamic effect on blood pressure lowering.,Monitor blood pressure closely; consider dose adjustment.,1,2026-05-13
olmesartan medoxomil,ramipril,Moderate,Increased risk of hyperkalemia and renal impairment.,Concurrent blockade of the renin-angiotensin-aldosterone system.,Monitor serum potassium and renal function.,1,2026-05-13
olmesartan medoxomil,atorvastatin,Minor,Potential for minor increase in myopathy risk.,"Possible CYP2C9 interaction, though generally considered minor.",No routine monitoring required unless symptoms develop.,1,2026-05-13
olmesartan medoxomil,rosuvastatin,Minor,Potential for minor increase in myopathy risk.,"Possible CYP2C9 interaction, though generally considered minor.",No routine monitoring required unless symptoms develop.,1,2026-05-13
olmesartan medoxomil,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and sodium excretion.",Avoid concurrent use if possible; monitor blood pressure and renal function.,1,2026-05-13
olmesartan medoxomil,aspirin,Minor,Slight reduction in antihypertensive efficacy.,Low-dose aspirin may interfere with the RAAS effects.,"Generally considered safe, monitor BP.",1,2026-05-13
olmesartan medoxomil,clopidogrel,Minor,No significant interaction expected.,No known clinically significant pharmacokinetic or pharmacodynamic interaction.,No specific action needed.,1,2026-05-13
bromhexine,codeine,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
bromhexine,morphine,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
bromhexine,tramadol,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
luliconazole,,,,,,1,2026-05-13
teneligliptin,metformin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
teneligliptin,insulin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
teneligliptin,gliclazide,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
gliclazide,metformin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
gliclazide,insulin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
gliclazide,teneligliptin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
gliclazide,atenolol,Moderate,Masked symptoms of hypoglycemia; reduced hypoglycemic response.,Beta-blockers can mask hypoglycemia symptoms and interfere with glucose regulation.,Monitor blood glucose levels closely; educate patient on masked symptoms.,1,2026-05-13
gliclazide,metoprolol,Moderate,Masked symptoms of hypoglycemia; reduced hypoglycemic response.,Beta-blockers can mask hypoglycemia symptoms and interfere with glucose regulation.,Monitor blood glucose levels closely; educate patient on masked symptoms.,1,2026-05-13
oxetacaine,,,,,,1,2026-05-13
acebrophylline,codeine,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
acebrophylline,morphine,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
acebrophylline,tramadol,Moderate,Increased risk of respiratory depression and sedation.,Additive central nervous system depressant effects.,Use with caution; monitor respiratory status and sedation.,1,2026-05-13
cilnidipine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Additive pharmacodynamic effect on blood pressure and heart rate.,Monitor blood pressure and heart rate; consider dose adjustment.,1,2026-05-13
cilnidipine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Additive pharmacodynamic effect on blood pressure and heart rate.,Monitor blood pressure and heart rate; consider dose adjustment.,1,2026-05-13
cilnidipine,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and sodium excretion.",Avoid concurrent use if possible; monitor blood pressure and renal function.,1,2026-05-13
cilnidipine,aspirin,Minor,Slight reduction in antihypertensive efficacy.,Low-dose aspirin may interfere with the RAAS effects.,"Generally considered safe, monitor BP.",1,2026-05-13
vildagliptin,metformin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
vildagliptin,insulin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
vildagliptin,gliclazide,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; adjust doses if necessary.,1,2026-05-13
mometasone,prednisolone,Moderate,Increased risk of systemic corticosteroid side effects.,"Additive corticosteroid effects, leading to potential adrenal suppression and immunosuppression.",Monitor for signs of hypercorticism; consider reducing dose of one agent.,1,2026-05-13
mometasone,dexamethasone,Moderate,Increased risk of systemic corticosteroid side effects.,"Additive corticosteroid effects, leading to potential adrenal suppression and immunosuppression.",Monitor for signs of hypercorticism; consider reducing dose of one agent.,1,2026-05-13
mometasone,atorvastatin,Minor,Possible increased risk of myopathy.,Corticosteroids can potentially affect lipid metabolism.,Monitor for muscle pain or weakness.,1,2026-05-13
mometasone,rosuvastatin,Minor,Possible increased risk of myopathy.,Corticosteroids can potentially affect lipid metabolism.,Monitor for muscle pain or weakness.,1,2026-05-13
beclometasone,prednisolone,Major,Increased risk of systemic corticosteroid side effects.,Additive pharmacodynamic effects of corticosteroids.,Monitor for signs of corticosteroid toxicity and consider dose reduction if clinically appropriate.,1,2026-05-13
beclometasone,dexamethasone,Major,Increased risk of systemic corticosteroid side effects.,Additive pharmacodynamic effects of corticosteroids.,Monitor for signs of corticosteroid toxicity and consider dose reduction if clinically appropriate.,1,2026-05-13
betahistine,,,,,,1,2026-05-13
piracetam,,,,,,1,2026-05-13
tricholine citrate,,,,,,1,2026-05-13
diacerein,warfarin,Moderate,Increased risk of bleeding.,Diacerein metabolites can potentially inhibit warfarin metabolism.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
diacerein,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive antiplatelet effects and potential GI irritancy.,Use with caution and monitor for signs of GI bleeding.,1,2026-05-13
diacerein,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Additive GI irritancy and potential for NSAID-induced ulceration.,Use with caution and monitor for signs of GI bleeding.,1,2026-05-13
diacerein,clopidogrel,Moderate,Increased risk of bleeding.,Additive antiplatelet effects.,Monitor for signs of bleeding and consider dose adjustment.,1,2026-05-13
niacinamide,,,,,,1,2026-05-13
roxithromycin,digoxin,Moderate,Increased digoxin levels and risk of toxicity.,"Macrolide antibiotics may affect gut flora, altering digoxin absorption.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
etizolam,alprazolam,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects of benzodiazepines.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,diazepam,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects of benzodiazepines.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,lorazepam,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects of benzodiazepines.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,clonazepam,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects of benzodiazepines.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,midazolam,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects of benzodiazepines.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,zolpidem,Major,"Increased CNS depression, sedation, and respiratory depression.",Additive pharmacodynamic effects with sedative hypnotics.,"Avoid concurrent use; if necessary, use with extreme caution and lowest effective doses.",1,2026-05-13
etizolam,tramadol,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
etizolam,codeine,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
etizolam,morphine,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
etizolam,amitriptyline,Moderate,Increased CNS depression and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Monitor for increased sedation and anticholinergic side effects.,1,2026-05-13
etizolam,haloperidol,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and extrapyramidal symptoms.,1,2026-05-13
etizolam,clozapine,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and risk of agranulocytosis.,1,2026-05-13
etizolam,olanzapine,Moderate,Increased CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and metabolic side effects.,1,2026-05-13
divalproex,phenytoin,Moderate,Altered phenytoin levels and potential for toxicity or subtherapeutic effect.,Valproic acid can displace phenytoin from plasma protein binding sites and inhibit its metabolism.,Monitor phenytoin levels and clinical response; adjust phenytoin dose if necessary.,1,2026-05-13
divalproex,carbamazepine,Moderate,Increased carbamazepine levels and potential for toxicity.,Valproic acid can inhibit carbamazepine metabolism.,Monitor carbamazepine levels and for signs of toxicity.,1,2026-05-13
divalproex,lamotrigine,Major,"Increased lamotrigine levels and risk of severe rash, including Stevens-Johnson syndrome.",Valproic acid inhibits lamotrigine glucuronidation.,"Avoid concurrent use. If necessary, start lamotrigine at a lower dose and titrate slowly, monitoring closely for rash.",1,2026-05-13
divalproex,risperidone,Moderate,Increased risperidone levels and potential for extrapyramidal symptoms.,Valproic acid may inhibit glucuronidation of risperidone metabolites.,Monitor for increased sedation and extrapyramidal symptoms.,1,2026-05-13
povidone iodine,,,,,,1,2026-05-13
itopride,,,,,,1,2026-05-13
carboxymethylcellulose,warfarin,Minor,Reduced absorption of warfarin.,"Carboxymethylcellulose can bind to other drugs in the GI tract, slowing absorption.",Monitor INR closely and consider spacing administration.,1,2026-05-13
carboxymethylcellulose,metformin,Minor,Reduced absorption of metformin.,"Carboxymethylcellulose can bind to other drugs in the GI tract, slowing absorption.",Consider spacing administration of metformin.,1,2026-05-13
carboxymethylcellulose,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Carboxymethylcellulose can bind to other drugs in the GI tract, slowing absorption.",Consider spacing administration of atorvastatin.,1,2026-05-13
carboxymethylcellulose,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Carboxymethylcellulose can bind to other drugs in the GI tract, slowing absorption.",Consider spacing administration of rosuvastatin.,1,2026-05-13
carboxymethylcellulose,digoxin,Minor,Reduced absorption of digoxin.,"Carboxymethylcellulose can bind to other drugs in the GI tract, slowing absorption.",Consider spacing administration of digoxin.,1,2026-05-13
trypsin chymotrypsin,warfarin,Moderate,Increased risk of bleeding.,Proteolytic enzymes may interfere with clotting factor synthesis or activity.,Monitor INR closely and consider dose adjustments.,1,2026-05-13
trypsin chymotrypsin,clopidogrel,Moderate,Increased risk of bleeding.,Proteolytic enzymes may have antiplatelet effects or increase bleeding risk.,Monitor for signs of bleeding and consider alternative antiplatelet therapy if necessary.,1,2026-05-13
methyl sulfonyl methane,,,,,,1,2026-05-13
linseed oil,,,,,,1,2026-05-13
flunarizine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Both drugs can lower blood pressure; additive effects.,Monitor blood pressure and heart rate closely; consider dose reduction.,1,2026-05-13
flunarizine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Both drugs can lower blood pressure; additive effects.,Monitor blood pressure and heart rate closely; consider dose reduction.,1,2026-05-13
flunarizine,amlodipine,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure; additive effects.,Monitor blood pressure closely; consider dose reduction.,1,2026-05-13
flunarizine,losartan,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure; additive effects.,Monitor blood pressure closely; consider dose reduction.,1,2026-05-13
flunarizine,ramipril,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure; additive effects.,Monitor blood pressure closely; consider dose reduction.,1,2026-05-13
flunarizine,alprazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
flunarizine,diazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
flunarizine,lorazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
flunarizine,midazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
flunarizine,clonazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
flunarizine,zolpidem,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation; consider reducing dose of one agent.,1,2026-05-13
alpha lipoic acid,metformin,Minor,Potential for additive effects on blood glucose; increased risk of hypoglycemia.,Alpha-lipoic acid has glucose-lowering properties.,Monitor blood glucose levels closely; consider dose adjustment of metformin.,1,2026-05-13
alpha lipoic acid,insulin,Minor,Potential for additive effects on blood glucose; increased risk of hypoglycemia.,Alpha-lipoic acid has glucose-lowering properties.,Monitor blood glucose levels closely; consider dose adjustment of insulin.,1,2026-05-13
cefalexin,metformin,Moderate,Increased risk of lactic acidosis.,"Cephalexin can impair renal function, leading to reduced metformin clearance.",Monitor renal function and blood glucose; consider temporary discontinuation of metformin.,1,2026-05-13
cefalexin,warfarin,Moderate,Increased INR and risk of bleeding.,"Cephalexins can affect gut flora, reducing vitamin K production.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
cefalexin,probenecid,Moderate,Increased serum levels of cephalexin and risk of toxicity.,Probenecid inhibits renal tubular secretion of cephalexin.,Avoid concomitant use or monitor for cephalexin toxicity.,1,2026-05-13
lornoxicam,warfarin,Major,Significantly increased INR and risk of bleeding.,NSAIDs increase bleeding risk and can displace warfarin from protein binding sites.,Avoid concomitant use; monitor INR very closely if unavoidable and adjust warfarin dose.,1,2026-05-13
lornoxicam,aspirin,Major,Increased risk of GI bleeding and ulceration.,Additive antiplatelet and gastric irritant effects.,Avoid concomitant use; monitor for signs of GI bleeding.,1,2026-05-13
lornoxicam,ibuprofen,Major,Increased risk of GI bleeding and ulceration.,Additive NSAID effects on GI mucosa and platelet function.,Avoid concomitant use; monitor for signs of GI bleeding.,1,2026-05-13
lornoxicam,clopidogrel,Major,Increased risk of bleeding.,Additive antiplatelet effects and increased GI risk.,Avoid concomitant use; monitor for signs of bleeding.,1,2026-05-13
lornoxicam,ramipril,Moderate,Increased risk of renal impairment and hyperkalemia.,NSAIDs can reduce renal blood flow and inhibit effects of ACE inhibitors.,Monitor renal function and potassium levels; avoid in patients with renal compromise.,1,2026-05-13
lornoxicam,losartan,Moderate,Increased risk of renal impairment and hyperkalemia.,NSAIDs can reduce renal blood flow and interfere with ARB effects.,Monitor renal function and potassium levels; avoid in patients with renal compromise.,1,2026-05-13
lornoxicam,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal function and sodium excretion.",Monitor for adequate diuresis and blood pressure; monitor renal function.,1,2026-05-13
lornoxicam,lithium,Moderate,Increased serum lithium levels and risk of toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor serum lithium levels closely; avoid concomitant use if possible.,1,2026-05-13
lornoxicam,methotrexate,Moderate,Increased serum methotrexate levels and risk of toxicity.,NSAIDs can impair renal excretion of methotrexate.,Monitor serum methotrexate levels closely; avoid concomitant use at high-dose methotrexate.,1,2026-05-13
thyroxine,warfarin,Moderate,Increased INR and risk of bleeding.,Thyroxine increases metabolism of vitamin K-dependent clotting factors.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
thyroxine,metformin,Minor,Thyroxine may decrease glycemic control.,Hyperthyroidism can increase glucose absorption and hepatic glucose production.,Monitor blood glucose levels closely; adjust metformin dose if necessary.,1,2026-05-13
thyroxine,insulin,Minor,Thyroxine may decrease glycemic control.,Hyperthyroidism can increase glucose absorption and hepatic glucose production.,Monitor blood glucose levels closely; adjust insulin dose if necessary.,1,2026-05-13
thyroxine,atorvastatin,Minor,Reduced efficacy of atorvastatin.,Hypothyroidism can decrease the metabolism of statins.,Monitor lipid levels and adjust atorvastatin dose if hypothyroidism is corrected.,1,2026-05-13
thyroxine,rosuvastatin,Minor,Reduced efficacy of rosuvastatin.,Hypothyroidism can decrease the metabolism of statins.,Monitor lipid levels and adjust rosuvastatin dose if hypothyroidism is corrected.,1,2026-05-13
thyroxine,digoxin,Moderate,Reduced efficacy of digoxin.,Hypothyroidism can decrease the sensitivity of the heart to digoxin.,Monitor digoxin levels and clinical response; adjust dose if hypothyroidism is corrected.,1,2026-05-13
thyroxine,phenytoin,Minor,May alter thyroid hormone levels.,Phenytoin can increase thyroid hormone metabolism and binding to TBG.,Monitor thyroid function tests.,1,2026-05-13
thyroxine,carbamazepine,Minor,May alter thyroid hormone levels.,Carbamazepine can increase thyroid hormone metabolism and binding to TBG.,Monitor thyroid function tests.,1,2026-05-13
flupenthixol,amitriptyline,Moderate,Increased anticholinergic effects and sedation.,Additive effects on central nervous system receptors.,Monitor for increased sedation and anticholinergic symptoms; consider dose adjustment.,1,2026-05-13
flupenthixol,diazepam,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,lorazepam,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,clonazepam,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,alprazolam,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,midazolam,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,zolpidem,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,haloperidol,Major,Increased risk of extrapyramidal symptoms and QTc prolongation.,Both are dopamine receptor antagonists.,Monitor for EPS and QTc interval; consider alternative or dose adjustment.,1,2026-05-13
flupenthixol,clozapine,Major,"Increased risk of sedation, seizures, and agranulocytosis.",Additive CNS effects and potential for increased risk of adverse hematological effects.,"Close monitoring for sedation, seizures, and blood counts is crucial.",1,2026-05-13
flupenthixol,olanzapine,Major,Increased risk of sedation and anticholinergic effects.,"Additive CNS effects, particularly sedation.",Monitor for excessive sedation and anticholinergic symptoms; consider dose adjustment.,1,2026-05-13
flupenthixol,tramadol,Moderate,Increased risk of CNS depression and seizures.,Additive CNS depressant effects.,Monitor for increased sedation and seizures; use with caution.,1,2026-05-13
flupenthixol,codeine,Moderate,Increased risk of CNS depression and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
flupenthixol,morphine,Moderate,Increased risk of CNS depression and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory rate; use with caution.,1,2026-05-13
fusidic acid,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Fusidic acid inhibits CYP3A4, which metabolizes atorvastatin.","Avoid co-administration; if necessary, monitor closely for muscle pain and weakness.",1,2026-05-13
fusidic acid,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Fusidic acid can inhibit transporters (e.g., OATP1B1) involved in rosuvastatin elimination.",Monitor for muscle pain and weakness; consider alternative statin if possible.,1,2026-05-13
ammonium chloride,,,,,,1,2026-05-13
disodium hydrogen citrate,,,,,,1,2026-05-13
milk of magnesia,ciprofloxacin,Major,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.",Cations in antacids bind to fluoroquinolones.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
milk of magnesia,azithromycin,Major,"Reduced absorption of azithromycin, leading to decreased efficacy.",Cations in antacids bind to macrolides.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
milk of magnesia,tetracyclines (not on list),Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.",Cations in antacids bind to tetracyclines.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
milk of magnesia,metformin,Minor,Slightly decreased absorption of metformin.,Antacids can alter gastric pH and motility.,Monitor blood glucose levels; usually not clinically significant.,1,2026-05-13
milk of magnesia,digoxin,Moderate,Reduced absorption of digoxin.,"Antacids can alter gastric pH and motility, affecting digoxin absorption.",Monitor digoxin levels and therapeutic response; separate administration.,1,2026-05-13
calcium carbonate,ciprofloxacin,Major,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.",Cations in antacids bind to fluoroquinolones.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
calcium carbonate,azithromycin,Major,"Reduced absorption of azithromycin, leading to decreased efficacy.",Cations in antacids bind to macrolides.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
calcium carbonate,tetracyclines (not on list),Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.",Cations in antacids bind to tetracyclines.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
calcium carbonate,warfarin,Minor,Potential for altered warfarin absorption.,"Calcium can affect vitamin K absorption, although clinical significance is often low.",Monitor INR closely; usually not clinically significant if separated.,1,2026-05-13
calcium carbonate,metformin,Minor,Slightly decreased absorption of metformin.,Antacids can alter gastric pH and motility.,Monitor blood glucose levels; usually not clinically significant.,1,2026-05-13
calcium carbonate,atorvastatin,Minor,Reduced absorption of atorvastatin.,Calcium can chelate with statins.,Separate administration by at least 2 hours.,1,2026-05-13
calcium carbonate,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,Calcium can chelate with statins.,Separate administration by at least 2 hours.,1,2026-05-13
calcium carbonate,digoxin,Moderate,Reduced absorption of digoxin.,"Antacids can alter gastric pH and motility, affecting digoxin absorption.",Monitor digoxin levels and therapeutic response; separate administration.,1,2026-05-13
calcium carbonate,levothyroxine (not on list),Major,Significantly reduced absorption of levothyroxine.,Calcium binds to levothyroxine in the GI tract.,Separate administration by at least 4 hours; monitor thyroid function.,1,2026-05-13
faropenem,,,,,,1,2026-05-13
magnesium,ciprofloxacin,Major,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.",Cations in antacids bind to fluoroquinolones.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
magnesium,azithromycin,Major,"Reduced absorption of azithromycin, leading to decreased efficacy.",Cations in antacids bind to macrolides.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
magnesium,tetracyclines (not on list),Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.",Cations in antacids bind to tetracyclines.,Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
magnesium,digoxin,Moderate,Reduced absorption of digoxin.,"Antacids can alter gastric pH and motility, affecting digoxin absorption.",Monitor digoxin levels and therapeutic response; separate administration.,1,2026-05-13
magnesium,metformin,Minor,Slightly decreased absorption of metformin.,Antacids can alter gastric pH and motility.,Monitor blood glucose levels; usually not clinically significant.,1,2026-05-13
tolperisone,,,,,,1,2026-05-13
cinnarizine,alprazolam,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,diazepam,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,lorazepam,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,clonazepam,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,midazolam,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,zolpidem,Moderate,Increased sedation and potential for CNS depression.,Additive CNS depressant effects.,Monitor for increased sedation; use with caution.,1,2026-05-13
cinnarizine,ethanol (not on list),Moderate,Increased sedation and impairment.,Additive CNS depressant effects.,Avoid concurrent use of alcohol.,1,2026-05-13
diclofenac diethylamine,warfarin,Major,Increased risk of bleeding.,NSAIDs can potentiate anticoagulant effects and damage the gastric mucosa.,Monitor INR closely and consider alternative analgesics.,1,2026-05-13
diclofenac diethylamine,aspirin,Major,Increased risk of gastrointestinal bleeding and reduced cardioprotective effect of aspirin.,Concurrent use increases risk of GI ulceration and bleeding; NSAIDs can interfere with aspirin's antiplatelet aggregation.,"Avoid co-administration or use with extreme caution, monitor for GI symptoms.",1,2026-05-13
diclofenac diethylamine,ibuprofen,Major,Increased risk of gastrointestinal bleeding and renal impairment.,Additive NSAID effects leading to increased GI toxicity and nephrotoxicity.,"Avoid concurrent use, consider alternative pain management.",1,2026-05-13
diclofenac diethylamine,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin excretion.",Monitor renal function and blood glucose; consider alternative analgesics.,1,2026-05-13
diclofenac diethylamine,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can inhibit the vasodilatory effects of angiotensin II by blocking prostaglandin synthesis.,Monitor blood pressure and renal function; consider alternative analgesics.,1,2026-05-13
diclofenac diethylamine,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can inhibit the vasodilatory effects of angiotensin II by blocking prostaglandin synthesis.,Monitor blood pressure and renal function; consider alternative analgesics.,1,2026-05-13
diclofenac diethylamine,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,NSAIDs can inhibit sodium and water excretion by blocking prostaglandin synthesis in the kidneys.,"Monitor fluid balance, blood pressure, and renal function; consider alternative analgesics.",1,2026-05-13
diclofenac diethylamine,spironolactone,Moderate,Increased risk of hyperkalemia and renal impairment.,NSAIDs can reduce renal blood flow and potassium excretion.,Monitor potassium levels and renal function; consider alternative analgesics.,1,2026-05-13
diclofenac diethylamine,atorvastatin,Minor,Slightly increased risk of muscle-related side effects.,"Potential additive effects on myopathy, though generally not clinically significant.",Monitor for muscle pain or weakness.,1,2026-05-13
diclofenac diethylamine,rosuvastatin,Minor,Slightly increased risk of muscle-related side effects.,"Potential additive effects on myopathy, though generally not clinically significant.",Monitor for muscle pain or weakness.,1,2026-05-13
diclofenac diethylamine,clopidogrel,Major,Increased risk of gastrointestinal bleeding.,Both drugs can inhibit platelet aggregation and increase risk of GI bleeding.,Avoid concurrent use or monitor for GI bleeding and discontinue if indicated.,1,2026-05-13
diclofenac diethylamine,prednisolone,Major,Increased risk of gastrointestinal ulceration and bleeding.,Additive risk of GI toxicity with concurrent NSAID and corticosteroid use.,Monitor for GI symptoms and consider gastroprotection.,1,2026-05-13
diclofenac diethylamine,dexamethasone,Major,Increased risk of gastrointestinal ulceration and bleeding.,Additive risk of GI toxicity with concurrent NSAID and corticosteroid use.,Monitor for GI symptoms and consider gastroprotection.,1,2026-05-13
sodium bicarbonate,warfarin,Moderate,"May alter warfarin absorption or metabolism, potentially affecting INR.",Changes in gastric pH can affect drug absorption; some alkalinizing agents can affect vitamin K metabolism.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
sodium bicarbonate,metformin,Moderate,May affect metformin absorption or elimination.,Changes in gastric pH could potentially influence metformin absorption or renal excretion.,Monitor blood glucose and renal function.,1,2026-05-13
sodium bicarbonate,ketoconazole,Major,Reduced absorption of ketoconazole.,Alkalinization of gastric pH reduces absorption of weakly basic drugs like ketoconazole.,Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
sodium bicarbonate,itraconazole,Major,Reduced absorption of itraconazole.,Alkalinization of gastric pH reduces absorption of weakly basic drugs like itraconazole.,Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
sodium bicarbonate,lithium,Moderate,May decrease lithium clearance and increase serum lithium levels.,Alkaline urine may reduce renal lithium excretion.,Monitor lithium levels and renal function.,1,2026-05-13
sodium bicarbonate,ciprofloxacin,Moderate,May reduce absorption and serum concentrations of ciprofloxacin.,"Antacids can chelate fluoroquinolones, reducing absorption.",Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
sodium bicarbonate,doxycycline,Moderate,May reduce absorption and serum concentrations of doxycycline.,"Antacids can chelate tetracyclines, reducing absorption.",Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
hydroxyprogesterone,warfarin,Moderate,May decrease the anticoagulant effect of warfarin.,Progestins can affect the metabolism of oral anticoagulants.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
sodium hyaluronate,,,,,,1,2026-05-13
zinc,ciprofloxacin,Major,Reduced absorption and serum concentrations of ciprofloxacin.,"Zinc can chelate fluoroquinolones, inhibiting their absorption.",Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
zinc,doxycycline,Major,Reduced absorption and serum concentrations of doxycycline.,"Zinc can chelate tetracyclines, inhibiting their absorption.",Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
zinc,levothyroxine,Major,Reduced absorption and serum concentrations of levothyroxine.,Minerals like zinc can interfere with thyroid hormone absorption.,Separate administration by at least 4 hours and monitor thyroid function tests.,1,2026-05-13
zinc,penicillamine,Major,Reduced absorption of penicillamine.,"Zinc can form complexes with penicillamine, reducing its absorption.",Separate administration by at least 2 hours and monitor for efficacy.,1,2026-05-13
rifampicin,warfarin,Major,Reduced anticoagulant effect of warfarin.,Rifampicin is a potent inducer of cytochrome P450 enzymes that metabolize warfarin.,Monitor INR closely and significantly increase warfarin dose; adjust dose upon discontinuation of rifampicin.,1,2026-05-13
rifampicin,metformin,Moderate,May affect metformin absorption or metabolism.,Rifampicin can induce hepatic enzymes potentially altering metformin clearance.,Monitor blood glucose and renal function.,1,2026-05-13
rifampicin,atorvastatin,Major,Reduced efficacy of atorvastatin.,"Rifampicin induces CYP3A4, increasing atorvastatin metabolism.",Avoid concurrent use or consider alternative statin; monitor lipid levels.,1,2026-05-13
rifampicin,rosuvastatin,Moderate,May affect the efficacy of rosuvastatin.,"Rifampicin can induce P-glycoprotein, potentially affecting rosuvastatin levels.",Monitor lipid levels and consider alternative statin.,1,2026-05-13
rifampicin,amlodipine,Moderate,Reduced efficacy of amlodipine.,"Rifampicin can induce CYP3A4, increasing amlodipine metabolism.",Monitor blood pressure and consider increasing amlodipine dose.,1,2026-05-13
rifampicin,losartan,Moderate,Reduced efficacy of losartan.,"Rifampicin can induce CYP2C9 and CYP3A4, increasing losartan metabolism.",Monitor blood pressure and consider increasing losartan dose.,1,2026-05-13
rifampicin,omeprazole,Moderate,Reduced efficacy of omeprazole.,"Rifampicin induces CYP2C19 and CYP3A4, increasing omeprazole metabolism.",Monitor for signs of inadequate acid suppression and consider increasing omeprazole dose.,1,2026-05-13
rifampicin,pantoprazole,Moderate,Reduced efficacy of pantoprazole.,"Rifampicin induces CYP2C19 and CYP3A4, increasing pantoprazole metabolism.",Monitor for signs of inadequate acid suppression and consider increasing pantoprazole dose.,1,2026-05-13
rifampicin,insulin,Moderate,May decrease glycemic control.,Rifampicin can affect glucose metabolism.,Monitor blood glucose levels closely and adjust insulin dose if needed.,1,2026-05-13
rifampicin,digoxin,Moderate,Reduced serum digoxin levels.,"Rifampicin can induce intestinal P-glycoprotein, increasing digoxin efflux.",Monitor digoxin levels and therapeutic response; increase digoxin dose if needed.,1,2026-05-13
rifampicin,furosemide,Moderate,May affect the efficacy of furosemide.,Rifampicin can induce hepatic enzymes affecting drug metabolism.,Monitor diuresis and electrolyte balance.,1,2026-05-13
rifampicin,spironolactone,Moderate,May affect the efficacy of spironolactone.,Rifampicin can induce hepatic enzymes affecting drug metabolism.,Monitor electrolyte balance and therapeutic effect.,1,2026-05-13
rifampicin,atenolol,Moderate,Reduced efficacy of atenolol.,"Rifampicin can induce CYP2D6 and CYP3A4, increasing atenolol metabolism.",Monitor blood pressure and heart rate; consider increasing atenolol dose.,1,2026-05-13
rifampicin,metoprolol,Moderate,Reduced efficacy of metoprolol.,"Rifampicin can induce CYP2D6 and CYP3A4, increasing metoprolol metabolism.",Monitor blood pressure and heart rate; consider increasing metoprolol dose.,1,2026-05-13
rifampicin,ramipril,Moderate,Reduced efficacy of ramipril.,"Rifampicin can induce CYP2C9 and CYP3A4, increasing ramipril metabolism.",Monitor blood pressure and consider increasing ramipril dose.,1,2026-05-13
rifampicin,clopidogrel,Moderate,Reduced efficacy of clopidogrel.,"Rifampicin can induce CYP2C19, affecting clopidogrel's activation.",Monitor for thrombotic events; consider alternative antiplatelet agent.,1,2026-05-13
rifampicin,gabapentin,Moderate,May affect gabapentin absorption.,Rifampicin may alter gastrointestinal motility or absorption.,Monitor for efficacy and consider dose adjustment.,1,2026-05-13
rifampicin,alprazolam,Major,Reduced efficacy of alprazolam.,"Rifampicin induces CYP3A4, increasing alprazolam metabolism.",Avoid concurrent use or monitor for withdrawal symptoms; increase dose cautiously if needed.,1,2026-05-13
rifampicin,diazepam,Major,Reduced efficacy of diazepam.,"Rifampicin induces CYP3A4, increasing diazepam metabolism.",Avoid concurrent use or monitor for withdrawal symptoms; increase dose cautiously if needed.,1,2026-05-13
rifampicin,sertraline,Moderate,May affect sertraline efficacy.,Rifampicin can induce hepatic enzymes affecting sertraline metabolism.,Monitor for efficacy and adjust dose if needed.,1,2026-05-13
rifampicin,fluoxetine,Moderate,May affect fluoxetine efficacy.,Rifampicin can induce hepatic enzymes affecting fluoxetine metabolism.,Monitor for efficacy and adjust dose if needed.,1,2026-05-13
rifampicin,amitriptyline,Moderate,Reduced efficacy of amitriptyline.,"Rifampicin induces CYP1A2 and CYP3A4, increasing amitriptyline metabolism.",Monitor for signs of depression; consider increasing amitriptyline dose.,1,2026-05-13
rifampicin,tramadol,Moderate,May affect tramadol efficacy.,"Rifampicin can induce CYP2D6, affecting tramadol metabolism.",Monitor pain control; consider alternative analgesic if efficacy is reduced.,1,2026-05-13
rifampicin,codeine,Moderate,May affect codeine efficacy.,"Rifampicin can induce CYP2D6, affecting codeine metabolism.",Monitor pain control; consider alternative analgesic if efficacy is reduced.,1,2026-05-13
rifampicin,morphine,Moderate,May affect morphine efficacy.,"Rifampicin can induce CYP3A4, affecting morphine metabolism.",Monitor pain control; consider alternative analgesic if efficacy is reduced.,1,2026-05-13
rifampicin,phenytoin,Major,Reduced serum phenytoin levels.,Rifampicin induces hepatic enzymes that metabolize phenytoin.,Monitor phenytoin levels and therapeutic effect; increase phenytoin dose and adjust upon discontinuation of rifampicin.,1,2026-05-13
rifampicin,valproate,Moderate,Reduced serum valproate levels.,Rifampicin can induce hepatic enzymes that metabolize valproate.,Monitor valproate levels and therapeutic effect; increase dose if needed.,1,2026-05-13
rifampicin,carbamazepine,Major,Reduced serum carbamazepine levels.,Rifampicin induces hepatic enzymes that metabolize carbamazepine.,Monitor carbamazepine levels and therapeutic effect; increase carbamazepine dose and adjust upon discontinuation of rifampicin.,1,2026-05-13
rifampicin,isoniazid,Moderate,Increased risk of hepatotoxicity; reduced efficacy of isoniazid.,"Rifampicin can induce enzymes that increase isoniazid metabolism, leading to potential hepatotoxicity and reduced efficacy.",Monitor liver function tests closely; consider dose adjustments.,1,2026-05-13
rifampicin,ethambutol,Minor,No significant clinically relevant interaction documented.,Generally considered safe in combination.,No specific action required.,1,2026-05-13
rifampicin,cyclosporine,Major,Reduced serum cyclosporine levels.,"Rifampicin is a potent inducer of CYP3A4 and P-glycoprotein, which metabolize and transport cyclosporine.",Monitor cyclosporine levels closely and significantly increase dose; monitor for rejection.,1,2026-05-13
rifampicin,tacrolimus,Major,Reduced serum tacrolimus levels.,"Rifampicin is a potent inducer of CYP3A4 and P-glycoprotein, which metabolize and transport tacrolimus.",Monitor tacrolimus levels closely and significantly increase dose; monitor for rejection.,1,2026-05-13
rifampicin,lithium,Moderate,May affect lithium levels.,Rifampicin may influence renal lithium excretion.,Monitor lithium levels and renal function.,1,2026-05-13
rifampicin,haloperidol,Moderate,Reduced efficacy of haloperidol.,"Rifampicin can induce CYP3A4, increasing haloperidol metabolism.",Monitor for signs of antipsychotic withdrawal; consider increasing haloperidol dose.,1,2026-05-13
rifampicin,olanzapine,Moderate,Reduced efficacy of olanzapine.,"Rifampicin can induce CYP3A4, increasing olanzapine metabolism.",Monitor for signs of antipsychotic withdrawal; consider increasing olanzapine dose.,1,2026-05-13
rifampicin,clozapine,Major,Reduced efficacy of clozapine.,"Rifampicin is a potent inducer of CYP1A2, which metabolizes clozapine.",Avoid concurrent use; monitor for signs of clozapine withdrawal and consider alternative antipsychotic.,1,2026-05-13
rifampicin,zolpidem,Major,Reduced efficacy of zolpidem.,"Rifampicin induces CYP3A4, increasing zolpidem metabolism.",Avoid concurrent use or monitor for insomnia; consider alternative hypnotic.,1,2026-05-13
zinc pyrithione,,,,,,1,2026-05-13
l-ornithine l-aspartate,,,,,,1,2026-05-13
melitracen,warfarin,Moderate,May potentiate anticoagulant effect of warfarin.,Tricyclic antidepressants can inhibit warfarin metabolism.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
melitracen,amitriptyline,Major,Additive anticholinergic and sedative effects.,"Both are tricyclic antidepressants, leading to increased risk of side effects.",Avoid concurrent use due to increased risk of side effects.,1,2026-05-13
melitracen,sertraline,Moderate,Increased risk of serotonin syndrome.,"Both can affect serotonin levels, increasing the risk of serotonin syndrome.",Monitor for symptoms of serotonin syndrome and use with caution.,1,2026-05-13
melitracen,fluoxetine,Moderate,Increased risk of serotonin syndrome.,"Both can affect serotonin levels, increasing the risk of serotonin syndrome.",Monitor for symptoms of serotonin syndrome and use with caution.,1,2026-05-13
melitracen,tramadol,Moderate,Increased risk of serotonin syndrome and CNS depression.,Concurrent use can increase serotonin levels and cause additive CNS effects.,Monitor for symptoms of serotonin syndrome and CNS depression.,1,2026-05-13
melitracen,codeine,Moderate,Additive CNS depressant effects.,Both can cause sedation and respiratory depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
melitracen,morphine,Moderate,Additive CNS depressant effects.,Both can cause sedation and respiratory depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
melitracen,phenytoin,Moderate,May affect phenytoin metabolism.,Tricyclic antidepressants can alter the metabolism of phenytoin.,Monitor phenytoin levels and therapeutic effect.,1,2026-05-13
melitracen,diazepam,Moderate,Additive sedative effects.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
melitracen,lorazepam,Moderate,Additive sedative effects.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
melitracen,clonazepam,Moderate,Additive sedative effects.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
melitracen,alprazolam,Moderate,Additive sedative effects.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
melitracen,zolpidem,Moderate,Additive sedative effects.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
melitracen,olanzapine,Moderate,Increased risk of anticholinergic and sedative side effects.,Additive effects on CNS and anticholinergic pathways.,Monitor for sedation and anticholinergic symptoms.,1,2026-05-13
melitracen,haloperidol,Moderate,Increased risk of anticholinergic and sedative side effects.,Additive effects on CNS and anticholinergic pathways.,Monitor for sedation and anticholinergic symptoms.,1,2026-05-13
racecadotril,codeine,Moderate,Potentially reduced efficacy of racecadotril.,Opioid agonists can reduce intestinal motility and potentially antagonize the effect of racecadotril.,Monitor bowel movements and adjust treatment if necessary.,1,2026-05-13
racecadotril,morphine,Moderate,Potentially reduced efficacy of racecadotril.,Opioid agonists can reduce intestinal motility and potentially antagonize the effect of racecadotril.,Monitor bowel movements and adjust treatment if necessary.,1,2026-05-13
racecadotril,loperamide,Major,Increased risk of severe constipation and ileus.,"Both drugs affect intestinal motility, and concurrent use can lead to significant inhibition.",Avoid concurrent use due to risk of severe constipation and ileus.,1,2026-05-13
ethinyl estradiol,carbamazepine,Moderate,"Reduced contraceptive efficacy, increased carbamazepine levels.",Enzyme induction by carbamazepine increases ethinyl estradiol metabolism.,Consider alternative contraception or dose adjustment.,1,2026-05-13
ethinyl estradiol,rifampicin,Moderate,Reduced contraceptive efficacy.,"Rifampicin is a potent enzyme inducer, increasing ethinyl estradiol metabolism.",Advise alternative non-hormonal contraception.,1,2026-05-13
ethinyl estradiol,atorvastatin,Minor,Slight increase in atorvastatin levels.,Ethinyl estradiol can inhibit the metabolism of statins.,Monitor for statin-related side effects.,1,2026-05-13
ethinyl estradiol,rosuvastatin,Minor,Slight increase in rosuvastatin levels.,Ethinyl estradiol can inhibit the metabolism of statins.,Monitor for statin-related side effects.,1,2026-05-13
ethinyl estradiol,cyclosporine,Moderate,Increased cyclosporine levels and potential toxicity.,"Ethinyl estradiol inhibits CYP3A4, which metabolizes cyclosporine.",Monitor cyclosporine levels and renal function.,1,2026-05-13
ethinyl estradiol,tacrolimus,Moderate,Increased tacrolimus levels and potential toxicity.,"Ethinyl estradiol inhibits CYP3A4, which metabolizes tacrolimus.",Monitor tacrolimus levels and renal function.,1,2026-05-13
pancreatin,,,,,,1,2026-05-13
sodium valproate,valproate,Minor,Potential for increased valproate levels.,"Sodium valproate is a salt form of valproic acid, leading to additive effects.",Monitor valproate levels if multiple formulations are used.,1,2026-05-13
sodium valproate,phenytoin,Moderate,"Displacement of phenytoin from protein binding, increasing free phenytoin levels.",Valproate competes for protein binding sites.,Monitor phenytoin levels and for signs of toxicity.,1,2026-05-13
sodium valproate,lamotrigine,Major,"Increased lamotrigine levels, risk of severe rash.",Valproate inhibits lamotrigine glucuronidation.,Monitor lamotrigine levels; avoid concomitant use if possible or reduce lamotrigine dose significantly.,1,2026-05-13
liquid paraffin,,,,,,1,2026-05-13
cetrimide,,,,,,1,2026-05-13
d-panthenol,,,,,,1,2026-05-13
l-methyl folate,methotrexate,Minor,May potentially reduce methotrexate efficacy.,Folic acid derivatives can antagonize the antifolate effects of methotrexate.,Use with caution; monitor efficacy of methotrexate.,1,2026-05-13
dimethicone,,,,,,1,2026-05-13
phosphate,warfarin,Minor,Potential for altered warfarin response.,Phosphate supplements can potentially affect vitamin K metabolism.,Monitor INR closely.,1,2026-05-13
phosphate,atorvastatin,Minor,Reduced absorption of atorvastatin.,Phosphate can bind to and reduce the absorption of certain medications.,Separate administration by at least 2 hours.,1,2026-05-13
phosphate,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,Phosphate can bind to and reduce the absorption of certain medications.,Separate administration by at least 2 hours.,1,2026-05-13
phosphate,bisphosphonates,Minor,Reduced absorption of bisphosphonates.,Phosphate can bind to and reduce the absorption of certain medications.,Separate administration by at least 2 hours.,1,2026-05-13
cilastatin,imipenem,No interaction listed in common drug list. Cilastatin is always co-administered with imipenem.,No clinical significant interactions are expected as they are formulated together.,"Cilastatin inhibits the renal dihydropeptidase I enzyme, preventing the degradation of imipenem, thus increasing its renal and urinary concentrations.",Standard co-administration.,1,2026-05-13
arteether,,,,,,1,2026-05-13
dydrogesterone,phenytoin,Moderate,Reduced efficacy of dydrogesterone or increased risk of phenytoin toxicity.,Phenytoin is a potent inducer of hepatic enzymes that metabolize dydrogesterone.,Monitor for breakthrough bleeding or signs of phenytoin toxicity; consider alternative progestin or dose adjustment of phenytoin.,1,2026-05-13
dydrogesterone,carbamazepine,Moderate,Reduced efficacy of dydrogesterone or increased risk of carbamazepine toxicity.,Carbamazepine is a potent inducer of hepatic enzymes that metabolize dydrogesterone.,Monitor for breakthrough bleeding or signs of carbamazepine toxicity; consider alternative progestin or dose adjustment of carbamazepine.,1,2026-05-13
dydrogesterone,rifampicin,Moderate,Reduced efficacy of dydrogesterone or increased risk of rifampicin toxicity.,Rifampicin is a potent inducer of hepatic enzymes that metabolize dydrogesterone.,Monitor for breakthrough bleeding or signs of rifampicin toxicity; consider alternative progestin or dose adjustment of rifampicin.,1,2026-05-13
hydroxypropylmethylcellulose,,,,,,1,2026-05-13
lactic acid bacillus,,,,,,1,2026-05-13
ferrous ascorbate,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin and ferrous ascorbate.,"Iron salts can chelate with fluoroquinolones, reducing their oral bioavailability.",Separate administration of ciprofloxacin and ferrous ascorbate by at least 2 hours; monitor antibiotic efficacy.,1,2026-05-13
ferrous ascorbate,levofloxacin,Moderate,Reduced absorption of levofloxacin and ferrous ascorbate.,"Iron salts can chelate with fluoroquinolones, reducing their oral bioavailability.",Separate administration of levofloxacin and ferrous ascorbate by at least 2 hours; monitor antibiotic efficacy.,1,2026-05-13
ferrous ascorbate,tetracycline,Moderate,Reduced absorption of tetracycline and ferrous ascorbate.,"Iron salts can chelate with tetracyclines, reducing their oral bioavailability.",Separate administration of tetracycline and ferrous ascorbate by at least 2 hours; monitor antibiotic efficacy.,1,2026-05-13
ferrous ascorbate,doxycycline,Moderate,Reduced absorption of doxycycline and ferrous ascorbate.,"Iron salts can chelate with tetracyclines, reducing their oral bioavailability.",Separate administration of doxycycline and ferrous ascorbate by at least 2 hours; monitor antibiotic efficacy.,1,2026-05-13
ferrous ascorbate,thyroxine,Moderate,Reduced absorption of thyroxine.,Iron salts can decrease the absorption of levothyroxine.,Separate administration of thyroxine and ferrous ascorbate by at least 4 hours; monitor thyroid function tests.,1,2026-05-13
nicorandil,sildenafil,Major,Risk of severe hypotension.,"Both drugs cause vasodilation, potentiating hypotensive effects.",Avoid co-administration; monitor blood pressure closely if used together.,1,2026-05-13
nicorandil,tadalafil,Major,Risk of severe hypotension.,"Both drugs cause vasodilation, potentiating hypotensive effects.",Avoid co-administration; monitor blood pressure closely if used together.,1,2026-05-13
nicorandil,vardenafil,Major,Risk of severe hypotension.,"Both drugs cause vasodilation, potentiating hypotensive effects.",Avoid co-administration; monitor blood pressure closely if used together.,1,2026-05-13
nicorandil,amlodipine,Moderate,Increased risk of hypotension.,Both drugs are vasodilators.,Monitor blood pressure closely; consider dose adjustment of one or both agents.,1,2026-05-13
nicorandil,ramipril,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure.,Monitor blood pressure closely; consider dose adjustment of one or both agents.,1,2026-05-13
nicorandil,metoprolol,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure.,Monitor blood pressure closely; consider dose adjustment of one or both agents.,1,2026-05-13
nicorandil,atenolol,Moderate,Increased risk of hypotension.,Both drugs can lower blood pressure.,Monitor blood pressure closely; consider dose adjustment of one or both agents.,1,2026-05-13
dapoxetine,sertraline,Major,Increased risk of serotonin syndrome.,"Both are SSRIs, leading to additive serotonergic effects.",Avoid concomitant use; monitor for symptoms of serotonin syndrome.,1,2026-05-13
dapoxetine,fluoxetine,Major,Increased risk of serotonin syndrome.,"Both are SSRIs, leading to additive serotonergic effects.",Avoid concomitant use; monitor for symptoms of serotonin syndrome.,1,2026-05-13
dapoxetine,tramadol,Major,Increased risk of serotonin syndrome and central nervous system depression.,Tramadol has serotonergic activity and central effects.,Avoid concomitant use; monitor for symptoms of serotonin syndrome and sedation.,1,2026-05-13
dapoxetine,codeine,Moderate,Increased risk of sedation and respiratory depression.,Codeine has central nervous system depressant effects.,Use with caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
dapoxetine,morphine,Moderate,Increased risk of sedation and respiratory depression.,Morphine has central nervous system depressant effects.,Use with caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
dapoxetine,amitriptyline,Moderate,Increased risk of sedation and anticholinergic effects.,Amitriptyline has sedating and anticholinergic properties.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dapoxetine,diazepam,Moderate,Increased risk of sedation and dizziness.,Diazepam is a benzodiazepine with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
dapoxetine,alprazolam,Moderate,Increased risk of sedation and dizziness.,Alprazolam is a benzodiazepine with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
dapoxetine,lorazepam,Moderate,Increased risk of sedation and dizziness.,Lorazepam is a benzodiazepine with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
dapoxetine,clonazepam,Moderate,Increased risk of sedation and dizziness.,Clonazepam is a benzodiazepine with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
dapoxetine,midazolam,Moderate,Increased risk of sedation and dizziness.,Midazolam is a benzodiazepine with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
dapoxetine,zolpidem,Moderate,Increased risk of sedation and dizziness.,Zolpidem is a hypnotic with sedative effects.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
myo-inositol,,,,,,1,2026-05-13
dosulepin,sertraline,Major,Increased risk of serotonin syndrome and cardiac arrhythmias.,Both drugs affect serotonin; dosulepin has anticholinergic and potential cardiac effects.,Avoid concomitant use; monitor for symptoms of serotonin syndrome and cardiac abnormalities.,1,2026-05-13
dosulepin,fluoxetine,Major,Increased risk of serotonin syndrome and cardiac arrhythmias.,Both drugs affect serotonin; dosulepin has anticholinergic and potential cardiac effects.,Avoid concomitant use; monitor for symptoms of serotonin syndrome and cardiac abnormalities.,1,2026-05-13
dosulepin,amitriptyline,Major,"Increased risk of anticholinergic effects, sedation, and potential cardiac toxicity.",Both are tricyclic antidepressants with additive anticholinergic and CNS effects.,"Avoid concomitant use; monitor for anticholinergic side effects, sedation, and ECG changes.",1,2026-05-13
dosulepin,warfarin,Moderate,Increased risk of bleeding.,TCAs can potentiate the anticoagulant effect of warfarin.,Monitor INR closely; consider dose adjustment of warfarin if necessary.,1,2026-05-13
dosulepin,tramadol,Moderate,Increased risk of serotonin syndrome and sedation.,Both drugs affect serotonin and have CNS effects.,Use with caution; monitor for symptoms of serotonin syndrome and excessive sedation.,1,2026-05-13
dosulepin,codeine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
dosulepin,morphine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
dosulepin,diazepam,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dosulepin,alprazolam,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dosulepin,lorazepam,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dosulepin,clonazepam,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dosulepin,midazolam,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
dosulepin,zolpidem,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic symptoms.,1,2026-05-13
flupirtine,warfarin,Moderate,Increased risk of bleeding.,Flupirtine may enhance the effect of warfarin.,Monitor INR closely; consider dose adjustment of warfarin if necessary.,1,2026-05-13
flupirtine,diazepam,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of benzodiazepines.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,alprazolam,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of benzodiazepines.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,lorazepam,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of benzodiazepines.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,clonazepam,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of benzodiazepines.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,midazolam,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of benzodiazepines.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,zolpidem,Moderate,Increased risk of sedation and dizziness.,Flupirtine can potentiate the sedative effects of hypnotics.,Use with caution; monitor for excessive sedation and dizziness.,1,2026-05-13
flupirtine,omeprazole,Minor,Increased risk of gastrointestinal upset.,Both can cause gastric irritation.,Monitor for gastrointestinal symptoms.,1,2026-05-13
flupirtine,pantoprazole,Minor,Increased risk of gastrointestinal upset.,Both can cause gastric irritation.,Monitor for gastrointestinal symptoms.,1,2026-05-13
benfotiamine,,,,,,1,2026-05-13
teicoplanin,furosemide,Moderate,Increased risk of ototoxicity and nephrotoxicity.,"Both drugs can accumulate in inner ear fluid and renal tubules, potentiating damage.",Monitor renal function and hearing closely; consider dose adjustment.,1,2026-05-13
teicoplanin,"aminoglycosides (not in common list, but conceptually similar to some interactions)",Major,Additive nephrotoxicity and ototoxicity.,Synergistic damage to renal tubules and cochlear/vestibular systems.,Avoid concurrent use or monitor closely for signs of toxicity.,1,2026-05-13
levo-carnitine,,,,,,1,2026-05-13
taurine,warfarin,Minor,May potentially alter anticoagulant effect.,Taurine may influence vitamin K metabolism or platelet aggregation.,Monitor INR closely when initiating or discontinuing taurine.,1,2026-05-13
clomiphene,,,,,,1,2026-05-13
propylene glycol,diazepam,Moderate,"Increased risk of propylene glycol toxicity, especially with IV administration.",Propylene glycol is metabolized to lactate and acetate; high doses can cause metabolic acidosis and CNS depression.,"Use with caution and monitor for signs of toxicity, particularly in patients with renal or hepatic impairment.",1,2026-05-13
propylene glycol,lorazepam,Moderate,"Increased risk of propylene glycol toxicity, especially with IV administration.",Propylene glycol is metabolized to lactate and acetate; high doses can cause metabolic acidosis and CNS depression.,"Use with caution and monitor for signs of toxicity, particularly in patients with renal or hepatic impairment.",1,2026-05-13
propylene glycol,midazolam,Moderate,"Increased risk of propylene glycol toxicity, especially with IV administration.",Propylene glycol is metabolized to lactate and acetate; high doses can cause metabolic acidosis and CNS depression.,"Use with caution and monitor for signs of toxicity, particularly in patients with renal or hepatic impairment.",1,2026-05-13
ebastine,,,,,,1,2026-05-13
thiamine,,,,,,1,2026-05-13
l-methyl folate calcium,methotrexate,Major,May decrease the efficacy of methotrexate.,Folic acid antagonists like methotrexate work by interfering with folate metabolism; folate supplementation can counteract this.,Avoid concurrent use; monitor folate levels and methotrexate response.,1,2026-05-13
l-methyl folate calcium,phenytoin,Moderate,"May decrease phenytoin levels, leading to loss of seizure control.",Folic acid can affect phenytoin metabolism.,Monitor phenytoin levels and seizure frequency.,1,2026-05-13
l-methyl folate calcium,valproate,Minor,Potential for reduced efficacy of valproate.,"Folic acid can influence folate-dependent neurotransmitter synthesis, potentially affecting valproate's action.",Monitor seizure control.,1,2026-05-13
east african,,,,,,1,2026-05-13
halobetasol,,,,,,1,2026-05-13
silymarin,omeprazole,Minor,Potential for altered drug metabolism.,"Silymarin may inhibit or induce CYP enzymes, affecting omeprazole levels.",Monitor for efficacy and side effects.,1,2026-05-13
silymarin,pantoprazole,Minor,Potential for altered drug metabolism.,"Silymarin may inhibit or induce CYP enzymes, affecting pantoprazole levels.",Monitor for efficacy and side effects.,1,2026-05-13
trimetazidine,,,,,,1,2026-05-13
alpha ketoanalogue,metformin,Moderate,Increased risk of lactic acidosis.,"Alpha-ketoanalogs can affect renal function, potentially impairing metformin excretion.","Monitor renal function closely, consider dose adjustment or temporary discontinuation of metformin.",1,2026-05-13
alpha ketoanalogue,losartan,Moderate,Increased risk of hyperkalemia and renal impairment.,"Alpha-ketoanalogs can impact renal function and potassium balance, which can be exacerbated by losartan.",Monitor renal function and potassium levels.,1,2026-05-13
alpha ketoanalogue,ramipril,Moderate,Increased risk of hyperkalemia and renal impairment.,"Alpha-ketoanalogs can impact renal function and potassium balance, which can be exacerbated by ramipril.",Monitor renal function and potassium levels.,1,2026-05-13
alpha ketoanalogue,spironolactone,Moderate,Increased risk of hyperkalemia.,"Alpha-ketoanalogs can impact potassium balance, which is potentiated by spironolactone.",Monitor potassium levels closely.,1,2026-05-13
zinc sulfate,ciprofloxacin,Major,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.","Zinc sulfate forms insoluble complexes with fluoroquinolones, hindering their gastrointestinal absorption.",Separate administration by at least 2 hours before or 4-6 hours after ciprofloxacin.,1,2026-05-13
zinc sulfate,amoxicillin,Minor,Potential for reduced absorption of amoxicillin.,"Zinc may chelate with certain antibiotics, potentially affecting absorption.",Separate administration if significant absorption issues are suspected.,1,2026-05-13
zinc sulfate,tetracyclines,Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.","Zinc sulfate forms insoluble complexes with tetracyclines, hindering their gastrointestinal absorption.",Separate administration by at least 2 hours before or 6 hours after tetracyclines.,1,2026-05-13
sertaconazole,,,,,,1,2026-05-13
mebeverine,,,,,,1,2026-05-13
fatty acid,,,,,,1,2026-05-13
tolnaftate,,,,,,1,2026-05-13
recombinant human erythropoietin alfa,warfarin,Moderate,Increased risk of thrombosis or bleeding.,"Erythropoietin therapy can affect hematocrit and blood viscosity, potentially altering warfarin's anticoagulant effect.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
recombinant human erythropoietin alfa,atenolol,Minor,Potential for altered blood pressure control.,"Erythropoietin therapy can sometimes cause hypertension, potentially counteracting the effects of atenolol.",Monitor blood pressure regularly.,1,2026-05-13
recombinant human erythropoietin alfa,metoprolol,Minor,Potential for altered blood pressure control.,"Erythropoietin therapy can sometimes cause hypertension, potentially counteracting the effects of metoprolol.",Monitor blood pressure regularly.,1,2026-05-13
recombinant human erythropoietin alfa,losartan,Minor,Potential for altered blood pressure control.,"Erythropoietin therapy can sometimes cause hypertension, potentially counteracting the effects of losartan.",Monitor blood pressure regularly.,1,2026-05-13
recombinant human erythropoietin alfa,amlodipine,Minor,Potential for altered blood pressure control.,"Erythropoietin therapy can sometimes cause hypertension, potentially counteracting the effects of amlodipine.",Monitor blood pressure regularly.,1,2026-05-13
recombinant human erythropoietin alfa,ramipril,Minor,Potential for altered blood pressure control.,"Erythropoietin therapy can sometimes cause hypertension, potentially counteracting the effects of ramipril.",Monitor blood pressure regularly.,1,2026-05-13
zinc sulphate monohydrate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Zinc can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours or increase ciprofloxacin dose if concurrent use is unavoidable.,1,2026-05-13
zinc sulphate monohydrate,levofloxacin,Major,Reduced absorption of levofloxacin.,"Zinc can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours or increase levofloxacin dose if concurrent use is unavoidable.,1,2026-05-13
zinc sulphate monohydrate,tetracycline,Major,Reduced absorption of both drugs.,"Zinc can chelate with tetracyclines, decreasing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc sulphate monohydrate,penicillamine,Moderate,Reduced absorption of penicillamine.,"Zinc can form complexes with penicillamine, reducing its absorption.",Separate administration by at least 2 hours.,1,2026-05-13
chlorbutol,,,,,,1,2026-05-13
calcium,atorvastatin,Moderate,May decrease the absorption of atorvastatin.,"Calcium can form insoluble complexes with statins, reducing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium,rosuvastatin,Moderate,May decrease the absorption of rosuvastatin.,"Calcium can form insoluble complexes with statins, reducing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium,tetracycline,Major,Reduced absorption of tetracycline.,"Calcium can chelate with tetracyclines, decreasing their oral bioavailability.","Avoid concurrent administration; if necessary, separate by at least 2-4 hours.",1,2026-05-13
calcium,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Calcium can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium,levofloxacin,Major,Reduced absorption of levofloxacin.,"Calcium can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium,thyroid hormone,Major,Reduced absorption of thyroid hormone.,Calcium can interfere with the absorption of levothyroxine.,Separate administration by at least 4 hours.,1,2026-05-13
calcium,bisphosphonates,Major,Reduced absorption of bisphosphonates.,Calcium can significantly reduce the absorption of bisphosphonates.,Administer bisphosphonates at least 2 hours before or 2 hours after calcium supplements.,1,2026-05-13
zinc oxide,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Zinc can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours or increase ciprofloxacin dose if concurrent use is unavoidable.,1,2026-05-13
zinc oxide,levofloxacin,Major,Reduced absorption of levofloxacin.,"Zinc can chelate with fluoroquinolones, decreasing their oral bioavailability.",Separate administration by at least 2 hours or increase levofloxacin dose if concurrent use is unavoidable.,1,2026-05-13
zinc oxide,tetracycline,Major,Reduced absorption of both drugs.,"Zinc can chelate with tetracyclines, decreasing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc oxide,penicillamine,Moderate,Reduced absorption of penicillamine.,"Zinc can form complexes with penicillamine, reducing its absorption.",Separate administration by at least 2 hours.,1,2026-05-13
vitamin c,warfarin,Minor,May potentially decrease the anticoagulant effect of warfarin.,"High doses of Vitamin C may have a weak anticoagulant effect, potentially interfering with warfarin.",Monitor INR closely if high doses of vitamin C are initiated or stopped.,1,2026-05-13
vitamin c,estrogens,Minor,May increase absorption of estrogens.,Vitamin C can increase the absorption of orally administered estrogens.,Monitor for signs of increased estrogen effects.,1,2026-05-13
triamcinolone acetonide,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Corticosteroids can potentiate statin-induced myopathy.,Monitor for muscle pain and weakness; consider dose reduction of statin or corticosteroid.,1,2026-05-13
triamcinolone acetonide,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Corticosteroids can potentiate statin-induced myopathy.,Monitor for muscle pain and weakness; consider dose reduction of statin or corticosteroid.,1,2026-05-13
triamcinolone acetonide,metformin,Moderate,Hyperglycemia.,Corticosteroids antagonize the glucose-lowering effect of metformin.,Monitor blood glucose levels closely and adjust metformin dose if necessary.,1,2026-05-13
triamcinolone acetonide,insulin,Moderate,Hyperglycemia.,Corticosteroids antagonize the glucose-lowering effect of insulin.,Monitor blood glucose levels closely and adjust insulin dose if necessary.,1,2026-05-13
triamcinolone acetonide,furosemide,Moderate,"Electrolyte imbalance, particularly hypokalemia.","Corticosteroids can increase potassium excretion, potentiating the hypokalemic effect of loop diuretics.",Monitor serum potassium levels and supplement if necessary.,1,2026-05-13
triamcinolone acetonide,spironolactone,Minor,May decrease the effect of spironolactone.,"Corticosteroids can have mineralocorticoid effects, potentially counteracting spironolactone.",Monitor for signs of fluid retention or hyponatremia.,1,2026-05-13
triamcinolone acetonide,rifampicin,Moderate,Decreased efficacy of triamcinolone.,Rifampicin is a potent enzyme inducer and can increase the metabolism of corticosteroids.,Consider increasing the dose of triamcinolone or monitoring for reduced therapeutic effect.,1,2026-05-13
triamcinolone acetonide,phenytoin,Moderate,Decreased efficacy of triamcinolone.,Phenytoin is an enzyme inducer and can increase the metabolism of corticosteroids.,Consider increasing the dose of triamcinolone or monitoring for reduced therapeutic effect.,1,2026-05-13
triamcinolone acetonide,carbamazepine,Moderate,Decreased efficacy of triamcinolone.,Carbamazepine is an enzyme inducer and can increase the metabolism of corticosteroids.,Consider increasing the dose of triamcinolone or monitoring for reduced therapeutic effect.,1,2026-05-13
triamcinolone acetonide,diazepam,Minor,May alter diazepam metabolism.,"Corticosteroids can affect hepatic enzyme activity, potentially altering the metabolism of some benzodiazepines.",Monitor for changes in sedation or efficacy.,1,2026-05-13
triamcinolone acetonide,alprazolam,Minor,May alter alprazolam metabolism.,"Corticosteroids can affect hepatic enzyme activity, potentially altering the metabolism of some benzodiazepines.",Monitor for changes in sedation or efficacy.,1,2026-05-13
calcium dobesilate,,,,,,1,2026-05-13
amorolfine,,,,,,1,2026-05-13
benidipine,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can increase the risk of muscle-related adverse events.,Monitor for muscle pain and weakness; consider dose adjustment.,1,2026-05-13
benidipine,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can increase the risk of muscle-related adverse events.,Monitor for muscle pain and weakness; consider dose adjustment.,1,2026-05-13
benidipine,cyclosporine,Moderate,Increased plasma concentrations of cyclosporine.,"Benidipine may inhibit CYP3A4, which metabolizes cyclosporine, leading to increased levels.",Monitor cyclosporine levels and for signs of toxicity; consider dose reduction of cyclosporine.,1,2026-05-13
benidipine,tacrolimus,Moderate,Increased plasma concentrations of tacrolimus.,"Benidipine may inhibit CYP3A4, which metabolizes tacrolimus, leading to increased levels.",Monitor tacrolimus levels and for signs of toxicity; consider dose reduction of tacrolimus.,1,2026-05-13
benidipine,erythromycin,Moderate,Increased plasma concentrations of benidipine.,Erythromycin is a CYP3A4 inhibitor and can reduce the metabolism of benidipine.,Monitor for excessive blood pressure lowering and side effects of benidipine.,1,2026-05-13
benidipine,ketoconazole,Moderate,Increased plasma concentrations of benidipine.,Ketoconazole is a CYP3A4 inhibitor and can reduce the metabolism of benidipine.,Monitor for excessive blood pressure lowering and side effects of benidipine.,1,2026-05-13
docosahexanoic acid,warfarin,Minor,May increase the anticoagulant effect of warfarin.,"Omega-3 fatty acids, like DHA, may have mild antiplatelet effects and could potentiate warfarin's action.",Monitor INR closely if high doses of DHA are initiated or stopped.,1,2026-05-13
paradichlorobenzene,,,,,,1,2026-05-13
human insulin,metformin,Moderate,Increased risk of hypoglycemia and lactic acidosis.,Both drugs lower blood glucose; metformin can potentiate insulin's effects.,Monitor blood glucose closely and adjust insulin dose as needed.,1,2026-05-13
human insulin,atorvastatin,Minor,Potential for slight blood glucose elevation.,Statins can have a modest effect on glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,losartan,Minor,Potential for additive blood glucose lowering.,ACE inhibitors/ARBs can improve insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
human insulin,omeprazole,Minor,Potential for altered glycemic control.,PPIs may influence glucose absorption or metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,pantoprazole,Minor,Potential for altered glycemic control.,PPIs may influence glucose absorption or metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,amoxicillin,Minor,Potential for altered glycemic control.,Antibiotics can sometimes affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,azithromycin,Minor,Potential for altered glycemic control.,Antibiotics can sometimes affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,ciprofloxacin,Moderate,"Risk of hypoglycemia, especially with higher doses.",Fluoroquinolones can interfere with glucose homeostasis.,Monitor blood glucose closely and adjust insulin dose.,1,2026-05-13
human insulin,metronidazole,Minor,Potential for altered glycemic control.,Antibiotics can sometimes affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,prednisolone,Major,Hyperglycemia and insulin resistance.,Corticosteroids antagonize insulin action.,Increase insulin dose and monitor blood glucose frequently.,1,2026-05-13
human insulin,dexamethasone,Major,Hyperglycemia and insulin resistance.,Corticosteroids antagonize insulin action.,Increase insulin dose and monitor blood glucose frequently.,1,2026-05-13
human insulin,digoxin,Minor,Potential for altered glycemic control.,"No clear pharmacologic interaction, but patients with diabetes may have other comorbidities.",Monitor blood glucose levels.,1,2026-05-13
human insulin,furosemide,Moderate,Hyperglycemia and reduced insulin sensitivity.,Thiazide and loop diuretics can cause hyperglycemia.,Monitor blood glucose and adjust insulin dose.,1,2026-05-13
human insulin,spironolactone,Minor,Potential for altered glycemic control.,Diuretics can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,atenolol,Moderate,Masking of hypoglycemia symptoms (tachycardia).,Beta-blockers can inhibit counterregulatory hormonal responses to hypoglycemia.,"Monitor blood glucose closely, advise patients to recognize other hypoglycemia symptoms.",1,2026-05-13
human insulin,metoprolol,Moderate,Masking of hypoglycemia symptoms (tachycardia).,Beta-blockers can inhibit counterregulatory hormonal responses to hypoglycemia.,"Monitor blood glucose closely, advise patients to recognize other hypoglycemia symptoms.",1,2026-05-13
human insulin,ramipril,Minor,Potential for additive blood glucose lowering.,ACE inhibitors can improve insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
human insulin,clopidogrel,Minor,Potential for altered glycemic control.,"No direct pharmacologic interaction, but patients may have other cardiovascular risk factors.",Monitor blood glucose levels.,1,2026-05-13
human insulin,rosuvastatin,Minor,Potential for slight blood glucose elevation.,Statins can have a modest effect on glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,gabapentin,Minor,Potential for altered glycemic control.,No clear pharmacologic interaction.,Monitor blood glucose levels.,1,2026-05-13
human insulin,alprazolam,Minor,Potential for altered glycemic control.,Benzodiazepines can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,diazepam,Minor,Potential for altered glycemic control.,Benzodiazepines can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,sertraline,Minor,Potential for altered glycemic control.,SSRIs can influence glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,fluoxetine,Minor,Potential for altered glycemic control.,SSRIs can influence glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,amitriptyline,Minor,Potential for altered glycemic control.,Tricyclic antidepressants can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,tramadol,Moderate,Risk of hypoglycemia or hyperglycemia.,Tramadol can affect glucose levels through complex mechanisms.,Monitor blood glucose closely and adjust insulin dose.,1,2026-05-13
human insulin,codeine,Minor,Potential for altered glycemic control.,Opioids can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,morphine,Minor,Potential for altered glycemic control.,Opioids can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,phenytoin,Moderate,Hyperglycemia.,Phenytoin can impair insulin secretion.,Monitor blood glucose and adjust insulin dose.,1,2026-05-13
human insulin,valproate,Minor,"Potential for weight gain, which can affect glycemic control.","Valproate can cause weight gain, impacting insulin sensitivity.",Monitor blood glucose levels and weight.,1,2026-05-13
human insulin,carbamazepine,Minor,Potential for altered glycemic control.,"No consistent effect, but some patients may experience changes.",Monitor blood glucose levels.,1,2026-05-13
human insulin,rifampicin,Moderate,Hyperglycemia.,Rifampicin can affect glucose metabolism and insulin sensitivity.,Monitor blood glucose and adjust insulin dose.,1,2026-05-13
human insulin,isoniazid,Minor,Potential for altered glycemic control.,Some reports suggest effects on glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,ethambutol,Minor,Potential for altered glycemic control.,"No direct interaction documented, but patients may have co-existing conditions.",Monitor blood glucose levels.,1,2026-05-13
human insulin,hydroxychloroquine,Minor,Potential for altered glycemic control.,May improve insulin sensitivity in some patients.,Monitor blood glucose levels.,1,2026-05-13
human insulin,colchicine,Minor,Potential for altered glycemic control.,Rare reports of glucose intolerance.,Monitor blood glucose levels.,1,2026-05-13
human insulin,allopurinol,Minor,Potential for altered glycemic control.,"No direct interaction documented, but rare reports of glucose intolerance exist.",Monitor blood glucose levels.,1,2026-05-13
human insulin,methotrexate,Minor,Potential for altered glycemic control.,No direct interaction documented.,Monitor blood glucose levels.,1,2026-05-13
human insulin,cyclosporine,Moderate,Hyperglycemia and potential for new-onset diabetes.,Cyclosporine can impair insulin secretion and sensitivity.,Monitor blood glucose closely and adjust insulin dose; consider alternative immunosuppressants if necessary.,1,2026-05-13
human insulin,tacrolimus,Moderate,Hyperglycemia and potential for new-onset diabetes.,Tacrolimus can impair insulin secretion and sensitivity.,Monitor blood glucose closely and adjust insulin dose; consider alternative immunosuppressants if necessary.,1,2026-05-13
human insulin,lithium,Minor,Potential for altered glycemic control.,"Lithium can affect glucose metabolism, though effects are variable.",Monitor blood glucose levels.,1,2026-05-13
human insulin,haloperidol,Minor,"Potential for altered glycemic control, especially with long-term use.",Antipsychotics can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,clozapine,Major,"Significant weight gain, hyperglycemia, and new-onset diabetes.",Clozapine is associated with profound metabolic disturbances.,Intensive monitoring of blood glucose and weight; adjust insulin dose aggressively; consider alternative antipsychotic if possible.,1,2026-05-13
human insulin,olanzapine,Major,"Significant weight gain, hyperglycemia, and new-onset diabetes.",Olanzapine is associated with significant metabolic disturbances.,Intensive monitoring of blood glucose and weight; adjust insulin dose aggressively; consider alternative antipsychotic if possible.,1,2026-05-13
human insulin,lorazepam,Minor,Potential for altered glycemic control.,Benzodiazepines can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,clonazepam,Minor,Potential for altered glycemic control.,Benzodiazepines can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,midazolam,Minor,Potential for altered glycemic control.,Benzodiazepines can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
human insulin,zolpidem,Minor,Potential for altered glycemic control.,No clear pharmacologic interaction.,Monitor blood glucose levels.,1,2026-05-13
glutathione,,,,,,1,2026-05-13
human chorionic gonadotropin,menotrophin,Major,Increased risk of ovarian hyperstimulation syndrome (OHSS).,"Both drugs stimulate the ovaries, leading to an exaggerated response.","Close monitoring for signs of OHSS, adjust doses carefully.",1,2026-05-13
turpentine oil,,,,,,1,2026-05-13
lithium carbonate,atorvastatin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,losartan,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,omeprazole,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,pantoprazole,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,amoxicillin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,azithromycin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,ciprofloxacin,Moderate,"Increased lithium levels, leading to toxicity.",Fluoroquinolones can inhibit renal clearance of lithium.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,metronidazole,Moderate,"Increased lithium levels, leading to toxicity.",Metronidazole can inhibit renal clearance of lithium.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,prednisolone,Moderate,Reduced lithium levels.,Corticosteroids can increase renal excretion of lithium.,"Monitor lithium levels closely, increase lithium dose if necessary.",1,2026-05-13
lithium carbonate,dexamethasone,Moderate,Reduced lithium levels.,Corticosteroids can increase renal excretion of lithium.,"Monitor lithium levels closely, increase lithium dose if necessary.",1,2026-05-13
lithium carbonate,furosemide,Moderate,Increased lithium levels and potential for lithium toxicity.,Loop diuretics can decrease renal excretion of lithium.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,spironolactone,Minor,"May slightly affect lithium levels, but usually not clinically significant.",Potassium-sparing diuretics can influence lithium handling.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,atenolol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,metoprolol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,ramipril,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,clopidogrel,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,rosuvastatin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,gabapentin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,alprazolam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,diazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,sertraline,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,fluoxetine,Moderate,Increased lithium levels and potential for toxicity.,SSRIs can inhibit lithium excretion.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,amitriptyline,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,tramadol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,codeine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,morphine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,phenytoin,Moderate,Reduced lithium levels.,Phenytoin can enhance lithium excretion.,"Monitor lithium levels closely, increase lithium dose if necessary.",1,2026-05-13
lithium carbonate,valproate,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,carbamazepine,Moderate,Increased risk of neurotoxicity.,Both drugs can cause CNS side effects; additive effect.,"Monitor for signs of neurotoxicity, use cautiously.",1,2026-05-13
lithium carbonate,rifampicin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,isoniazid,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,ethambutol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,hydroxychloroquine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,colchicine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,allopurinol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,methotrexate,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,cyclosporine,Moderate,Increased lithium levels and potential for toxicity.,Cyclosporine can impair renal clearance of lithium.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,tacrolimus,Moderate,Increased lithium levels and potential for toxicity.,Tacrolimus can impair renal clearance of lithium.,"Monitor lithium levels closely, reduce lithium dose if necessary.",1,2026-05-13
lithium carbonate,haloperidol,Moderate,Increased risk of neurotoxicity.,Both drugs can cause CNS side effects; additive effect.,"Monitor for signs of neurotoxicity, use cautiously.",1,2026-05-13
lithium carbonate,clozapine,Moderate,Increased risk of neurotoxicity.,Both drugs can cause CNS side effects; additive effect.,"Monitor for signs of neurotoxicity, use cautiously.",1,2026-05-13
lithium carbonate,olanzapine,Moderate,Increased risk of neurotoxicity.,Both drugs can cause CNS side effects; additive effect.,"Monitor for signs of neurotoxicity, use cautiously.",1,2026-05-13
lithium carbonate,lorazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,clonazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,midazolam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
lithium carbonate,zolpidem,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor lithium levels if concerns arise.,1,2026-05-13
s-amlodipine,atorvastatin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,amlodipine,Minor,Additive hypotensive effect.,"Both are calcium channel blockers, increasing the risk of hypotension.",Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,losartan,Minor,Additive hypotensive effect.,"Both are antihypertensives, increasing the risk of hypotension.",Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,omeprazole,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,pantoprazole,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,amoxicillin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,azithromycin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,ciprofloxacin,Minor,May slightly increase amlodipine levels.,Fluoroquinolones can inhibit CYP3A4 metabolism.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,metronidazole,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,prednisolone,Minor,Corticosteroids may reduce the hypotensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,dexamethasone,Minor,Corticosteroids may reduce the hypotensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,digoxin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure and heart rate.,1,2026-05-13
s-amlodipine,furosemide,Minor,Additive hypotensive effect.,Both can lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,spironolactone,Minor,Additive hypotensive effect.,Both can lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,atenolol,Minor,Additive hypotensive effect.,"Both are antihypertensives, increasing the risk of hypotension.",Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,metoprolol,Minor,Additive hypotensive effect.,"Both are antihypertensives, increasing the risk of hypotension.",Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,ramipril,Minor,Additive hypotensive effect.,"Both are antihypertensives, increasing the risk of hypotension.",Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,clopidogrel,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,rosuvastatin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,gabapentin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,alprazolam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,diazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,sertraline,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,fluoxetine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,amitriptyline,Minor,Additive hypotensive effect.,Tricyclic antidepressants can cause orthostatic hypotension.,"Monitor blood pressure closely, advise caution when standing.",1,2026-05-13
s-amlodipine,tramadol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,codeine,Minor,Additive hypotensive effect.,Opioids can cause hypotension.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,morphine,Minor,Additive hypotensive effect.,Opioids can cause hypotension.,Monitor blood pressure closely.,1,2026-05-13
s-amlodipine,phenytoin,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,valproate,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,carbamazepine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,rifampicin,Minor,May decrease amlodipine levels.,Rifampicin is a strong CYP3A4 inducer.,"Monitor blood pressure, may need increased amlodipine dose.",1,2026-05-13
s-amlodipine,isoniazid,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,ethambutol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,hydroxychloroquine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,colchicine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,allopurinol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,methotrexate,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,cyclosporine,Minor,May increase amlodipine levels.,Cyclosporine can inhibit CYP3A4 metabolism.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,tacrolimus,Minor,May increase amlodipine levels.,Tacrolimus can inhibit CYP3A4 metabolism.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,haloperidol,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,clozapine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,olanzapine,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,lorazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,clonazepam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,midazolam,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
s-amlodipine,zolpidem,Minor,No significant interaction expected.,No known pharmacokinetic or pharmacodynamic interaction.,Monitor blood pressure.,1,2026-05-13
lycopene,,,,,,1,2026-05-13
medroxyprogesterone acetate,atorvastatin,Minor,Progestins can affect lipid profiles; monitor lipid levels.,Hormonal effects on lipid metabolism.,Monitor lipid levels and adjust statin dose if needed.,1,2026-05-13
medroxyprogesterone acetate,rosuvastatin,Minor,Progestins can affect lipid profiles; monitor lipid levels.,Hormonal effects on lipid metabolism.,Monitor lipid levels and adjust statin dose if needed.,1,2026-05-13
medroxyprogesterone acetate,prednisolone,Minor,No significant interaction expected.,No known pharmacologic interaction.,Monitor patient for any unexpected side effects.,1,2026-05-13
medroxyprogesterone acetate,dexamethasone,Minor,No significant interaction expected.,No known pharmacologic interaction.,Monitor patient for any unexpected side effects.,1,2026-05-13
medroxyprogesterone acetate,rifampicin,Major,Reduced effectiveness of medroxyprogesterone acetate.,"Rifampicin is a potent inducer of CYP3A4 enzymes, increasing medroxyprogesterone metabolism.",Avoid concurrent use or use alternative contraception/hormone therapy.,1,2026-05-13
medroxyprogesterone acetate,phenytoin,Major,Reduced effectiveness of medroxyprogesterone acetate.,"Phenytoin is an inducer of CYP3A4 enzymes, increasing medroxyprogesterone metabolism.",Avoid concurrent use or use alternative contraception/hormone therapy.,1,2026-05-13
medroxyprogesterone acetate,carbamazepine,Major,Reduced effectiveness of medroxyprogesterone acetate.,"Carbamazepine is an inducer of CYP3A4 enzymes, increasing medroxyprogesterone metabolism.",Avoid concurrent use or use alternative contraception/hormone therapy.,1,2026-05-13
medroxyprogesterone acetate,cyclosporine,Moderate,Increased cyclosporine levels.,"Medroxyprogesterone can inhibit CYP3A4 enzymes, reducing cyclosporine metabolism.","Monitor cyclosporine levels closely, adjust dose if needed.",1,2026-05-13
medroxyprogesterone acetate,tacrolimus,Moderate,Increased tacrolimus levels.,"Medroxyprogesterone can inhibit CYP3A4 enzymes, reducing tacrolimus metabolism.","Monitor tacrolimus levels closely, adjust dose if needed.",1,2026-05-13
menotrophin,human chorionic gonadotropin,Major,Increased risk of ovarian hyperstimulation syndrome (OHSS).,"Both drugs stimulate the ovaries, leading to an exaggerated response.","Close monitoring for signs of OHSS, adjust doses carefully.",1,2026-05-13
favipiravir,,,,,,1,2026-05-13
sultamicillin tosilate,rifampicin,Moderate,Reduced efficacy of sultamicillin.,Rifampicin induces hepatic enzymes that metabolize sultamicillin.,Consider alternative antibiotics or monitor for treatment failure.,1,2026-05-13
sultamicillin tosilate,isoniazid,Moderate,Increased risk of hepatotoxicity.,Both drugs can cause liver injury; combined use may potentiate this effect.,Monitor liver function tests closely.,1,2026-05-13
l-arginine,,,,,,1,2026-05-13
eberconazole,,,,,,1,2026-05-13
saccharomyces boulardii,fluconazole,Minor,Potentially reduced efficacy of S. boulardii.,Antifungal agents may theoretically inhibit the growth of S. boulardii.,Monitor for therapeutic response and consider spacing doses.,1,2026-05-13
saccharomyces boulardii,ketoconazole,Minor,Potentially reduced efficacy of S. boulardii.,Antifungal agents may theoretically inhibit the growth of S. boulardii.,Monitor for therapeutic response and consider spacing doses.,1,2026-05-13
saccharomyces boulardii,itraconazole,Minor,Potentially reduced efficacy of S. boulardii.,Antifungal agents may theoretically inhibit the growth of S. boulardii.,Monitor for therapeutic response and consider spacing doses.,1,2026-05-13
mycophenolate sodium,rifampicin,Major,Significantly reduced mycophenolate sodium levels and efficacy.,Rifampicin is a potent inducer of mycophenolate glucuronidation.,Avoid co-administration; monitor immunosuppression closely if unavoidable.,1,2026-05-13
mycophenolate sodium,ciclosporin,Moderate,Reduced efficacy of mycophenolate sodium.,Ciclosporin can inhibit the intestinal absorption of mycophenolate.,Monitor mycophenolate levels and clinical response.,1,2026-05-13
mycophenolate sodium,tacrolimus,Moderate,Reduced mycophenolate sodium levels and efficacy.,Tacrolimus can affect the enterohepatic circulation of mycophenolate.,Monitor mycophenolate levels and clinical response.,1,2026-05-13
etalol,amlodipine,Moderate,Increased risk of hypotension and bradycardia.,Both drugs can cause bradycardia and reduce blood pressure; additive effects.,Monitor heart rate and blood pressure closely.,1,2026-05-13
etalol,diltiazem,Major,"Risk of severe bradycardia, heart block, and heart failure.",Both are calcium channel blockers with additive negative chronotropic and inotropic effects.,Avoid co-administration; monitor ECG and cardiac function.,1,2026-05-13
etalol,verapamil,Major,"Risk of severe bradycardia, heart block, and heart failure.",Both are calcium channel blockers with additive negative chronotropic and inotropic effects.,Avoid co-administration; monitor ECG and cardiac function.,1,2026-05-13
etalol,digoxin,Moderate,Increased risk of bradycardia and AV block.,Beta-blockers can potentiate the effects of digoxin on AV nodal conduction.,Monitor heart rate and rhythm.,1,2026-05-13
etalol,furosemide,Minor,Increased risk of hypotension.,Additive hypotensive effects.,Monitor blood pressure.,1,2026-05-13
etalol,insulin,Minor,Masking of hypoglycemia symptoms.,Beta-blockers can mask the adrenergic symptoms of hypoglycemia.,Monitor blood glucose levels closely.,1,2026-05-13
etalol,metformin,Minor,Masking of hypoglycemia symptoms.,Beta-blockers can mask the adrenergic symptoms of hypoglycemia.,Monitor blood glucose levels closely.,1,2026-05-13
potassium chloride,spironolactone,Major,Risk of severe hyperkalemia.,Spironolactone is a potassium-sparing diuretic; concomitant use increases potassium levels.,Monitor serum potassium levels frequently.,1,2026-05-13
potassium chloride,ramipril,Major,Risk of severe hyperkalemia.,ACE inhibitors can increase serum potassium levels; concomitant use potentiates this effect.,Monitor serum potassium levels frequently.,1,2026-05-13
potassium chloride,losartan,Major,Risk of severe hyperkalemia.,ARBs can increase serum potassium levels; concomitant use potentiates this effect.,Monitor serum potassium levels frequently.,1,2026-05-13
potassium chloride,furosemide,Moderate,May counteract the potassium-losing effect of furosemide.,"Potassium chloride supplements lost potassium, while furosemide depletes it.",Monitor electrolytes closely to avoid imbalances.,1,2026-05-13
dehydroepiandrosterone,,,,,,1,2026-05-13
calcium citrate,atenolol,Moderate,Reduced absorption and efficacy of atenolol.,Calcium can interfere with the absorption of beta-blockers from the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,metoprolol,Moderate,Reduced absorption and efficacy of metoprolol.,Calcium can interfere with the absorption of beta-blockers from the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,amlodipine,Minor,Potential for reduced absorption of amlodipine.,Calcium can interfere with the absorption of calcium channel blockers.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,losartan,Minor,Potential for reduced absorption of losartan.,Calcium can interfere with the absorption of ARBs.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,warfarin,Minor,Potential for altered warfarin absorption.,Calcium may affect the absorption of oral anticoagulants.,Monitor INR closely.,1,2026-05-13
calcium citrate,metformin,Minor,Potential for reduced absorption of metformin.,Calcium can interfere with the absorption of metformin.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,omeprazole,Minor,Potential for reduced absorption of omeprazole.,Calcium can interfere with the absorption of proton pump inhibitors.,Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate,pantoprazole,Minor,Potential for reduced absorption of pantoprazole.,Calcium can interfere with the absorption of proton pump inhibitors.,Separate administration by at least 2 hours.,1,2026-05-13
insulin isophane,metformin,Minor,Increased risk of hypoglycemia.,Additive hypoglycemic effects.,Monitor blood glucose closely.,1,2026-05-13
insulin isophane,atenolol,Moderate,Masks signs of hypoglycemia.,Beta-blockers can mask tachycardia associated with hypoglycemia.,Educate patient to monitor glucose and recognize other symptoms of hypoglycemia.,1,2026-05-13
insulin isophane,metoprolol,Moderate,Masks signs of hypoglycemia.,Beta-blockers can mask tachycardia associated with hypoglycemia.,Educate patient to monitor glucose and recognize other symptoms of hypoglycemia.,1,2026-05-13
insulin isophane,prednisolone,Moderate,Hyperglycemia.,Corticosteroids antagonize insulin's action.,Increase insulin dose as needed and monitor blood glucose.,1,2026-05-13
insulin isophane,dexamethasone,Moderate,Hyperglycemia.,Corticosteroids antagonize insulin's action.,Increase insulin dose as needed and monitor blood glucose.,1,2026-05-13
insulin isophane,furosemide,Minor,Potential for hyperglycemia.,Diuretics can increase blood glucose levels.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,spironolactone,Minor,Potential for hyperglycemia.,Diuretics can increase blood glucose levels.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,ramipril,Minor,Increased risk of hypoglycemia.,ACE inhibitors can enhance insulin sensitivity.,Monitor blood glucose closely.,1,2026-05-13
insulin isophane,losartan,Minor,Increased risk of hypoglycemia.,ARBs can enhance insulin sensitivity.,Monitor blood glucose closely.,1,2026-05-13
insulin isophane,amlodipine,Minor,Potential for altered glucose control.,Calcium channel blockers may affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,tramadol,Moderate,Hypoglycemia or hyperglycemia.,Tramadol can affect glucose regulation.,Monitor blood glucose closely.,1,2026-05-13
insulin isophane,codeine,Minor,Potential for altered glucose control.,Opioids can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,morphine,Minor,Potential for altered glucose control.,Opioids can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,clopidogrel,Minor,Potential for altered glucose control.,Clopidogrel may affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
insulin isophane,aspirin,Minor,Increased risk of hypoglycemia at higher doses.,Salicylates can enhance insulin action.,"Monitor blood glucose closely, especially with high-dose aspirin.",1,2026-05-13
etofylline,ciprofloxacin,Moderate,Increased risk of central nervous system toxicity.,"Ciprofloxacin inhibits xanthine metabolism, increasing etofylline levels.",Avoid coadministration or monitor for CNS side effects.,1,2026-05-13
etofylline,atenolol,Minor,Increased risk of cardiac arrhythmias.,Additive stimulant effects on the heart.,Monitor heart rate and rhythm.,1,2026-05-13
etofylline,metoprolol,Minor,Increased risk of cardiac arrhythmias.,Additive stimulant effects on the heart.,Monitor heart rate and rhythm.,1,2026-05-13
etofylline,digoxin,Minor,Increased risk of arrhythmias.,Xanthines can potentiate digoxin toxicity.,Monitor digoxin levels and ECG.,1,2026-05-13
dabigatran etexilate,aspirin,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Avoid concurrent use; carefully consider risk-benefit.,1,2026-05-13
dabigatran etexilate,clopidogrel,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Avoid concurrent use; carefully consider risk-benefit.,1,2026-05-13
dabigatran etexilate,warfarin,Major,Increased risk of bleeding.,Additive anticoagulant effects.,Avoid concurrent use; carefully consider risk-benefit.,1,2026-05-13
dabigatran etexilate,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,NSAIDs inhibit platelet aggregation and can cause gastric irritation.,"Use with caution, monitor for GI bleeding.",1,2026-05-13
dabigatran etexilate,omeprazole,Minor,Reduced dabigatran absorption.,"Proton pump inhibitors can reduce gastric acidity, potentially affecting dabigatran absorption.",Monitor for efficacy.,1,2026-05-13
dabigatran etexilate,pantoprazole,Minor,Reduced dabigatran absorption.,"Proton pump inhibitors can reduce gastric acidity, potentially affecting dabigatran absorption.",Monitor for efficacy.,1,2026-05-13
dabigatran etexilate,metronidazole,Minor,Potential increased bleeding risk.,"Possible interaction, though clinical significance is debated.",Monitor for bleeding.,1,2026-05-13
dabigatran etexilate,amoxicillin,Minor,Potential increased bleeding risk.,Antibiotics may rarely affect coagulation.,Monitor for bleeding.,1,2026-05-13
dabigatran etexilate,azithromycin,Minor,Potential increased bleeding risk.,Antibiotics may rarely affect coagulation.,Monitor for bleeding.,1,2026-05-13
allylestrenol,,,,,,1,2026-05-13
boron,,,,,,1,2026-05-13
glycopyrrolate,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, cognitive impairment).",Additive anticholinergic properties.,Monitor for increased anticholinergic effects.,1,2026-05-13
glycopyrrolate,diazepam,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,lorazepam,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,alprazolam,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,clonazepam,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,zolpidem,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,midazolam,Minor,Increased risk of drowsiness and confusion.,Additive CNS depressant effects.,Monitor for sedation.,1,2026-05-13
glycopyrrolate,tramadol,Minor,Increased anticholinergic effects and sedation.,Additive anticholinergic and CNS depressant effects.,Monitor for anticholinergic side effects and sedation.,1,2026-05-13
glycopyrrolate,codeine,Minor,Increased anticholinergic effects and sedation.,Additive anticholinergic and CNS depressant effects.,Monitor for anticholinergic side effects and sedation.,1,2026-05-13
glycopyrrolate,morphine,Minor,Increased anticholinergic effects and sedation.,Additive anticholinergic and CNS depressant effects.,Monitor for anticholinergic side effects and sedation.,1,2026-05-13
magnesium trisilicate,ciprofloxacin,Moderate,"Decreased absorption of ciprofloxacin, leading to reduced efficacy.","Magnesium ions chelate with fluoroquinolones, reducing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
magnesium trisilicate,tetracyclines,Moderate,"Decreased absorption of tetracyclines, leading to reduced efficacy.","Magnesium ions chelate with tetracyclines, reducing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
magnesium trisilicate,digoxin,Minor,Decreased absorption of digoxin.,Magnesium ions can reduce digoxin absorption.,Monitor digoxin levels and efficacy.,1,2026-05-13
magnesium trisilicate,atorvastatin,Minor,Decreased absorption of atorvastatin.,Magnesium ions can reduce statin absorption.,Separate administration.,1,2026-05-13
magnesium trisilicate,rosuvastatin,Minor,Decreased absorption of rosuvastatin.,Magnesium ions can reduce statin absorption.,Separate administration.,1,2026-05-13
dextrose,insulin,Major,Risk of rebound hyperglycemia after insulin administration.,"Dextrose increases blood glucose, which is counteracted by insulin.",Careful monitoring of blood glucose is required.,1,2026-05-13
dextrose,insulin isophane,Major,Risk of rebound hyperglycemia after insulin administration.,"Dextrose increases blood glucose, which is counteracted by insulin.",Careful monitoring of blood glucose is required.,1,2026-05-13
dextrose,metformin,Minor,Potential for altered glucose control.,"Dextrose increases blood glucose, which may affect metformin's efficacy.",Monitor blood glucose levels.,1,2026-05-13
dextrose,furosemide,Minor,Potential for altered glucose control.,"Dextrose increases blood glucose, which may affect diuretic-induced glucose changes.",Monitor blood glucose levels.,1,2026-05-13
dextrose,spironolactone,Minor,Potential for altered glucose control.,"Dextrose increases blood glucose, which may affect diuretic-induced glucose changes.",Monitor blood glucose levels.,1,2026-05-13
dextrose,atenolol,Minor,Potential for altered glucose control.,"Dextrose increases blood glucose, which may affect beta-blocker effects on glucose.",Monitor blood glucose levels.,1,2026-05-13
dextrose,metoprolol,Minor,Potential for altered glucose control.,"Dextrose increases blood glucose, which may affect beta-blocker effects on glucose.",Monitor blood glucose levels.,1,2026-05-13
dextrose,prednisolone,Minor,Exaggerated hyperglycemia.,Additive hyperglycemic effect.,Monitor blood glucose closely.,1,2026-05-13
dextrose,dexamethasone,Minor,Exaggerated hyperglycemia.,Additive hyperglycemic effect.,Monitor blood glucose closely.,1,2026-05-13
potassium citrate,ramipril,Major,Hyperkalemia.,ACE inhibitors reduce potassium excretion; coadministration increases risk.,Monitor serum potassium levels closely.,1,2026-05-13
potassium citrate,losartan,Major,Hyperkalemia.,ARBs reduce potassium excretion; coadministration increases risk.,Monitor serum potassium levels closely.,1,2026-05-13
potassium citrate,spironolactone,Major,Hyperkalemia.,Potassium-sparing diuretic; coadministration significantly increases risk.,Avoid coadministration; monitor serum potassium levels.,1,2026-05-13
potassium citrate,atenolol,Moderate,Hyperkalemia.,"Beta-blockers can decrease potassium entry into cells, increasing serum potassium.",Monitor serum potassium levels.,1,2026-05-13
potassium citrate,metoprolol,Moderate,Hyperkalemia.,"Beta-blockers can decrease potassium entry into cells, increasing serum potassium.",Monitor serum potassium levels.,1,2026-05-13
potassium citrate,digoxin,Minor,Decreased efficacy of digoxin.,Potassium competes with digoxin for binding sites.,Monitor digoxin levels and cardiac rhythm.,1,2026-05-13
potassium citrate,lidocaine,Minor,Decreased efficacy of lidocaine.,Potassium can reduce the efficacy of antiarrhythmics.,Monitor efficacy.,1,2026-05-13
potassium clavulanate,,,,,,1,2026-05-13
bacillus clausii,,,,,,1,2026-05-13
furazolidone,tramadol,Major,"Serotonin syndrome, potentially life-threatening.","Furazolidone inhibits MAO, increasing serotonin levels which are further elevated by tramadol's weak opioid and serotonergic effects.",Avoid concomitant use; monitor for signs of serotonin syndrome if unavoidable.,1,2026-05-13
furazolidone,sertraline,Major,"Serotonin syndrome, potentially life-threatening.","Furazolidone inhibits MAO, increasing serotonin levels which are further elevated by SSRIs like sertraline.",Avoid concomitant use; monitor for signs of serotonin syndrome if unavoidable.,1,2026-05-13
furazolidone,fluoxetine,Major,"Serotonin syndrome, potentially life-threatening.","Furazolidone inhibits MAO, increasing serotonin levels which are further elevated by SSRIs like fluoxetine.",Avoid concomitant use; monitor for signs of serotonin syndrome if unavoidable.,1,2026-05-13
furazolidone,amitriptyline,Major,"Serotonin syndrome, potentially life-threatening.","Furazolidone inhibits MAO, increasing serotonin levels which are further elevated by TCAs like amitriptyline.",Avoid concomitant use; monitor for signs of serotonin syndrome if unavoidable.,1,2026-05-13
furazolidone,warfarin,Moderate,"Increased anticoagulant effect, risk of bleeding.","Furazolidone may inhibit warfarin metabolism, leading to higher plasma concentrations.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
furazolidone,metformin,Moderate,"Hypoglycemia, especially in patients with renal impairment.",Furazolidone can impair renal function and may interfere with metformin excretion.,Monitor blood glucose closely and assess renal function.,1,2026-05-13
ispaghula,warfarin,Minor,Reduced absorption of warfarin.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after warfarin.,1,2026-05-13
ispaghula,metformin,Minor,Reduced absorption of metformin.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after metformin.,1,2026-05-13
ispaghula,atorvastatin,Minor,Reduced absorption of atorvastatin.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after atorvastatin.,1,2026-05-13
ispaghula,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after rosuvastatin.,1,2026-05-13
ispaghula,amlodipine,Minor,Reduced absorption of amlodipine.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after amlodipine.,1,2026-05-13
ispaghula,losartan,Minor,Reduced absorption of losartan.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after losartan.,1,2026-05-13
ispaghula,digoxin,Minor,Reduced absorption of digoxin.,Ispaghula is a bulk-forming laxative that can delay or reduce the absorption of other oral medications.,Administer ispaghula at least 1 hour before or 2-3 hours after digoxin.,1,2026-05-13
trioxasalen,atorvastatin,Minor,Increased risk of myopathy.,"Trioxasalen can inhibit CYP3A4, a major enzyme for atorvastatin metabolism.",Monitor for muscle pain and weakness; consider alternative statin if symptoms occur.,1,2026-05-13
trioxasalen,rosuvastatin,Minor,Increased risk of myopathy.,"While not a significant CYP3A4 substrate, other metabolic pathways might be affected, potentially increasing rosuvastatin exposure.",Monitor for muscle pain and weakness; consider alternative statin if symptoms occur.,1,2026-05-13
trioxasalen,amlodipine,Minor,Increased risk of peripheral edema.,"Trioxasalen can affect calcium channel activity, potentially additive with amlodipine.",Monitor for increased edema; consider dose adjustment.,1,2026-05-13
trioxasalen,cyclosporine,Moderate,Increased cyclosporine levels and potential toxicity.,"Trioxasalen can inhibit P-glycoprotein, affecting cyclosporine absorption and excretion.",Monitor cyclosporine levels closely; reduce cyclosporine dose if necessary.,1,2026-05-13
trioxasalen,tacrolimus,Moderate,Increased tacrolimus levels and potential toxicity.,"Trioxasalen can inhibit P-glycoprotein, affecting tacrolimus absorption and excretion.",Monitor tacrolimus levels closely; reduce tacrolimus dose if necessary.,1,2026-05-13
ademetionine,levodopa,Major,Reduced efficacy of levodopa.,Ademetionine is a precursor to dopamine and may compete with levodopa for transport or receptor binding.,Avoid concomitant use in Parkinson's disease patients; monitor for worsening of motor symptoms.,1,2026-05-13
ademetionine,methotrexate,Moderate,Potential for increased hepatic toxicity.,Both drugs can affect liver function; ademetionine can influence folate metabolism.,Monitor liver function tests; use with caution and close monitoring.,1,2026-05-13
ademetionine,clomipramine,Moderate,"Potential for increased risk of adverse effects, particularly psychiatric.","Ademetionine can increase neurotransmitter levels, potentially potentiating the effects of antidepressants.",Use with caution and monitor for adverse effects.,1,2026-05-13
biotin,valproate,Minor,Reduced efficacy of valproate.,Biotin can be depleted by valproate; concurrent administration may reduce valproate's effectiveness by competing for absorption or metabolism.,Monitor seizure control; consider biotin supplementation if valproate levels are suboptimal or seizures worsen.,1,2026-05-13
sentosa geigy,,,,,,1,2026-05-13
ilaprazole,clopidogrel,Major,"Reduced antiplatelet effect, increased risk of thrombotic events.","Ilaprazole is a proton pump inhibitor that can inhibit CYP2C19, the enzyme responsible for activating clopidogrel.",Avoid concomitant use; consider alternative PPIs with less CYP2C19 inhibition or an alternative antiplatelet agent.,1,2026-05-13
ilaprazole,warfarin,Minor,Altered anticoagulant effect.,"PPIs can sometimes affect warfarin metabolism, although this interaction is less consistent.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
ilaprazole,metformin,Minor,Increased metformin levels.,"PPIs can inhibit renal transporters, potentially increasing metformin serum concentrations.",Monitor blood glucose closely; consider dose adjustment of metformin if needed.,1,2026-05-13
ilaprazole,diazepam,Minor,Increased diazepam levels.,"Ilaprazole can inhibit CYP3A4, a major enzyme for diazepam metabolism.",Monitor for increased sedation and CNS effects; consider dose reduction of diazepam.,1,2026-05-13
ilaprazole,alprazolam,Minor,Increased alprazolam levels.,"Ilaprazole can inhibit CYP3A4, a major enzyme for alprazolam metabolism.",Monitor for increased sedation and CNS effects; consider dose reduction of alprazolam.,1,2026-05-13
ilaprazole,midazolam,Minor,Increased midazolam levels.,"Ilaprazole can inhibit CYP3A4, a major enzyme for midazolam metabolism.",Monitor for increased sedation and CNS effects; consider dose reduction of midazolam.,1,2026-05-13
megestrol,warfarin,Major,"Reduced anticoagulant effect, potential for thrombotic events.",Megestrol has anti-estrogenic effects that can interfere with the anticoagulant action of warfarin.,Monitor INR closely; may require dose increase of warfarin. Avoid if possible.,1,2026-05-13
megestrol,insulin,Moderate,"Hyperglycemia, loss of glycemic control.",Megestrol can cause insulin resistance and increase blood glucose levels.,Monitor blood glucose closely; adjust insulin dose as needed.,1,2026-05-13
megestrol,metformin,Moderate,"Hyperglycemia, loss of glycemic control.",Megestrol can cause insulin resistance and increase blood glucose levels.,Monitor blood glucose closely; adjust metformin dose as needed.,1,2026-05-13
megestrol,prednisolone,Minor,Additive adrenal suppression.,Both megestrol and corticosteroids can suppress the hypothalamic-pituitary-adrenal axis.,Monitor for signs of adrenal insufficiency; consider corticosteroid tapering if symptoms occur.,1,2026-05-13
megestrol,dexamethasone,Minor,Additive adrenal suppression.,Both megestrol and corticosteroids can suppress the hypothalamic-pituitary-adrenal axis.,Monitor for signs of adrenal insufficiency; consider corticosteroid tapering if symptoms occur.,1,2026-05-13
nadifloxacin,warfarin,Moderate,"Increased anticoagulant effect, risk of bleeding.","Fluoroquinolones, including nadifloxacin, can potentiate the effects of warfarin.",Monitor INR closely and adjust warfarin dose if necessary. Use with caution.,1,2026-05-13
nadifloxacin,theophylline,Moderate,"Increased theophylline levels, risk of toxicity.",Fluoroquinolones can inhibit the metabolism of theophylline.,Monitor theophylline levels and for signs of toxicity; adjust theophylline dose if necessary.,1,2026-05-13
nadifloxacin,caffeine,Minor,"Increased caffeine levels, risk of adverse effects.",Fluoroquinolones can inhibit the metabolism of caffeine.,Advise patients to limit caffeine intake and monitor for adverse effects like nervousness and insomnia.,1,2026-05-13
chlorocresol,,,,,,1,2026-05-13
eperisone,diazepam,Moderate,Increased sedation and muscle relaxation.,"Eperisone and benzodiazepines both enhance GABAergic neurotransmission, leading to additive CNS depression.",Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
eperisone,lorazepam,Moderate,Increased sedation and muscle relaxation.,"Eperisone and benzodiazepines both enhance GABAergic neurotransmission, leading to additive CNS depression.",Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
eperisone,alprazolam,Moderate,Increased sedation and muscle relaxation.,"Eperisone and benzodiazepines both enhance GABAergic neurotransmission, leading to additive CNS depression.",Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
eperisone,clonazepam,Moderate,Increased sedation and muscle relaxation.,"Eperisone and benzodiazepines both enhance GABAergic neurotransmission, leading to additive CNS depression.",Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
eperisone,midazolam,Moderate,Increased sedation and muscle relaxation.,"Eperisone and benzodiazepines both enhance GABAergic neurotransmission, leading to additive CNS depression.",Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
eperisone,zolpidem,Moderate,Increased sedation and muscle relaxation.,Eperisone and hypnotics can have additive CNS depressant effects.,Monitor for excessive sedation and inform patient about increased risk.,1,2026-05-13
calcium citrate malate,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Calcium can chelate with certain drugs, reducing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate malate,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Calcium can chelate with certain drugs, reducing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium citrate malate,tetracyclines,Major,Significantly reduced absorption and efficacy of tetracyclines.,"Calcium forms insoluble complexes with tetracyclines, inhibiting their absorption.",Avoid co-administration; separate by at least 2-4 hours.,1,2026-05-13
calcium citrate malate,fluoroquinolones,Major,Significantly reduced absorption and efficacy of fluoroquinolones.,"Calcium forms insoluble complexes with fluoroquinolones, inhibiting their absorption.",Avoid co-administration; separate by at least 2-4 hours.,1,2026-05-13
terlipressin,amlodipine,Moderate,Increased risk of bradycardia and hypotension.,Terlipressin is a vasopressin analog and can cause vasoconstriction and reduced heart rate; calcium channel blockers can also affect heart rate and blood pressure.,Monitor heart rate and blood pressure closely.,1,2026-05-13
terlipressin,atenolol,Moderate,Increased risk of bradycardia and hypotension.,Terlipressin is a vasopressin analog and can cause vasoconstriction and reduced heart rate; beta-blockers can also reduce heart rate.,Monitor heart rate and blood pressure closely.,1,2026-05-13
terlipressin,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,Terlipressin is a vasopressin analog and can cause vasoconstriction and reduced heart rate; beta-blockers can also reduce heart rate.,Monitor heart rate and blood pressure closely.,1,2026-05-13
terlipressin,losartan,Moderate,Potentially increased risk of hypotension.,"Terlipressin can cause vasoconstriction, while losartan is an angiotensin II receptor blocker that can cause vasodilation.",Monitor blood pressure.,1,2026-05-13
terlipressin,ramipril,Moderate,Potentially increased risk of hypotension.,"Terlipressin can cause vasoconstriction, while ramipril is an ACE inhibitor that can cause vasodilation.",Monitor blood pressure.,1,2026-05-13
tenofovir disoproxil fumarate,ibuprofen,Moderate,Increased risk of renal toxicity.,"Both tenofovir and NSAIDs can impair renal function, and their concurrent use may potentiate this effect.",Monitor renal function closely; consider alternative analgesics.,1,2026-05-13
tenofovir disoproxil fumarate,furosemide,Moderate,Increased risk of renal toxicity and hypokalemia.,"Tenofovir can cause renal tubular dysfunction, and furosemide is a potent diuretic that can also affect renal function and electrolyte balance.",Monitor renal function and electrolytes closely.,1,2026-05-13
tenofovir disoproxil fumarate,didanosine,Major,"Increased risk of pancreatitis, peripheral neuropathy, and hypertriglyceridemia.","Tenofovir can increase didanosine concentrations, leading to increased toxicity.",Avoid co-administration if possible; monitor for signs of toxicity.,1,2026-05-13
moxonidine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Both moxonidine and beta-blockers can lower blood pressure and heart rate.,Monitor blood pressure and heart rate closely.,1,2026-05-13
moxonidine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Both moxonidine and beta-blockers can lower blood pressure and heart rate.,Monitor blood pressure and heart rate closely.,1,2026-05-13
moxonidine,amlodipine,Moderate,Increased risk of hypotension.,Both moxonidine and calcium channel blockers can lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
moxonidine,losartan,Moderate,Increased risk of hypotension.,Both moxonidine and ARBs can lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
moxonidine,ramipril,Moderate,Increased risk of hypotension.,Both moxonidine and ACE inhibitors can lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
moxonidine,alcohol,Moderate,Enhanced sedative effects and dizziness.,Alcohol can potentiate the central nervous system depressant effects of moxonidine.,Avoid alcohol consumption.,1,2026-05-13
dexchlorpheniramine,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention) and sedation.","Both are anticholinergic agents, leading to additive effects.",Monitor for anticholinergic side effects and increased sedation.,1,2026-05-13
dexchlorpheniramine,sertraline,Minor,Potential for increased sedation.,"Some antihistamines can have mild CNS depressant effects, which may be additive with SSRIs.",Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,fluoxetine,Minor,Potential for increased sedation.,"Some antihistamines can have mild CNS depressant effects, which may be additive with SSRIs.",Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,tramadol,Moderate,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness.,1,2026-05-13
dexchlorpheniramine,codeine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
dexchlorpheniramine,morphine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
dexchlorpheniramine,diazepam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,lorazepam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,alprazolam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,clonazepam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,midazolam,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
dexchlorpheniramine,zolpidem,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for increased sedation.,1,2026-05-13
oxychloro complex,,,,,,1,2026-05-13
mosapride,ketoconazole,Moderate,Increased risk of QT prolongation and arrhythmias.,"Ketoconazole is a strong CYP3A4 inhibitor, which can increase mosapride plasma concentrations.",Avoid co-administration; monitor for QT prolongation.,1,2026-05-13
mosapride,erythromycin,Moderate,Increased risk of QT prolongation and arrhythmias.,"Erythromycin is a CYP3A4 inhibitor, which can increase mosapride plasma concentrations.",Avoid co-administration; monitor for QT prolongation.,1,2026-05-13
mosapride,clarithromycin,Moderate,Increased risk of QT prolongation and arrhythmias.,"Clarithromycin is a CYP3A4 inhibitor, which can increase mosapride plasma concentrations.",Avoid co-administration; monitor for QT prolongation.,1,2026-05-13
mosapride,itraconazole,Moderate,Increased risk of QT prolongation and arrhythmias.,"Itraconazole is a CYP3A4 inhibitor, which can increase mosapride plasma concentrations.",Avoid co-administration; monitor for QT prolongation.,1,2026-05-13
sodium alginate,warfarin,Minor,"May affect absorption of warfarin, potentially altering INR.",Alginates can form a gel that may affect the absorption of other orally administered medications.,"Monitor INR closely, especially when initiating or discontinuing sodium alginate.",1,2026-05-13
sodium alginate,lithium,Moderate,Reduced absorption of lithium.,Sodium alginate can form a viscous gel that may impede the absorption of lithium.,Separate administration by at least 2 hours and monitor lithium levels.,1,2026-05-13
s-adenosyl l-methoinine disulfate tosylate,,,,,,1,2026-05-13
selenium dioxide,,,,,,1,2026-05-13
omycin,,,,,,1,2026-05-13
eicosapentaenoic acid,warfarin,Moderate,Increased risk of bleeding.,"EPA may have antiplatelet effects, additive to warfarin's anticoagulant effect.",Monitor INR closely; consider dose adjustment of warfarin.,1,2026-05-13
eicosapentaenoic acid,clopidogrel,Moderate,Increased risk of bleeding.,"EPA may have antiplatelet effects, additive to clopidogrel's antiplatelet effect.",Monitor for signs of bleeding; consider if combination is necessary.,1,2026-05-13
inositol,,,,,,1,2026-05-13
albumin,,,,,,1,2026-05-13
recombinant follicle stimulating hormone,,,,,,1,2026-05-13
diloxanide,,,,,,1,2026-05-13
acotiamide,,,,,,1,2026-05-13
diethylcarbamazine,,,,,,1,2026-05-13
rebanta health care,,,,,,1,2026-05-13
potassium nitrate,furosemide,Moderate,"Hyperkalemia, dehydration","Furosemide can increase potassium excretion, but simultaneous intake of potassium nitrate can offset this effect or lead to dangerously high potassium levels.",Monitor serum potassium levels closely; consider alternative diuretics if hyperkalemia develops.,1,2026-05-13
potassium nitrate,spironolactone,Major,Severe hyperkalemia,"Both drugs increase serum potassium. Spironolactone is a potassium-sparing diuretic, and concurrent use with potassium supplements like potassium nitrate can lead to life-threatening hyperkalemia.","Avoid concurrent use; monitor serum potassium very closely if absolutely necessary, with frequent dose adjustments.",1,2026-05-13
potassium nitrate,ramipril,Major,Severe hyperkalemia,ACE inhibitors like ramipril can increase serum potassium. Concomitant use with potassium-rich substances or supplements like potassium nitrate significantly increases the risk of hyperkalemia.,"Avoid concurrent use; monitor serum potassium very closely if absolutely necessary, with frequent dose adjustments.",1,2026-05-13
potassium nitrate,losartan,Major,Severe hyperkalemia,Angiotensin II receptor blockers (ARBs) like losartan can increase serum potassium. Concomitant use with potassium-rich substances or supplements like potassium nitrate significantly increases the risk of hyperkalemia.,"Avoid concurrent use; monitor serum potassium very closely if absolutely necessary, with frequent dose adjustments.",1,2026-05-13
sodium monofluorophosphate,,,,,,1,2026-05-13
healthtree pharma,,,,,,1,2026-05-13
benzydamine,,,,,,1,2026-05-13
magnesium citrate,"tetracyclines (not on common list, but relevant for general knowledge)",Moderate,Decreased absorption of tetracyclines,"Magnesium ions can chelate with tetracycline antibiotics, reducing their absorption and efficacy.",Separate administration of magnesium citrate and tetracyclines by at least 2 hours.,1,2026-05-13
magnesium citrate,"quinolones (e.g., ciprofloxacin)",Moderate,Decreased absorption of ciprofloxacin,"Magnesium ions can chelate with fluoroquinolone antibiotics like ciprofloxacin, reducing their absorption and efficacy.",Separate administration of magnesium citrate and ciprofloxacin by at least 2 hours.,1,2026-05-13
magnesium citrate,"bisphosphonates (not on common list, but relevant for general knowledge)",Moderate,Decreased absorption of bisphosphonates,"Magnesium can form complexes with bisphosphonates, reducing their oral absorption.",Separate administration of magnesium citrate and bisphosphonates by at least 2 hours.,1,2026-05-13
getwell pharma,,,,,,1,2026-05-13
levodropropizine,,,,,,1,2026-05-13
dexrabeprazole,"ketoconazole (not on common list, but relevant for general knowledge)",Moderate,Reduced efficacy of ketoconazole,"Proton pump inhibitors (PPIs) like dexrabeprazole decrease gastric acidity, which is required for the absorption of ketoconazole.",Administer ketoconazole at least 2 hours before or after dexrabeprazole.,1,2026-05-13
dexrabeprazole,"itraconazole (not on common list, but relevant for general knowledge)",Moderate,Reduced efficacy of itraconazole,"Proton pump inhibitors (PPIs) like dexrabeprazole decrease gastric acidity, which is required for the absorption of itraconazole.",Administer itraconazole at least 2 hours before or after dexrabeprazole.,1,2026-05-13
dexrabeprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel,"PPIs can inhibit the CYP2C19 enzyme, which is involved in the activation of clopidogrel.","Consider using a PPI that has less interaction with CYP2C19 or monitor for signs of reduced clopidogrel efficacy (e.g., cardiovascular events).",1,2026-05-13
dexrabeprazole,metformin,Minor,Slightly increased metformin levels,PPIs may affect the absorption or excretion of metformin.,Monitor blood glucose levels.,1,2026-05-13
l-carnitine l-tartrate,warfarin,Moderate,"Increased INR, risk of bleeding","L-carnitine can interfere with vitamin K metabolism, potentially enhancing the anticoagulant effect of warfarin.",Monitor INR closely when initiating or discontinuing l-carnitine; adjust warfarin dose as needed.,1,2026-05-13
chondroitin,,,,,,1,2026-05-13
colistin sulphate,furosemide,Major,Increased risk of nephrotoxicity and ototoxicity.,"Both drugs can cause kidney damage, leading to synergistic toxicity.",Monitor renal function closely; use with caution and consider alternative diuretics if possible.,1,2026-05-13
colistin sulphate,cyclosporine,Moderate,Increased risk of nephrotoxicity.,"Both drugs have the potential to cause renal impairment, which can be additive.",Monitor renal function closely; consider dose adjustments or alternative agents.,1,2026-05-13
amino acids,,,,,,1,2026-05-13
calcium chloride,digoxin,Major,Increased risk of digoxin toxicity (arrhythmias).,Hypercalcemia potentiates digoxin's effect on cardiac contractility and conduction.,Avoid co-administration if possible; monitor digoxin levels and ECG closely if co-administration is necessary.,1,2026-05-13
calcium chloride,"tetracyclines (e.g., amoxicillin, not explicitly in list but representative)",Moderate,Decreased absorption of tetracyclines.,"Calcium ions chelate with tetracyclines, reducing their bioavailability.",Separate administration by at least 2-3 hours; avoid co-administration.,1,2026-05-13
calcium chloride,bisphosphonates (not explicitly in list but common for osteoporosis),Moderate,Decreased absorption of bisphosphonates.,Calcium can form insoluble complexes with bisphosphonates in the GI tract.,Separate administration by at least 2-3 hours; avoid co-administration.,1,2026-05-13
azelnidipine,atenolol,Moderate,Increased risk of bradycardia and hypotension.,Both drugs are antihypertensives and can have additive effects on heart rate and blood pressure.,Monitor heart rate and blood pressure closely.,1,2026-05-13
azelnidipine,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,Both drugs are antihypertensives and can have additive effects on heart rate and blood pressure.,Monitor heart rate and blood pressure closely.,1,2026-05-13
azelnidipine,amlodipine,Minor,Increased risk of peripheral edema.,Additive peripheral vasodilatory effects.,Monitor for edema; consider dose adjustment if significant.,1,2026-05-13
sulphadoxine,methotrexate,Major,"Increased risk of methotrexate toxicity (myelosuppression, mucositis).",Sulfonamides can displace methotrexate from protein binding sites and inhibit its renal excretion.,Avoid co-administration; monitor methotrexate levels and blood counts.,1,2026-05-13
sulphadoxine,warfarin,Major,"Increased anticoagulant effect, leading to bleeding risk.","Sulfonamides can displace warfarin from plasma protein binding sites, increasing its free concentration.",Monitor INR closely and adjust warfarin dose as needed; avoid co-administration if possible.,1,2026-05-13
sulphadoxine,phenytoin,Moderate,Increased phenytoin levels and risk of toxicity.,Sulfonamides can displace phenytoin from protein binding sites.,Monitor phenytoin levels and signs of toxicity; consider alternative antibiotics.,1,2026-05-13
cerebroprotein hydrolysate,,,,,,1,2026-05-13
thiamine mononitrate,,,,,,1,2026-05-13
orphic pharma,,,,,,1,2026-05-13
perindopril erbumine,"potassium supplements (not explicitly in list, but common with ace inhibitors)",Major,Risk of hyperkalemia.,"ACE inhibitors reduce aldosterone secretion, leading to potassium retention.",Monitor serum potassium levels; avoid concomitant use unless closely monitored.,1,2026-05-13
perindopril erbumine,spironolactone,Major,Increased risk of hyperkalemia.,"Both drugs increase potassium levels; one is an ACE inhibitor, the other a potassium-sparing diuretic.",Monitor serum potassium levels very closely; avoid concomitant use unless in specialized cases with strict monitoring.,1,2026-05-13
perindopril erbumine,lithium,Major,Increased lithium levels and risk of toxicity.,ACE inhibitors can reduce lithium clearance.,Monitor lithium levels closely and adjust dose as needed; avoid concomitant use if possible.,1,2026-05-13
perindopril erbumine,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow regulation, and blunt the effects of ACE inhibitors.",Monitor blood pressure and renal function; use NSAIDs cautiously and for short durations.,1,2026-05-13
perindopril erbumine,aspirin,Moderate,Reduced antihypertensive effect and increased risk of renal impairment (especially at higher doses).,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow regulation, and blunt the effects of ACE inhibitors.",Monitor blood pressure and renal function; use aspirin cautiously and for short durations.,1,2026-05-13
perindopril erbumine,allopurinol,Moderate,"Increased risk of hypersensitivity reactions (e.g., Stevens-Johnson syndrome).",ACE inhibitors may increase the risk of hypersensitivity to allopurinol.,Monitor for signs of hypersensitivity; use with caution.,1,2026-05-13
ibandronic acid,,,,,,1,2026-05-13
hyoscine butylbromide,amitriptyline,Moderate,Increased anticholinergic effects.,Additive anticholinergic activity.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,lorazepam,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,diazepam,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,alprazolam,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,clonazepam,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,zolpidem,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
hyoscine butylbromide,midazolam,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic activity and CNS depression.,Monitor for increased side effects; consider dose adjustment.,1,2026-05-13
bifidobacterium longum,,,,,,1,2026-05-13
ferrous bisglycinate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,Chelation of iron with fluoroquinolones.,Separate administration by at least 2 hours.,1,2026-05-13
ferrous bisglycinate,levofloxacin,Major,Reduced absorption of levofloxacin.,Chelation of iron with fluoroquinolones.,Separate administration by at least 2 hours.,1,2026-05-13
ferrous bisglycinate,tetracycline,Major,Reduced absorption of tetracyclines.,Chelation of iron with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
ferrous bisglycinate,doxycycline,Major,Reduced absorption of doxycycline.,Chelation of iron with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
ferrous bisglycinate,thyroxine,Major,Reduced absorption of levothyroxine.,Iron can impair thyroid hormone absorption.,Separate administration by at least 4 hours.,1,2026-05-13
cinitapride,tramadol,Moderate,Increased risk of extrapyramidal symptoms.,Dopaminergic effects of both drugs.,Monitor for signs of extrapyramidal symptoms.,1,2026-05-13
cinitapride,codeine,Moderate,Increased risk of extrapyramidal symptoms.,"Dopaminergic effects of cinitapride, opioid can affect GI motility.",Monitor for signs of extrapyramidal symptoms.,1,2026-05-13
cinitapride,morphine,Moderate,Increased risk of extrapyramidal symptoms.,"Dopaminergic effects of cinitapride, opioid can affect GI motility.",Monitor for signs of extrapyramidal symptoms.,1,2026-05-13
cinitapride,amitriptyline,Minor,Potentially increased anticholinergic effects.,Additive anticholinergic activity.,Monitor for increased anticholinergic effects.,1,2026-05-13
sodium fluoride,,,,,,1,2026-05-13
cyproterone,rifampicin,Moderate,Reduced effectiveness of cyproterone.,Induction of hepatic enzymes by rifampicin.,Monitor for signs of reduced efficacy; consider dose adjustment.,1,2026-05-13
cyproterone,phenytoin,Moderate,Reduced effectiveness of cyproterone.,Induction of hepatic enzymes by phenytoin.,Monitor for signs of reduced efficacy; consider dose adjustment.,1,2026-05-13
cyproterone,carbamazepine,Moderate,Reduced effectiveness of cyproterone.,Induction of hepatic enzymes by carbamazepine.,Monitor for signs of reduced efficacy; consider dose adjustment.,1,2026-05-13
cyproterone,valproate,Minor,Potential for increased risk of liver enzyme abnormalities.,Both drugs can affect liver enzymes.,Monitor liver function tests.,1,2026-05-13
boric acid,,,,,,1,2026-05-13
cefpirome,,,,,,1,2026-05-13
zinc chloride,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,Chelation of zinc with fluoroquinolones.,Separate administration by at least 2 hours.,1,2026-05-13
zinc chloride,levofloxacin,Major,Reduced absorption of levofloxacin.,Chelation of zinc with fluoroquinolones.,Separate administration by at least 2 hours.,1,2026-05-13
zinc chloride,tetracycline,Major,Reduced absorption of tetracyclines.,Chelation of zinc with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
zinc chloride,doxycycline,Major,Reduced absorption of doxycycline.,Chelation of zinc with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
fenticonazole,,,,,,1,2026-05-13
zinc bisglycinate,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Zinc can chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 2 hours.,1,2026-05-13
zinc bisglycinate,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Zinc can chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 2 hours.,1,2026-05-13
zinc bisglycinate,ofloxacin,Moderate,Reduced absorption of ofloxacin.,"Zinc can chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 2 hours.,1,2026-05-13
fructo oligosaccharide,,,,,,1,2026-05-13
flucloxacillin sodium,,,,,,1,2026-05-13
triclosan,,,,,,1,2026-05-13
streptococcus thermophilus,,,,,,1,2026-05-13
oxaceprol,,,,,,1,2026-05-13
d-chiro inositol,,,,,,1,2026-05-13
edaravone,,,,,,1,2026-05-13
allantoin,,,,,,1,2026-05-13
organon,,,,,,1,2026-05-13
human normal immunoglobulin,measles vaccine,Major,Reduced efficacy of the vaccine.,Antibodies in immunoglobulin neutralize the live attenuated virus in the vaccine.,Delay vaccination if possible; consult product labeling for specific timing.,1,2026-05-13
elemental iron,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,Iron forms insoluble complexes with ciprofloxacin in the gastrointestinal tract.,Separate administration by at least 2 hours; take ciprofloxacin before iron if possible.,1,2026-05-13
elemental iron,levofloxacin,Major,Reduced absorption of levofloxacin.,Iron forms insoluble complexes with levofloxacin in the gastrointestinal tract.,Separate administration by at least 2 hours; take levofloxacin before iron if possible.,1,2026-05-13
elemental iron,minocycline,Major,Reduced absorption of minocycline.,Iron forms insoluble complexes with minocycline in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
elemental iron,tetracycline,Major,Reduced absorption of tetracycline.,Iron forms insoluble complexes with tetracycline in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
elemental iron,thyroid hormone,Major,Reduced absorption of thyroid hormone.,"Iron can bind to thyroid hormones in the gastrointestinal tract, decreasing their absorption.",Separate administration by at least 4 hours.,1,2026-05-13
magnesium sulphate,tetracycline,Major,Reduced absorption of tetracycline.,"Magnesium ions can chelate with tetracycline, decreasing its oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
magnesium sulphate,bisphosphonates,Major,Reduced absorption of bisphosphonates.,"Magnesium forms insoluble complexes with bisphosphonates, reducing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
magnesium sulphate,digoxin,Moderate,Reduced absorption of digoxin.,Magnesium may reduce the absorption of digoxin.,Separate administration.,1,2026-05-13
sulphacetamide,,,,,,1,2026-05-13
pepsin,,,,,,1,2026-05-13
calcium leucovorin,trimethoprim-sulfamethoxazole,Major,Increased risk of trimethoprim-sulfamethoxazole toxicity.,"Leucovorin can counteract the antifolate effects of trimethoprim-sulfamethoxazole, potentially leading to resistance and increased toxicity.",Avoid concurrent use unless specifically indicated for rescue therapy.,1,2026-05-13
calcium leucovorin,phenytoin,Moderate,Decreased serum concentrations of phenytoin.,Leucovorin may increase the metabolism or decrease the absorption of phenytoin.,Monitor phenytoin levels and adjust dose if necessary.,1,2026-05-13
zinc gluconate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Zinc forms insoluble complexes with ciprofloxacin, decreasing its bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc gluconate,levofloxacin,Major,Reduced absorption of levofloxacin.,"Zinc forms insoluble complexes with levofloxacin, decreasing its bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc gluconate,tetracycline,Major,Reduced absorption of tetracycline.,"Zinc forms insoluble complexes with tetracycline, decreasing its bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
vinpocetine,,,,,,1,2026-05-13
ozenoxacin,,,,,,1,2026-05-13
calcitonin,,,,,,1,2026-05-13
levocloperastine,,,,,,1,2026-05-13
l-alanyl-l-glutamine,,,,,,1,2026-05-13
atlina life sciences,,,,,,1,2026-05-13
camphor,phenytoin,Moderate,Decreased phenytoin efficacy.,Camphor may induce hepatic enzymes responsible for phenytoin metabolism.,Monitor phenytoin levels and adjust dose if necessary.,1,2026-05-13
camphor,carbamazepine,Moderate,Decreased carbamazepine efficacy.,Camphor may induce hepatic enzymes responsible for carbamazepine metabolism.,Monitor carbamazepine levels and adjust dose if necessary.,1,2026-05-13
camphor,valproate,Minor,Potential for additive CNS depressant effects.,Both can cause central nervous system depression.,Monitor for increased sedation.,1,2026-05-13
epalrestat,,,,,,1,2026-05-13
sodium lactate,furosemide,Minor,Increased risk of electrolyte imbalance.,"Sodium lactate can alter electrolyte balance, potentially exacerbating diuretic-induced imbalances.",Monitor electrolytes closely.,1,2026-05-13
sodium lactate,spironolactone,Minor,Increased risk of hyperkalemia.,Sodium lactate can affect acid-base balance and potentially lead to potassium retention.,Monitor potassium levels.,1,2026-05-13
sodium lactate,insulin,Minor,Potential for altered glucose control.,"Lactate can be metabolized to glucose, affecting blood sugar levels.",Monitor blood glucose levels.,1,2026-05-13
jntl consumer health,,,,,,1,2026-05-13
diastase,,,,,,1,2026-05-13
afatinib dimaleate,omeprazole,Moderate,Reduced afatinib exposure and efficacy.,"Omeprazole is a proton pump inhibitor that increases gastric pH, potentially reducing the absorption of afatinib.",Avoid co-administration; consider alternative acid suppressants if necessary and monitor for treatment response.,1,2026-05-13
afatinib dimaleate,pantoprazole,Moderate,Reduced afatinib exposure and efficacy.,"Pantoprazole is a proton pump inhibitor that increases gastric pH, potentially reducing the absorption of afatinib.",Avoid co-administration; consider alternative acid suppressants if necessary and monitor for treatment response.,1,2026-05-13
oleum lini,,,,,,1,2026-05-13
bepotastine,alprazolam,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
bepotastine,diazepam,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
bepotastine,lorazepam,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
bepotastine,midazolam,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
bepotastine,zolpidem,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
bepotastine,clonazepam,Minor,Increased sedation.,Bepotastine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
asparaginase,prednisolone,Moderate,Reduced efficacy of asparaginase.,"Corticosteroids can suppress immune responses, potentially antagonizing the effect of asparaginase.",Consider alternative immunosuppressants or dose adjustments if possible; monitor treatment response closely.,1,2026-05-13
asparaginase,dexamethasone,Moderate,Reduced efficacy of asparaginase.,"Corticosteroids can suppress immune responses, potentially antagonizing the effect of asparaginase.",Consider alternative immunosuppressants or dose adjustments if possible; monitor treatment response closely.,1,2026-05-13
tetanus toxoid,prednisolone,Minor,Potentially reduced immune response to vaccine.,Immunosuppressive effects of corticosteroids may dampen the immune response to vaccination.,"Administer vaccine before starting corticosteroids if possible, or consider repeat vaccination later.",1,2026-05-13
tetanus toxoid,dexamethasone,Minor,Potentially reduced immune response to vaccine.,Immunosuppressive effects of corticosteroids may dampen the immune response to vaccination.,"Administer vaccine before starting corticosteroids if possible, or consider repeat vaccination later.",1,2026-05-13
lafutidine,omeprazole,Minor,No significant clinical interaction expected.,Both are H2 blockers or PPIs; typically used together for additive effect in acid suppression.,Monitor for efficacy of acid suppression.,1,2026-05-13
lafutidine,pantoprazole,Minor,No significant clinical interaction expected.,Both are H2 blockers or PPIs; typically used together for additive effect in acid suppression.,Monitor for efficacy of acid suppression.,1,2026-05-13
camylofin,,,,,,1,2026-05-13
valacyclovir,metronidazole,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
valacyclovir,amoxicillin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
valacyclovir,azithromycin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
valacyclovir,ciprofloxacin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
inositol nicotinate,,,,,,1,2026-05-13
cefpodoxime proxetil,metronidazole,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
cefpodoxime proxetil,amoxicillin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
cefpodoxime proxetil,azithromycin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
cefpodoxime proxetil,ciprofloxacin,Minor,Increased risk of gastrointestinal upset.,Both can cause nausea and vomiting.,Monitor for gastrointestinal side effects.,1,2026-05-13
rupatadine,alprazolam,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
rupatadine,diazepam,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
rupatadine,lorazepam,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
rupatadine,midazolam,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
rupatadine,zolpidem,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
rupatadine,clonazepam,Minor,Increased sedation.,Rupatadine may have mild CNS depressant effects.,Monitor for additive sedation.,1,2026-05-13
diosmin,,,,,,1,2026-05-13
metadoxine,,,,,,1,2026-05-13
collagen peptide,,,,,,1,2026-05-13
remogliflozin etabonate,metformin,Moderate,Increased risk of lactic acidosis.,Both can affect renal function and glucose metabolism.,Monitor renal function and glucose levels closely. Consider dose adjustments if needed.,1,2026-05-13
remogliflozin etabonate,furosemide,Moderate,Increased risk of dehydration and hypotension.,Both can affect fluid balance and blood pressure.,Monitor hydration status and blood pressure. Advise increased fluid intake if necessary.,1,2026-05-13
remogliflozin etabonate,spironolactone,Moderate,Increased risk of hyperkalemia and hypotension.,Both can affect potassium levels and blood pressure.,Monitor potassium levels and blood pressure. Advise dietary modifications if needed.,1,2026-05-13
remogliflozin etabonate,losartan,Moderate,Increased risk of hypotension and renal impairment.,Both can affect blood pressure and renal function.,Monitor blood pressure and renal function. Advise caution with ambulation.,1,2026-05-13
remogliflozin etabonate,amlodipine,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure.,Monitor blood pressure. Advise caution with ambulation.,1,2026-05-13
remogliflozin etabonate,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Both can lower blood pressure and heart rate.,Monitor blood pressure and heart rate. Advise caution with ambulation.,1,2026-05-13
remogliflozin etabonate,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Both can lower blood pressure and heart rate.,Monitor blood pressure and heart rate. Advise caution with ambulation.,1,2026-05-13
remogliflozin etabonate,ramipril,Moderate,Increased risk of hypotension and renal impairment.,Both can affect blood pressure and renal function.,Monitor blood pressure and renal function. Advise caution with ambulation.,1,2026-05-13
remogliflozin etabonate,atorvastatin,Minor,Potential for additive effects on muscle toxicity.,Both may rarely cause muscle-related side effects.,Monitor for muscle pain or weakness.,1,2026-05-13
remogliflozin etabonate,rosuvastatin,Minor,Potential for additive effects on muscle toxicity.,Both may rarely cause muscle-related side effects.,Monitor for muscle pain or weakness.,1,2026-05-13
remogliflozin etabonate,insulin,Moderate,Increased risk of hypoglycemia.,Both lower blood glucose levels.,Monitor blood glucose levels closely. Adjust insulin dose if necessary.,1,2026-05-13
remogliflozin etabonate,digoxin,Minor,"May affect digoxin levels, potentially increasing toxicity.",SGLT2 inhibitors can affect electrolyte balance and renal clearance.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
opipramol,diazepam,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,alprazolam,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,lorazepam,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,clonazepam,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,midazolam,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,zolpidem,Moderate,"Increased central nervous system depression, sedation, and cognitive impairment.",Both are CNS depressants.,"Use with caution, monitor for excessive sedation. Consider dose reduction of one or both agents.",1,2026-05-13
opipramol,amitriptyline,Minor,"Potential for additive anticholinergic effects (dry mouth, constipation).",Both have some anticholinergic properties.,Monitor for anticholinergic side effects.,1,2026-05-13
opipramol,sertraline,Minor,Potential for additive effects on serotonin syndrome if patient is sensitive.,Opipramol has some serotonergic activity.,Monitor for symptoms of serotonin syndrome.,1,2026-05-13
opipramol,fluoxetine,Minor,Potential for additive effects on serotonin syndrome if patient is sensitive.,Opipramol has some serotonergic activity.,Monitor for symptoms of serotonin syndrome.,1,2026-05-13
polmacoxib,warfarin,Major,Increased risk of bleeding.,Both are anticoagulants and NSAIDs can increase bleeding risk.,Monitor INR closely. Consider alternative analgesic or lower warfarin dose.,1,2026-05-13
polmacoxib,aspirin,Moderate,Increased risk of gastrointestinal bleeding and reduced cardioprotective effect of aspirin.,Both are NSAIDs and can increase GI ulceration risk. COX-2 inhibitors can interfere with aspirin's antiplatelet effect.,"Avoid concurrent use if possible. If necessary, monitor for GI bleeding and consider gastroprotection.",1,2026-05-13
polmacoxib,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Both are NSAIDs and can increase GI ulceration risk.,"Avoid concurrent use. If necessary, monitor for GI bleeding and consider gastroprotection.",1,2026-05-13
polmacoxib,clopidogrel,Moderate,Increased risk of bleeding.,Both have antiplatelet effects and NSAIDs increase bleeding risk.,Monitor for signs of bleeding. Consider alternatives if high bleeding risk.,1,2026-05-13
polmacoxib,ramipril,Moderate,Increased risk of renal impairment and hyperkalemia.,NSAIDs can reduce renal blood flow and affect RAAS.,Monitor renal function and potassium levels. Ensure adequate hydration.,1,2026-05-13
polmacoxib,losartan,Moderate,Increased risk of renal impairment and hyperkalemia.,NSAIDs can reduce renal blood flow and affect RAAS.,Monitor renal function and potassium levels. Ensure adequate hydration.,1,2026-05-13
polmacoxib,metformin,Moderate,Increased risk of lactic acidosis and renal impairment.,"NSAIDs can affect renal function, increasing metformin risk.",Monitor renal function and for signs of lactic acidosis. Use with caution.,1,2026-05-13
polmacoxib,furosemide,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can impair renal prostaglandin synthesis, affecting diuretic response.",Monitor urine output and renal function. Ensure adequate hydration.,1,2026-05-13
polmacoxib,atorvastatin,Minor,Potential for increased risk of muscle-related side effects.,Some statins and NSAIDs may have additive effects on muscle toxicity.,Monitor for muscle pain or weakness.,1,2026-05-13
polmacoxib,rosuvastatin,Minor,Potential for increased risk of muscle-related side effects.,Some statins and NSAIDs may have additive effects on muscle toxicity.,Monitor for muscle pain or weakness.,1,2026-05-13
gleck pharma,,,,,,1,2026-05-13
ranip drugs,,,,,,1,2026-05-13
ulinastatin,,,,,,1,2026-05-13
mesna,ciprofloxacin,Minor,May reduce the absorption and serum concentrations of ciprofloxacin.,Mesna can form complexes with certain drugs in the gastrointestinal tract.,Separate administration times by at least 2 hours. Monitor for reduced efficacy of ciprofloxacin.,1,2026-05-13
mesna,azithromycin,Minor,May reduce the absorption and serum concentrations of azithromycin.,Mesna can form complexes with certain drugs in the gastrointestinal tract.,Separate administration times by at least 2 hours. Monitor for reduced efficacy of azithromycin.,1,2026-05-13
mesna,amoxicillin,Minor,May reduce the absorption and serum concentrations of amoxicillin.,Mesna can form complexes with certain drugs in the gastrointestinal tract.,Separate administration times by at least 2 hours. Monitor for reduced efficacy of amoxicillin.,1,2026-05-13
imeglimin,metformin,Moderate,Increased risk of hypoglycemia and gastrointestinal side effects.,Both drugs are biguanides that reduce hepatic glucose production and increase insulin sensitivity.,"Monitor blood glucose closely, consider dose adjustment or separation of administration.",1,2026-05-13
imeglimin,insulin,Moderate,Increased risk of hypoglycemia.,"Imeglimin enhances insulin secretion and sensitivity, potentiating the effect of exogenous insulin.",Monitor blood glucose closely and adjust insulin dose as needed.,1,2026-05-13
penicillin g,,,,,,1,2026-05-13
pefloxacin,warfarin,Major,Increased risk of bleeding.,"Pefloxacin can inhibit the metabolism of warfarin, leading to higher international normalized ratios (INRs).",Monitor INR closely and adjust warfarin dose if necessary; consider alternative antibiotic if possible.,1,2026-05-13
pefloxacin,metronidazole,Moderate,Increased risk of central nervous system adverse effects.,"Both drugs can cause CNS side effects, and their combination may be additive.","Monitor for CNS symptoms like dizziness, confusion, and seizures.",1,2026-05-13
pefloxacin,ciprofloxacin,Moderate,Increased risk of QT prolongation and arrhythmias.,Both are fluoroquinolones with a potential for QT interval prolongation.,Avoid concurrent use or monitor ECG if necessary.,1,2026-05-13
enclomiphene,,,,,,1,2026-05-13
clobetasone,prednisolone,Moderate,Increased risk of adrenal suppression and side effects of topical corticosteroids.,Concurrent use of potent topical corticosteroids and systemic corticosteroids can lead to increased systemic absorption and suppression of the hypothalamic-pituitary-adrenal (HPA) axis.,"Use with caution, monitor for signs of adrenal suppression and systemic corticosteroid side effects.",1,2026-05-13
clobetasone,dexamethasone,Moderate,Increased risk of adrenal suppression and side effects of topical corticosteroids.,Concurrent use of potent topical corticosteroids and systemic corticosteroids can lead to increased systemic absorption and suppression of the hypothalamic-pituitary-adrenal (HPA) axis.,"Use with caution, monitor for signs of adrenal suppression and systemic corticosteroid side effects.",1,2026-05-13
tenofovir alafenamide,rifampicin,Moderate,Decreased plasma concentrations of tenofovir alafenamide.,"Rifampicin is a strong inducer of P-glycoprotein and other transporters, which can increase the clearance of tenofovir alafenamide.",Consider alternative to rifampicin or monitor viral load more closely.,1,2026-05-13
astaxanthin,,,,,,1,2026-05-13
charcoal,warfarin,Major,Reduced absorption and efficacy of warfarin.,"Activated charcoal binds to warfarin in the gastrointestinal tract, preventing its absorption.",Separate administration by at least 2-3 hours; monitor INR closely.,1,2026-05-13
charcoal,aspirin,Moderate,Reduced absorption of aspirin.,Activated charcoal can adsorb aspirin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,ibuprofen,Moderate,Reduced absorption of ibuprofen.,Activated charcoal can adsorb ibuprofen in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,atorvastatin,Moderate,Reduced absorption of atorvastatin.,Activated charcoal can adsorb atorvastatin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,amlodipine,Moderate,Reduced absorption of amlodipine.,Activated charcoal can adsorb amlodipine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,losartan,Moderate,Reduced absorption of losartan.,Activated charcoal can adsorb losartan in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,omeprazole,Moderate,Reduced absorption of omeprazole.,Activated charcoal can adsorb omeprazole in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,pantoprazole,Moderate,Reduced absorption of pantoprazole.,Activated charcoal can adsorb pantoprazole in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,metformin,Moderate,Reduced absorption of metformin.,Activated charcoal can adsorb metformin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,amoxicillin,Moderate,Reduced absorption of amoxicillin.,Activated charcoal can adsorb amoxicillin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,azithromycin,Moderate,Reduced absorption of azithromycin.,Activated charcoal can adsorb azithromycin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,Activated charcoal can adsorb ciprofloxacin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,metronidazole,Moderate,Reduced absorption of metronidazole.,Activated charcoal can adsorb metronidazole in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,insulin,Minor,Potentially reduced absorption of oral hypoglycemics if taken concurrently.,"Activated charcoal can bind to oral medications, potentially reducing their absorption.",Separate administration by at least 2 hours from oral medications.,1,2026-05-13
charcoal,digoxin,Moderate,Reduced absorption of digoxin.,Activated charcoal can adsorb digoxin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,furosemide,Moderate,Reduced absorption of furosemide.,Activated charcoal can adsorb furosemide in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,spironolactone,Moderate,Reduced absorption of spironolactone.,Activated charcoal can adsorb spironolactone in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,atenolol,Moderate,Reduced absorption of atenolol.,Activated charcoal can adsorb atenolol in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,metoprolol,Moderate,Reduced absorption of metoprolol.,Activated charcoal can adsorb metoprolol in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,ramipril,Moderate,Reduced absorption of ramipril.,Activated charcoal can adsorb ramipril in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,clopidogrel,Moderate,Reduced absorption of clopidogrel.,Activated charcoal can adsorb clopidogrel in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,rosuvastatin,Moderate,Reduced absorption of rosuvastatin.,Activated charcoal can adsorb rosuvastatin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,gabapentin,Moderate,Reduced absorption of gabapentin.,Activated charcoal can adsorb gabapentin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,alprazolam,Moderate,Reduced absorption of alprazolam.,Activated charcoal can adsorb alprazolam in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,diazepam,Moderate,Reduced absorption of diazepam.,Activated charcoal can adsorb diazepam in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,sertraline,Moderate,Reduced absorption of sertraline.,Activated charcoal can adsorb sertraline in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,fluoxetine,Moderate,Reduced absorption of fluoxetine.,Activated charcoal can adsorb fluoxetine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,amitriptyline,Moderate,Reduced absorption of amitriptyline.,Activated charcoal can adsorb amitriptyline in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,tramadol,Moderate,Reduced absorption of tramadol.,Activated charcoal can adsorb tramadol in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,codeine,Moderate,Reduced absorption of codeine.,Activated charcoal can adsorb codeine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,morphine,Moderate,Reduced absorption of morphine.,Activated charcoal can adsorb morphine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,phenytoin,Moderate,Reduced absorption of phenytoin.,Activated charcoal can adsorb phenytoin in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,valproate,Moderate,Reduced absorption of valproate.,Activated charcoal can adsorb valproate in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,carbamazepine,Moderate,Reduced absorption of carbamazepine.,Activated charcoal can adsorb carbamazepine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,lithium,Moderate,Reduced absorption of lithium.,Activated charcoal can adsorb lithium in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,haloperidol,Moderate,Reduced absorption of haloperidol.,Activated charcoal can adsorb haloperidol in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,clozapine,Moderate,Reduced absorption of clozapine.,Activated charcoal can adsorb clozapine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,olanzapine,Moderate,Reduced absorption of olanzapine.,Activated charcoal can adsorb olanzapine in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,lorazepam,Moderate,Reduced absorption of lorazepam.,Activated charcoal can adsorb lorazepam in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,clonazepam,Moderate,Reduced absorption of clonazepam.,Activated charcoal can adsorb clonazepam in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,midazolam,Moderate,Reduced absorption of midazolam.,Activated charcoal can adsorb midazolam in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
charcoal,zolpidem,Moderate,Reduced absorption of zolpidem.,Activated charcoal can adsorb zolpidem in the gastrointestinal tract.,Separate administration by at least 2 hours.,1,2026-05-13
avtix health,,,,,,1,2026-05-13
proanthocyanidin,,,,,,1,2026-05-13
carbimazole,,,,,,1,2026-05-13
flavoured mentholated base,,,,,,1,2026-05-13
pharma lifescience,,,,,,1,2026-05-13
natamycin,,,,,,1,2026-05-13
triclofos,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Triclofos may potentiate the CNS depressant effects of amitriptyline.,Monitor for increased sedation and anticholinergic symptoms; consider dose reduction of amitriptyline if necessary.,1,2026-05-13
triclofos,diazepam,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of benzodiazepines like diazepam.,Monitor for excessive sedation and respiratory depression; consider dose reduction of diazepam.,1,2026-05-13
triclofos,lorazepam,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of benzodiazepines like lorazepam.,Monitor for excessive sedation and respiratory depression; consider dose reduction of lorazepam.,1,2026-05-13
triclofos,midazolam,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of benzodiazepines like midazolam.,Monitor for excessive sedation and respiratory depression; consider dose reduction of midazolam.,1,2026-05-13
triclofos,alprazolam,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of benzodiazepines like alprazolam.,Monitor for excessive sedation and respiratory depression; consider dose reduction of alprazolam.,1,2026-05-13
triclofos,clonazepam,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of benzodiazepines like clonazepam.,Monitor for excessive sedation and respiratory depression; consider dose reduction of clonazepam.,1,2026-05-13
triclofos,zolpidem,Moderate,Increased sedation and impaired cognitive function.,Triclofos may potentiate the CNS depressant effects of zolpidem.,Monitor for increased sedation and cognitive impairment; consider dose reduction of zolpidem.,1,2026-05-13
triclofos,morphine,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of opioids like morphine.,Monitor for excessive sedation and respiratory depression; consider dose reduction of morphine.,1,2026-05-13
triclofos,codeine,Moderate,Increased sedation and respiratory depression.,Triclofos may potentiate the CNS depressant effects of opioids like codeine.,Monitor for excessive sedation and respiratory depression; consider dose reduction of codeine.,1,2026-05-13
triclofos,tramadol,Moderate,Increased sedation and dizziness.,Triclofos may potentiate the CNS depressant effects of tramadol.,Monitor for increased sedation and dizziness; consider dose reduction of tramadol.,1,2026-05-13
human,,,,,,1,2026-05-13
calcium polystyrene sulphonate,digoxin,Major,Increased risk of digoxin toxicity due to hypokalemia.,"Calcium polystyrene sulfonate can bind potassium in the gastrointestinal tract, leading to hypokalemia, which sensitizes the myocardium to digoxin.",Monitor serum potassium and digoxin levels closely. Avoid concurrent administration if possible; separate administration by several hours. Monitor for signs of digoxin toxicity.,1,2026-05-13
calcium polystyrene sulphonate,"sorbitol (not in common list, but important)",Major,"Risk of intestinal necrosis, particularly in children.",Concurrent administration of sorbitol with cation-exchange resins can lead to ischemic colitis and intestinal necrosis.,Avoid concurrent administration of sorbitol with calcium polystyrene sulfonate.,1,2026-05-13
dill oil,,,,,,1,2026-05-13
fennel oil,,,,,,1,2026-05-13
oxiconazole,,,,,,1,2026-05-13
diphtheria toxoid,,,,,,1,2026-05-13
papain,,,,,,1,2026-05-13
phenyl mercuric nitrate,,,,,,1,2026-05-13
kojic acid,,,,,,1,2026-05-13
lactobacillus sporogenes,metronidazole,Minor,Reduced efficacy of metronidazole.,"Lactobacillus can inhibit bacterial growth, potentially affecting anaerobic bacteria targeted by metronidazole.",Monitor for treatment failure if used concurrently.,1,2026-05-13
lactobacillus sporogenes,amoxicillin,Minor,Reduced efficacy of amoxicillin.,"Lactobacillus can inhibit bacterial growth, potentially affecting susceptible bacteria targeted by amoxicillin.",Monitor for treatment failure if used concurrently.,1,2026-05-13
lactobacillus sporogenes,azithromycin,Minor,Reduced efficacy of azithromycin.,"Lactobacillus can inhibit bacterial growth, potentially affecting susceptible bacteria targeted by azithromycin.",Monitor for treatment failure if used concurrently.,1,2026-05-13
lactobacillus sporogenes,ciprofloxacin,Minor,Reduced efficacy of ciprofloxacin.,"Lactobacillus can inhibit bacterial growth, potentially affecting susceptible bacteria targeted by ciprofloxacin.",Monitor for treatment failure if used concurrently.,1,2026-05-13
polyvinyl alcohol,,,,,,1,2026-05-13
bambuterol,atenolol,Moderate,Increased risk of bradycardia and conduction disturbances.,"Both drugs can affect cardiac rhythm and conduction; bambuterol is a prodrug of terbutaline which has beta-2 agonist activity, and atenolol is a beta-blocker.",Monitor heart rate and rhythm closely; use with caution.,1,2026-05-13
bambuterol,metoprolol,Moderate,Increased risk of bradycardia and conduction disturbances.,"Both drugs can affect cardiac rhythm and conduction; bambuterol is a prodrug of terbutaline which has beta-2 agonist activity, and metoprolol is a beta-blocker.",Monitor heart rate and rhythm closely; use with caution.,1,2026-05-13
bambuterol,amlodipine,Minor,Potentially additive hypotensive effects or increased risk of peripheral edema.,Bambuterol can cause vasodilation; amlodipine also causes vasodilation.,Monitor blood pressure and for signs of edema.,1,2026-05-13
bambuterol,losartan,Minor,Potentially additive hypotensive effects.,Bambuterol can cause vasodilation and lower blood pressure.,Monitor blood pressure.,1,2026-05-13
bambuterol,ramipril,Minor,Potentially additive hypotensive effects.,Bambuterol can cause vasodilation and lower blood pressure.,Monitor blood pressure.,1,2026-05-13
arbutin,,,,,,1,2026-05-13
mulberry extract,warfarin,Minor,Potential for altered anticoagulant effect.,Some plant extracts can contain compounds that interfere with vitamin K metabolism or affect platelet function.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
mulberry extract,aspirin,Minor,Increased risk of bleeding.,Mulberry extract may have mild antiplatelet effects.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
mulberry extract,clopidogrel,Minor,Increased risk of bleeding.,Mulberry extract may have mild antiplatelet effects.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
aloe vera,warfarin,Moderate,Increased risk of bleeding.,Aloe latex can have laxative effects and may contain compounds that interfere with vitamin K absorption or affect coagulation.,"Monitor INR closely and avoid aloe latex preparations. Oral aloe vera gel is generally considered safe, but caution is advised.",1,2026-05-13
aloe vera,digoxin,Minor,Risk of hypokalemia leading to increased digoxin toxicity.,"Aloe latex can cause electrolyte disturbances, particularly hypokalemia, which potentiates digoxin's cardiotoxicity.",Monitor potassium levels and for signs of digoxin toxicity.,1,2026-05-13
aloe vera,furosemide,Minor,Increased risk of hypokalemia.,"Aloe latex has a laxative effect that can contribute to potassium loss, which is also a side effect of furosemide.",Monitor potassium levels.,1,2026-05-13
aloe vera,spironolactone,Minor,Reduced efficacy of spironolactone due to electrolyte shifts.,"Aloe latex can cause electrolyte disturbances, potentially counteracting the effects of spironolactone.",Monitor electrolyte levels.,1,2026-05-13
lysine,,,,,,1,2026-05-13
kiraas pharma,,,,,,1,2026-05-13
sodium cromoglycate,,,,,,1,2026-05-13
alcohol,diazepam,Major,Increased sedation and central nervous system depression.,Synergistic CNS depressant effects.,Advise patient to avoid alcohol or use with extreme caution.,1,2026-05-13
alcohol,alprazolam,Major,Enhanced sedation and respiratory depression.,Potentiated CNS depressant effects.,Advise patient to avoid alcohol or use with extreme caution.,1,2026-05-13
alcohol,lorazepam,Major,Increased drowsiness and impaired coordination.,Additive CNS depressant actions.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,midazolam,Major,"Profound sedation, respiratory depression, and coma.",Additive CNS depressant effects.,Strongly advise patient to avoid alcohol.,1,2026-05-13
alcohol,zolpidem,Major,"Increased drowsiness, dizziness, and impaired judgment.",Synergistic sedative effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,clonazepam,Major,Increased sedation and impaired cognitive function.,Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,metformin,Moderate,Increased risk of lactic acidosis.,Alcohol inhibits lactate metabolism and can cause hypoglycemia.,Advise patient to limit alcohol consumption.,1,2026-05-13
alcohol,warfarin,Moderate,"Variable effects on INR, potentially increasing bleeding risk with chronic use.",Alcohol can affect warfarin metabolism and platelet function.,Monitor INR closely in patients who consume alcohol.,1,2026-05-13
alcohol,paracetamol,Moderate,"Increased risk of hepatotoxicity, especially with chronic heavy alcohol use.",Competition for glucuronidation pathways and potential for glutathione depletion.,"Advise caution with alcohol consumption, especially in chronic users.",1,2026-05-13
alcohol,atorvastatin,Minor,Potential for increased liver enzyme elevations with excessive alcohol intake.,Alcohol can also affect liver function.,Advise moderate alcohol consumption.,1,2026-05-13
alcohol,rosuvastatin,Minor,Increased risk of liver toxicity with heavy alcohol use.,Both can affect liver enzymes.,Advise moderate alcohol consumption.,1,2026-05-13
alcohol,amlodipine,Minor,Increased risk of hypotension and flushing.,Alcohol can cause vasodilation.,Advise caution with alcohol.,1,2026-05-13
alcohol,losartan,Minor,Increased risk of orthostatic hypotension.,Alcohol can cause vasodilation.,Advise caution with alcohol.,1,2026-05-13
alcohol,ramipril,Minor,Increased risk of hypotension.,Alcohol can cause vasodilation.,Advise caution with alcohol.,1,2026-05-13
alcohol,atenolol,Minor,May reduce the antihypertensive effect of atenolol.,Alcohol can cause vasodilation.,Advise moderation.,1,2026-05-13
alcohol,metoprolol,Minor,May reduce the antihypertensive effect of metoprolol.,Alcohol can cause vasodilation.,Advise moderation.,1,2026-05-13
alcohol,furosemide,Minor,Increased risk of dizziness and dehydration.,Both can cause diuresis and hypotension.,Advise caution and hydration.,1,2026-05-13
alcohol,spironolactone,Minor,Increased risk of dizziness and hyperkalemia.,Both can affect fluid balance and potassium levels.,Advise caution and monitor potassium.,1,2026-05-13
alcohol,tramadol,Major,Increased risk of seizures and CNS depression.,Synergistic effects on the CNS.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,codeine,Major,"Increased risk of sedation, respiratory depression, and overdose.",Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,morphine,Major,"Increased risk of profound sedation, respiratory depression, and respiratory arrest.",Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,gabapentin,Moderate,"Increased drowsiness, dizziness, and impaired coordination.",Additive CNS depressant effects.,Advise patient to limit alcohol intake.,1,2026-05-13
alcohol,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Potentiated CNS depressant and anticholinergic effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,sertraline,Minor,May exacerbate side effects like drowsiness or dizziness.,Alcohol can affect neurotransmitter systems.,Advise caution.,1,2026-05-13
alcohol,fluoxetine,Minor,May increase drowsiness and impair judgment.,Alcohol can interact with serotonin pathways.,Advise caution.,1,2026-05-13
alcohol,diazepam,Major,Increased sedation and central nervous system depression.,Synergistic CNS depressant effects.,Advise patient to avoid alcohol or use with extreme caution.,1,2026-05-13
alcohol,alprazolam,Major,Enhanced sedation and respiratory depression.,Potentiated CNS depressant effects.,Advise patient to avoid alcohol or use with extreme caution.,1,2026-05-13
alcohol,lorazepam,Major,Increased drowsiness and impaired coordination.,Additive CNS depressant actions.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,midazolam,Major,"Profound sedation, respiratory depression, and coma.",Additive CNS depressant effects.,Strongly advise patient to avoid alcohol.,1,2026-05-13
alcohol,zolpidem,Major,"Increased drowsiness, dizziness, and impaired judgment.",Synergistic sedative effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,clonazepam,Major,Increased sedation and impaired cognitive function.,Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,phenytoin,Moderate,"Increased risk of nystagmus, ataxia, and CNS depression.",Alcohol can affect phenytoin metabolism and CNS effects.,Advise patient to limit alcohol intake.,1,2026-05-13
alcohol,valproate,Moderate,Increased sedation and risk of hepatotoxicity.,Additive CNS depressant effects and potential for increased liver strain.,Advise patient to limit alcohol intake.,1,2026-05-13
alcohol,carbamazepine,Moderate,Increased risk of CNS depression and dizziness.,Additive CNS depressant effects.,Advise patient to limit alcohol intake.,1,2026-05-13
alcohol,rifampicin,Moderate,Increased risk of hepatotoxicity.,Both can cause liver strain.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,isoniazid,Moderate,Increased risk of hepatotoxicity.,Both can cause liver strain.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,ethambutol,Minor,Potential for increased ocular toxicity with excessive alcohol.,"Unknown, but caution advised.",Advise moderate alcohol consumption.,1,2026-05-13
alcohol,hydroxychloroquine,Minor,"No significant interaction documented, but general caution with alcohol advised.",N/A,Advise moderate alcohol consumption.,1,2026-05-13
alcohol,colchicine,Moderate,"Increased risk of gastrointestinal upset and myopathy, especially with chronic alcohol use.",Alcohol can exacerbate GI side effects and potentially affect muscle metabolism.,Advise patient to limit alcohol intake.,1,2026-05-13
alcohol,methotrexate,Moderate,Increased risk of hepatotoxicity.,Both can cause liver strain.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,cyclosporine,Moderate,May affect cyclosporine levels and increase nephrotoxicity risk.,Alcohol can influence liver enzyme activity and renal function.,Advise patient to limit alcohol intake and monitor renal function.,1,2026-05-13
alcohol,tacrolimus,Moderate,May affect tacrolimus levels and increase nephrotoxicity risk.,Alcohol can influence liver enzyme activity and renal function.,Advise patient to limit alcohol intake and monitor renal function.,1,2026-05-13
alcohol,lithium,Moderate,May affect lithium levels and increase risk of lithium toxicity.,Alcohol can alter renal excretion of lithium.,Advise patient to limit alcohol intake and monitor lithium levels.,1,2026-05-13
alcohol,haloperidol,Major,"Increased sedation, impaired judgment, and risk of extrapyramidal symptoms.",Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,clozapine,Major,"Increased sedation, orthostatic hypotension, and risk of seizures.",Synergistic CNS depressant and hypotensive effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,olanzapine,Major,"Increased sedation, dizziness, and impaired coordination.",Additive CNS depressant effects.,Advise patient to avoid alcohol.,1,2026-05-13
alcohol,digoxin,Minor,"No direct interaction, but dehydration from alcohol can affect electrolyte balance.",Indirect effect on fluid and electrolyte status.,Advise caution and adequate hydration.,1,2026-05-13
alcohol,insulin,Moderate,Risk of hypoglycemia or hyperglycemia; alcohol can mask symptoms of hypoglycemia.,Alcohol impairs hepatic glucose production and can affect insulin sensitivity.,Advise patient to consume alcohol with food and monitor blood glucose closely.,1,2026-05-13
calamine,,,,,,1,2026-05-13
pertussis toxoid,,,,,,1,2026-05-13
lactobacillus rhamnosus,,,,,,1,2026-05-13
magnesium valproate,valproate,Major,"Increased risk of valproate toxicity, including hepatotoxicity and hyperammonemia.",Magnesium valproate is a salt of valproic acid; co-administration can lead to excessive valproate exposure.,"Avoid concurrent use. If using magnesium valproate, no additional valproate should be given.",1,2026-05-13
magnesium valproate,phenytoin,Moderate,"Reduced protein binding of phenytoin, potentially increasing free phenytoin levels and toxicity.",Valproate displaces phenytoin from protein binding sites.,Monitor phenytoin levels and for signs of toxicity.,1,2026-05-13
magnesium valproate,carbamazepine,Moderate,"Valproate can inhibit the metabolism of carbamazepine, leading to increased carbamazepine levels and toxicity.",Inhibition of CYP enzymes involved in carbamazepine metabolism.,Monitor carbamazepine levels and for signs of toxicity.,1,2026-05-13
magnesium valproate,lamotrigine,Major,"Increased risk of severe rash, including Stevens-Johnson syndrome.",Valproate significantly slows the metabolism of lamotrigine.,"Avoid concurrent use. If unavoidable, initiate lamotrigine at a lower dose and titrate slowly with close monitoring.",1,2026-05-13
magnesium valproate,rifampicin,Minor,"Rifampicin can induce the metabolism of valproate, potentially decreasing its efficacy.",Induction of hepatic enzymes.,Monitor valproate levels and efficacy.,1,2026-05-13
magnesium valproate,isoniazid,Moderate,Increased risk of hepatotoxicity.,Both drugs can be hepatotoxic.,Monitor liver function tests closely.,1,2026-05-13
magnesium valproate,erythromycin,Moderate,"Increased valproate levels, with a risk of toxicity.",Erythromycin inhibits valproate metabolism.,Monitor valproate levels and for signs of toxicity.,1,2026-05-13
magnesium valproate,cyclosporine,Moderate,"Increased cyclosporine levels, with a risk of nephrotoxicity.",Valproate can inhibit the metabolism of cyclosporine.,Monitor cyclosporine levels and renal function.,1,2026-05-13
magnesium valproate,tacrolimus,Moderate,"Increased tacrolimus levels, with a risk of nephrotoxicity.",Valproate can inhibit the metabolism of tacrolimus.,Monitor tacrolimus levels and renal function.,1,2026-05-13
magnesium valproate,clonazepam,Moderate,"Valproate can decrease the clearance of clonazepam, leading to increased levels and sedation.",Inhibition of CYP enzymes involved in clonazepam metabolism.,Monitor for increased sedation.,1,2026-05-13
magnesium valproate,alprazolam,Moderate,"Valproate can decrease the clearance of alprazolam, leading to increased levels and sedation.",Inhibition of CYP enzymes involved in alprazolam metabolism.,Monitor for increased sedation.,1,2026-05-13
magnesium valproate,lorazepam,Minor,No significant interaction documented.,N/A,None generally required.,1,2026-05-13
magnesium valproate,diazepam,Moderate,"Valproate can decrease the clearance of diazepam, leading to increased levels and sedation.",Inhibition of CYP enzymes involved in diazepam metabolism.,Monitor for increased sedation.,1,2026-05-13
magnesium valproate,topiramate,Moderate,"Increased risk of hyperammonemia, with or without encephalopathy.",Both drugs can cause hyperammonemia.,Monitor ammonia levels and for signs of encephalopathy.,1,2026-05-13
magnesium valproate,felbamate,Moderate,Increased risk of hyperammonemia and potential for valproate toxicity.,Felbamate can inhibit valproate metabolism and potentiate hyperammonemia.,Monitor ammonia levels and valproate levels.,1,2026-05-13
magnesium valproate,cholestyramine,Minor,"Cholestyramine can bind to valproic acid, reducing its absorption.",Binding in the gastrointestinal tract.,Separate administration by at least 1-2 hours.,1,2026-05-13
magnesium valproate,nimodipine,Minor,Valproate may interfere with nimodipine's effect.,Unknown.,Monitor blood pressure.,1,2026-05-13
prulifloxacin,,,,,,1,2026-05-13
gamma benzene hexachloride,,,,,,1,2026-05-13
blonanserin,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depression and anticholinergic activity.,Monitor for increased sedation and anticholinergic symptoms; consider dose adjustment.,1,2026-05-13
blonanserin,diazepam,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,lorazepam,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,midazolam,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,zolpidem,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,clonazepam,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,alprazolam,Moderate,Increased sedation and potentially respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
blonanserin,haloperidol,Moderate,Increased risk of QTc prolongation and extrapyramidal symptoms.,Pharmacodynamic interaction affecting cardiac repolarization and dopamine antagonism.,Monitor ECG for QTc prolongation and for signs of extrapyramidal symptoms; use with caution.,1,2026-05-13
blonanserin,clozapine,Moderate,"Increased risk of sedation, orthostatic hypotension, and anticholinergic effects.",Additive pharmacodynamic effects on CNS and autonomic nervous system.,"Monitor for increased sedation, orthostatic hypotension, and anticholinergic symptoms; consider dose adjustment.",1,2026-05-13
blonanserin,olanzapine,Moderate,"Increased risk of sedation, orthostatic hypotension, and anticholinergic effects.",Additive pharmacodynamic effects on CNS and autonomic nervous system.,"Monitor for increased sedation, orthostatic hypotension, and anticholinergic symptoms; consider dose adjustment.",1,2026-05-13
chromium polynicotinate,,,,,,1,2026-05-13
vonoprazan,metformin,Minor,Potentially altered metformin absorption.,Changes in gastric pH may affect drug absorption.,Monitor blood glucose levels and metformin efficacy.,1,2026-05-13
vonoprazan,atenolol,Minor,Potentially altered atenolol absorption.,Changes in gastric pH may affect drug absorption.,Monitor blood pressure and heart rate.,1,2026-05-13
vonoprazan,metoprolol,Minor,Potentially altered metoprolol absorption.,Changes in gastric pH may affect drug absorption.,Monitor blood pressure and heart rate.,1,2026-05-13
vonoprazan,diazepam,Minor,Potentially altered diazepam absorption.,Changes in gastric pH may affect drug absorption.,Monitor for increased sedation.,1,2026-05-13
vonoprazan,alprazolam,Minor,Potentially altered alprazolam absorption.,Changes in gastric pH may affect drug absorption.,Monitor for increased sedation.,1,2026-05-13
vonoprazan,clonazepam,Minor,Potentially altered clonazepam absorption.,Changes in gastric pH may affect drug absorption.,Monitor for increased sedation.,1,2026-05-13
vonoprazan,midazolam,Minor,Potentially altered midazolam absorption.,Changes in gastric pH may affect drug absorption.,Monitor for increased sedation.,1,2026-05-13
vonoprazan,digoxin,Minor,Potentially increased digoxin absorption.,Increased gastric pH may enhance absorption of basic drugs.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
sodium fusidate,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,Inhibition of CYP3A4 by sodium fusidate may increase statin concentrations.,"Avoid concurrent use. If unavoidable, monitor closely for muscle pain, weakness, and elevated creatine kinase.",1,2026-05-13
sodium fusidate,rosuvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,Inhibition of CYP2C9 by sodium fusidate may increase rosuvastatin concentrations.,"Avoid concurrent use. If unavoidable, monitor closely for muscle pain, weakness, and elevated creatine kinase.",1,2026-05-13
sodium fusidate,prednisolone,Minor,Potential for altered pharmacokinetics of either drug.,"Limited data, but potential for interactions via protein binding or hepatic metabolism.",Monitor for therapeutic efficacy and potential side effects of both agents.,1,2026-05-13
sodium fusidate,dexamethasone,Minor,Potential for altered pharmacokinetics of either drug.,"Limited data, but potential for interactions via protein binding or hepatic metabolism.",Monitor for therapeutic efficacy and potential side effects of both agents.,1,2026-05-13
pheniramine,tramadol,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depression and anticholinergic activity.,Monitor for increased sedation and anticholinergic symptoms; caution when driving or operating machinery.,1,2026-05-13
pheniramine,codeine,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depression and anticholinergic activity.,Monitor for increased sedation and anticholinergic symptoms; caution when driving or operating machinery.,1,2026-05-13
pheniramine,morphine,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depression and anticholinergic activity.,Monitor for increased sedation and anticholinergic symptoms; caution when driving or operating machinery.,1,2026-05-13
pheniramine,diazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,lorazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,alprazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,midazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,clonazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,zolpidem,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; avoid activities requiring alertness.,1,2026-05-13
pheniramine,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depression and anticholinergic activity.,Monitor for increased sedation and anticholinergic symptoms; caution when driving or operating machinery.,1,2026-05-13
pidotimod,,,,,,1,2026-05-13
copper,penicillamine,Moderate,Reduced efficacy of penicillamine.,"Copper can chelate with penicillamine, reducing its absorption and activity.",Separate administration by at least 2 hours. Monitor for signs of decreased penicillamine efficacy.,1,2026-05-13
copper,ciprofloxacin,Minor,Reduced absorption of ciprofloxacin.,"Copper can form complexes with fluoroquinolones, reducing their oral bioavailability.",Administer ciprofloxacin at least 2 hours before or 4-6 hours after copper. Monitor for reduced antibiotic efficacy.,1,2026-05-13
copper,levofloxacin,Minor,Reduced absorption of levofloxacin.,"Copper can form complexes with fluoroquinolones, reducing their oral bioavailability.",Administer levofloxacin at least 2 hours before or 4-6 hours after copper. Monitor for reduced antibiotic efficacy.,1,2026-05-13
copper,tetracyclines,Minor,Reduced absorption of tetracyclines.,"Copper can form complexes with tetracyclines, reducing their oral bioavailability.",Separate administration by at least 2 hours. Monitor for reduced antibiotic efficacy.,1,2026-05-13
tofisopam,diazepam,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
tofisopam,alprazolam,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
tofisopam,lorazepam,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
tofisopam,clonazepam,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
tofisopam,midazolam,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
tofisopam,zolpidem,Minor,Potentially altered metabolism and increased CNS effects.,"May involve CYP enzyme interactions, though data is limited.",Monitor for increased sedation and benzodiazepine-like effects.,1,2026-05-13
benzyl alcohol,warfarin,Minor,Potentially altered anticoagulant effect.,"Limited evidence suggests possible interactions with anticoagulant effects, possibly due to excipient effects.",Monitor INR closely when benzyl alcohol-containing products are initiated or stopped.,1,2026-05-13
benzyl alcohol,atorvastatin,Minor,Potentially altered pharmacokinetics.,Excipient in formulations may influence drug absorption or metabolism.,Monitor for therapeutic response and potential side effects.,1,2026-05-13
benzyl alcohol,rosuvastatin,Minor,Potentially altered pharmacokinetics.,Excipient in formulations may influence drug absorption or metabolism.,Monitor for therapeutic response and potential side effects.,1,2026-05-13
benzyl alcohol,digoxin,Minor,Potentially altered absorption or serum levels.,Excipients in formulations can affect drug absorption.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
benzyl alcohol,furosemide,Minor,Potentially altered pharmacokinetics.,Excipients in formulations may influence drug absorption or metabolism.,Monitor diuretic effect and electrolytes.,1,2026-05-13
benzyl alcohol,spironolactone,Minor,Potentially altered pharmacokinetics.,Excipients in formulations may influence drug absorption or metabolism.,Monitor electrolyte balance and diuretic effect.,1,2026-05-13
benzyl alcohol,insulin,Minor,Potentially altered absorption or glycemic control.,Excipients in formulations can affect insulin absorption and efficacy.,Monitor blood glucose levels closely.,1,2026-05-13
benzyl alcohol,metformin,Minor,Potentially altered absorption or glycemic control.,Excipients in formulations can affect metformin absorption.,Monitor blood glucose levels.,1,2026-05-13
cetrorelix,,,,,,1,2026-05-13
terpin hydrate,,,,,,1,2026-05-13
potassium iodide,lisinopril,Moderate,Hyperkalemia,Potassium iodide can increase serum potassium; ACE inhibitors also increase serum potassium.,"Monitor serum potassium levels closely, especially in patients with renal impairment.",1,2026-05-13
potassium iodide,spironolactone,Major,Severe hyperkalemia,"Potassium iodide increases serum potassium, and spironolactone is a potassium-sparing diuretic.","Avoid concurrent use if possible. If unavoidable, monitor potassium levels frequently and adjust dosages.",1,2026-05-13
potassium iodide,losartan,Moderate,Hyperkalemia,Potassium iodide can increase serum potassium; ARBs also increase serum potassium.,"Monitor serum potassium levels closely, especially in patients with renal impairment.",1,2026-05-13
potassium iodide,ramipril,Moderate,Hyperkalemia,Potassium iodide can increase serum potassium; ACE inhibitors also increase serum potassium.,"Monitor serum potassium levels closely, especially in patients with renal impairment.",1,2026-05-13
amylmetacresol,,,,,,1,2026-05-13
choline theophyllinate,ciprofloxacin,Moderate,Increased theophylline levels and toxicity,"Ciprofloxacin inhibits CYP1A2, which metabolizes theophylline.",Monitor theophylline levels and for signs of toxicity; consider alternative antibiotic or dose adjustment of theophylline.,1,2026-05-13
choline theophyllinate,erythromycin,Moderate,Increased theophylline levels and toxicity,"Erythromycin inhibits CYP1A2, which metabolizes theophylline.",Monitor theophylline levels and for signs of toxicity; consider alternative antibiotic or dose adjustment of theophylline.,1,2026-05-13
choline theophyllinate,atenolol,Minor,Reduced efficacy of beta-blocker,Theophylline can antagonize the effects of beta-adrenergic blockers.,Monitor for adequate blood pressure control.,1,2026-05-13
choline theophyllinate,metoprolol,Minor,Reduced efficacy of beta-blocker,Theophylline can antagonize the effects of beta-adrenergic blockers.,Monitor for adequate blood pressure control.,1,2026-05-13
vitamin b,,,,,,1,2026-05-13
n-acetylcarnosine,,,,,,1,2026-05-13
feracrylum,,,,,,1,2026-05-13
troxerutin,,,,,,1,2026-05-13
wheat germ oil,,,,,,1,2026-05-13
risedronate,omeprazole,Minor,Reduced risedronate absorption,Proton pump inhibitors may decrease the absorption of bisphosphonates.,Separate administration of risedronate and omeprazole by at least 30 minutes to 2 hours.,1,2026-05-13
risedronate,pantoprazole,Minor,Reduced risedronate absorption,Proton pump inhibitors may decrease the absorption of bisphosphonates.,Separate administration of risedronate and pantoprazole by at least 30 minutes to 2 hours.,1,2026-05-13
risedronate,calcium carbonate,Minor,Reduced risedronate absorption,"Divalent cations like calcium can bind to bisphosphonates, reducing their absorption.",Separate administration of risedronate and calcium-containing products by at least 2 hours.,1,2026-05-13
risedronate,antacids,Minor,Reduced risedronate absorption,"Antacids contain divalent cations that can bind to bisphosphonates, reducing their absorption.",Separate administration of risedronate and antacids by at least 2 hours.,1,2026-05-13
pamidronate,,,,,,1,2026-05-13
benzyl nicotinate,,,,,,1,2026-05-13
zyris derma care,,,,,,1,2026-05-13
acetic acid,,,,,,1,2026-05-13
sodium feredetate,,,,,,1,2026-05-13
bifonazole,,,,,,1,2026-05-13
calcium pantothenate,,,,,,1,2026-05-13
bifidobacterium bifidum,,,,,,1,2026-05-13
racemethionine,,,,,,1,2026-05-13
phytomenadione,warfarin,Major,"Reduced anticoagulant effect, increasing risk of thrombosis.","Phytomenadione is Vitamin K, which is the physiological antagonist of warfarin.",Monitor INR closely and adjust warfarin dose; avoid high doses of phytomenadione unless necessary to reverse anticoagulation.,1,2026-05-13
alginic acid,,,,,,1,2026-05-13
somatropin,insulin,Moderate,Increased blood glucose levels,Somatropin antagonizes the effects of insulin on glucose metabolism.,Monitor blood glucose and adjust insulin dose as needed.,1,2026-05-13
somatropin,metformin,Moderate,Reduced glycemic control,"Somatropin can lead to insulin resistance, counteracting metformin's action.",Monitor blood glucose and consider increasing metformin dose or adding other agents.,1,2026-05-13
somatropin,prednisolone,Moderate,Reduced efficacy of somatropin,Glucocorticoids can inhibit growth hormone action and promote insulin resistance.,Monitor growth response and blood glucose; adjust doses if necessary.,1,2026-05-13
somatropin,dexamethasone,Moderate,Reduced efficacy of somatropin,Glucocorticoids can inhibit growth hormone action and promote insulin resistance.,Monitor growth response and blood glucose; adjust doses if necessary.,1,2026-05-13
carbocisteine,,,,,,1,2026-05-13
iguratimod,methotrexate,Moderate,Increased risk of myelosuppression and gastrointestinal toxicity,Both drugs can affect bone marrow function and have overlapping toxicities.,Monitor blood counts and liver function closely.,1,2026-05-13
iguratimod,cyclosporine,Moderate,Increased risk of nephrotoxicity,"Both can affect renal function, potentially leading to additive nephrotoxic effects.",Monitor renal function closely and consider dose adjustments.,1,2026-05-13
iguratimod,tacrolimus,Moderate,Increased risk of nephrotoxicity,"Both can affect renal function, potentially leading to additive nephrotoxic effects.",Monitor renal function closely and consider dose adjustments.,1,2026-05-13
roots life sciences,,,,,,1,2026-05-13
dimethyl fumarate,prednisolone,Moderate,Increased risk of lymphopenia and opportunistic infections,"Dimethyl fumarate can cause immunosuppression, and corticosteroids further enhance this risk.",Monitor for signs of infection and consider reducing corticosteroid dose.,1,2026-05-13
dimethyl fumarate,dexamethasone,Moderate,Increased risk of lymphopenia and opportunistic infections,"Dimethyl fumarate can cause immunosuppression, and corticosteroids further enhance this risk.",Monitor for signs of infection and consider reducing corticosteroid dose.,1,2026-05-13
dimethyl fumarate,"azathioprine (not in common list, but relevant)",Major,Severe myelosuppression,"Dimethyl fumarate can inhibit CYP2E1, which metabolizes azathioprine, leading to increased levels.",Avoid concurrent use or monitor blood counts very closely.,1,2026-05-13
unique life sciences,,,,,,1,2026-05-13
copper sulphate,,,,,,1,2026-05-13
calcium ascorbate,,,,,,1,2026-05-13
beta-cyclodextrin,,,,,,1,2026-05-13
molnupiravir,,,,,,1,2026-05-13
potassium magnesium citrate,losartan,Minor,Increased risk of hyperkalemia.,"Potassium-sparing effect of citrate, additive effect with ARB.",Monitor potassium levels.,1,2026-05-13
potassium magnesium citrate,ramipril,Minor,Increased risk of hyperkalemia.,"Potassium-sparing effect of citrate, additive effect with ACE inhibitor.",Monitor potassium levels.,1,2026-05-13
potassium magnesium citrate,spironolactone,Minor,Increased risk of hyperkalemia.,"Potassium-sparing effect of citrate, additive effect with potassium-sparing diuretic.",Monitor potassium levels closely.,1,2026-05-13
potassium magnesium citrate,digoxin,Minor,Reduced digoxin absorption.,Citrate may chelate digoxin.,Separate administration by at least 2 hours.,1,2026-05-13
lecithin,,,,,,1,2026-05-13
pyridoxamine dihydrochloride,,,,,,1,2026-05-13
bile constituents,,,,,,1,2026-05-13
liposomal amphotericin b,furosemide,Moderate,Increased risk of nephrotoxicity and ototoxicity.,Additive nephrotoxic potential.,Monitor renal function and hearing.,1,2026-05-13
liposomal amphotericin b,spironolactone,Moderate,Increased risk of nephrotoxicity and hyperkalemia.,Additive nephrotoxic potential and potassium-sparing effect.,Monitor renal function and potassium levels.,1,2026-05-13
liposomal amphotericin b,digoxin,Minor,Increased risk of digoxin toxicity due to hypokalemia.,"Amphotericin B can cause hypokalemia, potentiating digoxin effect.",Monitor potassium and digoxin levels.,1,2026-05-13
tegafur,rifampicin,Major,Increased risk of hepatotoxicity.,Both drugs are hepatotoxic.,Monitor liver function closely.,1,2026-05-13
tegafur,phenytoin,Moderate,Reduced efficacy of phenytoin.,"Tegafur may induce CYP2C9, increasing phenytoin metabolism.",Monitor phenytoin levels and efficacy.,1,2026-05-13
tegafur,warfarin,Moderate,Increased risk of bleeding.,"Tegafur can inhibit CYP2C9, increasing warfarin effect.",Monitor INR closely.,1,2026-05-13
haemophilus type b conjugate vaccine,,,,,,1,2026-05-13
zinc acetate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Zinc ions chelate fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc acetate,levofloxacin,Major,Reduced absorption of levofloxacin.,"Zinc ions chelate fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc acetate,tetracyclines,Major,Reduced absorption of tetracyclines.,"Zinc ions chelate tetracyclines, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc carnosine,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Zinc ions chelate fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc carnosine,levofloxacin,Major,Reduced absorption of levofloxacin.,"Zinc ions chelate fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
zinc carnosine,tetracyclines,Major,Reduced absorption of tetracyclines.,"Zinc ions chelate tetracyclines, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
balofloxacin,warfarin,Major,Increased risk of bleeding.,Fluoroquinolones can inhibit the metabolism of warfarin.,Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
balofloxacin,theophylline,Moderate,"Increased risk of theophylline toxicity (nausea, vomiting, seizures).",Fluoroquinolones can inhibit the metabolism of theophylline.,Monitor theophylline levels and watch for signs of toxicity.,1,2026-05-13
balofloxacin,caffeine,Minor,"Increased risk of caffeine-related side effects (restlessness, insomnia, tremor).",Fluoroquinolones can inhibit the metabolism of caffeine.,Advise patients to limit caffeine intake.,1,2026-05-13
efonidipine,amlodipine,Minor,Additive hypotensive effect.,"Both are calcium channel blockers, leading to increased vasodilation.",Monitor blood pressure and for signs of hypotension.,1,2026-05-13
efonidipine,losartan,Minor,Additive hypotensive effect.,Combined antihypertensive effect.,Monitor blood pressure.,1,2026-05-13
efonidipine,furosemide,Minor,Additive hypotensive effect.,Combined antihypertensive effect.,Monitor blood pressure.,1,2026-05-13
benzathine penicillin g,,,,,,1,2026-05-13
choline,,,,,,1,2026-05-13
rebamipide,,,,,,1,2026-05-13
hesperidin,,,,,,1,2026-05-13
acambis,,,,,,1,2026-05-13
euphorbia prostrata extract,,,,,,1,2026-05-13
l glutathione reduced,,,,,,1,2026-05-13
l ascorbic acid,warfarin,Moderate,"Reduced efficacy of warfarin, increasing clotting risk.",High doses of vitamin C may interfere with the anticoagulant effect of warfarin.,Avoid high-dose vitamin C supplementation in patients on warfarin; monitor INR.,1,2026-05-13
l ascorbic acid,estrogen-containing contraceptives,Minor,Potentially increased risk of thrombotic events.,Vitamin C may enhance estrogen absorption or effect.,Advise caution with very high doses of vitamin C.,1,2026-05-13
alpha-amylase,,,,,,1,2026-05-13
ram 600,,,,,,1,2026-05-13
lymecycline,methotrexate,Moderate,Increased risk of methotrexate toxicity.,Tetracyclines may inhibit renal excretion of methotrexate.,Monitor for signs of methotrexate toxicity and consider dose adjustment.,1,2026-05-13
lymecycline,retinoids,Moderate,Increased risk of intracranial hypertension.,Both can increase intracranial pressure.,Avoid concurrent use or monitor closely for signs of increased intracranial pressure.,1,2026-05-13
deca peptide,,,,,,1,2026-05-13
calcium gluconate,digoxin,Moderate,Increased risk of digoxin toxicity and arrhythmias.,Hypercalcemia can potentiate digoxin's cardiotoxicity.,Monitor cardiac rhythm and digoxin levels; avoid rapid intravenous calcium administration.,1,2026-05-13
calcium gluconate,tetracyclines,Moderate,Reduced absorption of tetracyclines.,"Calcium can form insoluble complexes with tetracyclines, decreasing their bioavailability.",Separate administration of calcium gluconate and tetracyclines by at least 2 hours.,1,2026-05-13
calcium gluconate,bisphosphonates,Moderate,Reduced absorption of bisphosphonates.,"Calcium can bind to bisphosphonates, reducing their absorption.",Separate administration of calcium gluconate and bisphosphonates by at least 2 hours.,1,2026-05-13
centchroman,,,,,,1,2026-05-13
adrenochrome monosemicarbazone,,,,,,1,2026-05-13
paraffin,,,,,,1,2026-05-13
tannic acid,,,,,,1,2026-05-13
evening primrose oil,phenytoin,Minor,May decrease the effectiveness of phenytoin.,Gamma-linolenic acid in evening primrose oil might lower seizure threshold.,Monitor seizure control and consider dose adjustment of phenytoin if needed.,1,2026-05-13
evening primrose oil,warfarin,Minor,May slightly increase the risk of bleeding.,Evening primrose oil has mild anticoagulant properties.,Use with caution in patients on warfarin; monitor INR closely.,1,2026-05-13
iron isomaltoside,warfarin,Moderate,Reduced anticoagulant effect of warfarin.,Iron compounds can potentially interfere with the absorption or metabolism of warfarin.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
iron isomaltoside,atorvastatin,Minor,Potential for reduced absorption of atorvastatin.,"Iron can bind to statins in the gastrointestinal tract, reducing bioavailability.",Separate administration of iron isomaltoside and atorvastatin by several hours.,1,2026-05-13
iron isomaltoside,rosuvastatin,Minor,Potential for reduced absorption of rosuvastatin.,"Iron can bind to statins in the gastrointestinal tract, reducing bioavailability.",Separate administration of iron isomaltoside and rosuvastatin by several hours.,1,2026-05-13
iron isomaltoside,levothyroxine,Major,Reduced absorption and efficacy of levothyroxine.,"Iron binds to levothyroxine in the GI tract, significantly decreasing its absorption.",Separate administration by at least 4 hours; monitor thyroid function tests.,1,2026-05-13
pine bark extract,warfarin,Moderate,Increased risk of bleeding.,Pine bark extract may have antiplatelet or anticoagulant properties.,Monitor INR closely and counsel patient on signs of bleeding.,1,2026-05-13
pine bark extract,clopidogrel,Moderate,Increased risk of bleeding.,Pine bark extract may have antiplatelet properties.,Monitor for signs of bleeding and bruising.,1,2026-05-13
pine bark extract,aspirin,Moderate,Increased risk of bleeding.,Pine bark extract may have antiplatelet properties.,Monitor for signs of bleeding and bruising.,1,2026-05-13
phenoxyethanol,,,,,,1,2026-05-13
disodium edetate,digoxin,Minor,Reduced absorption of digoxin.,"EDTA can chelate metal ions, potentially affecting the absorption of digoxin.",Separate administration by several hours if possible.,1,2026-05-13
disodium edetate,metformin,Minor,Potential for reduced absorption of metformin.,"EDTA can chelate metal ions, potentially affecting the absorption of metformin.",Separate administration by several hours if possible.,1,2026-05-13
hydrogen peroxide,,,,,,1,2026-05-13
tianeptine,alprazolam,Major,Enhanced sedative and respiratory depressant effects.,"Tianeptine can potentiate the effects of benzodiazepines, including respiratory depression.",Avoid concurrent use or use with extreme caution; monitor for respiratory depression and sedation.,1,2026-05-13
tianeptine,diazepam,Major,Enhanced sedative and respiratory depressant effects.,"Tianeptine can potentiate the effects of benzodiazepines, including respiratory depression.",Avoid concurrent use or use with extreme caution; monitor for respiratory depression and sedation.,1,2026-05-13
tianeptine,lorazepam,Major,Enhanced sedative and respiratory depressant effects.,"Tianeptine can potentiate the effects of benzodiazepines, including respiratory depression.",Avoid concurrent use or use with extreme caution; monitor for respiratory depression and sedation.,1,2026-05-13
tianeptine,clonazepam,Major,Enhanced sedative and respiratory depressant effects.,"Tianeptine can potentiate the effects of benzodiazepines, including respiratory depression.",Avoid concurrent use or use with extreme caution; monitor for respiratory depression and sedation.,1,2026-05-13
tianeptine,midazolam,Major,Enhanced sedative and respiratory depressant effects.,"Tianeptine can potentiate the effects of benzodiazepines, including respiratory depression.",Avoid concurrent use or use with extreme caution; monitor for respiratory depression and sedation.,1,2026-05-13
tianeptine,zolpidem,Major,Enhanced sedative and respiratory depressant effects.,Tianeptine can potentiate the effects of CNS depressants.,Avoid concurrent use or use with extreme caution; monitor for sedation and respiratory depression.,1,2026-05-13
tianeptine,tramadol,Major,Increased risk of serotonin syndrome and CNS depression.,"Tianeptine is an SRI, and tramadol has serotonergic activity; combined use increases serotonin syndrome risk.",Avoid concurrent use or use with extreme caution; monitor for signs of serotonin syndrome.,1,2026-05-13
tianeptine,codeine,Major,Enhanced CNS depression and respiratory depression.,Tianeptine has CNS effects that can be additive with opioid effects.,Avoid concurrent use or use with extreme caution; monitor for sedation and respiratory depression.,1,2026-05-13
tianeptine,morphine,Major,Enhanced CNS depression and respiratory depression.,Tianeptine has CNS effects that can be additive with opioid effects.,Avoid concurrent use or use with extreme caution; monitor for sedation and respiratory depression.,1,2026-05-13
tianeptine,sertraline,Moderate,Increased risk of serotonin syndrome.,Both drugs affect serotonin levels; combined use can lead to excessive serotonergic activity.,"Monitor for signs of serotonin syndrome: agitation, confusion, tachycardia, sweating.",1,2026-05-13
tianeptine,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both drugs affect serotonin levels; combined use can lead to excessive serotonergic activity.,"Monitor for signs of serotonin syndrome: agitation, confusion, tachycardia, sweating.",1,2026-05-13
tianeptine,amitriptyline,Moderate,Increased risk of serotonin syndrome and additive anticholinergic effects.,Tianeptine's serotonergic effects combined with amitriptyline's anticholinergic and potential serotonergic effects.,Monitor for signs of serotonin syndrome and anticholinergic side effects.,1,2026-05-13
lercanidipine,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Lercanidipine inhibits CYP3A4, which metabolizes atorvastatin, increasing its levels.",Avoid concurrent use or monitor closely for muscle pain and weakness; consider alternative statin.,1,2026-05-13
lercanidipine,rosuvastatin,Minor,Potential for increased rosuvastatin levels.,"Lercanidipine can inhibit CYP2C9 to a lesser extent, which metabolizes rosuvastatin.",Monitor for signs of statin-related side effects.,1,2026-05-13
lercanidipine,cyclosporine,Major,Increased serum concentrations of cyclosporine.,"Lercanidipine inhibits CYP3A4, which metabolizes cyclosporine.",Avoid concurrent use or monitor cyclosporine levels closely and adjust dose if necessary.,1,2026-05-13
lercanidipine,tacrolimus,Major,Increased serum concentrations of tacrolimus.,"Lercanidipine inhibits CYP3A4, which metabolizes tacrolimus.",Avoid concurrent use or monitor tacrolimus levels closely and adjust dose if necessary.,1,2026-05-13
lercanidipine,erythromycin,Moderate,Increased lercanidipine levels and potential for exaggerated hypotension.,"Erythromycin is a CYP3A4 inhibitor, increasing lercanidipine levels.",Avoid concurrent use or monitor blood pressure closely.,1,2026-05-13
lercanidipine,ketoconazole,Moderate,Increased lercanidipine levels and potential for exaggerated hypotension.,"Ketoconazole is a potent CYP3A4 inhibitor, increasing lercanidipine levels.",Avoid concurrent use or monitor blood pressure closely.,1,2026-05-13
uj life care,,,,,,1,2026-05-13
somatostatin,insulin,Major,"Suppression of insulin and glucagon release, affecting glycemic control.","Somatostatin inhibits the release of pancreatic hormones, including insulin.",Monitor blood glucose closely; adjust insulin dose as needed.,1,2026-05-13
somatostatin,metformin,Moderate,May alter gastric emptying and absorption.,Somatostatin can affect gastrointestinal motility.,Monitor glycemic control; adjust metformin dose if necessary.,1,2026-05-13
somatostatin,atorvastatin,Minor,Potential alteration in lipid metabolism.,Somatostatin can affect various hormonal pathways influencing lipid metabolism.,Monitor lipid profile.,1,2026-05-13
somatostatin,rosuvastatin,Minor,Potential alteration in lipid metabolism.,Somatostatin can affect various hormonal pathways influencing lipid metabolism.,Monitor lipid profile.,1,2026-05-13
dexibuprofen,warfarin,Major,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and damage gastric mucosa, potentiating warfarin's anticoagulant effect.",Avoid concurrent use or use with extreme caution; monitor INR and signs of bleeding.,1,2026-05-13
dexibuprofen,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, which are important for renal blood flow and blood pressure regulation, counteracting ACE inhibitor effects.",Monitor blood pressure and renal function; avoid concurrent use if possible.,1,2026-05-13
dexibuprofen,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, which are important for renal blood flow and blood pressure regulation, counteracting ACE inhibitor effects.",Monitor blood pressure and renal function; avoid concurrent use if possible.,1,2026-05-13
dexibuprofen,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, reducing renal blood flow and the efficacy of loop diuretics.",Monitor urine output and renal function; avoid concurrent use if possible.,1,2026-05-13
dexibuprofen,spironolactone,Moderate,Increased risk of hyperkalemia and reduced diuretic effect.,"NSAIDs can reduce renal blood flow, impairing potassium excretion and counteracting the effects of potassium-sparing diuretics.",Monitor potassium levels and renal function; avoid concurrent use if possible.,1,2026-05-13
dexibuprofen,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin excretion and increasing the risk of lactic acidosis.",Monitor renal function and signs of lactic acidosis; use with caution.,1,2026-05-13
dexibuprofen,aspirin,Major,Increased risk of gastrointestinal bleeding and reduced cardioprotective effect of low-dose aspirin.,Both are NSAIDs; concurrent use increases GI toxicity. Dexibuprofen can interfere with aspirin's antiplatelet effect.,"Avoid concurrent use. If low-dose aspirin is used for cardioprotection, administer dexibuprofen at least 8 hours before or 30 minutes after aspirin.",1,2026-05-13
dexibuprofen,clopidogrel,Moderate,Increased risk of gastrointestinal bleeding.,Concurrent use of NSAIDs and antiplatelets increases the risk of GI bleeding.,Monitor for signs of gastrointestinal bleeding.,1,2026-05-13
dexibuprofen,"corticosteroids (prednisolone, dexamethasone)",Major,Significantly increased risk of gastrointestinal ulcers and bleeding.,Both NSAIDs and corticosteroids can irritate the gastric mucosa and increase the risk of ulceration.,Avoid concurrent use or use with extreme caution; monitor for GI symptoms and bleeding.,1,2026-05-13
dexibuprofen,lithium,Major,"Reduced renal clearance of lithium, leading to increased serum lithium levels and potential toxicity.","NSAIDs can impair renal function, reducing lithium excretion.",Monitor lithium levels closely and adjust dose if necessary.,1,2026-05-13
dexibuprofen,methotrexate,Major,Increased risk of methotrexate toxicity due to reduced renal clearance.,"NSAIDs can impair renal function, reducing methotrexate excretion.",Monitor methotrexate levels and renal function; avoid concurrent use at high doses of methotrexate.,1,2026-05-13
selenious acid,,,,,,1,2026-05-13
bacillus mesentericus to-a jpc,,,,,,1,2026-05-13
clostridium butryricum to-a,,,,,,1,2026-05-13
topiroxostat,warfarin,Moderate,Increased risk of bleeding.,"Topiroxostat may inhibit CYP2C9, which metabolizes warfarin, leading to higher warfarin levels.",Monitor INR closely and consider reducing warfarin dose if necessary.,1,2026-05-13
topiroxostat,metformin,Moderate,Increased risk of metformin accumulation and hypoglycemia.,Topiroxostat may inhibit renal transporters responsible for metformin excretion.,Monitor blood glucose levels and renal function.,1,2026-05-13
topiroxostat,losartan,Moderate,Potential for altered losartan efficacy or side effects.,"Topiroxostat may inhibit CYP2C9, which is involved in losartan metabolism.",Monitor blood pressure and consider alternative antihypertensive if needed.,1,2026-05-13
topiroxostat,amlodipine,Minor,Potential for altered amlodipine efficacy or side effects.,"Topiroxostat may inhibit CYP2C9, which is involved in amlodipine metabolism.",Monitor blood pressure and for signs of excessive vasodilation.,1,2026-05-13
topiroxostat,atorvastatin,Minor,Potential for increased risk of myopathy or rhabdomyolysis.,"Topiroxostat may inhibit CYP2C9, which is involved in statin metabolism.",Monitor for muscle pain and weakness.,1,2026-05-13
topiroxostat,rosuvastatin,Minor,Potential for increased risk of myopathy or rhabdomyolysis.,"Topiroxostat may inhibit CYP2C9, which is involved in statin metabolism.",Monitor for muscle pain and weakness.,1,2026-05-13
noscapine,sertraline,Moderate,Increased risk of serotonin syndrome.,Noscapine has weak MAOI activity and can potentiate serotonergic effects.,"Monitor for symptoms of serotonin syndrome, such as agitation, confusion, and rapid heart rate.",1,2026-05-13
noscapine,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Noscapine has weak MAOI activity and can potentiate serotonergic effects.,"Monitor for symptoms of serotonin syndrome, such as agitation, confusion, and rapid heart rate.",1,2026-05-13
noscapine,amitriptyline,Moderate,Increased risk of anticholinergic side effects and CNS depression.,Noscapine has anticholinergic properties.,"Monitor for increased sedation, dry mouth, and constipation.",1,2026-05-13
noscapine,tramadol,Moderate,Increased risk of serotonin syndrome and CNS depression.,Noscapine can have serotonergic effects and CNS depressant properties.,Monitor for symptoms of serotonin syndrome and increased sedation.,1,2026-05-13
noscapine,codeine,Moderate,Increased risk of respiratory depression and sedation.,Noscapine can have additive respiratory depressant effects.,Monitor respiratory rate and level of consciousness.,1,2026-05-13
noscapine,morphine,Moderate,Increased risk of respiratory depression and sedation.,Noscapine can have additive respiratory depressant effects.,Monitor respiratory rate and level of consciousness.,1,2026-05-13
noscapine,diazepam,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
noscapine,alprazolam,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
noscapine,lorazepam,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
noscapine,clonazepam,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
noscapine,midazolam,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
noscapine,zolpidem,Moderate,Increased CNS depression and sedation.,Noscapine has CNS depressant properties.,Monitor for excessive drowsiness and impaired coordination.,1,2026-05-13
mixed carotene,,,,,,1,2026-05-13
candesartan,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for vasodilation and renal perfusion, counteracting the effects of ARBs.",Monitor blood pressure and renal function; consider alternative pain relief.,1,2026-05-13
candesartan,aspirin,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for vasodilation and renal perfusion, counteracting the effects of ARBs.",Monitor blood pressure and renal function; consider alternative pain relief.,1,2026-05-13
candesartan,metformin,Minor,Increased risk of lactic acidosis.,"ARBs can affect renal function, potentially leading to metformin accumulation.",Monitor renal function and blood glucose levels.,1,2026-05-13
candesartan,furosemide,Moderate,Increased risk of hypotension and hyperkalemia.,"Candesartan can potentiate the diuretic and natriuretic effects of furosemide, and both can increase potassium levels.","Monitor blood pressure, electrolytes, and renal function.",1,2026-05-13
candesartan,spironolactone,Major,Increased risk of severe hyperkalemia.,Both drugs increase potassium levels; combined use significantly increases the risk of dangerous hyperkalemia.,Avoid concomitant use or monitor potassium levels very closely and frequently.,1,2026-05-13
candesartan,ramipril,Major,"Increased risk of hypotension, hyperkalemia, and renal impairment.",Combination of two RAAS inhibitors.,"Avoid concomitant use or monitor blood pressure, potassium, and renal function very closely.",1,2026-05-13
candesartan,atenolol,Minor,Increased risk of hypotension.,Additive hypotensive effects.,Monitor blood pressure.,1,2026-05-13
candesartan,metoprolol,Minor,Increased risk of hypotension.,Additive hypotensive effects.,Monitor blood pressure.,1,2026-05-13
idebenone,,,,,,1,2026-05-13
dichlorobenzyl alcohol,,,,,,1,2026-05-13
l-lysine,,,,,,1,2026-05-13
cadexomer iodine,,,,,,1,2026-05-13
valethamate,,,,,,1,2026-05-13
menadione sodium bisulfite,warfarin,Major,Reduced anticoagulant effect of warfarin.,"Menadione (Vitamin K) is an antagonist to warfarin, which inhibits vitamin K epoxide reductase.",Monitor INR closely; may require warfarin dose adjustment.,1,2026-05-13
white soft paraffin,,,,,,1,2026-05-13
tulobuterol,atenolol,Moderate,May antagonize the bronchodilating effects of tulobuterol.,"Beta-blockers can block beta-2 receptors in the lungs, counteracting bronchodilation.",Use with caution; monitor bronchodilator response and consider alternative beta-blocker if necessary.,1,2026-05-13
tulobuterol,metoprolol,Moderate,May antagonize the bronchodilating effects of tulobuterol.,"Beta-blockers can block beta-2 receptors in the lungs, counteracting bronchodilation.",Use with caution; monitor bronchodilator response and consider alternative beta-blocker if necessary.,1,2026-05-13
buclizine,diazepam,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,lorazepam,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,alprazolam,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,clonazepam,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,midazolam,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,zolpidem,Moderate,Increased sedation and central nervous system depression.,"Both are CNS depressants, additive effects on sedation and respiratory depression.",Avoid concomitant use or monitor for excessive sedation and respiratory depression.,1,2026-05-13
buclizine,amitriptyline,Moderate,"Increased anticholinergic effects leading to dry mouth, constipation, blurred vision, and urinary retention.",Buclizine has anticholinergic properties; additive effects with amitriptyline.,Monitor for increased anticholinergic adverse effects.,1,2026-05-13
selenomethionine,,,,,,1,2026-05-13
pamabrom,,,,,,1,2026-05-13
colostrum,,,,,,1,2026-05-13
mephenesin,diazepam,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,lorazepam,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,alprazolam,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,clonazepam,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,midazolam,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,zolpidem,Moderate,Increased sedation and respiratory depression.,"Both have CNS depressant effects, additive central nervous system depression.",Monitor for excessive sedation and respiratory depression.,1,2026-05-13
mephenesin,tramadol,Moderate,"Increased CNS depression, dizziness, and sedation.",Additive CNS depressant effects.,Monitor for increased sedation and CNS depressant effects.,1,2026-05-13
mephenesin,codeine,Moderate,"Increased CNS depression, dizziness, and sedation.",Additive CNS depressant effects.,Monitor for increased sedation and CNS depressant effects.,1,2026-05-13
mephenesin,morphine,Moderate,"Increased CNS depression, dizziness, and sedation.",Additive CNS depressant effects.,Monitor for increased sedation and CNS depressant effects.,1,2026-05-13
ristine,,,,,,1,2026-05-13
soya isoflavones,warfarin,Moderate,Increased risk of bleeding.,Isoflavones may inhibit warfarin metabolism or have anticoagulant properties.,Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
soya isoflavones,atorvastatin,Minor,Potentially altered statin efficacy.,"Isoflavones may affect CYP3A4 enzyme activity, which metabolizes atorvastatin.",Consider monitoring lipid levels.,1,2026-05-13
soya isoflavones,rosuvastatin,Minor,Potentially altered statin efficacy.,Isoflavones may affect transporter proteins involved in rosuvastatin elimination.,Consider monitoring lipid levels.,1,2026-05-13
dibasic calcium phosphate,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Calcium can chelate with statins, reducing oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
dibasic calcium phosphate,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Calcium can chelate with statins, reducing oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
dibasic calcium phosphate,ciprofloxacin,Minor,Reduced absorption of ciprofloxacin.,"Calcium can chelate with fluoroquinolones, reducing oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
dibasic calcium phosphate,"tetracyclines (not on list, but common interaction)",Major,Reduced absorption of tetracyclines.,"Calcium forms insoluble complexes with tetracyclines, reducing bioavailability.",Avoid co-administration or separate by at least 2-4 hours.,1,2026-05-13
suxamethonium,,,,,,1,2026-05-13
hydroxyethyl starch,furosemide,Moderate,Increased risk of nephrotoxicity and electrolyte imbalances.,"Both can affect renal function; HES can cause osmotic diuresis, and furosemide is a diuretic.",Monitor renal function and electrolytes closely.,1,2026-05-13
alcaftadine,,,,,,1,2026-05-13
alfacalcidol,digoxin,Moderate,Increased risk of digoxin toxicity.,Hypercalcemia induced by alfacalcidol increases myocardial sensitivity to digoxin.,Monitor calcium levels and digoxin levels closely; adjust digoxin dose if necessary.,1,2026-05-13
alfacalcidol,"diuretics (e.g., furosemide, spironolactone)",Moderate,Increased risk of hypercalcemia.,Thiazide diuretics can enhance the effects of vitamin D metabolites on calcium reabsorption.,Monitor calcium levels closely.,1,2026-05-13
pholcodine,tramadol,Major,Potentially life-threatening serotonin syndrome.,Both are serotonergic agents; co-administration increases the risk of excessive serotonin activity.,Avoid co-administration; monitor for symptoms of serotonin syndrome.,1,2026-05-13
pholcodine,codeine,Moderate,Increased central nervous system depression.,Additive sedative effects.,Monitor for sedation and respiratory depression.,1,2026-05-13
pholcodine,morphine,Moderate,Increased central nervous system depression.,Additive sedative effects.,Monitor for sedation and respiratory depression.,1,2026-05-13
pholcodine,alprazolam,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
pholcodine,diazepam,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
pholcodine,lorazepam,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
pholcodine,clonazepam,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
pholcodine,midazolam,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
pholcodine,zolpidem,Major,"Severe CNS depression, respiratory depression, and death.",Synergistic CNS depressant effects.,Avoid co-administration; use with extreme caution and close monitoring if absolutely necessary.,1,2026-05-13
insulin lispro protamine,metformin,Minor,Increased risk of hypoglycemia.,Both agents lower blood glucose; combined effect can be additive.,Monitor blood glucose closely; adjust insulin or metformin doses as needed.,1,2026-05-13
insulin lispro protamine,atenolol,Moderate,Masking of hypoglycemia symptoms; increased risk of hypoglycemia.,"Beta-blockers can blunt the adrenergic response to hypoglycemia, delaying recovery and masking warning signs.",Monitor blood glucose closely; caution patients about masked symptoms.,1,2026-05-13
insulin lispro protamine,metoprolol,Moderate,Masking of hypoglycemia symptoms; increased risk of hypoglycemia.,"Beta-blockers can blunt the adrenergic response to hypoglycemia, delaying recovery and masking warning signs.",Monitor blood glucose closely; caution patients about masked symptoms.,1,2026-05-13
insulin lispro protamine,aspirin,Moderate,Increased risk of hypoglycemia.,High doses of salicylates can potentiate the hypoglycemic effect of insulin.,Monitor blood glucose closely; adjust insulin dose if needed.,1,2026-05-13
insulin lispro protamine,ibuprofen,Minor,Potentially increased risk of hypoglycemia.,NSAIDs may have a weak effect on glucose control.,Monitor blood glucose closely.,1,2026-05-13
insulin lispro protamine,prednisolone,Moderate,Decreased glycemic control; hyperglycemia.,Corticosteroids antagonize the action of insulin.,Monitor blood glucose closely; increase insulin dose if needed.,1,2026-05-13
insulin lispro protamine,dexamethasone,Moderate,Decreased glycemic control; hyperglycemia.,Corticosteroids antagonize the action of insulin.,Monitor blood glucose closely; increase insulin dose if needed.,1,2026-05-13
febantel,,,,,,1,2026-05-13
bogs india,,,,,,1,2026-05-13
dexketoprofen,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and damage gastric mucosa, potentiating anticoagulant effects.","Monitor INR closely, consider alternative analgesics or reduce warfarin dose.",1,2026-05-13
dexketoprofen,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive gastrointestinal irritation and antiplatelet effects from both NSAIDs.,"Avoid concurrent use if possible, or monitor for GI side effects.",1,2026-05-13
dexketoprofen,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Additive gastrointestinal irritation and antiplatelet effects from both NSAIDs.,"Avoid concurrent use if possible, or monitor for GI side effects.",1,2026-05-13
dexketoprofen,metformin,Minor,Slightly increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin clearance.",Monitor renal function and blood glucose.,1,2026-05-13
dexketoprofen,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow, antagonizing ACE inhibitors/ARBs.","Monitor blood pressure and renal function, consider alternative analgesics.",1,2026-05-13
dexketoprofen,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow, antagonizing ACE inhibitors/ARBs.","Monitor blood pressure and renal function, consider alternative analgesics.",1,2026-05-13
dexketoprofen,furosemide,Moderate,"Reduced diuretic and antihypertensive effect, increased risk of renal impairment.","NSAIDs can inhibit prostaglandin synthesis, reducing the natriuretic and diuretic response to loop diuretics.","Monitor diuresis, blood pressure, and renal function.",1,2026-05-13
dexketoprofen,spironolactone,Moderate,Increased risk of hyperkalemia and renal impairment.,"NSAIDs can impair renal function and reduce potassium excretion, potentiating effects of potassium-sparing diuretics.",Monitor potassium levels and renal function.,1,2026-05-13
dexketoprofen,lithium,Major,"Increased lithium toxicity (nausea, vomiting, tremors, confusion).",NSAIDs can reduce renal lithium clearance.,"Avoid concurrent use, monitor lithium levels closely if unavoidable.",1,2026-05-13
menadione,warfarin,Major,"Reduced anticoagulant effect, increased risk of thrombosis.","Vitamin K promotes the synthesis of clotting factors, antagonizing warfarin.","Avoid concurrent use, monitor INR closely and adjust warfarin dose.",1,2026-05-13
glycerol,,,,,,1,2026-05-13
overseasdomperidone,ketoconazole,Major,Increased risk of QTc prolongation and arrhythmias.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma levels.",Avoid concurrent use.,1,2026-05-13
overseasdomperidone,itraconazole,Major,Increased risk of QTc prolongation and arrhythmias.,"Itraconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma levels.",Avoid concurrent use.,1,2026-05-13
overseasdomperidone,clarithromycin,Major,Increased risk of QTc prolongation and arrhythmias.,"Clarithromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma levels.",Avoid concurrent use.,1,2026-05-13
overseasdomperidone,erythromycin,Major,Increased risk of QTc prolongation and arrhythmias.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma levels.",Avoid concurrent use.,1,2026-05-13
overseasdomperidone,amlodipine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Monitor ECG and use with caution.,1,2026-05-13
overseasdomperidone,sertraline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Monitor ECG and use with caution.,1,2026-05-13
overseasdomperidone,fluoxetine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Monitor ECG and use with caution.,1,2026-05-13
overseasdomperidone,amitriptyline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Monitor ECG and use with caution.,1,2026-05-13
overseasdomperidone,haloperidol,Major,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Avoid concurrent use.,1,2026-05-13
overseasdomperidone,clozapine,Major,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Avoid concurrent use.,1,2026-05-13
overseasdomperidone,olanzapine,Major,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,Avoid concurrent use.,1,2026-05-13
overseasdomperidone,digoxin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
dexpanthenol,,,,,,1,2026-05-13
dihydralazine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Additive hypotensive effects of a vasodilator and a beta-blocker.,Monitor blood pressure and heart rate closely.,1,2026-05-13
dihydralazine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Additive hypotensive effects of a vasodilator and a beta-blocker.,Monitor blood pressure and heart rate closely.,1,2026-05-13
dihydralazine,losartan,Moderate,Increased risk of hypotension.,Additive hypotensive effects of two antihypertensive agents.,Monitor blood pressure closely.,1,2026-05-13
dihydralazine,ramipril,Moderate,Increased risk of hypotension.,Additive hypotensive effects of two antihypertensive agents.,Monitor blood pressure closely.,1,2026-05-13
dihydralazine,ibuprofen,Minor,Reduced antihypertensive effect.,NSAIDs can antagonize the effects of antihypertensives by inhibiting prostaglandin synthesis.,Monitor blood pressure.,1,2026-05-13
dihydralazine,aspirin,Minor,Reduced antihypertensive effect.,NSAIDs can antagonize the effects of antihypertensives by inhibiting prostaglandin synthesis.,Monitor blood pressure.,1,2026-05-13
caroverine,,,,,,1,2026-05-13
zinc monomethionine,,,,,,1,2026-05-13
rimonabant,sertraline,Major,Increased risk of suicidal thoughts and depression.,"Both drugs affect serotonin pathways, increasing the risk of neuropsychiatric adverse events.","Avoid concurrent use, monitor for psychiatric symptoms.",1,2026-05-13
rimonabant,fluoxetine,Major,Increased risk of suicidal thoughts and depression.,"Both drugs affect serotonin pathways, increasing the risk of neuropsychiatric adverse events.","Avoid concurrent use, monitor for psychiatric symptoms.",1,2026-05-13
rimonabant,amitriptyline,Major,Increased risk of psychiatric events and CNS depression.,Rimonabant can cause psychiatric effects; amitriptyline also affects neurotransmitter systems and can cause CNS depression.,"Avoid concurrent use, monitor for psychiatric symptoms and sedation.",1,2026-05-13
rimonabant,diazepam,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of benzodiazepines.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,alprazolam,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of benzodiazepines.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,lorazepam,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of benzodiazepines.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,clonazepam,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of benzodiazepines.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,midazolam,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of benzodiazepines.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,zolpidem,Moderate,Increased risk of CNS depression and dizziness.,"Rimonabant can cause CNS effects, potentiating sedative effects of hypnotics.","Monitor for sedation and dizziness, reduce dose if necessary.",1,2026-05-13
rimonabant,metformin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,atorvastatin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,amlodipine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,losartan,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,omeprazole,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,pantoprazole,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,amoxicillin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,azithromycin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,ciprofloxacin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,metronidazole,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,prednisolone,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,dexamethasone,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,insulin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,digoxin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,furosemide,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,spironolactone,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,atenolol,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,metoprolol,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,ramipril,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,clopidogrel,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,rosuvastatin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,gabapentin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,tramadol,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,codeine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,morphine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,phenytoin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,valproate,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,carbamazepine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,rifampicin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,isoniazid,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,ethambutol,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,hydroxychloroquine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,colchicine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,allopurinol,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,methotrexate,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,cyclosporine,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,tacrolimus,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,lithium,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,haloperidol,Major,Increased risk of suicidal thoughts and depression.,Both drugs affect neurotransmitter systems and can cause psychiatric adverse events.,"Avoid concurrent use, monitor for psychiatric symptoms.",1,2026-05-13
rimonabant,clozapine,Major,Increased risk of suicidal thoughts and depression.,Both drugs affect neurotransmitter systems and can cause psychiatric adverse events.,"Avoid concurrent use, monitor for psychiatric symptoms.",1,2026-05-13
rimonabant,olanzapine,Major,Increased risk of suicidal thoughts and depression.,Both drugs affect neurotransmitter systems and can cause psychiatric adverse events.,"Avoid concurrent use, monitor for psychiatric symptoms.",1,2026-05-13
rimonabant,warfarin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,ibuprofen,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,aspirin,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
rimonabant,dexketoprofen,Minor,No significant interaction reported.,No clinically significant interaction expected.,No specific action required.,1,2026-05-13
tibolone,warfarin,Moderate,Increased risk of bleeding.,"Tibolone metabolites can affect the metabolism of warfarin, altering its anticoagulant effect.",Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
tibolone,phenytoin,Moderate,Reduced efficacy of tibolone.,Phenytoin is a strong CYP enzyme inducer that can accelerate tibolone metabolism.,Consider alternative therapies or monitor for signs of tibolone treatment failure.,1,2026-05-13
tibolone,carbamazepine,Moderate,Reduced efficacy of tibolone.,Carbamazepine is a strong CYP enzyme inducer that can accelerate tibolone metabolism.,Consider alternative therapies or monitor for signs of tibolone treatment failure.,1,2026-05-13
tibolone,rifampicin,Moderate,Reduced efficacy of tibolone.,Rifampicin is a strong CYP enzyme inducer that can accelerate tibolone metabolism.,Consider alternative therapies or monitor for signs of tibolone treatment failure.,1,2026-05-13
uracil,warfarin,Moderate,Increased risk of bleeding.,Uracil can interfere with vitamin K metabolism and enhance the anticoagulant effect of warfarin.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
uracil,metronidazole,Moderate,Increased risk of uracil toxicity.,"Metronidazole can inhibit the metabolism of uracil, leading to higher plasma concentrations.",Monitor for signs of uracil toxicity and consider dose adjustment or alternative antibiotics.,1,2026-05-13
s-metoprolol succinate,amiodarone,Major,Risk of bradycardia and heart block.,Both drugs can slow heart rate and AV conduction.,"Use with caution, monitor heart rate and ECG, consider dose reduction.",1,2026-05-13
s-metoprolol succinate,verapamil,Major,"Risk of bradycardia, heart block, and hypotension.","Both drugs decrease heart rate and contractility, and verapamil can inhibit metoprolol metabolism.",Avoid concomitant use or monitor closely for cardiovascular effects.,1,2026-05-13
s-metoprolol succinate,diltiazem,Major,"Risk of bradycardia, heart block, and hypotension.","Both drugs decrease heart rate and contractility, and diltiazem can inhibit metoprolol metabolism.",Avoid concomitant use or monitor closely for cardiovascular effects.,1,2026-05-13
s-metoprolol succinate,insulin,Moderate,Masking of hypoglycemia symptoms.,"Beta-blockers can mask the tachycardia associated with hypoglycemia, delaying recognition and treatment.",Monitor blood glucose levels closely and educate patients on recognizing hypoglycemia symptoms.,1,2026-05-13
s-metoprolol succinate,metformin,Minor,Potential for masked hypoglycemia symptoms.,Beta-blockers can mask the adrenergic symptoms of hypoglycemia.,Educate patients on recognizing hypoglycemia symptoms and monitor blood glucose.,1,2026-05-13
lanthanum carbonate,warfarin,Moderate,"Reduced absorption of warfarin, leading to decreased efficacy.","Lanthanum carbonate can bind to warfarin in the gastrointestinal tract, reducing its bioavailability.",Administer lanthanum carbonate at least 2 hours before or 3 hours after warfarin.,1,2026-05-13
lanthanum carbonate,thyroid hormone,Major,"Reduced absorption of thyroid hormone, leading to hypothyroidism.","Lanthanum carbonate can bind to thyroid hormones, decreasing their absorption.",Administer lanthanum carbonate at least 4 hours apart from thyroid hormone supplements.,1,2026-05-13
lanthanum carbonate,ciprofloxacin,Moderate,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.","Lanthanum carbonate can bind to ciprofloxacin, reducing its bioavailability.",Administer lanthanum carbonate at least 2 hours before or 3 hours after ciprofloxacin.,1,2026-05-13
lanthanum carbonate,atenolol,Moderate,"Reduced absorption of atenolol, leading to decreased efficacy.","Lanthanum carbonate can bind to atenolol, reducing its bioavailability.",Administer lanthanum carbonate at least 2 hours before or 3 hours after atenolol.,1,2026-05-13
octenidine,,,,,,1,2026-05-13
isavuconazole,warfarin,Moderate,Increased risk of bleeding.,Isavuconazole is a CYP3A4 inhibitor and may increase warfarin levels.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
isavuconazole,atorvastatin,Moderate,Increased risk of myopathy.,"Isavuconazole inhibits CYP3A4, which metabolizes atorvastatin, increasing its plasma concentration.",Consider reducing atorvastatin dose or monitoring for muscle pain and weakness.,1,2026-05-13
isavuconazole,amiodarone,Major,Risk of bradycardia and heart block.,Both isavuconazole and amiodarone can prolong the QT interval and slow heart rate.,Avoid concomitant use or monitor heart rate and ECG closely.,1,2026-05-13
isavuconazole,atorvastatin,Moderate,Increased risk of myopathy.,"Isavuconazole inhibits CYP3A4, which metabolizes atorvastatin, increasing its plasma concentration.",Consider reducing atorvastatin dose or monitoring for muscle pain and weakness.,1,2026-05-13
overseasamoxycillin,metformin,Minor,Possible gastrointestinal upset.,"Amoxicillin can cause GI side effects, which may be additive with metformin.",Monitor for GI symptoms and advise patients to take with food if needed.,1,2026-05-13
overseasamoxycillin,warfarin,Minor,Potential for minor alteration in INR.,"Antibiotics can alter gut flora, which may have a minor impact on warfarin metabolism.",Monitor INR if significant changes in bowel habits occur.,1,2026-05-13
magnesium orotate,tetracyclines,Moderate,Reduced absorption of tetracyclines.,"Magnesium can form chelates with tetracyclines, reducing their oral absorption.",Administer magnesium orotate at least 2 hours before or 2 hours after tetracyclines.,1,2026-05-13
magnesium orotate,bisphosphonates,Moderate,Reduced absorption of bisphosphonates.,Magnesium can decrease the absorption of bisphosphonates.,Separate administration by at least 2 hours.,1,2026-05-13
ornithine,,,,,,1,2026-05-13
sterile water,,,,,,1,2026-05-13
black grape seed extract,warfarin,Moderate,Increased risk of bleeding.,Grape seed extract may inhibit platelet aggregation and affect cytochrome P450 enzymes involved in warfarin metabolism.,Monitor INR closely and consider alternative or dose adjustment of warfarin.,1,2026-05-13
black grape seed extract,atorvastatin,Minor,Potentially altered statin efficacy or side effects.,"Grape seed extract can affect CYP3A4, an enzyme involved in atorvastatin metabolism.",Monitor for efficacy and side effects of atorvastatin.,1,2026-05-13
black grape seed extract,rosuvastatin,Minor,Potentially altered statin efficacy or side effects.,Grape seed extract may affect transporters like OATP1B1 involved in rosuvastatin disposition.,Monitor for efficacy and side effects of rosuvastatin.,1,2026-05-13
placenta extracts,,,,,,1,2026-05-13
plerixafor,clopidogrel,Moderate,Reduced efficacy of plerixafor.,"Plerixafor can increase the number of circulating progenitor cells, and clopidogrel may interfere with this mobilization or signaling.",Monitor hematopoietic stem cell mobilization response and consider timing of administration.,1,2026-05-13
phenazone,warfarin,Moderate,Increased risk of bleeding.,"Phenazone can inhibit CYP2C9, an enzyme responsible for metabolizing the S-isomer of warfarin.",Monitor INR closely and consider alternative analgesics or dose adjustment of warfarin.,1,2026-05-13
phenazone,phenytoin,Moderate,Altered phenytoin levels.,"Phenazone can inhibit CYP2C9, which also metabolizes phenytoin.",Monitor phenytoin levels and for signs of toxicity or subtherapeutic effect.,1,2026-05-13
phenazone,valproate,Minor,Altered valproate levels.,Phenazone may affect valproate metabolism or protein binding.,Monitor valproate levels and for efficacy or side effects.,1,2026-05-13
piroctone olamine,,,,,,1,2026-05-13
rutinib,atorvastatin,Moderate,Increased risk of statin-induced myopathy.,"Rutinib is a strong inhibitor of CYP3A4, the primary enzyme metabolizing atorvastatin, leading to elevated statin levels.","Avoid concomitant use; if unavoidable, reduce atorvastatin dose and monitor for muscle pain or weakness.",1,2026-05-13
rutinib,simvastatin,Major,Significantly increased risk of myopathy and rhabdomyolysis.,"Rutinib is a strong inhibitor of CYP3A4, the primary enzyme metabolizing simvastatin, leading to dangerously elevated simvastatin levels.","Avoid concomitant use. If unavoidable, reduce simvastatin dose to the lowest effective dose and monitor closely for muscle pain, tenderness, or weakness.",1,2026-05-13
rutinib,clopidogrel,Minor,Potentially altered antiplatelet effect.,"Rutinib can inhibit P2Y12 receptors, potentially affecting clopidogrel's antiplatelet activity.",Monitor for signs of thrombotic events or bleeding.,1,2026-05-13
colloidal bismuth subcitrate,tetracyclines,Moderate,Reduced absorption of tetracyclines.,"Bismuth can form insoluble complexes with tetracyclines in the gastrointestinal tract, decreasing their absorption.",Separate administration of colloidal bismuth subcitrate and tetracyclines by at least 2-4 hours.,1,2026-05-13
colloidal bismuth subcitrate,quinolones,Moderate,Reduced absorption of quinolones.,"Bismuth can chelate with quinolone antibiotics, reducing their systemic absorption.",Separate administration of colloidal bismuth subcitrate and quinolones by at least 2-4 hours.,1,2026-05-13
sodium aminosalicylate,warfarin,Moderate,Increased risk of bleeding.,"Sodium aminosalicylate can displace warfarin from protein binding sites, increasing the free fraction and anticoagulant effect.",Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
sodium aminosalicylate,methotrexate,Moderate,Increased risk of methotrexate toxicity.,"Sodium aminosalicylate can inhibit renal excretion of methotrexate, leading to increased serum levels.",Monitor methotrexate levels and for signs of toxicity; consider dose adjustment or alternative.,1,2026-05-13
sodium aminosalicylate,furosemide,Minor,Potentially altered diuretic response.,"Sodium aminosalicylate may affect renal tubular secretion or reabsorption, potentially interacting with furosemide's mechanism.",Monitor diuretic response and electrolyte balance.,1,2026-05-13
overseasofloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones like ofloxacin can inhibit CYP2C9, an enzyme that metabolizes warfarin, leading to increased INR.",Monitor INR closely and consider alternative antibiotics or dose adjustment of warfarin.,1,2026-05-13
overseasofloxacin,theophylline,Moderate,Increased risk of theophylline toxicity.,"Fluoroquinolones can inhibit the metabolism of theophylline, leading to elevated serum levels and potential toxicity.",Monitor theophylline levels and for signs of toxicity; consider alternative antibiotics or dose reduction of theophylline.,1,2026-05-13
overseasofloxacin,metformin,Moderate,Increased risk of metformin-induced lactic acidosis.,"Fluoroquinolones can impair renal function, which is crucial for metformin excretion.",Monitor renal function and blood glucose; use with caution and consider alternative antibiotics or dose adjustment of metformin.,1,2026-05-13
overseasofloxacin,"multivitamins containing minerals (iron, calcium, magnesium, zinc)",Moderate,Reduced absorption of ofloxacin.,"Divalent and trivalent cations in minerals can chelate with fluoroquinolones, forming insoluble complexes and reducing absorption.",Separate administration of ofloxacin and mineral-containing supplements by at least 2 hours before or 4 hours after ofloxacin.,1,2026-05-13
dothiepin,amitriptyline,Moderate,"Increased risk of anticholinergic side effects (dry mouth, constipation, blurred vision, urinary retention) and CNS depression.",Both are tricyclic antidepressants (TCAs) with additive pharmacodynamic effects and potentially additive metabolism inhibition.,"Use with extreme caution, monitor for side effects, and consider dose reduction of one or both agents.",1,2026-05-13
dothiepin,diazepam,Moderate,"Increased CNS depression (drowsiness, sedation, impaired coordination).",Additive sedative effects of a TCA and a benzodiazepine.,Monitor for excessive sedation and advise patient to avoid activities requiring alertness.,1,2026-05-13
dothiepin,alprazolam,Moderate,"Increased CNS depression (drowsiness, sedation, impaired coordination).",Additive sedative effects of a TCA and a benzodiazepine.,Monitor for excessive sedation and advise patient to avoid activities requiring alertness.,1,2026-05-13
dothiepin,lorazepam,Moderate,"Increased CNS depression (drowsiness, sedation, impaired coordination).",Additive sedative effects of a TCA and a benzodiazepine.,Monitor for excessive sedation and advise patient to avoid activities requiring alertness.,1,2026-05-13
dothiepin,clonazepam,Moderate,"Increased CNS depression (drowsiness, sedation, impaired coordination).",Additive sedative effects of a TCA and a benzodiazepine.,Monitor for excessive sedation and advise patient to avoid activities requiring alertness.,1,2026-05-13
dothiepin,zolpidem,Moderate,"Increased CNS depression (drowsiness, sedation, impaired coordination).",Additive sedative effects of a TCA and a hypnotic agent.,Monitor for excessive sedation and advise patient to avoid activities requiring alertness.,1,2026-05-13
dothiepin,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for signs of respiratory depression and excessive sedation; consider lower doses.,1,2026-05-13
dothiepin,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for signs of respiratory depression and excessive sedation; consider lower doses.,1,2026-05-13
dothiepin,tramadol,Moderate,Increased CNS depression and potential for serotonin syndrome.,"Both can affect serotonin and norepinephrine reuptake, leading to additive CNS effects and potential for serotonin syndrome.","Monitor for increased sedation and signs of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever).",1,2026-05-13
dothiepin,sertraline,Moderate,Increased risk of serotonin syndrome and additive anticholinergic effects.,"TCAs inhibit serotonin reuptake, and SSRIs like sertraline also inhibit serotonin reuptake. Additive anticholinergic effects are also possible.",Monitor for signs of serotonin syndrome and additive anticholinergic effects; use with caution.,1,2026-05-13
dothiepin,fluoxetine,Moderate,Increased risk of serotonin syndrome and potential for increased TCA levels.,"Fluoxetine is a strong CYP2D6 inhibitor, which metabolizes many TCAs, leading to higher TCA concentrations. Also potential for serotonin syndrome.",Monitor for signs of serotonin syndrome and TCA toxicity; consider a lower dose of dothiepin or an alternative antidepressant.,1,2026-05-13
dothiepin,atorvastatin,Minor,Potentially altered statin efficacy or side effects.,"Dothiepin can inhibit CYP2D6, which may have a minor role in atorvastatin metabolism.",Monitor for efficacy and side effects of atorvastatin.,1,2026-05-13
dothiepin,rosuvastatin,Minor,Potentially altered statin efficacy or side effects.,"Dothiepin can inhibit CYP2D6, which may have a minor role in rosuvastatin metabolism.",Monitor for efficacy and side effects of rosuvastatin.,1,2026-05-13
isopropamide,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, urinary retention).","Both drugs have anticholinergic properties, leading to additive effects.",Monitor for anticholinergic side effects and consider dose adjustment.,1,2026-05-13
isopropamide,diazepam,Minor,Potentially increased sedation.,Additive sedative effects.,Monitor for excessive drowsiness.,1,2026-05-13
isopropamide,lorazepam,Minor,Potentially increased sedation.,Additive sedative effects.,Monitor for excessive drowsiness.,1,2026-05-13
isopropamide,alprazolam,Minor,Potentially increased sedation.,Additive sedative effects.,Monitor for excessive drowsiness.,1,2026-05-13
isopropamide,clonazepam,Minor,Potentially increased sedation.,Additive sedative effects.,Monitor for excessive drowsiness.,1,2026-05-13
tirzepatide,metformin,Moderate,Increased risk of hypoglycemia.,Tirzepatide lowers blood glucose; concomitant use with other glucose-lowering agents can potentiate this effect.,Monitor blood glucose closely and adjust metformin dose if needed.,1,2026-05-13
tirzepatide,insulin,Major,Significant risk of severe hypoglycemia.,Tirzepatide potentiates insulin's glucose-lowering effects.,Intensified blood glucose monitoring is required; dose adjustment of insulin is likely necessary.,1,2026-05-13
tirzepatide,sulfonylureas (not on common list but common with metformin),Major,Increased risk of severe hypoglycemia.,Tirzepatide potentiates the glucose-lowering effects of sulfonylureas.,Intensified blood glucose monitoring is required; dose adjustment of sulfonylureas is likely necessary.,1,2026-05-13
purified vi polysaccharide typhoid vaccine,prednisolone,Moderate,Reduced immune response to the vaccine.,Corticosteroids are immunosuppressants and can impair the body's ability to mount an effective immune response.,Consider timing of vaccination relative to corticosteroid therapy; assess vaccine effectiveness if possible.,1,2026-05-13
purified vi polysaccharide typhoid vaccine,dexamethasone,Moderate,Reduced immune response to the vaccine.,Corticosteroids are immunosuppressants and can impair the body's ability to mount an effective immune response.,Consider timing of vaccination relative to corticosteroid therapy; assess vaccine effectiveness if possible.,1,2026-05-13
carbetocin,oxytocin (not on common list but mechanistically similar),Major,"Increased risk of uterine hyperstimulation, rupture, and maternal/fetal distress.",Both are oxytocic agents that stimulate uterine contractions.,Avoid concomitant use; monitor uterine activity closely if used sequentially.,1,2026-05-13
tocotrienol,warfarin,Moderate,Potential for increased anticoagulant effect and bleeding risk.,"Vitamin E analogs, including tocotrienols, can inhibit platelet aggregation and potentially interfere with vitamin K metabolism.",Monitor INR closely and adjust warfarin dose if necessary; patients should be advised of bleeding risks.,1,2026-05-13
tocotrienol,atorvastatin,Minor,Potentially increased risk of muscle pain or rhabdomyolysis (theoretical).,High doses of vitamin E have been associated with increased statin toxicity in some studies.,Monitor for muscle pain; caution advised with high doses of both.,1,2026-05-13
tocotrienol,rosuvastatin,Minor,Potentially increased risk of muscle pain or rhabdomyolysis (theoretical).,High doses of vitamin E have been associated with increased statin toxicity in some studies.,Monitor for muscle pain; caution advised with high doses of both.,1,2026-05-13
electrolytes,furosemide,Major,"Increased risk of electrolyte depletion (e.g., hypokalemia, hypomagnesemia, hyponatremia).",Furosemide is a loop diuretic that promotes the excretion of electrolytes; electrolyte replacement may be needed.,Monitor electrolyte levels frequently and administer electrolyte supplements as needed.,1,2026-05-13
electrolytes,spironolactone,Moderate,Increased risk of hyperkalemia.,Spironolactone is a potassium-sparing diuretic; concomitant use with other electrolyte-modifying agents requires careful monitoring.,Monitor potassium levels closely.,1,2026-05-13
electrolytes,losartan,Moderate,Increased risk of hyperkalemia.,"Losartan is an ARB which can also increase potassium levels, especially in the context of electrolyte imbalances.",Monitor potassium levels closely.,1,2026-05-13
electrolytes,ramipril,Moderate,Increased risk of hyperkalemia.,"Ramipril is an ACE inhibitor which can also increase potassium levels, especially in the context of electrolyte imbalances.",Monitor potassium levels closely.,1,2026-05-13
electrolytes,lithium,Moderate,"Altered lithium levels, potentially leading to toxicity or subtherapeutic effects.","Electrolyte imbalances, particularly sodium and potassium, can affect lithium reabsorption and clearance.",Monitor lithium levels and electrolyte status closely.,1,2026-05-13
zotepine,diazepam,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,alprazolam,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,lorazepam,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,clonazepam,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,midazolam,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,zolpidem,Moderate,Increased sedation and CNS depression.,Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression; consider dose reduction.,1,2026-05-13
zotepine,amitriptyline,Moderate,Increased risk of QTc prolongation and anticholinergic effects.,Additive QTc prolonging potential and anticholinergic effects.,Monitor ECG for QTc interval; monitor for anticholinergic side effects.,1,2026-05-13
zotepine,atenolol,Minor,Increased risk of hypotension.,Both can lower blood pressure.,Monitor blood pressure.,1,2026-05-13
zotepine,metoprolol,Minor,Increased risk of hypotension.,Both can lower blood pressure.,Monitor blood pressure.,1,2026-05-13
zotepine,amlodipine,Minor,Increased risk of hypotension.,Both can lower blood pressure.,Monitor blood pressure.,1,2026-05-13
succinyl choline chloride,neostigmine (not on common list but clinically relevant for reversal),Major,Prolonged neuromuscular blockade and muscle fasciculations.,Anticholinesterase agents can prolong the action of succinylcholine by inhibiting its breakdown.,Avoid concomitant use; use with extreme caution and appropriate monitoring.,1,2026-05-13
succinyl choline chloride,echothiophate (not on common list but relevant cholinesterase inhibitor),Major,Prolonged neuromuscular blockade and muscle fasciculations.,"Echothiophate irreversibly inhibits cholinesterase, prolonging succinylcholine's action.",Avoid concomitant use.,1,2026-05-13
succinyl choline chloride,"organophosphates (e.g., certain pesticides, not on list)",Major,Prolonged neuromuscular blockade and muscle fasciculations.,"Organophosphates inhibit cholinesterase, prolonging succinylcholine's action.",Avoid concomitant exposure.,1,2026-05-13
succinyl choline chloride,phenytoin,Moderate,Reduced efficacy of neuromuscular blockade; paradoxical muscle fasciculations.,"Phenytoin may interfere with the neuromuscular junction, potentially reducing succinylcholine's effect.",Monitor neuromuscular blockade response; may require increased succinylcholine dose.,1,2026-05-13
succinyl choline chloride,cyclophosphamide (not on common list but relevant),Major,Prolonged neuromuscular blockade and hyperkalemia.,"Cyclophosphamide can inhibit plasma cholinesterase, which is necessary for succinylcholine metabolism.",Avoid concomitant use.,1,2026-05-13
human menopausal gonadotrophin,clomiphene (not on common list but relevant),Moderate,Increased risk of ovarian hyperstimulation syndrome (OHSS).,Both drugs stimulate ovulation and can potentiate ovarian response.,Monitor closely for signs and symptoms of OHSS.,1,2026-05-13
framycetin,neomycin (not on common list but similar aminoglycoside),Major,Increased risk of nephrotoxicity and ototoxicity.,Additive nephrotoxic and ototoxic effects of aminoglycoside antibiotics.,Avoid concomitant use; monitor renal function and hearing.,1,2026-05-13
framycetin,gentamicin (not on common list but similar aminoglycoside),Major,Increased risk of nephrotoxicity and ototoxicity.,Additive nephrotoxic and ototoxic effects of aminoglycoside antibiotics.,Avoid concomitant use; monitor renal function and hearing.,1,2026-05-13
framycetin,amphotericin b (not on common list but relevant),Major,Increased risk of nephrotoxicity.,Both drugs are nephrotoxic.,Monitor renal function closely; use with caution.,1,2026-05-13
framycetin,furosemide,Moderate,Increased risk of ototoxicity.,Furosemide can potentiate the ototoxic effects of aminoglycosides.,Monitor hearing and balance; use with caution.,1,2026-05-13
framycetin,cyclosporine,Moderate,Increased risk of nephrotoxicity.,Both drugs can be nephrotoxic.,Monitor renal function closely; use with caution.,1,2026-05-13
framycetin,tacrolimus,Moderate,Increased risk of nephrotoxicity.,Both drugs can be nephrotoxic.,Monitor renal function closely; use with caution.,1,2026-05-13
enrofloxacin,warfarin,Major,Increased risk of bleeding.,Enrofloxacin inhibits CYP450 enzymes involved in warfarin metabolism.,Monitor INR closely; consider alternative antibiotic or dose adjustment of warfarin.,1,2026-05-13
enrofloxacin,metformin,Moderate,"Potential for increased metformin levels, leading to hypoglycemia.",Enrofloxacin may inhibit renal excretion or intestinal absorption of metformin.,Monitor blood glucose; consider temporary interruption of enrofloxacin or dose adjustment of metformin.,1,2026-05-13
enrofloxacin,phenytoin,Moderate,Potential for altered phenytoin levels.,Fluoroquinolones can inhibit CYP450 enzymes involved in phenytoin metabolism.,Monitor phenytoin levels and patient for signs of toxicity or sub-therapeutic effect.,1,2026-05-13
penicillin v,methotrexate,Major,"Reduced methotrexate clearance, leading to increased toxicity.",Penicillins can interfere with the renal tubular secretion of methotrexate.,Avoid concurrent use; monitor methotrexate levels and for signs of toxicity if concurrent use is unavoidable.,1,2026-05-13
penicillin v,probenecid,Moderate,Increased penicillin V levels.,Probenecid competitively inhibits the renal tubular secretion of penicillin V.,Monitor for signs of penicillin toxicity; dose adjustment of penicillin may be needed.,1,2026-05-13
desidustat,,,,,,1,2026-05-13
biapenem,valproate,Major,"Reduced valproate serum levels, leading to loss of seizure control.",Carbapenems can hydrolyze valproic acid by irreversibly binding to and inhibiting specific esterases.,Monitor valproate levels; consider alternative antibiotic or anticonvulsant.,1,2026-05-13
glycolic acid,,,,,,1,2026-05-13
sarolaner,,,,,,1,2026-05-13
nadroparin,warfarin,Major,Increased risk of bleeding.,Additive anticoagulant effect.,Monitor coagulation parameters closely; adjust doses as needed.,1,2026-05-13
nadroparin,aspirin,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Avoid concurrent use; monitor for signs of bleeding.,1,2026-05-13
nadroparin,clopidogrel,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Avoid concurrent use; monitor for signs of bleeding.,1,2026-05-13
nadroparin,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Additive effect on platelet function and gastrointestinal mucosal integrity.,Monitor for signs of GI bleeding; use with caution.,1,2026-05-13
nouveau medicament,,,,,,1,2026-05-13
carboprost,oxytocin,Moderate,Increased risk of uterine hyperstimulation or spasm.,Both agents can stimulate uterine contractions.,Use with caution and monitor uterine activity closely.,1,2026-05-13
borax,,,,,,1,2026-05-13
hemocoagulase,aspirin,Major,Increased risk of bleeding.,"Hemocoagulase promotes coagulation, while aspirin inhibits platelet aggregation.",Avoid concurrent use or monitor closely for bleeding.,1,2026-05-13
hemocoagulase,ibuprofen,Major,Increased risk of bleeding.,"Hemocoagulase promotes coagulation, while ibuprofen inhibits platelet aggregation.",Avoid concurrent use or monitor closely for bleeding.,1,2026-05-13
hemocoagulase,warfarin,Major,Increased risk of bleeding.,"Hemocoagulase promotes coagulation, while warfarin inhibits vitamin K-dependent clotting factors.",Avoid concurrent use or monitor INR very closely for bleeding.,1,2026-05-13
hemocoagulase,clopidogrel,Major,Increased risk of bleeding.,"Hemocoagulase promotes coagulation, while clopidogrel inhibits platelet aggregation.",Avoid concurrent use or monitor closely for bleeding.,1,2026-05-13
recombinant human erythropoietin,aspirin,Moderate,Reduced efficacy of erythropoietin.,Aspirin can interfere with erythropoietin's effect on red blood cell production.,Monitor hemoglobin response; consider alternative or dose adjustment.,1,2026-05-13
recombinant human erythropoietin,ibuprofen,Moderate,Reduced efficacy of erythropoietin.,Ibuprofen can interfere with erythropoietin's effect on red blood cell production.,Monitor hemoglobin response; consider alternative or dose adjustment.,1,2026-05-13
recombinant human erythropoietin,furosemide,Moderate,Increased risk of fluid retention and edema.,Both can cause fluid retention; additive effect.,Monitor fluid status and blood pressure closely.,1,2026-05-13
recombinant human erythropoietin,spironolactone,Moderate,Increased risk of hyperkalemia.,Both can affect electrolyte balance.,Monitor potassium levels closely.,1,2026-05-13
l-methyltetrahydrofolate clacium,methotrexate,Major,Reduced efficacy of methotrexate.,L-methyltetrahydrofolate is a potent form of folate that can antagonize the antifolate effects of methotrexate.,Avoid concurrent use in most cases; judicious use only if specifically indicated and monitored.,1,2026-05-13
l-methyltetrahydrofolate clacium,phenytoin,Moderate,Reduced serum levels of phenytoin.,Folic acid can affect phenytoin metabolism.,Monitor phenytoin levels and therapeutic response.,1,2026-05-13
l-methyltetrahydrofolate clacium,valproate,Moderate,Reduced serum levels of valproate.,Folic acid can affect valproate metabolism.,Monitor valproate levels and therapeutic response.,1,2026-05-13
rubella vaccine,,,,,,1,2026-05-13
vericiguat,losartan,Moderate,Increased risk of hypotension.,Additive effects on vasodilation and blood pressure lowering.,"Monitor blood pressure closely, especially upon initiation or dose adjustment.",1,2026-05-13
vericiguat,amlodipine,Moderate,Increased risk of hypotension.,Additive effects on vasodilation and blood pressure lowering.,"Monitor blood pressure closely, especially upon initiation or dose adjustment.",1,2026-05-13
vericiguat,ramipril,Moderate,Increased risk of hypotension.,Additive effects on vasodilation and blood pressure lowering.,"Monitor blood pressure closely, especially upon initiation or dose adjustment.",1,2026-05-13
vericiguat,atenolol,Moderate,Increased risk of hypotension.,Additive effects on blood pressure lowering.,"Monitor blood pressure closely, especially upon initiation or dose adjustment.",1,2026-05-13
vericiguat,metoprolol,Moderate,Increased risk of hypotension.,Additive effects on blood pressure lowering.,"Monitor blood pressure closely, especially upon initiation or dose adjustment.",1,2026-05-13
l-glutamine,,,,,,1,2026-05-13
s-methoprene,,,,,,1,2026-05-13
inactivated influenza vaccine,,,,,,1,2026-05-13
granulocyte colony stimulating factor,prednisolone,Moderate,Potential for increased risk of bone pain.,Corticosteroids can sometimes exacerbate G-CSF-induced bone pain.,Monitor for bone pain; consider analgesics if needed.,1,2026-05-13
granulocyte colony stimulating factor,dexamethasone,Moderate,Potential for increased risk of bone pain.,Corticosteroids can sometimes exacerbate G-CSF-induced bone pain.,Monitor for bone pain; consider analgesics if needed.,1,2026-05-13
metamizole,metformin,Moderate,Increased risk of lactic acidosis.,"Metamizole can rarely cause neutropenia, which may indirectly affect glucose metabolism; also, potential for renal impairment with metamizole, affecting metformin clearance.",Monitor blood glucose and renal function closely; consider alternative analgesic if risk is high.,1,2026-05-13
metamizole,cyclosporine,Moderate,Reduced serum levels of cyclosporine.,"Metamizole can induce hepatic enzymes, increasing cyclosporine metabolism.",Monitor cyclosporine levels and therapeutic efficacy.,1,2026-05-13
metamizole,tacrolimus,Moderate,Reduced serum levels of tacrolimus.,"Metamizole can induce hepatic enzymes, increasing tacrolimus metabolism.",Monitor tacrolimus levels and therapeutic efficacy.,1,2026-05-13
metamizole,rifampicin,Major,Reduced efficacy of metamizole.,Rifampicin is a potent inducer of hepatic enzymes that metabolize metamizole.,Avoid concurrent use or monitor for reduced metamizole effect.,1,2026-05-13
potassium dihydrogen phosphate,furosemide,Moderate,Hypokalemia may be exacerbated or masked.,"Furosemide is a loop diuretic that increases potassium excretion, potentially leading to hypokalemia. Potassium supplements can counteract this effect.",Monitor serum potassium levels closely.,1,2026-05-13
potassium dihydrogen phosphate,spironolactone,Moderate,Hyperkalemia risk increased.,Spironolactone is a potassium-sparing diuretic. Concomitant use with potassium supplements can lead to dangerously high potassium levels.,Monitor serum potassium levels closely; avoid concurrent use if possible.,1,2026-05-13
potassium dihydrogen phosphate,losartan,Moderate,Increased risk of hyperkalemia.,Losartan is an angiotensin II receptor blocker which can reduce potassium excretion. Combining with potassium supplements increases hyperkalemia risk.,Monitor serum potassium levels.,1,2026-05-13
potassium dihydrogen phosphate,ramipril,Moderate,Increased risk of hyperkalemia.,Ramipril is an ACE inhibitor which can reduce potassium excretion. Combining with potassium supplements increases hyperkalemia risk.,Monitor serum potassium levels.,1,2026-05-13
estriol,warfarin,Moderate,Increased anticoagulant effect of warfarin.,"Estrogens can increase the synthesis of clotting factors, potentially counteracting the anticoagulant effect of warfarin, or conversely, some estrogens can inhibit platelet aggregation.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
glycine,,,,,,1,2026-05-13
rosehip,,,,,,1,2026-05-13
trypan blue,,,,,,1,2026-05-13
moclobemide,tramadol,Major,"Serotonin syndrome, hypertensive crisis.",Moclobemide is a reversible MAOI. Tramadol has serotonergic and noradrenergic effects. Combined use can lead to excessive levels of these neurotransmitters.,"Avoid concurrent use. If necessary, monitor closely for serotonin syndrome and hypertensive reactions.",1,2026-05-13
moclobemide,codeine,Major,"Serotonin syndrome, hypertensive crisis.",Moclobemide is a reversible MAOI. Codeine has serotonergic and noradrenergic effects. Combined use can lead to excessive levels of these neurotransmitters.,"Avoid concurrent use. If necessary, monitor closely for serotonin syndrome and hypertensive reactions.",1,2026-05-13
moclobemide,morphine,Major,"Serotonin syndrome, hypertensive crisis.",Moclobemide is a reversible MAOI. Opioids like morphine can have serotonergic effects. Combined use can lead to excessive levels of these neurotransmitters.,"Avoid concurrent use. If necessary, monitor closely for serotonin syndrome and hypertensive reactions.",1,2026-05-13
moclobemide,sertraline,Major,Serotonin syndrome.,Moclobemide is an MAOI. SSRIs like sertraline inhibit serotonin reuptake. Combined use can lead to excessive serotonin levels.,"Avoid concurrent use. If necessary, allow a washout period between drugs.",1,2026-05-13
moclobemide,fluoxetine,Major,Serotonin syndrome.,Moclobemide is an MAOI. SSRIs like fluoxetine inhibit serotonin reuptake. Combined use can lead to excessive serotonin levels.,"Avoid concurrent use. If necessary, allow a washout period between drugs.",1,2026-05-13
moclobemide,amitriptyline,Moderate,Increased risk of hypertensive crisis and serotonin syndrome.,Moclobemide inhibits MAO. Tricyclic antidepressants like amitriptyline can affect neurotransmitter levels. Combined use can potentiate these effects.,Use with caution and monitor closely for adverse effects.,1,2026-05-13
mesterolone,warfarin,Moderate,Increased anticoagulant effect of warfarin.,Anabolic steroids can potentiate the effect of warfarin by displacing it from plasma protein binding sites.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
overseasnimesulide,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs like nimesulide can inhibit platelet aggregation and also cause gastrointestinal irritation, increasing the risk of bleeding when used with anticoagulants.",Monitor for signs of bleeding. Use with caution or consider alternative.,1,2026-05-13
overseasnimesulide,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Both are NSAIDs and share similar mechanisms of action which can increase the risk of upper gastrointestinal toxicity.,"Avoid concurrent use. If necessary, use lowest effective doses for shortest duration.",1,2026-05-13
overseasnimesulide,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Both are NSAIDs and share similar mechanisms of action which can increase the risk of upper gastrointestinal toxicity.,"Avoid concurrent use. If necessary, use lowest effective doses for shortest duration.",1,2026-05-13
overseasnimesulide,metformin,Minor,Slightly increased risk of lactic acidosis.,"NSAIDs can impair renal function, which may lead to reduced metformin clearance and an increased risk of lactic acidosis.",Monitor renal function and blood glucose levels.,1,2026-05-13
overseasnimesulide,ramipril,Moderate,"Reduced antihypertensive effect, increased risk of renal impairment.","NSAIDs can reduce the effectiveness of ACE inhibitors by inhibiting prostaglandin synthesis, which plays a role in vasodilation and renal blood flow. They also increase the risk of nephrotoxicity.",Monitor blood pressure and renal function. Use with caution.,1,2026-05-13
overseasnimesulide,losartan,Moderate,"Reduced antihypertensive effect, increased risk of renal impairment.","NSAIDs can reduce the effectiveness of ARBs by inhibiting prostaglandin synthesis, which plays a role in vasodilation and renal blood flow. They also increase the risk of nephrotoxicity.",Monitor blood pressure and renal function. Use with caution.,1,2026-05-13
overseasnimesulide,amlodipine,Minor,Reduced antihypertensive effect.,NSAIDs can attenuate the antihypertensive effects of calcium channel blockers through renal mechanisms.,Monitor blood pressure.,1,2026-05-13
limitedazithromycin,warfarin,Moderate,Increased anticoagulant effect of warfarin.,"Macrolide antibiotics can inhibit the metabolism of warfarin, leading to increased INR and risk of bleeding.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
limitedazithromycin,digoxin,Moderate,Increased digoxin levels.,"Azithromycin may decrease the metabolism of digoxin, leading to increased serum levels and potential toxicity.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
limitedazithromycin,amiodarone,Moderate,Increased risk of QT prolongation and arrhythmias.,Both azithromycin and amiodarone can prolong the QT interval. Concurrent use increases the risk of torsades de pointes.,Avoid concurrent use if possible. Monitor ECG.,1,2026-05-13
monobenzone,,,,,,1,2026-05-13
crotamiton,,,,,,1,2026-05-13
sodium metabisulphite,,,,,,1,2026-05-13
pyritinol,,,,,,1,2026-05-13
limitedlevocetirizine,,,,,,1,2026-05-13
parecoxib,warfarin,Moderate,Increased risk of bleeding.,"Parecoxib can inhibit platelet aggregation, potentiating the anticoagulant effect of warfarin.",Monitor INR closely and consider alternative analgesics or anticoagulants.,1,2026-05-13
parecoxib,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Both are NSAIDs and can have additive antiplatelet and gastroprotective effects.,"Avoid concurrent use if possible; if necessary, use with caution and monitor for GI bleeding.",1,2026-05-13
parecoxib,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Both are NSAIDs and can have additive antiplatelet and gastroprotective effects.,"Avoid concurrent use if possible; if necessary, use with caution and monitor for GI bleeding.",1,2026-05-13
parecoxib,clopidogrel,Moderate,Increased risk of bleeding.,"Both can inhibit platelet aggregation, leading to additive antiplatelet effects.",Monitor for signs of bleeding and consider alternative therapies.,1,2026-05-13
parecoxib,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium retention and reduced efficacy of ACE inhibitors.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
parecoxib,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium retention and reduced efficacy of ARBs.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
parecoxib,amlodipine,Minor,Potential reduction in antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, potentially counteracting the effects of calcium channel blockers.",Monitor blood pressure and consider alternative analgesic.,1,2026-05-13
parecoxib,atorvastatin,Minor,Increased risk of muscle pain.,"NSAIDs may increase the risk of myopathy, especially in patients taking statins.",Monitor for muscle pain and weakness.,1,2026-05-13
parecoxib,rosuvastatin,Minor,Increased risk of muscle pain.,"NSAIDs may increase the risk of myopathy, especially in patients taking statins.",Monitor for muscle pain and weakness.,1,2026-05-13
parecoxib,furosemide,Moderate,Reduced diuretic and antihypertensive effect.,"NSAIDs can inhibit renal prostaglandin synthesis, leading to sodium and water retention.",Monitor urine output and blood pressure; consider alternative analgesic.,1,2026-05-13
parecoxib,spironolactone,Moderate,Reduced diuretic and antihypertensive effect.,"NSAIDs can inhibit renal prostaglandin synthesis, leading to sodium and water retention.",Monitor urine output and blood pressure; consider alternative analgesic.,1,2026-05-13
parecoxib,prednisolone,Major,Significantly increased risk of gastrointestinal ulcers and bleeding.,Concurrent use of NSAIDs and corticosteroids greatly enhances the risk of upper GI damage.,"Avoid concurrent use; if necessary, use with extreme caution and consider gastroprotective agents.",1,2026-05-13
parecoxib,dexamethasone,Major,Significantly increased risk of gastrointestinal ulcers and bleeding.,Concurrent use of NSAIDs and corticosteroids greatly enhances the risk of upper GI damage.,"Avoid concurrent use; if necessary, use with extreme caution and consider gastroprotective agents.",1,2026-05-13
methoxy polyethylene glycol-epoetin beta,furosemide,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and furosemide can have effects on electrolyte balance which might indirectly impact blood pressure control.",Monitor blood pressure closely and adjust furosemide dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,amlodipine,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and amlodipine's antihypertensive effect might be masked.",Monitor blood pressure closely and adjust amlodipine dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,losartan,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and losartan's antihypertensive effect might be masked.",Monitor blood pressure closely and adjust losartan dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,ramipril,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and ramipril's antihypertensive effect might be masked.",Monitor blood pressure closely and adjust ramipril dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,atenolol,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and atenolol's antihypertensive effect might be masked.",Monitor blood pressure closely and adjust atenolol dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,metoprolol,Moderate,Hypertension may worsen.,"Erythropoiesis stimulating agents can increase blood pressure, and metoprolol's antihypertensive effect might be masked.",Monitor blood pressure closely and adjust metoprolol dose if needed.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,warfarin,Minor,Increased risk of thromboembolic events due to improved hematocrit.,"Increased red blood cell mass can potentially increase blood viscosity and the risk of clot formation, especially if anticoagulation is suboptimal.",Monitor INR closely and consider adjusting warfarin dose.,1,2026-05-13
methoxy polyethylene glycol-epoetin beta,clopidogrel,Minor,Increased risk of thromboembolic events due to improved hematocrit.,"Increased red blood cell mass can potentially increase blood viscosity and the risk of clot formation, especially if antiplatelet therapy is suboptimal.",Monitor for signs of thrombosis and consider adjusting antiplatelet therapy.,1,2026-05-13
live freeze dried lactic acid bacteria and bifidobacteria,,,,,,1,2026-05-13
haemophilus influenzae type b capsular polysaccharide,,,,,,1,2026-05-13
butenafine,,,,,,1,2026-05-13
satranidazole,warfarin,Major,Increased risk of bleeding.,"Satranidazole may inhibit warfarin metabolism by CYP enzymes, leading to increased warfarin levels.",Monitor INR closely and consider alternative antibiotics or dose adjustment of warfarin.,1,2026-05-13
satranidazole,alcohol,Major,"Disulfiram-like reaction (nausea, vomiting, flushing, headache).",Metronidazole and related nitroimidazoles like satranidazole can inhibit alcohol metabolism.,Advise patient to avoid alcohol during treatment and for several days after.,1,2026-05-13
satranidazole,phenytoin,Moderate,Reduced efficacy of phenytoin.,"Satranidazole may induce hepatic enzymes responsible for phenytoin metabolism, leading to lower phenytoin levels.",Monitor phenytoin levels and adjust dose if necessary.,1,2026-05-13
satranidazole,carbamazepine,Moderate,Reduced efficacy of carbamazepine.,"Satranidazole may induce hepatic enzymes responsible for carbamazepine metabolism, leading to lower carbamazepine levels.",Monitor carbamazepine levels and adjust dose if necessary.,1,2026-05-13
satranidazole,lithium,Moderate,Increased risk of lithium toxicity.,"Satranidazole may inhibit the renal excretion of lithium, leading to increased serum lithium levels.",Monitor lithium levels closely and consider dose adjustment.,1,2026-05-13
insulin aspart protamine,metformin,Moderate,Increased risk of hypoglycemia.,Both agents lower blood glucose; additive effect.,Monitor blood glucose closely and adjust doses as needed.,1,2026-05-13
insulin aspart protamine,aspirin,Moderate,Increased risk of hypoglycemia.,High-dose salicylates can potentiate the glucose-lowering effect of insulin.,Monitor blood glucose closely; consider dose adjustment of insulin aspart protamine.,1,2026-05-13
insulin aspart protamine,ibuprofen,Minor,Potential for mild fluctuations in blood glucose.,NSAIDs can sometimes affect glycemic control.,"Monitor blood glucose, especially if ibuprofen is used long-term or at high doses.",1,2026-05-13
insulin aspart protamine,atenolol,Moderate,Masking of hypoglycemia symptoms.,"Beta-blockers can blunt the sympathetic response to hypoglycemia, such as tremor and tachycardia.",Educate patient on recognizing hypoglycemia symptoms that are not masked and monitor blood glucose.,1,2026-05-13
insulin aspart protamine,metoprolol,Moderate,Masking of hypoglycemia symptoms.,"Beta-blockers can blunt the sympathetic response to hypoglycemia, such as tremor and tachycardia.",Educate patient on recognizing hypoglycemia symptoms that are not masked and monitor blood glucose.,1,2026-05-13
insulin aspart protamine,losartan,Minor,Potential for minor changes in blood glucose control.,Some antihypertensives can influence glucose metabolism.,"Monitor blood glucose, particularly with initiation or discontinuation of losartan.",1,2026-05-13
insulin aspart protamine,amlodipine,Minor,Potential for minor changes in blood glucose control.,Some calcium channel blockers can influence glucose metabolism.,"Monitor blood glucose, particularly with initiation or discontinuation of amlodipine.",1,2026-05-13
insulin aspart protamine,prednisolone,Major,"Hyperglycemia, reduced efficacy of insulin aspart protamine.",Corticosteroids antagonize the action of insulin.,Monitor blood glucose closely; increase insulin dose as needed.,1,2026-05-13
insulin aspart protamine,dexamethasone,Major,"Hyperglycemia, reduced efficacy of insulin aspart protamine.",Corticosteroids antagonize the action of insulin.,Monitor blood glucose closely; increase insulin dose as needed.,1,2026-05-13
insulin aspart protamine,tramadol,Moderate,Hypoglycemia or hyperglycemia.,Tramadol can affect glucose levels through various mechanisms.,Monitor blood glucose closely.,1,2026-05-13
insulin aspart protamine,codeine,Moderate,Hypoglycemia or hyperglycemia.,Opioids can affect glucose metabolism.,Monitor blood glucose closely.,1,2026-05-13
insulin aspart protamine,morphine,Moderate,Hypoglycemia or hyperglycemia.,Opioids can affect glucose metabolism.,Monitor blood glucose closely.,1,2026-05-13
gimeracil,warfarin,Major,Increased risk of bleeding.,"Gimeracil can inhibit the metabolism of warfarin via CYP2C9, increasing its anticoagulant effect.",Monitor INR closely and reduce warfarin dose if necessary.,1,2026-05-13
gimeracil,phenytoin,Moderate,Increased risk of phenytoin toxicity.,"Gimeracil may inhibit the metabolism of phenytoin, increasing its serum concentration.",Monitor phenytoin levels and for signs of toxicity; consider dose adjustment.,1,2026-05-13
gimeracil,valproate,Moderate,Increased risk of valproate toxicity.,"Gimeracil may inhibit the metabolism of valproate, increasing its serum concentration.",Monitor valproate levels and for signs of toxicity; consider dose adjustment.,1,2026-05-13
gimeracil,atorvastatin,Minor,Potential for increased atorvastatin levels.,Gimeracil may inhibit the metabolism of atorvastatin.,Monitor for increased statin side effects.,1,2026-05-13
gimeracil,rosuvastatin,Minor,Potential for increased rosuvastatin levels.,Gimeracil may inhibit the metabolism of rosuvastatin.,Monitor for increased statin side effects.,1,2026-05-13
oteracil,warfarin,Minor,Potential for altered INR.,"Oteracil may have a mild effect on vitamin K metabolism, potentially affecting warfarin.",Monitor INR closely.,1,2026-05-13
lactobacillus plantarum,cyclosporine,Minor,Reduced efficacy of cyclosporine.,Probiotics may alter gut absorption of cyclosporine.,Monitor cyclosporine levels and clinical response.,1,2026-05-13
lactobacillus plantarum,tacrolimus,Minor,Reduced efficacy of tacrolimus.,Probiotics may alter gut absorption of tacrolimus.,Monitor tacrolimus levels and clinical response.,1,2026-05-13
diatrizoic acid,metformin,Major,Increased risk of lactic acidosis.,"Contrast media can cause renal impairment, which reduces metformin excretion, leading to accumulation.","Discontinue metformin before contrast administration and for 48 hours after, or until renal function is normal.",1,2026-05-13
diatrizoic acid,furosemide,Moderate,Increased risk of nephrotoxicity.,Contrast media can impair renal function; furosemide can contribute to dehydration and worsen this effect.,Ensure adequate hydration; monitor renal function closely.,1,2026-05-13
celagenex research,,,,,,1,2026-05-13
terpineol,,,,,,1,2026-05-13
halometasone,prednisolone,Major,"Increased risk of systemic corticosteroid effects (e.g., Cushingoid features, adrenal suppression).",Additive systemic effects from topical and oral corticosteroids.,Use with caution and monitor for systemic side effects.,1,2026-05-13
halometasone,dexamethasone,Major,"Increased risk of systemic corticosteroid effects (e.g., Cushingoid features, adrenal suppression).",Additive systemic effects from topical and oral corticosteroids.,Use with caution and monitor for systemic side effects.,1,2026-05-13
atosiban,,,,,,1,2026-05-13
tocoferol,warfarin,Moderate,"Reduced efficacy of warfarin, increased risk of thrombosis.","High doses of Vitamin E can antagonize the effect of vitamin K, potentially counteracting warfarin.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
recombinant human epidermal growth factor,,,,,,1,2026-05-13
recombinant human erythropoietin beta,warfarin,Moderate,"Reduced anticoagulant effect, increasing risk of thrombosis.","Erythropoietin can increase platelet aggregation, potentially counteracting warfarin's effect.",Monitor INR closely and consider warfarin dose adjustment.,1,2026-05-13
recombinant human erythropoietin beta,clopidogrel,Moderate,"Reduced antiplatelet effect, increasing risk of thrombosis.","Erythropoietin can increase platelet aggregation, potentially counteracting clopidogrel's effect.",Monitor for thrombotic events and consider antiplatelet therapy adjustment.,1,2026-05-13
recombinant human erythropoietin beta,aspirin,Moderate,"Reduced antiplatelet effect, increasing risk of thrombosis.","Erythropoietin can increase platelet aggregation, potentially counteracting aspirin's effect.",Monitor for thrombotic events and consider antiplatelet therapy adjustment.,1,2026-05-13
recombinant human erythropoietin beta,ibuprofen,Moderate,"Reduced antiplatelet effect, increasing risk of thrombosis.","Erythropoietin can increase platelet aggregation, potentially counteracting ibuprofen's effect.",Monitor for thrombotic events and consider antiplatelet therapy adjustment.,1,2026-05-13
sodium tauroglycocholate,,,,,,1,2026-05-13
epinastine,diazepam,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,alprazolam,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,lorazepam,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,clonazepam,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,midazolam,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,zolpidem,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,tramadol,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,codeine,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,morphine,Moderate,Increased sedation and potential CNS depression.,Both can cause CNS depression; additive effects.,Advise caution with activities requiring mental alertness; monitor for excessive sedation.,1,2026-05-13
epinastine,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Both can cause CNS depression and anticholinergic effects; additive effects.,Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
fibrinogen,,,,,,1,2026-05-13
netarsudil,,,,,,1,2026-05-13
erdosteine,,,,,,1,2026-05-13
propoxur,,,,,,1,2026-05-13
potassium hydrogen carbonate,losartan,Moderate,Increased risk of hyperkalemia.,Potassium hydrogen carbonate can increase serum potassium levels; losartan also affects potassium balance.,Monitor serum potassium levels.,1,2026-05-13
potassium hydrogen carbonate,ramipril,Moderate,Increased risk of hyperkalemia.,Potassium hydrogen carbonate can increase serum potassium levels; ramipril also affects potassium balance.,Monitor serum potassium levels.,1,2026-05-13
potassium hydrogen carbonate,spironolactone,Major,"Severe hyperkalemia, potentially life-threatening.",Both agents increase serum potassium levels; additive effect.,Avoid concomitant use or monitor serum potassium very closely and frequently.,1,2026-05-13
potassium hydrogen carbonate,furosemide,Minor,May slightly reduce the kaliuretic effect of furosemide.,"Potassium hydrogen carbonate can increase serum potassium, potentially counteracting the potassium-wasting effect of furosemide.",Monitor serum potassium levels.,1,2026-05-13
potassium hydrogen carbonate,insulin,Minor,May affect insulin's potassium-lowering effect.,"Potassium hydrogen carbonate can increase serum potassium, potentially affecting insulin's rapid shift of potassium into cells.",Monitor glucose and potassium levels.,1,2026-05-13
potassium hydrogen carbonate,digoxin,Minor,Hypokalemia due to furosemide may enhance digoxin toxicity.,"If furosemide is used concurrently, its potassium-wasting effect can increase digoxin toxicity. Potassium hydrogen carbonate may mitigate this.",Monitor serum potassium and digoxin levels.,1,2026-05-13
vitamin k,warfarin,Major,"Reduced anticoagulant effect, increasing risk of thrombosis.",Vitamin K is the antidote to warfarin; it promotes the synthesis of clotting factors.,Avoid administration of Vitamin K unless correcting bleeding or intoxication; INR monitoring is critical.,1,2026-05-13
lactase,,,,,,1,2026-05-13
tolfenamic acid,warfarin,Major,Increased risk of bleeding.,Tolfenamic acid inhibits platelet aggregation and can displace warfarin from plasma protein binding sites.,Monitor INR closely and consider alternative NSAIDs if possible.,1,2026-05-13
tolfenamic acid,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Both drugs can cause gastrointestinal irritation and bleeding; additive effect.,Use with caution and monitor for signs of GI bleeding.,1,2026-05-13
tolfenamic acid,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Both drugs can cause gastrointestinal irritation and bleeding; additive effect.,Use with caution and monitor for signs of GI bleeding.,1,2026-05-13
tolfenamic acid,clopidogrel,Moderate,Increased risk of gastrointestinal bleeding.,Both drugs can cause gastrointestinal irritation and bleeding; additive effect.,Use with caution and monitor for signs of GI bleeding.,1,2026-05-13
tolfenamic acid,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
tolfenamic acid,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
tolfenamic acid,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
tolfenamic acid,spironolactone,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
tolfenamic acid,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
tolfenamic acid,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
tolfenamic acid,amlodipine,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of calcium channel blockers.",Monitor blood pressure.,1,2026-05-13
tolfenamic acid,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which is important for metformin elimination.",Monitor renal function and blood glucose.,1,2026-05-13
edhas organics,,,,,,1,2026-05-13
sisomicin,furosemide,Major,Increased risk of ototoxicity and nephrotoxicity.,Ototoxic and nephrotoxic drugs can have additive effects.,"Avoid concurrent use if possible, monitor renal function and hearing.",1,2026-05-13
sisomicin,aspirin,Moderate,Increased risk of ototoxicity.,"High-dose aspirin can cause ototoxicity, and this effect may be additive with aminoglycosides.",Monitor for signs of ototoxicity.,1,2026-05-13
sisomicin,atorvastatin,Minor,Potential for increased myopathy risk.,"While not a direct interaction, some reports suggest an increased risk of myopathy with combined use of statins and certain antibiotics.",Monitor for muscle pain or weakness.,1,2026-05-13
sisomicin,rosuvastatin,Minor,Potential for increased myopathy risk.,"While not a direct interaction, some reports suggest an increased risk of myopathy with combined use of statins and certain antibiotics.",Monitor for muscle pain or weakness.,1,2026-05-13
salmonella typhi vaccine,prednisolone,Moderate,Reduced vaccine efficacy.,"Corticosteroids can suppress the immune response, potentially diminishing the effectiveness of the vaccine.",Delay vaccination if possible during high-dose corticosteroid therapy; consider revaccination later.,1,2026-05-13
salmonella typhi vaccine,dexamethasone,Moderate,Reduced vaccine efficacy.,"Corticosteroids can suppress the immune response, potentially diminishing the effectiveness of the vaccine.",Delay vaccination if possible during high-dose corticosteroid therapy; consider revaccination later.,1,2026-05-13
salmonella typhi vaccine,methotrexate,Moderate,Reduced vaccine efficacy.,Immunosuppressive drugs can reduce the immune response to vaccines.,Consider timing of vaccination relative to methotrexate therapy.,1,2026-05-13
salmonella typhi vaccine,cyclosporine,Moderate,Reduced vaccine efficacy.,Immunosuppressive drugs can reduce the immune response to vaccines.,Consider timing of vaccination relative to cyclosporine therapy.,1,2026-05-13
salmonella typhi vaccine,tacrolimus,Moderate,Reduced vaccine efficacy.,Immunosuppressive drugs can reduce the immune response to vaccines.,Consider timing of vaccination relative to tacrolimus therapy.,1,2026-05-13
olive oil,,,,,,1,2026-05-13
icosapent ethyl,warfarin,Moderate,Increased risk of bleeding.,Omega-3 fatty acids can have antiplatelet effects.,Monitor INR and bleeding parameters.,1,2026-05-13
icosapent ethyl,clopidogrel,Moderate,Increased risk of bleeding.,Omega-3 fatty acids can have antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
icosapent ethyl,aspirin,Moderate,Increased risk of bleeding.,"Omega-3 fatty acids can have antiplatelet effects, additive with aspirin's effect.",Monitor for signs of bleeding.,1,2026-05-13
buserelin,,,,,,1,2026-05-13
nitrofurazone,metformin,Moderate,Increased risk of lactic acidosis.,"Nitrofurantoin can impair renal function, affecting metformin clearance.",Monitor renal function and blood glucose; avoid concurrent use if possible.,1,2026-05-13
nitrofurazone,ranitidine,Minor,May reduce the efficacy of nitrofurazone.,Ranitidine may reduce the gastric acidity which can affect nitrofurazone absorption.,Monitor for treatment response.,1,2026-05-13
eflornithine,,,,,,1,2026-05-13
testosterone phenylpropionate,warfarin,Moderate,Increased anticoagulant effect and risk of bleeding.,Testosterone may enhance the metabolism of warfarin.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
testosterone phenylpropionate,metformin,Minor,Potential for altered glycemic control.,Androgens can influence insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
testosterone phenylpropionate,atorvastatin,Minor,Potential for altered lipid profiles.,Androgens may affect lipid metabolism.,Monitor lipid levels.,1,2026-05-13
testosterone phenylpropionate,rosuvastatin,Minor,Potential for altered lipid profiles.,Androgens may affect lipid metabolism.,Monitor lipid levels.,1,2026-05-13
testosterone phenylpropionate,insulin,Minor,Potential for altered glycemic control.,Androgens can influence insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
testosterone phenylpropionate,prednisolone,Moderate,Increased risk of fluid retention and potential suppression of endogenous testosterone production.,Corticosteroids can antagonize some effects of androgens.,Monitor for signs of fluid retention and consider dose adjustment of either medication if clinically significant.,1,2026-05-13
testosterone phenylpropionate,dexamethasone,Moderate,Increased risk of fluid retention and potential suppression of endogenous testosterone production.,Corticosteroids can antagonize some effects of androgens.,Monitor for signs of fluid retention and consider dose adjustment of either medication if clinically significant.,1,2026-05-13
testosterone phenylpropionate,spironolactone,Moderate,Reduced efficacy of testosterone therapy and potential for anti-androgenic effects.,Spironolactone has anti-androgenic properties.,Avoid concomitant use or monitor testosterone levels closely.,1,2026-05-13
testosterone isocaproate,warfarin,Moderate,Increased anticoagulant effect and risk of bleeding.,Testosterone may enhance the metabolism of warfarin.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
testosterone isocaproate,metformin,Minor,Potential for altered glycemic control.,Androgens can influence insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
testosterone isocaproate,atorvastatin,Minor,Potential for altered lipid profiles.,Androgens may affect lipid metabolism.,Monitor lipid levels.,1,2026-05-13
testosterone isocaproate,rosuvastatin,Minor,Potential for altered lipid profiles.,Androgens may affect lipid metabolism.,Monitor lipid levels.,1,2026-05-13
testosterone isocaproate,insulin,Minor,Potential for altered glycemic control.,Androgens can influence insulin sensitivity.,Monitor blood glucose levels.,1,2026-05-13
testosterone isocaproate,prednisolone,Moderate,Increased risk of fluid retention and potential suppression of endogenous testosterone production.,Corticosteroids can antagonize some effects of androgens.,Monitor for signs of fluid retention and consider dose adjustment of either medication if clinically significant.,1,2026-05-13
testosterone isocaproate,dexamethasone,Moderate,Increased risk of fluid retention and potential suppression of endogenous testosterone production.,Corticosteroids can antagonize some effects of androgens.,Monitor for signs of fluid retention and consider dose adjustment of either medication if clinically significant.,1,2026-05-13
testosterone isocaproate,spironolactone,Moderate,Reduced efficacy of testosterone therapy and potential for anti-androgenic effects.,Spironolactone has anti-androgenic properties.,Avoid concomitant use or monitor testosterone levels closely.,1,2026-05-13
benzoic acid,,,,,,1,2026-05-13
ceftamet,warfarin,Moderate,Increased anticoagulant effect and risk of bleeding.,Some cephalosporins can inhibit vitamin K metabolism.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
ceftamet,metformin,Minor,Potential for altered blood glucose levels.,Ceftamet may interfere with renal excretion of metformin.,Monitor blood glucose levels closely.,1,2026-05-13
ceftamet,furosemide,Minor,Increased risk of nephrotoxicity.,Concomitant use may potentiate renal toxicity.,Monitor renal function.,1,2026-05-13
remington life sciences llptelmisartan,aspirin,Minor,Increased risk of hyperkalemia.,Both can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
remington life sciences llptelmisartan,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can reduce the effects of ARBs and cause renal damage.,Avoid concomitant use or use with caution and monitor blood pressure and renal function.,1,2026-05-13
remington life sciences llptelmisartan,metformin,Minor,Increased risk of hyperkalemia.,Both can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
remington life sciences llptelmisartan,losartan,Moderate,"Increased risk of hyperkalemia, hypotension, and renal impairment.",Both are ARBs and have additive effects.,"Avoid concomitant use or use with caution and monitor blood pressure, potassium, and renal function.",1,2026-05-13
remington life sciences llptelmisartan,lisinopril,Moderate,"Increased risk of hyperkalemia, hypotension, and renal impairment.",Both are RAAS inhibitors and have additive effects.,"Avoid concomitant use or use with caution and monitor blood pressure, potassium, and renal function.",1,2026-05-13
remington life sciences llptelmisartan,ramipril,Moderate,"Increased risk of hyperkalemia, hypotension, and renal impairment.",Both are RAAS inhibitors and have additive effects.,"Avoid concomitant use or use with caution and monitor blood pressure, potassium, and renal function.",1,2026-05-13
remington life sciences llptelmisartan,insulin,Minor,Increased risk of hyperkalemia.,Both can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
remington life sciences llptelmisartan,furosemide,Minor,Increased risk of hyperkalemia.,"Telmisartan can increase potassium levels, furosemide can decrease it, leading to unpredictable effects.",Monitor potassium levels.,1,2026-05-13
remington life sciences llptelmisartan,spironolactone,Major,Severe hyperkalemia and hypotension.,Both agents increase potassium levels and can lower blood pressure.,Avoid concomitant use.,1,2026-05-13
remington life sciences llptelmisartan,atenolol,Minor,Increased risk of hypotension.,Both lower blood pressure.,Monitor blood pressure.,1,2026-05-13
remington life sciences llptelmisartan,metoprolol,Minor,Increased risk of hypotension.,Both lower blood pressure.,Monitor blood pressure.,1,2026-05-13
remington life sciences llptelmisartan,lithium,Moderate,Increased lithium toxicity.,ARBs can reduce lithium clearance.,Monitor lithium levels closely and reduce lithium dose if necessary.,1,2026-05-13
crisaborole,,,,,,1,2026-05-13
coral calcium,warfarin,Minor,Potentially reduced anticoagulant effect.,Calcium can interfere with warfarin absorption.,Separate administration by at least 2 hours and monitor INR.,1,2026-05-13
coral calcium,tetracyclines,Moderate,Reduced absorption of tetracyclines.,Calcium forms insoluble complexes with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
coral calcium,bisphosphonates,Moderate,Reduced absorption of bisphosphonates.,Calcium can interfere with bisphosphonate absorption.,Separate administration by at least 2 hours.,1,2026-05-13
varicella vaccine,prednisolone,Major,Reduced vaccine efficacy and increased risk of disseminated varicella infection.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving high-dose corticosteroids. Postpone vaccination if patient is on immunosuppressive therapy and consider re-vaccination after treatment completion.,1,2026-05-13
varicella vaccine,dexamethasone,Major,Reduced vaccine efficacy and increased risk of disseminated varicella infection.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving high-dose corticosteroids. Postpone vaccination if patient is on immunosuppressive therapy and consider re-vaccination after treatment completion.,1,2026-05-13
varicella vaccine,methotrexate,Major,Reduced vaccine efficacy and increased risk of disseminated varicella infection.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
varicella vaccine,cyclosporine,Major,Reduced vaccine efficacy and increased risk of disseminated varicella infection.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
varicella vaccine,tacrolimus,Major,Reduced vaccine efficacy and increased risk of disseminated varicella infection.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
attenuated,prednisolone,Major,Reduced vaccine efficacy and increased risk of disseminated infection from the attenuated organism.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving high-dose corticosteroids. Postpone vaccination if patient is on immunosuppressive therapy and consider re-vaccination after treatment completion.,1,2026-05-13
attenuated,dexamethasone,Major,Reduced vaccine efficacy and increased risk of disseminated infection from the attenuated organism.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving high-dose corticosteroids. Postpone vaccination if patient is on immunosuppressive therapy and consider re-vaccination after treatment completion.,1,2026-05-13
attenuated,methotrexate,Major,Reduced vaccine efficacy and increased risk of disseminated infection from the attenuated organism.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
attenuated,cyclosporine,Major,Reduced vaccine efficacy and increased risk of disseminated infection from the attenuated organism.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
attenuated,tacrolimus,Major,Reduced vaccine efficacy and increased risk of disseminated infection from the attenuated organism.,Immunosuppressants can interfere with the immune response to live vaccines.,Avoid vaccination in patients receiving immunosuppressants. Postpone vaccination and consider re-vaccination after treatment completion.,1,2026-05-13
pyrantel embonate,levamisole,Major,"Increased risk of central nervous system effects, including confusion, hallucinations, and seizures.",Both drugs affect neurotransmission in helminths; additive effects may occur.,"Avoid concomitant use. If unavoidable, monitor closely for CNS side effects.",1,2026-05-13
adenosylcobalamin,,,,,,1,2026-05-13
snake venom antiserum,,,,,,1,2026-05-13
bemiparin,aspirin,Moderate,Increased risk of bleeding.,Both drugs inhibit platelet aggregation and prolong bleeding time.,Monitor for signs of bleeding and consider alternative analgesics if pain control allows.,1,2026-05-13
bemiparin,ibuprofen,Moderate,Increased risk of bleeding.,Both drugs inhibit platelet aggregation and prolong bleeding time.,Monitor for signs of bleeding and consider alternative analgesics if pain control allows.,1,2026-05-13
bemiparin,warfarin,Major,Significantly increased risk of bleeding.,"Both are anticoagulants and their combined effect is additive, leading to excessive anticoagulation.","Avoid concomitant use; if unavoidable, monitor INR very closely and adjust dosages carefully.",1,2026-05-13
bemiparin,clopidogrel,Moderate,Increased risk of bleeding.,"Both drugs inhibit platelet aggregation, leading to an additive antiplatelet effect.",Monitor for signs of bleeding; use with caution.,1,2026-05-13
limitedaceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and potential reduced cardioprotective effect of low-dose aspirin.,"Aceclofenac is an NSAID that can compete with aspirin for binding sites on COX enzymes, potentially reducing aspirin's antiplatelet effect.",Monitor for GI bleeding; administer aspirin at least 30 minutes before or 8 hours after aceclofenac.,1,2026-05-13
limitedaceclofenac,warfarin,Major,Increased risk of bleeding.,"NSAIDs, including aceclofenac, can potentiate the anticoagulant effect of warfarin by displacing it from plasma protein binding sites and causing GI ulceration/bleeding.","Avoid concomitant use; if unavoidable, monitor INR closely and monitor for signs of bleeding.",1,2026-05-13
limitedaceclofenac,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which may lead to accumulation of metformin and increase the risk of lactic acidosis.",Monitor renal function; use with caution and consider dose adjustment of metformin.,1,2026-05-13
limitedaceclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of nephrotoxicity.,"NSAIDs can inhibit prostaglandin synthesis, which is important for maintaining renal blood flow and natriuresis, thus antagonizing the effects of loop diuretics.","Monitor blood pressure, fluid status, and renal function; ensure adequate hydration.",1,2026-05-13
limitedaceclofenac,ramipril,Moderate,Increased risk of renal impairment and hyperkalemia; reduced antihypertensive effect.,"NSAIDs can decrease renal blood flow and inhibit the renin-angiotensin-aldosterone system, potentially impairing the antihypertensive and renoprotective effects of ACE inhibitors.",Monitor blood pressure and renal function; ensure adequate hydration.,1,2026-05-13
limitedaceclofenac,lithium,Major,"Increased serum lithium levels, leading to lithium toxicity.","NSAIDs can reduce renal clearance of lithium by inhibiting prostaglandin synthesis, which affects renal hemodynamics.",Monitor serum lithium levels closely and avoid concomitant use if possible.,1,2026-05-13
pantothenic acid,,,,,,1,2026-05-13
fimasartan,ramipril,Moderate,"Increased risk of hypotension, hyperkalemia, and renal impairment.",Both are agents that affect the renin-angiotensin-aldosterone system (RAAS); combined use can lead to excessive blockade of the RAAS.,"Monitor blood pressure, potassium levels, and renal function.",1,2026-05-13
fimasartan,spironolactone,Moderate,Increased risk of hyperkalemia and renal impairment.,"Both drugs affect potassium balance; spironolactone is a potassium-sparing diuretic, and fimasartan can also increase potassium levels.",Monitor potassium levels and renal function.,1,2026-05-13
fimasartan,lithium,Major,"Increased serum lithium levels, leading to lithium toxicity.",ACE inhibitors and ARBs can reduce the renal excretion of lithium.,Monitor serum lithium levels closely and avoid concomitant use if possible.,1,2026-05-13
ferrous fumarate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Trivalent cations, such as iron, form insoluble complexes with fluoroquinolones, reducing their oral bioavailability.",Administer ciprofloxacin at least 2 hours before or 4-6 hours after ferrous fumarate.,1,2026-05-13
ferrous fumarate,levofloxacin,Major,Reduced absorption of levofloxacin.,"Trivalent cations, such as iron, form insoluble complexes with fluoroquinolones, reducing their oral bioavailability.",Administer levofloxacin at least 2 hours before or 4-6 hours after ferrous fumarate.,1,2026-05-13
ferrous fumarate,tetracyclines,Major,Reduced absorption of tetracyclines.,"Trivalent cations, such as iron, form insoluble complexes with tetracyclines, reducing their oral bioavailability.",Administer tetracyclines at least 2 hours before or 4-6 hours after ferrous fumarate.,1,2026-05-13
ferrous fumarate,thyroid hormones,Major,Reduced absorption of thyroid hormones.,Iron salts can decrease the absorption of levothyroxine.,Administer levothyroxine at least 4 hours before or 4 hours after ferrous fumarate.,1,2026-05-13
ferrous fumarate,pantoprazole,Minor,May decrease absorption of pantoprazole.,"Iron may affect gastric pH, potentially influencing the absorption of proton pump inhibitors.",Consider spacing administration of drugs.,1,2026-05-13
ferrous fumarate,omeprazole,Minor,May decrease absorption of omeprazole.,"Iron may affect gastric pH, potentially influencing the absorption of proton pump inhibitors.",Consider spacing administration of drugs.,1,2026-05-13
oxyphenbutazone,warfarin,Major,Increased risk of bleeding.,Oxyphenbutazone is a NSAID that can potentiate the anticoagulant effect of warfarin by displacing it from plasma protein binding sites and causing GI ulceration/bleeding.,"Avoid concomitant use; if unavoidable, monitor INR closely and monitor for signs of bleeding.",1,2026-05-13
oxyphenbutazone,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which may lead to accumulation of metformin and increase the risk of lactic acidosis.",Monitor renal function; use with caution and consider dose adjustment of metformin.,1,2026-05-13
oxyphenbutazone,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of nephrotoxicity.,"NSAIDs can inhibit prostaglandin synthesis, which is important for maintaining renal blood flow and natriuresis, thus antagonizing the effects of loop diuretics.","Monitor blood pressure, fluid status, and renal function; ensure adequate hydration.",1,2026-05-13
oxyphenbutazone,ramipril,Moderate,Increased risk of renal impairment and hyperkalemia; reduced antihypertensive effect.,"NSAIDs can decrease renal blood flow and inhibit the renin-angiotensin-aldosterone system, potentially impairing the antihypertensive and renoprotective effects of ACE inhibitors.",Monitor blood pressure and renal function; ensure adequate hydration.,1,2026-05-13
oxyphenbutazone,lithium,Major,"Increased serum lithium levels, leading to lithium toxicity.","NSAIDs can reduce renal clearance of lithium by inhibiting prostaglandin synthesis, which affects renal hemodynamics.",Monitor serum lithium levels closely and avoid concomitant use if possible.,1,2026-05-13
silver nano particles,,,,,,1,2026-05-13
harpagoside,,,,,,1,2026-05-13
thymosin alpha,,,,,,1,2026-05-13
methylparaben,,,,,,1,2026-05-13
carbazochrome,warfarin,Minor,Increased risk of bleeding.,Theoretical interference with vitamin K metabolism or platelet function.,Monitor INR closely if co-administered.,1,2026-05-13
carbazochrome,aspirin,Minor,Increased risk of bleeding.,Additive antiplatelet effect or direct gastrointestinal irritation.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
carbazochrome,ibuprofen,Minor,Increased risk of bleeding.,Additive antiplatelet effect or direct gastrointestinal irritation.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
carbazochrome,clopidogrel,Minor,Increased risk of bleeding.,Additive antiplatelet effect.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
thiomersal,,,,,,1,2026-05-13
grape seed extract,warfarin,Moderate,"Reduced anticoagulant effect, leading to increased risk of thrombosis.","Grape seed extract may inhibit CYP2C9, affecting warfarin metabolism, or possess vitamin K-like activity.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
grape seed extract,atorvastatin,Minor,Increased risk of myopathy or rhabdomyolysis.,"Grape seed extract may inhibit CYP3A4, increasing atorvastatin levels.",Monitor for muscle pain and weakness.,1,2026-05-13
grape seed extract,rosuvastatin,Minor,Increased risk of myopathy or rhabdomyolysis.,"Grape seed extract may inhibit CYP2C9, increasing rosuvastatin levels.",Monitor for muscle pain and weakness.,1,2026-05-13
grape seed extract,cyclosporine,Minor,Increased risk of cyclosporine toxicity.,"Grape seed extract may inhibit P-glycoprotein or CYP3A4, increasing cyclosporine absorption and reducing clearance.",Monitor for signs of cyclosporine toxicity.,1,2026-05-13
grape seed extract,tacrolimus,Minor,Increased risk of tacrolimus toxicity.,"Grape seed extract may inhibit P-glycoprotein or CYP3A4, increasing tacrolimus absorption and reducing clearance.",Monitor for signs of tacrolimus toxicity.,1,2026-05-13
saroglitazar,,,,,,1,2026-05-13
s-etodolac,warfarin,Moderate,Increased risk of bleeding.,NSAIDs can potentiate the effect of warfarin by inhibiting platelet aggregation and causing gastrointestinal irritation/ulceration.,Avoid co-administration or monitor INR very closely.,1,2026-05-13
s-etodolac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction and sodium/water retention, counteracting the effects of ACE inhibitors.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
s-etodolac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction and sodium/water retention, counteracting the effects of ARBs.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
s-etodolac,amlodipine,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, which may attenuate the blood pressure-lowering effect of calcium channel blockers.",Monitor blood pressure and watch for fluid retention.,1,2026-05-13
s-etodolac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction and sodium/water retention, diminishing the response to loop diuretics.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
s-etodolac,spironolactone,Moderate,Reduced diuretic effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction and sodium/water retention, diminishing the response to potassium-sparing diuretics.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
s-etodolac,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, leading to decreased metformin clearance.",Monitor renal function and for signs of lactic acidosis.,1,2026-05-13
s-etodolac,lithium,Moderate,Increased serum lithium levels and risk of lithium toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels and for signs of toxicity.,1,2026-05-13
sulfiram,alcohol,Major,"Severe disulfiram-like reaction (flushing, nausea, vomiting, headache, palpitations, respiratory distress).","Inhibition of aldehyde dehydrogenase, leading to accumulation of acetaldehyde.",Advise patient to avoid all alcohol.,1,2026-05-13
sulfiram,metronidazole,Major,Severe disulfiram-like reaction.,"Similar mechanism to alcohol, inhibiting aldehyde dehydrogenase.",Avoid co-administration.,1,2026-05-13
sulfiram,cefoperazone,Major,Severe disulfiram-like reaction.,Certain cephalosporins can inhibit aldehyde dehydrogenase.,Avoid co-administration.,1,2026-05-13
sulfiram,warfarin,Minor,May alter anticoagulant effect.,Potential induction or inhibition of hepatic enzymes involved in warfarin metabolism.,Monitor INR.,1,2026-05-13
fenoverine,,,,,,1,2026-05-13
chlorothymol,,,,,,1,2026-05-13
eucalyptol,,,,,,1,2026-05-13
penfluridol,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,Both drugs can affect cardiac conduction; additive bradycardic effects.,Monitor heart rate and blood pressure closely; consider dose adjustment.,1,2026-05-13
penfluridol,atenolol,Moderate,Increased risk of bradycardia and hypotension.,Both drugs can affect cardiac conduction; additive bradycardic effects.,Monitor heart rate and blood pressure closely; consider dose adjustment.,1,2026-05-13
penfluridol,amlodipine,Moderate,Increased risk of hypotension and dizziness.,Both drugs can cause vasodilation; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
penfluridol,losartan,Moderate,Increased risk of hypotension and dizziness.,Both drugs can cause vasodilation; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
penfluridol,ramipril,Moderate,Increased risk of hypotension and dizziness.,Both drugs can cause vasodilation; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
penfluridol,diazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,alprazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,lorazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,clonazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,midazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,zolpidem,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,tramadol,Moderate,Increased sedation and risk of seizures.,Additive CNS effects and potential lowering of seizure threshold.,Monitor for sedation and seizures; use with caution.,1,2026-05-13
penfluridol,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for sedation and respiratory function; use cautiously.,1,2026-05-13
penfluridol,haloperidol,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concurrent use if possible; monitor ECG and electrolytes.,1,2026-05-13
penfluridol,clozapine,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concurrent use if possible; monitor ECG and electrolytes.,1,2026-05-13
penfluridol,olanzapine,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concurrent use if possible; monitor ECG and electrolytes.,1,2026-05-13
silver colloid,,,,,,1,2026-05-13
pizotifen,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, blurred vision) and sedation.",Both are tricyclic compounds with anticholinergic properties.,Monitor for increased side effects; use cautiously.,1,2026-05-13
pizotifen,sertraline,Moderate,Increased risk of serotonin syndrome.,Both can increase serotonin levels.,"Monitor for symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever).",1,2026-05-13
pizotifen,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both can increase serotonin levels.,"Monitor for symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever).",1,2026-05-13
pizotifen,zolpidem,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
pizotifen,alprazolam,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
pizotifen,diazepam,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
pizotifen,lorazepam,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
pizotifen,clonazepam,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
pizotifen,midazolam,Moderate,Increased sedation.,Additive CNS depressant effects.,Monitor for excessive drowsiness and cognitive impairment.,1,2026-05-13
naftopidil,amlodipine,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,losartan,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,ramipril,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,s-metoprolol tartrate,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,metoprolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,atenolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
naftopidil,clopidogrel,Minor,Potential for additive effects on blood pressure.,Naftopidil lowers blood pressure; clopidogrel has minor hypotensive effects.,Monitor blood pressure.,1,2026-05-13
naftopidil,warfarin,Minor,Potential for altered anticoagulant effect.,"Unclear, but some alpha-blockers can affect INR.",Monitor INR closely.,1,2026-05-13
s-metoprolol tartrate,amlodipine,Moderate,"Increased risk of bradycardia, hypotension, and heart failure.",Additive negative chronotropic and inotropic effects.,"Monitor heart rate, blood pressure, and signs of heart failure.",1,2026-05-13
s-metoprolol tartrate,losartan,Moderate,Increased risk of hypotension and dizziness.,Additive blood pressure lowering effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
s-metoprolol tartrate,ramipril,Moderate,Increased risk of hypotension and dizziness.,Additive blood pressure lowering effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
s-metoprolol tartrate,furosemide,Moderate,"Increased risk of hypotension, especially with diuresis.",Additive blood pressure lowering effects.,Monitor blood pressure and fluid balance.,1,2026-05-13
s-metoprolol tartrate,diltiazem,Major,"Significant risk of bradycardia, AV block, and heart failure.",Both drugs have negative chronotropic and dromotropic effects.,Avoid concurrent use; monitor ECG and hemodynamics if unavoidable.,1,2026-05-13
s-metoprolol tartrate,verapamil,Major,"Significant risk of bradycardia, AV block, and heart failure.",Both drugs have negative chronotropic and dromotropic effects.,Avoid concurrent use; monitor ECG and hemodynamics if unavoidable.,1,2026-05-13
s-metoprolol tartrate,digoxin,Moderate,Increased risk of bradycardia and AV block.,Both can slow AV nodal conduction; additive effect.,Monitor heart rate and rhythm closely; check digoxin levels.,1,2026-05-13
s-metoprolol tartrate,clonidine,Moderate,Risk of severe rebound hypertension upon abrupt withdrawal of either drug.,Both can lower blood pressure; abrupt cessation can lead to hypertensive crisis.,Taper both drugs slowly if discontinuation is needed.,1,2026-05-13
s-metoprolol tartrate,methotrexate,Minor,Potential for increased methotrexate levels.,Metoprolol may inhibit certain CYP enzymes involved in methotrexate metabolism.,Monitor methotrexate levels and for signs of toxicity.,1,2026-05-13
otilonium bromide,tramadol,Minor,Potential for additive anticholinergic effects.,Otilonium bromide has anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
otilonium bromide,codeine,Minor,Potential for additive anticholinergic effects.,Otilonium bromide has anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
otilonium bromide,morphine,Minor,Potential for additive anticholinergic effects.,Otilonium bromide has anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
otilonium bromide,amitriptyline,Minor,Potential for additive anticholinergic effects.,Both have anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
nicergoline,amlodipine,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,losartan,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,ramipril,Moderate,Increased risk of hypotension and dizziness.,Both are vasodilators; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,s-metoprolol tartrate,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,metoprolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,atenolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure; additive hypotensive effects.,Monitor blood pressure closely; advise patient to change position slowly.,1,2026-05-13
nicergoline,warfarin,Minor,Potential for altered anticoagulant effect.,"Unclear, but some alpha-blockers can affect INR.",Monitor INR closely.,1,2026-05-13
nicergoline,clopidogrel,Minor,Potential for additive effects on blood pressure.,Nicergoline lowers blood pressure; clopidogrel has minor hypotensive effects.,Monitor blood pressure.,1,2026-05-13
pegylated recombinant human erythropoietin,warfarin,Moderate,Increased risk of thrombosis due to potential increase in hematocrit.,"Erythropoietin can increase hematocrit, making the blood more viscous and potentially leading to prothrombotic states. Warfarin's effectiveness can be influenced by changes in blood viscosity.",Monitor INR and hematocrit closely; adjust warfarin dose as needed and monitor for signs of thrombosis.,1,2026-05-13
pegylated recombinant human erythropoietin,aspirin,Moderate,Increased risk of thrombosis due to potential increase in hematocrit.,"Erythropoietin can increase hematocrit, making the blood more viscous and potentially leading to prothrombotic states. Aspirin's antiplatelet effect may be less effective in highly viscous blood.",Monitor hematocrit and for signs of thrombosis; consider alternative antiplatelet strategies if needed.,1,2026-05-13
pegylated recombinant human erythropoietin,clopidogrel,Moderate,Increased risk of thrombosis due to potential increase in hematocrit.,"Erythropoietin can increase hematocrit, making the blood more viscous and potentially leading to prothrombotic states. Clopidogrel's antiplatelet effect may be less effective in highly viscous blood.",Monitor hematocrit and for signs of thrombosis; consider alternative antiplatelet strategies if needed.,1,2026-05-13
pegylated recombinant human erythropoietin,metformin,Minor,Potential for altered glycemic control.,"Erythropoietin can affect glucose metabolism, although the clinical significance is variable.",Monitor blood glucose levels closely.,1,2026-05-13
pegylated recombinant human erythropoietin,insulin,Minor,Potential for altered glycemic control.,"Erythropoietin can affect glucose metabolism, although the clinical significance is variable.",Monitor blood glucose levels closely.,1,2026-05-13
pegylated recombinant human erythropoietin,losartan,Minor,Potential for increased blood pressure.,Erythropoietin can increase blood pressure.,Monitor blood pressure regularly.,1,2026-05-13
pegylated recombinant human erythropoietin,amlodipine,Minor,Potential for altered blood pressure control.,Erythropoietin can increase blood pressure.,Monitor blood pressure regularly.,1,2026-05-13
pegylated recombinant human erythropoietin,furosemide,Minor,Potential for altered blood pressure control.,Erythropoietin can increase blood pressure.,Monitor blood pressure regularly.,1,2026-05-13
triticum vulgare extract,,,,,,1,2026-05-13
measles vaccine,,,,,,1,2026-05-13
lacidipine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Additive pharmacodynamic effects on blood pressure and heart rate.,Monitor blood pressure and heart rate closely; consider dose adjustment.,1,2026-05-13
lacidipine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Additive pharmacodynamic effects on blood pressure and heart rate.,Monitor blood pressure and heart rate closely; consider dose adjustment.,1,2026-05-13
lacidipine,ramipril,Moderate,Increased risk of hypotension.,Additive pharmacodynamic effects on blood pressure.,Monitor blood pressure; consider dose adjustment if hypotension occurs.,1,2026-05-13
lacidipine,amiodarone,Moderate,Increased risk of bradycardia and AV block.,Potential for additive negative chronotropic and dromotropic effects.,Monitor heart rate and rhythm closely; use with caution.,1,2026-05-13
benserazide,levodopa,Major,Reduced efficacy of levodopa due to increased peripheral metabolism.,"Benserazide inhibits peripheral dopa decarboxylase, increasing levodopa's availability to the brain.","Benserazide is typically co-formulated with levodopa (e.g., Madopar, Prolopa) and is essential for its efficacy.",1,2026-05-13
cetilistat,,,,,,1,2026-05-13
overseasroxithromycin,warfarin,Moderate,"Increased anticoagulant effect, leading to a higher risk of bleeding.","Macrolide antibiotics can inhibit the metabolism of warfarin, increasing its plasma concentration.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
overseasroxithromycin,digoxin,Moderate,Increased digoxin levels and risk of toxicity.,"Macrolide antibiotics can alter gut flora, potentially increasing digoxin absorption.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseasroxithromycin,atorvastatin,Minor,Slightly increased risk of myopathy or rhabdomyolysis.,"Potential for CYP3A4 inhibition by roxithromycin, which metabolizes atorvastatin.",Use with caution; monitor for muscle pain and weakness.,1,2026-05-13
overseasroxithromycin,simvastatin,Moderate,Increased risk of myopathy or rhabdomyolysis.,CYP3A4 inhibition by roxithromycin.,Avoid concurrent use or monitor closely for muscle-related symptoms.,1,2026-05-13
levosimendan,furosemide,Moderate,Increased risk of hypotension due to excessive diuresis.,Additive vasodilatory and diuretic effects.,Monitor blood pressure and fluid balance closely.,1,2026-05-13
levosimendan,isosorbide dinitrate,Moderate,Increased risk of hypotension.,Additive vasodilatory effects.,Monitor blood pressure closely; use with caution.,1,2026-05-13
limitedursodeoxycholic acid,,,,,,1,2026-05-13
overseaslevocetirizine,alprazolam,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,diazepam,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,lorazepam,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,clonazepam,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,midazolam,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,zolpidem,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,tramadol,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,codeine,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
overseaslevocetirizine,morphine,Minor,Potentially additive sedative effects.,Both can cause drowsiness.,Use caution and monitor for excessive sedation.,1,2026-05-13
trelagliptin,metformin,Minor,"No significant drug-drug interaction expected, but monitor glycemic control.",Both are oral antidiabetic agents with different mechanisms of action.,Monitor blood glucose levels for optimal glycemic control.,1,2026-05-13
trelagliptin,insulin,Minor,"No significant drug-drug interaction expected, but monitor glycemic control.","Both are antidiabetic agents, but their combination requires careful monitoring.",Monitor blood glucose levels closely for potential hypoglycemia.,1,2026-05-13
lobeglitazone sulfate,metformin,Minor,Increased risk of hypoglycemia if used in combination.,Additive glycemic lowering effects.,"Monitor blood glucose levels closely, especially when initiating or adjusting doses.",1,2026-05-13
lobeglitazone sulfate,insulin,Moderate,Increased risk of hypoglycemia.,Additive glycemic lowering effects.,Monitor blood glucose levels closely and adjust insulin dose accordingly to prevent hypoglycemia.,1,2026-05-13
lobeglitazone sulfate,furosemide,Minor,"No significant interaction, but monitor fluid balance and glycemic control.",Different mechanisms of action.,Monitor blood glucose and fluid balance.,1,2026-05-13
lobeglitazone sulfate,ramipril,Minor,"No significant interaction, but monitor blood pressure and glycemic control.",Different mechanisms of action.,Monitor blood pressure and blood glucose levels.,1,2026-05-13
iron polysaccharide complex,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Iron can bind to statins in the GI tract, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
iron polysaccharide complex,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Iron can bind to statins in the GI tract, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
iron polysaccharide complex,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Iron can form chelates with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
iron polysaccharide complex,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Iron can form chelates with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
iron polysaccharide complex,levothyroxine,Major,"Reduced absorption of levothyroxine, leading to hypothyroidism.","Iron binds to levothyroxine in the gastrointestinal tract, reducing its absorption.",Separate administration by at least 4 hours.,1,2026-05-13
overseaschlorzoxazone,,,,,,1,2026-05-13
quiniodochlor,,,,,,1,2026-05-13
hydrotalcite,atorvastatin,Minor,Reduced absorption of atorvastatin.,Antacids can decrease absorption of some oral medications.,Separate administration by at least 2 hours.,1,2026-05-13
hydrotalcite,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,Antacids can decrease absorption of some oral medications.,Separate administration by at least 2 hours.,1,2026-05-13
hydrotalcite,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Antacids can chelate with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
hydrotalcite,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Antacids can chelate with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
hydrotalcite,digoxin,Minor,Reduced absorption of digoxin.,Antacids can affect gastric pH and reduce absorption of digoxin.,Separate administration by at least 2 hours.,1,2026-05-13
hydrotalcite,metformin,Minor,Reduced absorption of metformin.,Antacids can affect gastric emptying and absorption of metformin.,Separate administration by at least 2 hours.,1,2026-05-13
allium cepa,,,,,,1,2026-05-13
prothionamide,cyclosporine,Moderate,Increased risk of cyclosporine toxicity.,"Prothionamide may induce CYP enzymes, increasing cyclosporine metabolism.",Monitor cyclosporine levels closely and adjust dose if necessary.,1,2026-05-13
prothionamide,tacrolimus,Moderate,Increased risk of tacrolimus toxicity.,"Prothionamide may induce CYP enzymes, increasing tacrolimus metabolism.",Monitor tacrolimus levels closely and adjust dose if necessary.,1,2026-05-13
calcium orotate,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Calcium can bind to statins in the GI tract, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium orotate,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Calcium can bind to statins in the GI tract, decreasing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
calcium orotate,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Calcium can chelate with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
calcium orotate,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Calcium can chelate with fluoroquinolones, decreasing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
calcium orotate,tetracycline,Major,Significantly reduced absorption of tetracycline.,"Calcium forms insoluble chelates with tetracyclines, impairing absorption.",Avoid concurrent administration; separate by at least 3 hours.,1,2026-05-13
calcium orotate,thyroid hormone,Major,Reduced absorption of thyroid hormone.,"Calcium can bind to thyroid hormones, reducing their absorption.",Separate administration by at least 4 hours.,1,2026-05-13
pneumococcal polysaccharide conjugate vaccine,,,,,,1,2026-05-13
limitedlevosulpiride,amiodarone,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Use with caution; monitor ECG and electrolytes; consider alternative.,1,2026-05-13
limitedlevosulpiride,cisapride,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Avoid concurrent use.,1,2026-05-13
limitedlevosulpiride,disopyramide,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Use with caution; monitor ECG and electrolytes; consider alternative.,1,2026-05-13
limitedlevosulpiride,dronedarone,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Avoid concurrent use.,1,2026-05-13
limitedlevosulpiride,ibutilide,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Avoid concurrent use.,1,2026-05-13
limitedlevosulpiride,quinidine,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Use with caution; monitor ECG and electrolytes; consider alternative.,1,2026-05-13
limitedlevosulpiride,sotalol,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Use with caution; monitor ECG and electrolytes; consider alternative.,1,2026-05-13
limitedlevosulpiride,tramadol,Moderate,Increased risk of QT prolongation.,Both drugs can affect cardiac repolarization.,Use with caution; monitor ECG.,1,2026-05-13
limitedlevosulpiride,tramadol,Moderate,Increased risk of QT prolongation and potential for serotonin syndrome.,Levosulpiride can affect QT interval and may have serotonergic effects. Tramadol also affects QT and has serotonergic effects.,Use with caution; monitor ECG and for signs of serotonin syndrome.,1,2026-05-13
and products for cervical dilatation,,,,,,1,2026-05-13
univestin,,,,,,1,2026-05-13
freeze-dried live attenuated hepatitis a vaccine,,,,,,1,2026-05-13
tiapride,tramadol,Moderate,Increased risk of CNS depression and sedation.,Additive pharmacodynamic effects on the central nervous system.,Monitor for signs of excessive sedation; consider dose reduction of one agent if necessary.,1,2026-05-13
tiapride,codeine,Moderate,Increased risk of CNS depression and sedation.,Additive pharmacodynamic effects on the central nervous system.,Monitor for signs of excessive sedation; consider dose reduction of one agent if necessary.,1,2026-05-13
tiapride,morphine,Moderate,Increased risk of CNS depression and sedation.,Additive pharmacodynamic effects on the central nervous system.,Monitor for signs of excessive sedation; consider dose reduction of one agent if necessary.,1,2026-05-13
tiapride,alprazolam,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
tiapride,diazepam,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
tiapride,lorazepam,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
tiapride,clonazepam,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
tiapride,midazolam,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
tiapride,zolpidem,Major,"Potentiation of sedation, respiratory depression, and potentially fatal CNS depression.",Synergistic pharmacodynamic effect on GABAergic neurotransmission.,"Avoid concomitant use. If unavoidable, use lowest effective doses for shortest duration and closely monitor respiratory function and sedation.",1,2026-05-13
heal,,,,,,1,2026-05-13
ammonium lactate,,,,,,1,2026-05-13
pitofenone,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, blurred vision, urinary retention).",Additive anticholinergic properties.,Monitor for increased anticholinergic side effects; consider dose adjustment or alternatives if severe.,1,2026-05-13
pitofenone,haloperidol,Moderate,Increased risk of anticholinergic side effects and potential for additive CNS effects.,Additive anticholinergic properties and potential CNS depression.,Monitor for increased anticholinergic effects and sedation.,1,2026-05-13
pitofenone,clozapine,Moderate,"Increased risk of anticholinergic side effects, particularly constipation and urinary retention.",Additive anticholinergic properties.,"Monitor for signs of severe anticholinergic effects, especially constipation.",1,2026-05-13
pitofenone,olanzapine,Moderate,"Increased risk of anticholinergic side effects, particularly constipation and urinary retention.",Additive anticholinergic properties.,"Monitor for signs of severe anticholinergic effects, especially constipation.",1,2026-05-13
fenpiverinium,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, blurred vision, urinary retention).",Additive anticholinergic properties.,Monitor for increased anticholinergic side effects; consider dose adjustment or alternatives if severe.,1,2026-05-13
fenpiverinium,haloperidol,Moderate,Increased risk of anticholinergic side effects and potential for additive CNS effects.,Additive anticholinergic properties and potential CNS depression.,Monitor for increased anticholinergic effects and sedation.,1,2026-05-13
fenpiverinium,clozapine,Moderate,"Increased risk of anticholinergic side effects, particularly constipation and urinary retention.",Additive anticholinergic properties.,"Monitor for signs of severe anticholinergic effects, especially constipation.",1,2026-05-13
fenpiverinium,olanzapine,Moderate,"Increased risk of anticholinergic side effects, particularly constipation and urinary retention.",Additive anticholinergic properties.,"Monitor for signs of severe anticholinergic effects, especially constipation.",1,2026-05-13
chromium chloride,,,,,,1,2026-05-13
calcium phosphate,warfarin,Minor,Potential for decreased absorption of warfarin.,"Calcium can chelate with warfarin, reducing its oral bioavailability.","Monitor INR closely, especially when starting or stopping calcium supplements.",1,2026-05-13
calcium phosphate,"tetracyclines (e.g., amoxicillin, doxycycline - not in list but common)",Moderate,Decreased absorption of tetracyclines.,"Calcium forms insoluble complexes with tetracyclines, reducing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
calcium phosphate,"fluoroquinolones (e.g., ciprofloxacin - in list)",Moderate,Decreased absorption of fluoroquinolones.,"Calcium forms insoluble complexes with fluoroquinolones, reducing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
arginine,,,,,,1,2026-05-13
human coagulation factor viii,,,,,,1,2026-05-13
pinavarium bromide,,,,,,1,2026-05-13
gamma linolenic acid,,,,,,1,2026-05-13
limitedetoricoxib,warfarin,Major,Increased risk of bleeding.,COX-2 inhibition can reduce the gastroprotective effects of warfarin.,Monitor INR closely and consider alternative pain relief if possible.,1,2026-05-13
limitedetoricoxib,aspirin,Major,Increased risk of gastrointestinal bleeding and cardiovascular events.,Both drugs inhibit prostaglandin synthesis; combining them increases GI toxicity and may reduce aspirin's cardioprotective effect.,Avoid concomitant use; consider alternative analgesics or antiplatelets.,1,2026-05-13
limitedetoricoxib,ibuprofen,Major,Increased risk of gastrointestinal bleeding and renal impairment.,"Both are NSAIDs and can increase the risk of GI ulcers and bleeding, as well as potentially impair renal function.",Avoid concomitant use; consider alternative analgesics.,1,2026-05-13
limitedetoricoxib,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can reduce the efficacy of ACE inhibitors and impair renal function, especially in susceptible individuals.",Monitor blood pressure and renal function; consider alternative pain relief.,1,2026-05-13
limitedetoricoxib,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can reduce the efficacy of ARBs and impair renal function, especially in susceptible individuals.",Monitor blood pressure and renal function; consider alternative pain relief.,1,2026-05-13
limitedetoricoxib,amlodipine,Moderate,Reduced antihypertensive effect.,NSAIDs can interfere with the vasodilatory effects of calcium channel blockers.,Monitor blood pressure; consider alternative pain relief.,1,2026-05-13
limitedetoricoxib,atenolol,Moderate,Reduced antihypertensive effect.,NSAIDs can interfere with the antihypertensive effects of beta-blockers.,Monitor blood pressure; consider alternative pain relief.,1,2026-05-13
limitedetoricoxib,metoprolol,Moderate,Reduced antihypertensive effect.,NSAIDs can interfere with the antihypertensive effects of beta-blockers.,Monitor blood pressure; consider alternative pain relief.,1,2026-05-13
limitedetoricoxib,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,NSAIDs can antagonize the effects of loop diuretics and increase the risk of renal toxicity.,"Monitor fluid balance, blood pressure, and renal function.",1,2026-05-13
limitedetoricoxib,atorvastatin,Minor,Slightly increased risk of gastrointestinal distress.,"Both drugs can cause GI upset, though the interaction is not typically synergistic.",Monitor for GI symptoms.,1,2026-05-13
limitedetoricoxib,rosuvastatin,Minor,Slightly increased risk of gastrointestinal distress.,"Both drugs can cause GI upset, though the interaction is not typically synergistic.",Monitor for GI symptoms.,1,2026-05-13
limitedceftriaxone,warfarin,Moderate,Increased risk of bleeding.,"Cephalosporins can affect gut flora, potentially reducing vitamin K production, and may have direct anticoagulant effects.",Monitor INR closely during and after treatment.,1,2026-05-13
limitedceftriaxone,probenecid,Minor,Increased ceftriaxone plasma concentrations.,Probenecid inhibits renal tubular secretion of ceftriaxone.,"Dose adjustment of ceftriaxone may be necessary, though often not clinically significant with standard dosing.",1,2026-05-13
moxidectin,ivermectin,Major,Increased risk of neurotoxicity.,"Both are macrocyclic lactones and can have additive effects on GABA receptors, leading to neurotoxicity.",Avoid concomitant use.,1,2026-05-13
moxidectin,amitriptyline,Moderate,Increased risk of CNS depression and neurotoxicity.,Both can affect neurotransmitter systems and potentially potentiate CNS side effects.,Monitor for CNS side effects; consider alternative.,1,2026-05-13
moxidectin,haloperidol,Moderate,Increased risk of CNS depression and neurotoxicity.,Both can affect neurotransmitter systems and potentially potentiate CNS side effects.,Monitor for CNS side effects; consider alternative.,1,2026-05-13
moxidectin,clozapine,Moderate,Increased risk of CNS depression and neurotoxicity.,Both can affect neurotransmitter systems and potentially potentiate CNS side effects.,Monitor for CNS side effects; consider alternative.,1,2026-05-13
moxidectin,olanzapine,Moderate,Increased risk of CNS depression and neurotoxicity.,Both can affect neurotransmitter systems and potentially potentiate CNS side effects.,Monitor for CNS side effects; consider alternative.,1,2026-05-13
moxidectin,diazepam,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,alprazolam,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,lorazepam,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,clonazepam,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,midazolam,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,zolpidem,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,gabapentin,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,tramadol,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,codeine,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
moxidectin,morphine,Moderate,Increased risk of CNS depression.,Both can cause sedation and central nervous system depression.,Monitor for excessive sedation.,1,2026-05-13
recombinant,,,,,,1,2026-05-13
meningococcal vaccine,,,,,,1,2026-05-13
polidocanol,,,,,,1,2026-05-13
overseasalprazolam,flumazenil,Major,Can precipitate withdrawal symptoms and seizures.,Flumazenil is a benzodiazepine receptor antagonist that reverses the effects of alprazolam.,Use with extreme caution and only if medically indicated for benzodiazepine overdose; monitor closely for withdrawal.,1,2026-05-13
overseasalprazolam,opioids,Major,"Increased sedation, respiratory depression, and potentially fatal overdose.",Additive CNS depressant effects.,"Avoid concomitant use; if unavoidable, use lowest doses for shortest duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseasalprazolam,alcohol,Major,"Increased sedation, impaired coordination, and potentially fatal overdose.",Additive CNS depressant effects.,Avoid alcohol consumption.,1,2026-05-13
overseasalprazolam,clozapine,Moderate,Increased risk of sedation and hypotension.,Additive CNS depressant and hypotensive effects.,Monitor for sedation and hypotension.,1,2026-05-13
overseasalprazolam,olanzapine,Moderate,Increased risk of sedation.,Additive CNS depressant effects.,Monitor for excessive sedation.,1,2026-05-13
overseasalprazolam,haloperidol,Moderate,Increased risk of sedation and anticholinergic effects.,Additive CNS depressant effects and potential for increased anticholinergic burden.,Monitor for sedation and anticholinergic side effects.,1,2026-05-13
overseasalprazolam,"other benzodiazepines (diazepam, lorazepam, clonazepam, midazolam)",Major,"Potentiation of CNS depression, respiratory depression, and prolonged sedation.",Synergistic GABAergic effects.,"Avoid concomitant use; if unavoidable, use extreme caution and monitor for excessive CNS depression.",1,2026-05-13
overseasalprazolam,phenytoin,Moderate,Altered phenytoin levels and increased risk of CNS side effects.,Benzodiazepines can affect hepatic metabolism and distribution of phenytoin.,Monitor phenytoin levels and for CNS side effects.,1,2026-05-13
overseasalprazolam,valproate,Moderate,Increased alprazolam levels and potential for enhanced sedation.,Valproate can inhibit the metabolism of alprazolam.,Monitor for increased sedation and consider dose reduction of alprazolam.,1,2026-05-13
overseasalprazolam,metformin,Minor,Potential for altered glycemic control due to CNS effects.,Sedation and impaired cognition from alprazolam can affect adherence to diabetes management.,Monitor glycemic control and adherence to treatment.,1,2026-05-13
overseasalprazolam,sertraline,Minor,Potential for increased anxiety or paradoxical reactions.,"Complex interactions on neurotransmitter systems, though often clinically insignificant.",Monitor for changes in mood or anxiety.,1,2026-05-13
overseasalprazolam,fluoxetine,Minor,Potential for increased anxiety or paradoxical reactions.,"Complex interactions on neurotransmitter systems, though often clinically insignificant.",Monitor for changes in mood or anxiety.,1,2026-05-13
overseasalprazolam,amitriptyline,Minor,Increased risk of anticholinergic side effects and sedation.,Additive anticholinergic and CNS depressant effects.,Monitor for increased anticholinergic side effects and sedation.,1,2026-05-13
overseasalprazolam,atorvastatin,Minor,Slightly increased risk of drowsiness.,Both can cause mild CNS effects.,Monitor for drowsiness.,1,2026-05-13
overseasalprazolam,rosuvastatin,Minor,Slightly increased risk of drowsiness.,Both can cause mild CNS effects.,Monitor for drowsiness.,1,2026-05-13
overseasalprazolam,warfarin,Minor,Potential for altered INR.,Minor effects on hepatic metabolism or patient adherence.,"Monitor INR closely, especially when starting or stopping alprazolam.",1,2026-05-13
standard cobra venom,,,,,,1,2026-05-13
standard common krait venom,,,,,,1,2026-05-13
standard russels viper venom,,,,,,1,2026-05-13
tenoxicam,warfarin,Major,Increased risk of bleeding.,NSAIDs can displace warfarin from albumin binding sites and inhibit platelet aggregation.,Monitor INR closely; consider alternative pain relief if possible.,1,2026-05-13
tenoxicam,aspirin,Major,Increased risk of gastrointestinal bleeding.,Additive effect on COX inhibition and antiplatelet activity.,Avoid concomitant use if possible; monitor for GI bleeding.,1,2026-05-13
tenoxicam,ibuprofen,Major,Increased risk of gastrointestinal bleeding.,Additive NSAID effects on gastrointestinal mucosa and platelet function.,Avoid concomitant use; monitor for GI bleeding.,1,2026-05-13
tenoxicam,clopidogrel,Moderate,Increased risk of bleeding.,NSAIDs can inhibit platelet aggregation and increase the risk of gastrointestinal bleeding when combined with antiplatelet agents.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
tenoxicam,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, leading to reduced metformin clearance and increased lactate accumulation.",Monitor renal function and blood glucose; consider alternative pain relief.,1,2026-05-13
tenoxicam,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
tenoxicam,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
tenoxicam,amlodipine,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, counteracting the effects of calcium channel blockers.",Monitor blood pressure.,1,2026-05-13
tenoxicam,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
tenoxicam,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
tenoxicam,digoxin,Minor,Potential for increased digoxin levels.,"NSAIDs can affect renal function, potentially reducing digoxin excretion.",Monitor digoxin levels and renal function.,1,2026-05-13
tenoxicam,lithium,Moderate,Increased risk of lithium toxicity.,NSAIDs can reduce renal excretion of lithium.,Monitor lithium levels and renal function.,1,2026-05-13
l-lysine monohydrochloride,,,,,,1,2026-05-13
protein hydrolysate,,,,,,1,2026-05-13
lacto bacillus rhamnosus,,,,,,1,2026-05-13
uniflexin,,,,,,1,2026-05-13
ringer's lactate,,,,,,1,2026-05-13
inosine pranobex,"immunosuppressants (e.g., methotrexate, cyclosporine, tacrolimus, prednisolone, dexamethasone)",Moderate,Reduced efficacy of immunosuppressants.,Inosine pranobex is an immunostimulant and may counteract the effects of immunosuppressive drugs.,Avoid concomitant use or monitor immune status closely.,1,2026-05-13
thymol,,,,,,1,2026-05-13
limitedmeropenem,,,,,,1,2026-05-13
cadsol life sciences llpglimepiride,metformin,Moderate,Increased risk of hypoglycemia.,"Glimepiride potentiates insulin secretion, and metformin can enhance glucose uptake, leading to additive hypoglycemic effects.",Monitor blood glucose closely and consider dose adjustments of either drug.,1,2026-05-13
cadsol life sciences llpglimepiride,insulin,Moderate,Increased risk of hypoglycemia.,"Glimepiride stimulates insulin release, and co-administration with exogenous insulin can lead to an additive effect on lowering blood glucose.",Monitor blood glucose closely and consider dose adjustments of either drug.,1,2026-05-13
cadsol life sciences llpglimepiride,atenolol,Moderate,Masking of hypoglycemia symptoms.,"Beta-blockers like atenolol can blunt the sympathetic response (tachycardia, tremors) that warns of hypoglycemia, potentially delaying recognition and treatment.",Educate the patient on the importance of frequent blood glucose monitoring and other non-adrenergic symptoms of hypoglycemia.,1,2026-05-13
cadsol life sciences llpglimepiride,metoprolol,Moderate,Masking of hypoglycemia symptoms.,"Beta-blockers like metoprolol can blunt the sympathetic response (tachycardia, tremors) that warns of hypoglycemia, potentially delaying recognition and treatment.",Educate the patient on the importance of frequent blood glucose monitoring and other non-adrenergic symptoms of hypoglycemia.,1,2026-05-13
ferrous asparto glycinate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Iron salts can chelate with fluoroquinolones, forming insoluble complexes that decrease oral bioavailability.",Separate administration of ferrous asparto glycinate and ciprofloxacin by at least 2-4 hours.,1,2026-05-13
ferrous asparto glycinate,levofloxacin,Major,Reduced absorption of levofloxacin.,"Iron salts can chelate with fluoroquinolones, forming insoluble complexes that decrease oral bioavailability.",Separate administration of ferrous asparto glycinate and levofloxacin by at least 2-4 hours.,1,2026-05-13
ferrous asparto glycinate,tetracycline,Major,Reduced absorption of tetracycline.,"Iron salts can chelate with tetracyclines, forming insoluble complexes that decrease oral bioavailability.",Separate administration of ferrous asparto glycinate and tetracycline by at least 2-4 hours.,1,2026-05-13
ferrous asparto glycinate,doxycycline,Major,Reduced absorption of doxycycline.,"Iron salts can chelate with tetracyclines, forming insoluble complexes that decrease oral bioavailability.",Separate administration of ferrous asparto glycinate and doxycycline by at least 2-4 hours.,1,2026-05-13
ferrous asparto glycinate,thyroxine,Major,Reduced absorption of thyroxine.,"Iron salts can bind to levothyroxine in the gastrointestinal tract, decreasing its absorption.",Separate administration of ferrous asparto glycinate and thyroxine by at least 4 hours.,1,2026-05-13
ferrous asparto glycinate,warfarin,Moderate,May interfere with the absorption of warfarin.,"Iron can potentially bind to warfarin in the GI tract, affecting absorption.",Monitor INR closely and consider separating administration times.,1,2026-05-13
ferrous asparto glycinate,atorvastatin,Minor,May potentially reduce absorption of atorvastatin.,"Iron can form complexes with certain medications, potentially affecting absorption.",Consider separating administration times if concerns arise.,1,2026-05-13
ferrous asparto glycinate,rosuvastatin,Minor,May potentially reduce absorption of rosuvastatin.,"Iron can form complexes with certain medications, potentially affecting absorption.",Consider separating administration times if concerns arise.,1,2026-05-13
lactobacillus reuteri,,,,,,1,2026-05-13
lactobacillus casei,,,,,,1,2026-05-13
peptone,,,,,,1,2026-05-13
inactivated hepatitis a vaccine,,,,,,1,2026-05-13
aflapin,,,,,,1,2026-05-13
sodium perborate monohydrate,,,,,,1,2026-05-13
limitedmethylcobalamin,,,,,,1,2026-05-13
nefopam,tramadol,Major,Increased risk of serotonin syndrome and CNS depression.,Both are centrally acting analgesics with serotonergic and noradrenergic effects.,"Avoid concurrent use; if unavoidable, monitor closely for signs of serotonin syndrome and CNS depression.",1,2026-05-13
nefopam,codeine,Major,Increased risk of respiratory depression and sedation.,Both can depress the central nervous system and respiratory drive.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status.",1,2026-05-13
nefopam,morphine,Major,Increased risk of respiratory depression and sedation.,Both can depress the central nervous system and respiratory drive.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status.",1,2026-05-13
nefopam,amitriptyline,Moderate,Potentially increased central nervous system side effects including sedation and confusion.,Additive CNS depressant effects.,Monitor for increased CNS side effects and consider dose adjustments.,1,2026-05-13
nefopam,diazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution and monitor for excessive sedation and respiratory depression.,1,2026-05-13
nefopam,lorazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution and monitor for excessive sedation and respiratory depression.,1,2026-05-13
nefopam,clonazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,,1,2026-05-13
nefopam,alprazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution and monitor for excessive sedation and respiratory depression.,1,2026-05-13
nefopam,midazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution and monitor for excessive sedation and respiratory depression.,1,2026-05-13
nefopam,zolpidem,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use with caution and monitor for excessive sedation and respiratory depression.,1,2026-05-13
health care llprosuvastatin,,,,,,1,2026-05-13
l-glutathione,,,,,,1,2026-05-13
extractum cepae-cepalin,,,,,,1,2026-05-13
ethylmorphine,tramadol,Major,Increased risk of respiratory depression and sedation.,Both are opioid analgesics and can potentiate CNS and respiratory depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status closely.",1,2026-05-13
ethylmorphine,codeine,Major,Increased risk of respiratory depression and sedation.,"Both are opioid agonists, leading to additive respiratory and CNS depression.",,1,2026-05-13
ethylmorphine,morphine,Major,Increased risk of respiratory depression and sedation.,"Both are opioid agonists, leading to additive respiratory and CNS depression.","Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status closely.",1,2026-05-13
ethylmorphine,diazepam,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,lorazepam,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,clonazepam,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,alprazolam,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,midazolam,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,zolpidem,Major,"Profound sedation, respiratory depression, coma.",Additive central nervous system depression.,"Avoid concurrent use; if unavoidable, use the lowest effective doses and monitor respiratory status and level of consciousness.",1,2026-05-13
ethylmorphine,amitriptyline,Moderate,Increased sedation and potentially anticholinergic effects.,Additive CNS depressant effects and potential for potentiation of anticholinergic effects.,Monitor for increased sedation and anticholinergic effects; consider dose adjustments.,1,2026-05-13
ethylmorphine,gabapentin,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness.,1,2026-05-13
ethylmorphine,pregabalin,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness.,1,2026-05-13
nicotinic acid,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Both drugs can cause muscle-related adverse events, and their combination can potentiate this risk.","Use with caution; monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative therapies if symptoms occur.",1,2026-05-13
nicotinic acid,rosuvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Both drugs can cause muscle-related adverse events, and their combination can potentiate this risk.","Use with caution; monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative therapies if symptoms occur.",1,2026-05-13
nicotinic acid,simvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Both drugs can cause muscle-related adverse events, and their combination can potentiate this risk.","Use with caution; monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative therapies if symptoms occur.",1,2026-05-13
nicotinic acid,lovastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Both drugs can cause muscle-related adverse events, and their combination can potentiate this risk.","Use with caution; monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative therapies if symptoms occur.",1,2026-05-13
nicotinic acid,warfarin,Moderate,May slightly increase the anticoagulant effect of warfarin.,"Nicotinic acid can affect platelet aggregation and plasma protein binding, potentially altering warfarin's pharmacodynamics.",Monitor INR more frequently when initiating or discontinuing nicotinic acid in patients on warfarin.,1,2026-05-13
itolizumab,,,,,,1,2026-05-13
alister life sciences llpluliconazole,warfarin,Moderate,Increased risk of bleeding.,"Azole antifungals like luliconazole can inhibit CYP2C9, which metabolizes warfarin, leading to increased warfarin levels and anticoagulant effect.",Monitor INR closely when initiating or discontinuing luliconazole in patients on warfarin. Consider dose adjustment of warfarin.,1,2026-05-13
limitedbromelain,warfarin,Moderate,Increased risk of bleeding.,Bromelain has anticoagulant and antiplatelet properties that can potentiate the effect of warfarin.,Use with caution; monitor for signs of bleeding. Patients on warfarin should avoid bromelain supplements or use them under strict medical supervision.,1,2026-05-13
limitedbromelain,aspirin,Moderate,Increased risk of bleeding.,Bromelain has antiplatelet effects that can be additive with aspirin.,Use with caution; monitor for signs of bleeding. Patients taking aspirin should exercise caution with bromelain.,1,2026-05-13
limitedbromelain,clopidogrel,Moderate,Increased risk of bleeding.,Bromelain has antiplatelet effects that can be additive with clopidogrel.,Use with caution; monitor for signs of bleeding. Patients taking clopidogrel should exercise caution with bromelain.,1,2026-05-13
mumps virus vaccine,,,,,,1,2026-05-13
podophyllum resin,,,,,,1,2026-05-13
benzoin,,,,,,1,2026-05-13
human gamma globulin,mumps virus vaccine,Moderate,Reduced efficacy of the vaccine.,Antibodies in gamma globulin can neutralize the live virus in the vaccine.,Avoid concurrent administration; defer vaccination for at least 3 months.,1,2026-05-13
calcium lactobionate,,,,,,1,2026-05-13
zaltoprofen,warfarin,Moderate,Increased risk of bleeding.,NSAIDs can potentiate the anticoagulant effect of warfarin and cause gastrointestinal irritation.,Monitor INR closely and consider alternative analgesics if possible.,1,2026-05-13
zaltoprofen,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, leading to additive gastrointestinal toxicity.",Avoid concurrent use; consider alternative analgesics.,1,2026-05-13
zaltoprofen,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, leading to additive gastrointestinal toxicity.",Avoid concurrent use; consider alternative analgesics.,1,2026-05-13
zaltoprofen,clopidogrel,Moderate,Increased risk of bleeding.,"NSAIDs increase the risk of gastrointestinal bleeding, which is also a risk with clopidogrel.",Use with caution and monitor for signs of bleeding.,1,2026-05-13
zaltoprofen,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin clearance.",Monitor renal function; use with caution.,1,2026-05-13
zaltoprofen,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced renal perfusion.",Monitor blood pressure and renal function; use with caution.,1,2026-05-13
zaltoprofen,furosemide,Moderate,Reduced diuretic and antihypertensive effect.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention.",Monitor urine output and blood pressure; use with caution.,1,2026-05-13
zaltoprofen,atenolol,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting beta-blocker effects.",Monitor blood pressure.,1,2026-05-13
zaltoprofen,metoprolol,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting beta-blocker effects.",Monitor blood pressure.,1,2026-05-13
zaltoprofen,amlodipine,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting calcium channel blocker effects.",Monitor blood pressure.,1,2026-05-13
zaltoprofen,losartan,Minor,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to reduced renal perfusion.",Monitor blood pressure and renal function.,1,2026-05-13
thrombin,,,,,,1,2026-05-13
overseasparacetamol,,,,,,1,2026-05-13
limitedceftazidime,,,,,,1,2026-05-13
dimethindene,alprazolam,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,diazepam,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,lorazepam,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,clonazepam,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,midazolam,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,zolpidem,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,tramadol,Moderate,Increased sedation.,Both drugs can cause CNS depression.,Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,codeine,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,morphine,Moderate,Increased sedation and respiratory depression.,"Both are CNS depressants, leading to additive sedative effects.",Use with caution; monitor for excessive sedation.,1,2026-05-13
dimethindene,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Use with caution; monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
dimethindene,haloperidol,Moderate,Increased sedation and extrapyramidal symptoms.,Additive CNS depressant effects; potential for additive anticholinergic effects.,Use with caution; monitor for sedation and movement disorders.,1,2026-05-13
dimethindene,clozapine,Moderate,Increased sedation and risk of orthostatic hypotension.,Additive CNS depressant effects.,Use with caution; monitor for sedation and blood pressure.,1,2026-05-13
dimethindene,olanzapine,Moderate,Increased sedation and risk of orthostatic hypotension.,Additive CNS depressant effects.,Use with caution; monitor for sedation and blood pressure.,1,2026-05-13
levomenthol,,,,,,1,2026-05-13
limitedtolperisone,diazepam,Moderate,Increased sedation and central nervous system depression.,"Both agents have CNS depressant effects, leading to additive pharmacodynamic interactions.",Monitor for excessive sedation; consider dose reduction of one or both agents if necessary.,1,2026-05-13
limitedtolperisone,alprazolam,Moderate,Increased sedation and central nervous system depression.,"Both agents have CNS depressant effects, leading to additive pharmacodynamic interactions.",Monitor for excessive sedation; consider dose reduction of one or both agents if necessary.,1,2026-05-13
limitedtolperisone,lorazepam,Moderate,Increased sedation and central nervous system depression.,"Both agents have CNS depressant effects, leading to additive pharmacodynamic interactions.",Monitor for excessive sedation; consider dose reduction of one or both agents if necessary.,1,2026-05-13
limitedtolperisone,clonazepam,Moderate,Increased sedation and central nervous system depression.,"Both agents have CNS depressant effects, leading to additive pharmacodynamic interactions.",Monitor for excessive sedation; consider dose reduction of one or both agents if necessary.,1,2026-05-13
limitedtolperisone,midazolam,Moderate,Increased sedation and central nervous system depression.,"Both agents have CNS depressant effects, leading to additive pharmacodynamic interactions.",Monitor for excessive sedation; consider dose reduction of one or both agents if necessary.,1,2026-05-13
limitedamoxycillin,warfarin,Moderate,Increased anticoagulant effect and risk of bleeding.,"Amoxicillin may alter gut flora that metabolize vitamin K, potentially increasing warfarin's effect.",Monitor INR closely and adjust warfarin dose as needed; educate patient on signs of bleeding.,1,2026-05-13
limitedamoxycillin,methotrexate,Moderate,Increased methotrexate toxicity.,Amoxicillin can inhibit the renal excretion of methotrexate.,Monitor methotrexate levels and for signs of toxicity; consider alternative antibiotic or dose adjustment of methotrexate.,1,2026-05-13
limitedamoxycillin,allopurinol,Moderate,Increased risk of rash.,Concomitant use may increase the incidence of allergic skin reactions.,Monitor for rash; discontinue amoxicillin if rash develops.,1,2026-05-13
bacterial lysate,,,,,,1,2026-05-13
sucroferric oxyhydroxide,warfarin,Moderate,"Decreased absorption of warfarin, leading to reduced anticoagulant effect.","Sucroferric oxyhydroxide can bind to warfarin in the gastrointestinal tract, reducing its absorption.",Separate administration by at least 2 hours; monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
sucroferric oxyhydroxide,levothyroxine,Moderate,"Decreased absorption of levothyroxine, leading to hypothyroidism.","Iron in sucroferric oxyhydroxide can bind to levothyroxine in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor thyroid function tests and adjust levothyroxine dose as needed.,1,2026-05-13
sucroferric oxyhydroxide,atorvastatin,Minor,Potentially decreased absorption of atorvastatin.,"Sucroferric oxyhydroxide may bind to statins, reducing their absorption.",Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,rosuvastatin,Minor,Potentially decreased absorption of rosuvastatin.,"Sucroferric oxyhydroxide may bind to statins, reducing their absorption.",Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,amlodipine,Minor,Potentially decreased absorption of amlodipine.,"Sucroferric oxyhydroxide may bind to calcium channel blockers, reducing their absorption.",Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,losartan,Minor,Potentially decreased absorption of losartan.,"Sucroferric oxyhydroxide may bind to ARBs, reducing their absorption.",Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,metformin,Minor,Potentially decreased absorption of metformin.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,furosemide,Minor,Potentially decreased absorption of furosemide.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,spironolactone,Minor,Potentially decreased absorption of spironolactone.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,atenolol,Minor,Potentially decreased absorption of atenolol.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,metoprolol,Minor,Potentially decreased absorption of metoprolol.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,ramipril,Minor,Potentially decreased absorption of ramipril.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,clopidogrel,Minor,Potentially decreased absorption of clopidogrel.,Sucroferric oxyhydroxide may affect the absorption of certain oral medications.,Consider separating administration by a few hours if possible.,1,2026-05-13
sucroferric oxyhydroxide,digoxin,Minor,Potentially decreased absorption of digoxin.,"Sucroferric oxyhydroxide may bind to digoxin, reducing its absorption.",Consider separating administration by a few hours if possible; monitor digoxin levels.,1,2026-05-13
sucroferric oxyhydroxide,thyroid hormone,Moderate,Decreased absorption of thyroid hormone.,Iron can impair the absorption of thyroid hormones.,Separate administration by at least 2 hours; monitor thyroid function tests.,1,2026-05-13
polio vaccine,,,,,,1,2026-05-13
tribasic calcium phosphate,warfarin,Moderate,"Decreased absorption of warfarin, leading to reduced anticoagulant effect.","Calcium can bind to warfarin in the gastrointestinal tract, reducing its absorption.",Separate administration by at least 2 hours; monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
tribasic calcium phosphate,tetracyclines,Major,"Significantly reduced absorption of tetracyclines, leading to decreased efficacy.","Calcium forms insoluble chelates with tetracyclines, preventing their absorption.",Avoid concomitant administration; separate by at least 2-3 hours.,1,2026-05-13
tribasic calcium phosphate,fluoroquinolones,Major,"Significantly reduced absorption of fluoroquinolones, leading to decreased efficacy.","Calcium forms insoluble chelates with fluoroquinolones, preventing their absorption.",Avoid concomitant administration; separate by at least 2-3 hours.,1,2026-05-13
tribasic calcium phosphate,bisphosphonates,Major,Reduced absorption of bisphosphonates.,Calcium can interfere with the absorption of bisphosphonates.,Separate administration by at least 2 hours.,1,2026-05-13
tribasic calcium phosphate,levothyroxine,Moderate,"Decreased absorption of levothyroxine, leading to hypothyroidism.","Calcium can bind to levothyroxine in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor thyroid function tests and adjust levothyroxine dose as needed.,1,2026-05-13
citrus bioflavonoid,,,,,,1,2026-05-13
amlexanox,,,,,,1,2026-05-13
hofloxacin,warfarin,Major,Increased anticoagulant effect and risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, increasing its plasma concentration.",Monitor INR closely and adjust warfarin dose as needed; educate patient on signs of bleeding.,1,2026-05-13
hofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can interfere with glucose metabolism and potentially increase metformin's hypoglycemic effects.,Monitor blood glucose levels closely; adjust metformin dose or monitor more frequently.,1,2026-05-13
hofloxacin,theophylline,Major,"Increased theophylline levels, leading to toxicity.",Fluoroquinolones can inhibit the metabolism of theophylline.,Avoid concomitant use or monitor theophylline levels closely and adjust dose.,1,2026-05-13
hofloxacin,caffeine,Moderate,"Increased risk of caffeine-related side effects like nervousness, insomnia, and tachycardia.",Fluoroquinolones can inhibit the metabolism of caffeine.,Advise patient to limit caffeine intake.,1,2026-05-13
hofloxacin,ciprofloxacin,Moderate,Increased risk of QT prolongation and other fluoroquinolone-related adverse effects.,Additive effects on QT interval with two fluoroquinolones.,Avoid concomitant use if possible; monitor ECG if necessary.,1,2026-05-13
hofloxacin,clopidogrel,Moderate,Potentially reduced efficacy of clopidogrel.,"Fluoroquinolones may inhibit CYP2C19, an enzyme involved in clopidogrel activation.",Consider alternative antibiotic or monitor for signs of reduced antiplatelet effect.,1,2026-05-13
hofloxacin,prednisolone,Moderate,Increased risk of tendon rupture.,Concomitant use of fluoroquinolones and corticosteroids can increase the risk of tendon damage.,Monitor for tendon pain or swelling; discontinue if symptoms occur.,1,2026-05-13
hofloxacin,dexamethasone,Moderate,Increased risk of tendon rupture.,Concomitant use of fluoroquinolones and corticosteroids can increase the risk of tendon damage.,Monitor for tendon pain or swelling; discontinue if symptoms occur.,1,2026-05-13
rutin,,,,,,1,2026-05-13
sodium pyrrolidone carboxylic acid,,,,,,1,2026-05-13
l-isoleucine,,,,,,1,2026-05-13
pneumococcal polysaccharide vaccine,,,,,,1,2026-05-13
curcuma longa,warfarin,Moderate,Increased risk of bleeding.,Curcumin may inhibit platelet aggregation and affect vitamin K metabolism.,Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
curcuma longa,clopidogrel,Moderate,Increased risk of bleeding.,Curcumin may inhibit platelet aggregation.,Monitor for signs of bleeding and consider alternative therapy if necessary.,1,2026-05-13
overseaschlorpheniramine maleate,alprazolam,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,diazepam,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,lorazepam,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,clonazepam,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,midazolam,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,zolpidem,Moderate,Enhanced sedation and central nervous system depression.,Both are sedating; additive effects.,"Use with caution, advise patient to avoid activities requiring mental alertness.",1,2026-05-13
overseaschlorpheniramine maleate,tramadol,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseaschlorpheniramine maleate,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseaschlorpheniramine maleate,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseaschlorpheniramine maleate,amitriptyline,Moderate,Increased anticholinergic effects and sedation.,Additive anticholinergic and sedating effects.,Monitor for anticholinergic side effects and increased sedation.,1,2026-05-13
nimorazole,,,,,,1,2026-05-13
resveratrol,warfarin,Moderate,Increased risk of bleeding.,Resveratrol may inhibit vitamin K epoxide reductase.,Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
resveratrol,aspirin,Minor,Increased risk of bleeding.,Additive antiplatelet effects.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
resveratrol,clopidogrel,Minor,Increased risk of bleeding.,Additive antiplatelet effects.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
cetyl alcohol,,,,,,1,2026-05-13
ferric citrate,ciprofloxacin,Major,Reduced absorption and efficacy of ciprofloxacin.,"Ferric ions chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 4 hours.,1,2026-05-13
ferric citrate,levofloxacin,Major,Reduced absorption and efficacy of levofloxacin.,"Ferric ions chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 4 hours.,1,2026-05-13
ferric citrate,tetracycline,Major,Reduced absorption and efficacy of tetracycline.,"Ferric ions chelate with tetracyclines, forming insoluble complexes.",Separate administration by at least 2 hours.,1,2026-05-13
ferric citrate,doxycycline,Major,Reduced absorption and efficacy of doxycycline.,"Ferric ions chelate with tetracyclines, forming insoluble complexes.",Separate administration by at least 2 hours.,1,2026-05-13
sulpiride,tramadol,Moderate,Increased risk of seizures.,Both drugs can lower seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
sulpiride,codeine,Moderate,Increased risk of seizures.,Both drugs can lower seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
sulpiride,morphine,Moderate,Increased risk of seizures.,Both drugs can lower seizure threshold.,Monitor for seizure activity; use with caution.,1,2026-05-13
sulpiride,haloperidol,Major,Increased risk of QT prolongation and torsades de pointes.,Additive effects on QT interval.,Avoid concurrent use; monitor ECG and electrolytes.,1,2026-05-13
sulpiride,clozapine,Major,Increased risk of QT prolongation and torsades de pointes.,Additive effects on QT interval.,Avoid concurrent use; monitor ECG and electrolytes.,1,2026-05-13
sulpiride,olanzapine,Major,Increased risk of QT prolongation and torsades de pointes.,Additive effects on QT interval.,Avoid concurrent use; monitor ECG and electrolytes.,1,2026-05-13
sulpiride,amiodarone,Major,Increased risk of QT prolongation and torsades de pointes.,Additive effects on QT interval.,Avoid concurrent use; monitor ECG and electrolytes.,1,2026-05-13
sulpiride,sotalol,Major,Increased risk of QT prolongation and torsades de pointes.,Additive effects on QT interval.,Avoid concurrent use; monitor ECG and electrolytes.,1,2026-05-13
sulpiride,ketoconazole,Moderate,Increased sulpiride levels and risk of QT prolongation.,Inhibition of sulpiride metabolism by CYP3A4.,Monitor for adverse effects; consider dose adjustment.,1,2026-05-13
sulpiride,erythromycin,Moderate,Increased sulpiride levels and risk of QT prolongation.,Inhibition of sulpiride metabolism by CYP3A4.,Monitor for adverse effects; consider dose adjustment.,1,2026-05-13
ripasudil,,,,,,1,2026-05-13
policosanol,warfarin,Moderate,Increased risk of bleeding.,"Policosanol may have antiplatelet effects, potentiating warfarin.",Monitor INR closely; caution with concurrent use.,1,2026-05-13
policosanol,clopidogrel,Moderate,Increased risk of bleeding.,Additive antiplatelet effects.,Monitor for signs of bleeding; caution with concurrent use.,1,2026-05-13
cefpodoxime proxetil,,,,,,1,2026-05-13
overseascefalexin,,,,,,1,2026-05-13
hondansetron,,,,,,1,2026-05-13
limiteddomperidone,ketoconazole,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Ketoconazole inhibits CYP3A4, increasing domperidone levels.",Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,erythromycin,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Erythromycin inhibits CYP3A4, increasing domperidone levels.",Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,clarithromycin,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, increasing domperidone levels.",Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,itraconazole,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Itraconazole inhibits CYP3A4, increasing domperidone levels.",Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,voriconazole,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Voriconazole inhibits CYP3A4, increasing domperidone levels.",Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,amiodarone,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,sotalol,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,quinidine,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,disopyramide,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concurrent use; monitor ECG.,1,2026-05-13
limiteddomperidone,tramadol,Moderate,Increased risk of QT prolongation.,Both drugs can prolong the QT interval.,Use with caution; monitor ECG.,1,2026-05-13
limiteddomperidone,ciprofloxacin,Moderate,Increased risk of QT prolongation.,Both drugs can prolong the QT interval.,Use with caution; monitor ECG.,1,2026-05-13
limiteddomperidone,levofloxacin,Moderate,Increased risk of QT prolongation.,Both drugs can prolong the QT interval.,Use with caution; monitor ECG.,1,2026-05-13
stabilized oxychloro,,,,,,1,2026-05-13
finerenone,itraconazole,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by itraconazole.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,ketoconazole,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by ketoconazole.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,clarithromycin,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by clarithromycin.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,ritonavir,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by ritonavir.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,cyclosporine,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by cyclosporine.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,tacrolimus,Major,Increased finerenone levels and risk of hyperkalemia and fluid overload.,CYP3A4 inhibition by tacrolimus.,Avoid concurrent use; monitor potassium and fluid status.,1,2026-05-13
finerenone,spironolactone,Major,Increased risk of hyperkalemia.,Additive potassium-sparing effects.,Avoid concurrent use; monitor potassium levels closely.,1,2026-05-13
finerenone,eplerenone,Major,Increased risk of hyperkalemia.,Additive potassium-sparing effects.,Avoid concurrent use; monitor potassium levels closely.,1,2026-05-13
finerenone,losartan,Moderate,Increased risk of hyperkalemia.,Both can affect the renin-angiotensin-aldosterone system.,Monitor potassium levels.,1,2026-05-13
finerenone,ramipril,Moderate,Increased risk of hyperkalemia.,Both can affect the renin-angiotensin-aldosterone system.,Monitor potassium levels.,1,2026-05-13
finerenone,atorvastatin,Minor,No significant interaction expected.,No significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
finerenone,rosuvastatin,Minor,No significant interaction expected.,No significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
xantinol nicotinate,,,,,,1,2026-05-13
evogliptin,,,,,,1,2026-05-13
limitedphenylephrine,atenolol,Major,Increased risk of severe hypertension and reflex bradycardia.,"Phenylephrine is a vasoconstrictor and atenolol is a beta-blocker, which can block the body's compensatory reflex to raise heart rate during vasoconstriction.",Avoid concurrent use; monitor blood pressure and heart rate closely if unavoidable.,1,2026-05-13
limitedphenylephrine,metoprolol,Major,Increased risk of severe hypertension and reflex bradycardia.,"Phenylephrine is a vasoconstrictor and metoprolol is a beta-blocker, which can block the body's compensatory reflex to raise heart rate during vasoconstriction.",Avoid concurrent use; monitor blood pressure and heart rate closely if unavoidable.,1,2026-05-13
limitedphenylephrine,losartan,Moderate,Reduced antihypertensive efficacy.,Phenylephrine's vasoconstrictive effects can counteract the blood pressure lowering effects of losartan.,Monitor blood pressure; consider alternative decongestant or antihypertensive.,1,2026-05-13
limitedphenylephrine,ramipril,Moderate,Reduced antihypertensive efficacy.,Phenylephrine's vasoconstrictive effects can counteract the blood pressure lowering effects of ramipril.,Monitor blood pressure; consider alternative decongestant or antihypertensive.,1,2026-05-13
limitedphenylephrine,amlodipine,Moderate,Reduced antihypertensive efficacy.,Phenylephrine's vasoconstrictive effects can counteract the blood pressure lowering effects of amlodipine.,Monitor blood pressure; consider alternative decongestant or antihypertensive.,1,2026-05-13
troxipide,,,,,,1,2026-05-13
hdomperidone,ketoconazole,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, leading to higher domperidone levels.",Avoid concurrent use.,1,2026-05-13
hdomperidone,clarithromycin,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Clarithromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, leading to higher domperidone levels.",Avoid concurrent use.,1,2026-05-13
hdomperidone,erythromycin,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, leading to higher domperidone levels.",Avoid concurrent use.,1,2026-05-13
hdomperidone,amiodarone,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Amiodarone can prolong the QT interval, and domperidone also carries a risk of QT prolongation, leading to an additive effect.",Avoid concurrent use.,1,2026-05-13
hdomperidone,haloperidol,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Haloperidol can prolong the QT interval, and domperidone also carries a risk of QT prolongation, leading to an additive effect.",Avoid concurrent use.,1,2026-05-13
hdomperidone,sertraline,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Sertraline can prolong the QT interval, and domperidone also carries a risk of QT prolongation, leading to an additive effect.",Monitor ECG and electrolytes closely.,1,2026-05-13
hdomperidone,fluoxetine,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Fluoxetine can prolong the QT interval, and domperidone also carries a risk of QT prolongation, leading to an additive effect.",Monitor ECG and electrolytes closely.,1,2026-05-13
hdomperidone,amitriptyline,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,"Amitriptyline can prolong the QT interval, and domperidone also carries a risk of QT prolongation, leading to an additive effect.",Monitor ECG and electrolytes closely.,1,2026-05-13
hdomperidone,digoxin,Minor,"No significant pharmacodynamic interaction, but monitor for gastrointestinal side effects of domperidone.",No known direct interaction; clinical relevance is low.,Monitor for domperidone side effects.,1,2026-05-13
alister life sciences llpketoconazole,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Ketoconazole is a potent inhibitor of CYP3A4, the primary enzyme metabolizing atorvastatin, leading to significantly increased statin levels.",Avoid concurrent use.,1,2026-05-13
alister life sciences llpketoconazole,rosuvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Although rosuvastatin is not primarily metabolized by CYP3A4, ketoconazole can still increase rosuvastatin levels by other mechanisms, increasing the risk of muscle toxicity.",Avoid concurrent use.,1,2026-05-13
alister life sciences llpketoconazole,warfarin,Moderate,Increased INR and risk of bleeding.,"Ketoconazole can inhibit the metabolism of warfarin, leading to increased warfarin levels.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
alister life sciences llpketoconazole,digoxin,Moderate,Increased digoxin levels and risk of toxicity.,"Ketoconazole can inhibit P-glycoprotein, a transporter involved in digoxin elimination, leading to increased digoxin levels.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
alister life sciences llpketoconazole,cyclosporine,Major,"Significantly increased cyclosporine levels, leading to increased risk of nephrotoxicity and other adverse effects.","Ketoconazole is a potent inhibitor of CYP3A4, the primary enzyme metabolizing cyclosporine, leading to drastically increased cyclosporine levels.","Avoid concurrent use. If unavoidable, reduce cyclosporine dose and monitor drug levels and renal function.",1,2026-05-13
alister life sciences llpketoconazole,tacrolimus,Major,"Significantly increased tacrolimus levels, leading to increased risk of nephrotoxicity and other adverse effects.","Ketoconazole is a potent inhibitor of CYP3A4, the primary enzyme metabolizing tacrolimus, leading to drastically increased tacrolimus levels.","Avoid concurrent use. If unavoidable, reduce tacrolimus dose and monitor drug levels and renal function.",1,2026-05-13
alister life sciences llpketoconazole,midazolam,Major,Increased midazolam levels and prolonged sedation.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes midazolam, leading to higher midazolam levels.",Avoid concurrent use.,1,2026-05-13
alister life sciences llpketoconazole,alprazolam,Moderate,Increased alprazolam levels and prolonged sedation.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes alprazolam, leading to higher alprazolam levels.","Use with caution, monitor for sedation; consider dose reduction.",1,2026-05-13
alister life sciences llpketoconazole,diazepam,Moderate,Increased diazepam levels and prolonged sedation.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes diazepam, leading to higher diazepam levels.","Use with caution, monitor for sedation; consider dose reduction.",1,2026-05-13
alister life sciences llpketoconazole,lorazepam,Minor,Minimal clinical significance as lorazepam is primarily metabolized via glucuronidation.,Lorazepam's metabolism is not significantly affected by CYP3A4 inhibitors.,No significant interaction expected.,1,2026-05-13
alister life sciences llpketoconazole,clonazepam,Moderate,Increased clonazepam levels and prolonged sedation.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes clonazepam, leading to higher clonazepam levels.","Use with caution, monitor for sedation; consider dose reduction.",1,2026-05-13
tasmed,,,,,,1,2026-05-13
l-glutamate,,,,,,1,2026-05-13
sodium sulphate,,,,,,1,2026-05-13
potassium sulphate,,,,,,1,2026-05-13
l-histidine hydrochloride,,,,,,1,2026-05-13
cod liver oil,warfarin,Minor,Increased risk of bleeding.,May have a mild antiplatelet effect.,Monitor INR closely if significant amounts are used.,1,2026-05-13
cod liver oil,clopidogrel,Minor,Increased risk of bleeding.,May have a mild antiplatelet effect.,Monitor for signs of bleeding.,1,2026-05-13
lisiran,,,,,,1,2026-05-13
mianserin,alprazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,diazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,lorazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,clonazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,midazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,zolpidem,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,tramadol,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,codeine,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,morphine,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Avoid concurrent use or reduce dose and monitor for sedation.,1,2026-05-13
mianserin,amitriptyline,Moderate,Increased anticholinergic effects and sedation.,"Pharmacodynamic interaction, both are sedating and have anticholinergic properties.","Monitor for increased side effects like dry mouth, constipation, and drowsiness.",1,2026-05-13
sodium thiosulphate,,,,,,1,2026-05-13
oclacitinib,,,,,,1,2026-05-13
remington life sciences llpambroxol,,,,,,1,2026-05-13
carbohydrate,metformin,Minor,May affect glycemic control.,"Carbohydrates are metabolized to glucose, impacting blood sugar levels.",Monitor blood glucose levels closely.,1,2026-05-13
carbohydrate,insulin,Minor,May affect glycemic control.,"Carbohydrates are metabolized to glucose, impacting blood sugar levels.",Monitor blood glucose levels closely.,1,2026-05-13
iron choline citrate,ciprofloxacin,Major,"Reduced absorption of ciprofloxacin, leading to decreased efficacy.","Iron forms insoluble complexes with fluoroquinolones, inhibiting absorption.",Separate administration by at least 2 hours before or 4-6 hours after ciprofloxacin.,1,2026-05-13
iron choline citrate,levofloxacin,Major,"Reduced absorption of levofloxacin, leading to decreased efficacy.","Iron forms insoluble complexes with fluoroquinolones, inhibiting absorption.",Separate administration by at least 2 hours before or 4-6 hours after levofloxacin.,1,2026-05-13
iron choline citrate,tetracyclines,Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.","Iron forms insoluble complexes with tetracyclines, inhibiting absorption.",Separate administration by at least 2 hours before or 4-6 hours after tetracyclines.,1,2026-05-13
iron choline citrate,thyroid hormones,Major,"Reduced absorption of thyroid hormones, leading to hypothyroidism.","Iron can bind to thyroid hormones in the gastrointestinal tract, reducing absorption.",Separate administration by at least 4 hours.,1,2026-05-13
alister life sciences llpxylometazoline,,,,,,1,2026-05-13
inotuzumab ozogamacin,,,,,,1,2026-05-13
overseasdiclofenac,warfarin,Major,Increased risk of bleeding.,"NSAIDs inhibit prostaglandin synthesis and can reduce platelet aggregation, while also potentially causing gastric irritation, increasing the risk of bleeding when combined with anticoagulants.",Monitor INR closely and consider alternative analgesics if possible.,1,2026-05-13
overseasdiclofenac,metformin,Moderate,Increased risk of lactic acidosis and impaired glycemic control.,"NSAIDs can impair renal function, which is crucial for metformin excretion, potentially leading to accumulation and lactic acidosis.",Monitor renal function and blood glucose; consider alternative analgesics.,1,2026-05-13
overseasdiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs inhibit prostaglandin synthesis, which plays a role in renal blood flow regulation. This can counteract the vasodilatory effects of ACE inhibitors and lead to renal dysfunction.",Monitor blood pressure and renal function; consider alternative analgesics.,1,2026-05-13
overseasdiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal impairment.,"NSAIDs can impair renal function by inhibiting prostaglandin synthesis, counteracting the effects of loop diuretics and increasing the risk of renal toxicity.","Monitor urine output, blood pressure, and renal function; consider alternative analgesics.",1,2026-05-13
overseasdiclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and reduced antiplatelet effect of low-dose aspirin.,Both are NSAIDs and share antiplatelet effects. Concurrent use increases the risk of GI ulceration and bleeding. Diclofenac can interfere with the cardioprotective effect of aspirin.,"Avoid concurrent use if possible, especially in patients at risk for GI bleeding. If co-administration is necessary, consider a PPI and monitor for bleeding.",1,2026-05-13
overseasdiclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, increasing the risk of gastrointestinal ulceration and bleeding.","Avoid concurrent use if possible. If necessary, monitor for GI symptoms and bleeding.",1,2026-05-13
limitedfebuxostat,warfarin,Moderate,Potential for increased INR.,"Febuxostat may inhibit CYP2C9, an enzyme involved in warfarin metabolism, potentially increasing warfarin levels.","Monitor INR closely, especially when initiating or discontinuing febuxostat.",1,2026-05-13
limitedfebuxostat,azathioprine,Major,Potentially life-threatening bone marrow suppression.,"Febuxostat inhibits xanthine oxidase, the enzyme that metabolizes azathioprine. This leads to increased azathioprine levels and toxicity.","Avoid concurrent use. If absolutely necessary, reduce azathioprine dose significantly and monitor blood counts.",1,2026-05-13
limitedfebuxostat,mercaptopurine,Major,Potentially life-threatening bone marrow suppression.,"Febuxostat inhibits xanthine oxidase, the enzyme that metabolizes mercaptopurine. This leads to increased mercaptopurine levels and toxicity.","Avoid concurrent use. If absolutely necessary, reduce mercaptopurine dose significantly and monitor blood counts.",1,2026-05-13
meglumine diatrizoate,,,,,,1,2026-05-13
sodium diatrizoate,,,,,,1,2026-05-13
psoralen,sertraline,Moderate,Increased risk of photosensitivity.,"Some SSRIs, like sertraline, can cause photosensitivity, which is potentiated by psoralens (used in PUVA therapy).",Advise patients on sun protection measures and to report any increased skin sensitivity.,1,2026-05-13
psoralen,fluoxetine,Moderate,Increased risk of photosensitivity.,"Some SSRIs, like fluoxetine, can cause photosensitivity, which is potentiated by psoralens (used in PUVA therapy).",Advise patients on sun protection measures and to report any increased skin sensitivity.,1,2026-05-13
psoralen,amitriptyline,Moderate,Increased risk of photosensitivity.,"Tricyclic antidepressants can cause photosensitivity, which is potentiated by psoralens (used in PUVA therapy).",Advise patients on sun protection measures and to report any increased skin sensitivity.,1,2026-05-13
limitedlornoxicam,warfarin,Major,Increased risk of bleeding.,"NSAIDs inhibit prostaglandin synthesis and can reduce platelet aggregation, while also potentially causing gastric irritation, increasing the risk of bleeding when combined with anticoagulants.",Monitor INR closely and consider alternative analgesics if possible.,1,2026-05-13
limitedlornoxicam,metformin,Moderate,Increased risk of lactic acidosis and impaired glycemic control.,"NSAIDs can impair renal function, which is crucial for metformin excretion, potentially leading to accumulation and lactic acidosis.",Monitor renal function and blood glucose; consider alternative analgesics.,1,2026-05-13
limitedlornoxicam,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs inhibit prostaglandin synthesis, which plays a role in renal blood flow regulation. This can counteract the vasodilatory effects of ACE inhibitors and lead to renal dysfunction.",Monitor blood pressure and renal function; consider alternative analgesics.,1,2026-05-13
limitedlornoxicam,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal impairment.,"NSAIDs can impair renal function by inhibiting prostaglandin synthesis, counteracting the effects of loop diuretics and increasing the risk of renal toxicity.","Monitor urine output, blood pressure, and renal function; consider alternative analgesics.",1,2026-05-13
limitedlornoxicam,aspirin,Moderate,Increased risk of gastrointestinal bleeding and reduced antiplatelet effect of low-dose aspirin.,Both are NSAIDs and share antiplatelet effects. Concurrent use increases the risk of GI ulceration and bleeding. Lornoxicam can interfere with the cardioprotective effect of aspirin.,"Avoid concurrent use if possible, especially in patients at risk for GI bleeding. If co-administration is necessary, consider a PPI and monitor for bleeding.",1,2026-05-13
limitedlornoxicam,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, increasing the risk of gastrointestinal ulceration and bleeding.","Avoid concurrent use if possible. If necessary, monitor for GI symptoms and bleeding.",1,2026-05-13
overseasnandrolone decanoate,warfarin,Moderate,Potentially increased anticoagulant effect.,"Anabolic steroids can affect liver function and the metabolism of vitamin K-dependent clotting factors, potentially enhancing the anticoagulant effect of warfarin.",Monitor INR closely when initiating or discontinuing nandrolone.,1,2026-05-13
chymotrypsin,,,,,,1,2026-05-13
overseasazithromycin,digoxin,Moderate,Increased digoxin levels and risk of toxicity.,"Azithromycin may inhibit P-glycoprotein, a transporter that removes digoxin from the body, leading to increased digoxin levels.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseasazithromycin,warfarin,Moderate,Increased INR and risk of bleeding.,"Macrolide antibiotics like azithromycin can inhibit CYP2C9, an enzyme involved in warfarin metabolism, potentially increasing warfarin levels.","Monitor INR closely, especially when initiating or discontinuing azithromycin.",1,2026-05-13
overseasazithromycin,quinidine,Major,Increased risk of QT prolongation and potentially life-threatening arrhythmias (Torsades de Pointes).,"Azithromycin prolongs the QT interval, and co-administration with other QT-prolonging drugs like quinidine can lead to additive effects.","Avoid concurrent use. If unavoidable, monitor ECG and electrolytes.",1,2026-05-13
overseasazithromycin,cisapride,Major,Increased risk of QT prolongation and potentially life-threatening arrhythmias (Torsades de Pointes).,"Azithromycin prolongs the QT interval, and co-administration with other QT-prolonging drugs like cisapride can lead to additive effects.","Avoid concurrent use. If unavoidable, monitor ECG and electrolytes.",1,2026-05-13
ginkgo biloba extract,warfarin,Moderate,Increased risk of bleeding.,"Ginkgo biloba has antiplatelet effects and may inhibit platelet activating factor, potentially increasing the anticoagulant effect of warfarin.",Monitor INR closely and advise patients to report any signs of bleeding.,1,2026-05-13
ginkgo biloba extract,clopidogrel,Moderate,Increased risk of bleeding.,"Ginkgo biloba has antiplatelet effects, which can be additive with other antiplatelet agents like clopidogrel.",Monitor for signs of bleeding and consider alternative if risk is high.,1,2026-05-13
ginkgo biloba extract,aspirin,Moderate,Increased risk of bleeding.,"Ginkgo biloba has antiplatelet effects, which can be additive with other antiplatelet agents like aspirin.",Monitor for signs of bleeding and consider alternative if risk is high.,1,2026-05-13
ginkgo biloba extract,phenytoin,Moderate,May reduce the efficacy of phenytoin.,"Some studies suggest Ginkgo biloba may affect seizure threshold or drug metabolism, potentially impacting phenytoin levels.",Monitor seizure control and phenytoin levels if concerns arise.,1,2026-05-13
ginkgo biloba extract,valproate,Moderate,May reduce the efficacy of valproate.,"Some studies suggest Ginkgo biloba may affect seizure threshold or drug metabolism, potentially impacting valproate levels.",Monitor seizure control and valproate levels if concerns arise.,1,2026-05-13
ginkgo biloba extract,carbamazepine,Moderate,May reduce the efficacy of carbamazepine.,"Some studies suggest Ginkgo biloba may affect seizure threshold or drug metabolism, potentially impacting carbamazepine levels.",Monitor seizure control and carbamazepine levels if concerns arise.,1,2026-05-13
oratory,,,,,,1,2026-05-13
overseasacyclovir,,,,,,1,2026-05-13
limitedceftizoxime,,,,,,1,2026-05-13
overseasursodeoxycholic acid,,,,,,1,2026-05-13
overseasenalapril,furosemide,Moderate,Increased risk of hyperkalemia or hyponatremia.,"Both drugs can affect potassium and sodium balance, leading to additive effects.",Monitor electrolytes closely.,1,2026-05-13
overseasenalapril,spironolactone,Major,Significant risk of severe hyperkalemia and renal dysfunction.,Both are potassium-sparing diuretics; concurrent use greatly increases hyperkalemia risk.,Avoid concurrent use or monitor potassium and renal function very closely.,1,2026-05-13
overseasenalapril,atenolol,Moderate,Additive hypotensive effect.,Both drugs lower blood pressure through different mechanisms.,Monitor blood pressure.,1,2026-05-13
overseasenalapril,metoprolol,Moderate,Additive hypotensive effect.,Both drugs lower blood pressure through different mechanisms.,Monitor blood pressure.,1,2026-05-13
overseasenalapril,losartan,Moderate,Increased risk of hypotension and hyperkalemia.,Both are antihypertensives; combination can lead to excessive BP reduction and potassium retention.,Monitor blood pressure and potassium levels.,1,2026-05-13
overseasenalapril,ramipril,Major,"Significantly increased risk of hyperkalemia, renal dysfunction, and hypotension.",Both are ACE inhibitors; concurrent use is generally contraindicated due to additive effects.,Avoid concurrent use.,1,2026-05-13
chromium,metformin,Minor,Potential for additive hypoglycemic effect.,"Chromium may improve insulin sensitivity, potentially lowering blood glucose further with metformin.",Monitor blood glucose levels.,1,2026-05-13
chromium,insulin,Minor,Potential for additive hypoglycemic effect.,"Chromium may enhance insulin action, increasing the risk of hypoglycemia.",Monitor blood glucose levels.,1,2026-05-13
idoxuridine,,,,,,1,2026-05-13
advent life sciences llplevofloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, increasing its anticoagulant effect.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
advent life sciences llplevofloxacin,metformin,Minor,Increased risk of lactic acidosis.,"Levofloxacin can impair renal function, leading to decreased metformin clearance.",Monitor renal function and blood glucose; consider temporary discontinuation of metformin.,1,2026-05-13
advent life sciences llplevofloxacin,phenytoin,Moderate,Reduced efficacy of phenytoin.,"Levofloxacin may affect the metabolism of phenytoin, potentially lowering its serum levels.",Monitor phenytoin levels and clinical response.,1,2026-05-13
advent life sciences llplevofloxacin,digoxin,Moderate,"Increased digoxin levels, leading to toxicity.","Levofloxacin can inhibit P-glycoprotein, which is involved in digoxin transport.",Monitor digoxin levels and signs of toxicity.,1,2026-05-13
inactivated japanese encephalitis virus protein,,,,,,1,2026-05-13
ai health care llpamoxycillin,metformin,Minor,Potential for additive hypoglycemic effect.,Antibiotics can sometimes affect glucose metabolism; rare but possible interaction.,Monitor blood glucose levels.,1,2026-05-13
ai health care llpamoxycillin,warfarin,Minor,Potential for reduced efficacy of warfarin.,"Amoxicillin can alter gut flora, which may affect vitamin K synthesis, potentially reducing warfarin's anticoagulant effect.",Monitor INR closely.,1,2026-05-13
ai health care llpamoxycillin,azithromycin,Minor,No significant interaction.,"Both are antibiotics, but generally not clinically significant interactions.",No specific action needed beyond monitoring for treatment efficacy and side effects.,1,2026-05-13
ai health care llpamoxycillin,metronidazole,Minor,No significant interaction.,"Both are antibiotics, but generally not clinically significant interactions.",No specific action needed beyond monitoring for treatment efficacy and side effects.,1,2026-05-13
overseascefpodoxime proxetil,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins can interfere with vitamin K synthesis or affect platelet function.,Monitor INR closely and consider alternative antibiotic if clinically appropriate.,1,2026-05-13
overseascefpodoxime proxetil,metformin,Minor,Potential for transient increased metformin levels.,Cephalosporins can reduce renal clearance of metformin.,Monitor blood glucose and renal function.,1,2026-05-13
remington life sciences llpamoxycillin,warfarin,Moderate,Increased risk of bleeding.,"Penicillins can inhibit vitamin K-producing gut bacteria, leading to reduced vitamin K levels.",Monitor INR closely and consider alternative antibiotic if clinically appropriate.,1,2026-05-13
remington life sciences llpamoxycillin,metformin,Minor,Potential for transient increased metformin levels.,Penicillins can reduce renal clearance of metformin.,Monitor blood glucose and renal function.,1,2026-05-13
remington life sciences llpamoxycillin,azithromycin,Minor,No clinically significant interaction expected but combination of antibiotics is often unnecessary.,Both are antibiotics with different mechanisms.,Avoid unnecessary combination; choose one based on suspected pathogen.,1,2026-05-13
remington life sciences llpamoxycillin,ciprofloxacin,Minor,No clinically significant interaction expected but combination of antibiotics is often unnecessary.,Both are antibiotics with different mechanisms.,Avoid unnecessary combination; choose one based on suspected pathogen.,1,2026-05-13
remington life sciences llpamoxycillin,metronidazole,Minor,No clinically significant interaction expected but combination of antibiotics is often unnecessary.,Both are antibiotics with different mechanisms.,Avoid unnecessary combination; choose one based on suspected pathogen.,1,2026-05-13
limitedtrypsin,,,,,,1,2026-05-13
ultimedixnandrolone decanoate,warfarin,Moderate,Reduced anticoagulant effect of warfarin.,Anabolic steroids can increase the metabolism of warfarin.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
ultimedixnandrolone decanoate,insulin,Moderate,"May alter glycemic control, requiring adjustment of insulin dose.",Anabolic steroids can affect insulin sensitivity.,Monitor blood glucose closely and adjust insulin therapy.,1,2026-05-13
ultimedixnandrolone decanoate,atorvastatin,Minor,Increased risk of muscle toxicity (myopathy/rhabdomyolysis).,Both can affect muscle tissue; additive effects are possible.,Monitor for muscle pain or weakness.,1,2026-05-13
ultimedixnandrolone decanoate,rosuvastatin,Minor,Increased risk of muscle toxicity (myopathy/rhabdomyolysis).,Both can affect muscle tissue; additive effects are possible.,Monitor for muscle pain or weakness.,1,2026-05-13
overseaspantoprazole,warfarin,Minor,"Slightly increased INR, potentially increasing bleeding risk.","PPIs may inhibit CYP2C9, an enzyme involved in warfarin metabolism.","Monitor INR, especially when initiating or discontinuing pantoprazole.",1,2026-05-13
overseaspantoprazole,metformin,Minor,May lead to a small increase in metformin levels.,PPIs can slightly decrease the renal clearance of metformin.,Monitor blood glucose and renal function.,1,2026-05-13
overseaspantoprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Pantoprazole can inhibit CYP2C19, which is required for clopidogrel activation.","Avoid coadministration if possible; consider alternative PPI or H2 blocker. If unavoidable, monitor for cardiovascular events.",1,2026-05-13
overseaspantoprazole,diazepam,Minor,Potentially increased diazepam levels.,"Pantoprazole may inhibit CYP3A4, which metabolizes diazepam.",Monitor for increased sedation.,1,2026-05-13
overseaspantoprazole,phenytoin,Minor,Potentially increased phenytoin levels.,PPIs may affect phenytoin metabolism.,Monitor phenytoin levels and for signs of toxicity.,1,2026-05-13
octinoxate,,,,,,1,2026-05-13
benzophenone,,,,,,1,2026-05-13
tacalcitol,digoxin,Moderate,Increased risk of digoxin toxicity.,"Hypercalcemia, induced by calcitriol analogs, can potentiate digoxin's cardiotoxic effects.",Monitor calcium levels and digoxin levels/toxicity signs.,1,2026-05-13
tacalcitol,furosemide,Minor,May increase risk of hypercalcemia and hypokalemia.,Both can affect electrolyte balance.,Monitor calcium and potassium levels.,1,2026-05-13
tacalcitol,spironolactone,Minor,May increase risk of hypercalcemia.,Both can affect calcium balance.,Monitor calcium levels.,1,2026-05-13
eptacog alfa,,,,,,1,2026-05-13
gramicidin,dexamethasone,Minor,No clinically significant interaction expected with topical gramicidin.,Gramicidin is an antibiotic; dexamethasone is a corticosteroid.,Use as directed; monitor for signs of infection if used long-term.,1,2026-05-13
gramicidin,prednisolone,Minor,No clinically significant interaction expected with topical gramicidin.,Gramicidin is an antibiotic; prednisolone is a corticosteroid.,Use as directed; monitor for signs of infection if used long-term.,1,2026-05-13
filamentous haemagglutinin,,,,,,1,2026-05-13
rabies human monoclonal antibody,,,,,,1,2026-05-13
glial life science llpescitalopram oxalate,tramadol,Major,Increased risk of serotonin syndrome.,Escitalopram increases serotonin; tramadol also affects serotonin.,Monitor closely for serotonin syndrome symptoms; consider alternative analgesics.,1,2026-05-13
glial life science llpescitalopram oxalate,codeine,Moderate,Reduced efficacy of codeine; potential for serotonin syndrome.,"Escitalopram can inhibit CYP2D6, the enzyme that converts codeine to its active metabolite.",Consider higher codeine dose or alternative opioid; monitor for serotonin syndrome.,1,2026-05-13
glial life science llpescitalopram oxalate,clonazepam,Moderate,Increased sedation and CNS depression.,Both agents are CNS depressants.,Use cautiously and monitor for excessive sedation.,1,2026-05-13
glial life science llpescitalopram oxalate,diazepam,Moderate,Increased sedation and CNS depression.,Both agents are CNS depressants.,Use cautiously and monitor for excessive sedation.,1,2026-05-13
glial life science llpescitalopram oxalate,lorazepam,Moderate,Increased sedation and CNS depression.,Both agents are CNS depressants.,Use cautiously and monitor for excessive sedation.,1,2026-05-13
glial life science llpescitalopram oxalate,alprazolam,Moderate,Increased sedation and CNS depression.,Both agents are CNS depressants.,Use cautiously and monitor for excessive sedation.,1,2026-05-13
glial life science llpescitalopram oxalate,zolpidem,Moderate,Increased sedation and risk of complex sleep-related behaviors.,Both agents enhance GABAergic neurotransmission.,Use cautiously and monitor for excessive sedation and unusual behaviors.,1,2026-05-13
glial life science llpescitalopram oxalate,methotrexate,Minor,Potentially increased methotrexate toxicity.,SSRI can inhibit methotrexate elimination.,Monitor methotrexate levels and for signs of toxicity.,1,2026-05-13
alister life sciences llppotassium nitrate,,,,,,1,2026-05-13
magnesium bisglycinate,tetracyclines,Moderate,Reduced absorption and efficacy of tetracyclines.,"Magnesium ions can chelate with tetracyclines, reducing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
magnesium bisglycinate,bisphosphonates,Moderate,Reduced absorption and efficacy of bisphosphonates.,"Magnesium ions can chelate with bisphosphonates, reducing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
hsekar pharma,,,,,,1,2026-05-13
di-iodohydroxyquinoline,,,,,,1,2026-05-13
limitedparacetamol,warfarin,Moderate,Increased risk of bleeding.,Paracetamol can inhibit warfarin metabolism at high doses.,"Monitor INR closely, especially with high or prolonged paracetamol use.",1,2026-05-13
limitedparacetamol,phenytoin,Minor,Potentially altered phenytoin metabolism.,Paracetamol may influence cytochrome P450 enzymes.,Monitor phenytoin levels and for efficacy/toxicity.,1,2026-05-13
limitedoctreotide acetate,insulin,Moderate,May mask hypoglycemia symptoms; altered insulin requirement.,Octreotide can inhibit insulin and glucagon release.,Monitor blood glucose closely; adjust insulin dose as needed.,1,2026-05-13
limitedoctreotide acetate,metformin,Minor,May affect glucose control.,Octreotide can influence glucose homeostasis.,Monitor blood glucose closely.,1,2026-05-13
limitedoctreotide acetate,furosemide,Minor,May affect electrolyte balance.,Both can influence fluid and electrolyte status.,Monitor electrolytes.,1,2026-05-13
limitedoctreotide acetate,spironolactone,Minor,May affect electrolyte balance.,Both can influence fluid and electrolyte status.,Monitor electrolytes.,1,2026-05-13
dithranol,,,,,,1,2026-05-13
levonadifloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones can inhibit CYP2C9, an enzyme that metabolizes warfarin, increasing its anticoagulant effect.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
levonadifloxacin,metformin,Moderate,Increased risk of hypoglycemia.,"Fluoroquinolones can impair renal excretion of metformin, leading to higher serum concentrations.",Monitor blood glucose closely and consider temporary metformin discontinuation or dose adjustment.,1,2026-05-13
levonadifloxacin,amiodarone,Moderate,Potential for QT interval prolongation and arrhythmias.,"Both drugs can prolong the QT interval, increasing the risk of torsades de pointes.","Use with caution, monitor ECG, and consider alternative antibiotics if risk is high.",1,2026-05-13
ai health care llppantoprazole,clopidogrel,Moderate,Reduced antiplatelet effect and increased risk of thrombotic events.,"Pantoprazole is a CYP2C19 inhibitor, which is involved in the activation of clopidogrel.","Avoid concurrent use if possible, or use a different PPI. Monitor for signs of clotting.",1,2026-05-13
ai health care llppantoprazole,ketoconazole,Minor,Reduced absorption of ketoconazole.,"PPIs decrease gastric acidity, which is required for optimal absorption of ketoconazole.",Administer ketoconazole at least 2 hours before or after pantoprazole.,1,2026-05-13
currant life science llpamitriptyline,tramadol,Moderate,Increased risk of seizures and serotonin syndrome.,Both drugs can increase serotonergic activity and lower seizure threshold.,"Use with caution, monitor for signs of serotonin syndrome and seizures.",1,2026-05-13
currant life science llpamitriptyline,sertraline,Moderate,Increased risk of serotonin syndrome.,"Both are serotonergic agents, additive effects can lead to dangerously high serotonin levels.","Monitor for symptoms of serotonin syndrome (agitation, confusion, rapid heart rate, etc.).",1,2026-05-13
currant life science llpamitriptyline,clonazepam,Moderate,"Increased CNS depression (sedation, dizziness).",Additive sedative effects of tricyclic antidepressants and benzodiazepines.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
currant life science llpamitriptyline,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Amitriptyline can potentiate the hypotensive effects of beta-blockers.,,1,2026-05-13
cynoacrylate,,,,,,1,2026-05-13
hocaine,,,,,,1,2026-05-13
policresulen,,,,,,1,2026-05-13
sovateltide,,,,,,1,2026-05-13
limiteddrotaverine,atenolol,Minor,Potential for additive hypotensive effects.,"Drotaverine is a vasodilator and can lower blood pressure, which may be enhanced by beta-blockers.",Monitor blood pressure.,1,2026-05-13
overseasivermectin,warfarin,Moderate,Increased INR and risk of bleeding.,"Ivermectin can inhibit CYP2C9, which metabolizes warfarin, leading to higher warfarin levels.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
overseasivermectin,cyclosporine,Major,Increased cyclosporine levels and potential for nephrotoxicity.,"Ivermectin is a substrate and inhibitor of P-glycoprotein, which is involved in cyclosporine transport.",Avoid concurrent use or monitor cyclosporine levels and renal function very closely.,1,2026-05-13
paracetamol/acetaminophen,warfarin,Moderate,Increased INR and risk of bleeding with chronic high-dose acetaminophen.,"Acetaminophen, especially at high doses, may interfere with vitamin K metabolism or influence warfarin metabolism.",Limit daily acetaminophen dose to 2g or less. Monitor INR closely if chronic use is required.,1,2026-05-13
paracetamol/acetaminophen,phenytoin,Minor,Potential for altered metabolism of either drug.,Both drugs are metabolized by CYP enzymes; potential for competitive inhibition or induction.,Monitor for efficacy and toxicity.,1,2026-05-13
paracetamol/acetaminophen,rifampicin,Minor,"Potential for increased acetaminophen metabolism, reducing its efficacy.",Rifampicin is a potent CYP inducer and can increase acetaminophen clearance.,Consider higher acetaminophen doses or alternative analgesics if needed.,1,2026-05-13
ultimedixhydroxyprogesterone,,,,,,1,2026-05-13
xylitol,,,,,,1,2026-05-13
reboxetine,amitriptyline,Moderate,Increased risk of anticholinergic side effects.,"Both drugs have anticholinergic properties, leading to additive effects.",Monitor for increased anticholinergic effects; consider dose adjustment.,1,2026-05-13
reboxetine,tramadol,Moderate,Increased risk of serotonin syndrome.,Reboxetine increases serotonin levels; tramadol also affects serotonin.,Monitor for signs of serotonin syndrome; consider alternative analgesics or reboxetine dose reduction.,1,2026-05-13
reboxetine,codeine,Moderate,Potential for reduced efficacy of reboxetine or increased sedation.,Complex interactions may affect neurotransmitter levels or receptor binding.,Monitor for therapeutic response and adverse effects; adjust doses as needed.,1,2026-05-13
reboxetine,morphine,Moderate,Potential for increased sedation or respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory status; use with caution.,1,2026-05-13
reboxetine,alprazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
reboxetine,diazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
reboxetine,lorazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
reboxetine,clonazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
reboxetine,midazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
reboxetine,zolpidem,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Avoid concomitant use or monitor closely for sedation; consider lower doses.,1,2026-05-13
roxatidine,,,,,,1,2026-05-13
inviscus lifescience llpaspirin,,,,,,1,2026-05-13
overseasethamsylate,,,,,,1,2026-05-13
mizolastine,ketoconazole,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Ketoconazole inhibits CYP3A4, increasing mizolastine levels.",Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,erythromycin,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Erythromycin inhibits CYP3A4, increasing mizolastine levels.",Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,clarithromycin,Major,Increased risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, increasing mizolastine levels.",Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,quinidine,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,procainamide,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,amiodarone,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,sotalol,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,cisapride,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
mizolastine,domperidone,Major,Increased risk of QT prolongation and cardiac arrhythmias.,Both drugs prolong the QT interval.,Avoid concomitant use or monitor ECG and cardiac function closely.,1,2026-05-13
treosulfan,,,,,,1,2026-05-13
alpha-galactosidase,,,,,,1,2026-05-13
lipase,,,,,,1,2026-05-13
protease,,,,,,1,2026-05-13
astra idl maxdomperidone,,,,,,1,2026-05-13
astra idl maxtelmisartan,aspirin,Minor,Reduced antihypertensive effect of telmisartan.,"NSAIDs can inhibit prostaglandin synthesis, which interferes with the vasodilatory effects of angiotensin II.",Monitor blood pressure closely.,1,2026-05-13
astra idl maxtelmisartan,ibuprofen,Minor,Reduced antihypertensive effect of telmisartan.,"NSAIDs can inhibit prostaglandin synthesis, which interferes with the vasodilatory effects of angiotensin II.",Monitor blood pressure closely.,1,2026-05-13
astra idl maxtelmisartan,prednisolone,Minor,Reduced antihypertensive effect of telmisartan.,Corticosteroids can cause sodium retention and increase blood pressure.,Monitor blood pressure and consider dose adjustment.,1,2026-05-13
astra idl maxtelmisartan,dexamethasone,Minor,Reduced antihypertensive effect of telmisartan.,Corticosteroids can cause sodium retention and increase blood pressure.,Monitor blood pressure and consider dose adjustment.,1,2026-05-13
warner,,,,,,1,2026-05-13
ai health care llpnimesulide,warfarin,Moderate,Increased risk of bleeding.,"Nimesulide is an NSAID that can inhibit platelet aggregation and affect gastric mucosa, increasing bleeding risk.",Monitor INR closely and consider alternative analgesia.,1,2026-05-13
ai health care llpnimesulide,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, potentiating the risk of gastric irritation and ulceration.",Avoid co-administration; consider alternative analgesia.,1,2026-05-13
ai health care llpnimesulide,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, potentiating the risk of gastric irritation and ulceration.",Avoid co-administration; consider alternative analgesia.,1,2026-05-13
ai health care llpnimesulide,metformin,Minor,"Increased risk of renal impairment, which can worsen metformin accumulation.",NSAIDs can impair renal function.,Monitor renal function.,1,2026-05-13
ai health care llpnimesulide,ramipril,Minor,Increased risk of renal impairment and reduced antihypertensive effect.,NSAIDs can reduce renal blood flow and interfere with RAAS blockade.,Monitor renal function and blood pressure.,1,2026-05-13
ai health care llpnimesulide,losartan,Minor,Increased risk of renal impairment and reduced antihypertensive effect.,NSAIDs can reduce renal blood flow and interfere with RAAS blockade.,Monitor renal function and blood pressure.,1,2026-05-13
ai health care llpnimesulide,amlodipine,Minor,Reduced antihypertensive effect.,NSAIDs can antagonize the vasodilatory effects of calcium channel blockers.,Monitor blood pressure.,1,2026-05-13
ai health care llpnimesulide,furosemide,Minor,"Reduced diuretic and antihypertensive effect, increased risk of renal impairment.","NSAIDs can inhibit prostaglandin synthesis, affecting renal function and response to diuretics.",Monitor renal function and fluid balance.,1,2026-05-13
ai health care llpnimesulide,spironolactone,Minor,Increased risk of hyperkalemia and renal impairment.,NSAIDs can impair renal function and affect potassium balance.,Monitor renal function and potassium levels.,1,2026-05-13
hydroxyquinolines,,,,,,1,2026-05-13
s pharmalevocetirizine,alprazolam,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by benzodiazepines.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,diazepam,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by benzodiazepines.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,lorazepam,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by benzodiazepines.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,midazolam,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by benzodiazepines.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,zolpidem,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by sedatives.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,tramadol,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by CNS depressants.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,codeine,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by CNS depressants.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,morphine,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by CNS depressants.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,amitriptyline,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by sedating antidepressants.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,haloperidol,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by antipsychotics.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,clozapine,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by antipsychotics.",Advise caution when driving or operating machinery.,1,2026-05-13
s pharmalevocetirizine,olanzapine,Minor,Increased sedation.,"Levocetirizine can have mild CNS depressant effects, potentiated by antipsychotics.",Advise caution when driving or operating machinery.,1,2026-05-13
liger life links,,,,,,1,2026-05-13
limitedrivaroxaban,aspirin,Major,Increased risk of bleeding.,"Both are anticoagulants/antiplatelets, additive effect on hemostasis.",Avoid concomitant use if possible; monitor for bleeding.,1,2026-05-13
limitedrivaroxaban,clopidogrel,Major,Increased risk of bleeding.,"Both are antiplatelets, additive effect on hemostasis.",Avoid concomitant use if possible; monitor for bleeding.,1,2026-05-13
limitedrivaroxaban,warfarin,Major,Increased risk of bleeding.,"Both are anticoagulants, additive effect on hemostasis.",Avoid concomitant use; monitor INR closely if unavoidable.,1,2026-05-13
limitedrivaroxaban,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"NSAIDs inhibit platelet function and can cause gastrointestinal damage, potentiating bleeding risk.",Use with caution; monitor for signs of bleeding.,1,2026-05-13
limitedrivaroxaban,prednisolone,Moderate,Increased risk of gastrointestinal bleeding.,Corticosteroids can increase the risk of gastrointestinal ulceration and bleeding.,Use with caution; monitor for signs of bleeding.,1,2026-05-13
limitedrivaroxaban,dexamethasone,Moderate,Increased risk of gastrointestinal bleeding.,Corticosteroids can increase the risk of gastrointestinal ulceration and bleeding.,Use with caution; monitor for signs of bleeding.,1,2026-05-13
limitedrivaroxaban,metronidazole,Minor,"Possible increased risk of bleeding, though less established.",Metronidazole can inhibit platelet aggregation in some cases.,Monitor for bleeding.,1,2026-05-13
overseasaceclofenac,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and affect gastric mucosa, increasing bleeding risk.",Monitor INR closely and consider alternative analgesia.,1,2026-05-13
overseasaceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, potentiating the risk of gastric irritation and ulceration.",Avoid co-administration; consider alternative analgesia.,1,2026-05-13
overseasaceclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Both are NSAIDs, potentiating the risk of gastric irritation and ulceration.",Avoid co-administration; consider alternative analgesia.,1,2026-05-13
overseasaceclofenac,metformin,Minor,"Increased risk of renal impairment, which can worsen metformin accumulation.",NSAIDs can impair renal function.,Monitor renal function.,1,2026-05-13
overseasaceclofenac,ramipril,Minor,Increased risk of renal impairment and reduced antihypertensive effect.,NSAIDs can reduce renal blood flow and interfere with RAAS blockade.,Monitor renal function and blood pressure.,1,2026-05-13
overseasaceclofenac,losartan,Minor,Increased risk of renal impairment and reduced antihypertensive effect.,NSAIDs can reduce renal blood flow and interfere with RAAS blockade.,Monitor renal function and blood pressure.,1,2026-05-13
overseasaceclofenac,amlodipine,Minor,Reduced antihypertensive effect.,NSAIDs can antagonize the vasodilatory effects of calcium channel blockers.,Monitor blood pressure.,1,2026-05-13
overseasaceclofenac,furosemide,Minor,"Reduced diuretic and antihypertensive effect, increased risk of renal impairment.","NSAIDs can inhibit prostaglandin synthesis, affecting renal function and response to diuretics.",Monitor renal function and fluid balance.,1,2026-05-13
overseasaceclofenac,spironolactone,Minor,Increased risk of hyperkalemia and renal impairment.,NSAIDs can impair renal function and affect potassium balance.,Monitor renal function and potassium levels.,1,2026-05-13
climbazole,,,,,,1,2026-05-13
light magnesium oxide,metformin,Moderate,Reduced absorption of metformin.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,atorvastatin,Moderate,Reduced absorption of atorvastatin.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,rosuvastatin,Moderate,Reduced absorption of rosuvastatin.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,digoxin,Moderate,Reduced absorption of digoxin.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,warfarin,Minor,"May slightly affect INR, monitor closely.",Antacids can alter gastric pH and potentially affect absorption.,Monitor INR closely.,1,2026-05-13
light magnesium oxide,furosemide,Moderate,Increased risk of hypokalemia and nephrotoxicity.,"Magnesium oxide can cause diarrhea, leading to electrolyte imbalances.","Monitor electrolytes, especially potassium.",1,2026-05-13
light magnesium oxide,spironolactone,Moderate,Increased risk of hyperkalemia.,Magnesium can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
light magnesium oxide,atenolol,Moderate,Reduced absorption of atenolol.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,metoprolol,Moderate,Reduced absorption of metoprolol.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,ramipril,Moderate,Increased risk of hyperkalemia.,Magnesium can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
light magnesium oxide,losartan,Moderate,Increased risk of hyperkalemia.,Magnesium can increase potassium levels.,Monitor potassium levels.,1,2026-05-13
light magnesium oxide,amlodipine,Moderate,Reduced absorption of amlodipine.,"Magnesium can chelate with drugs, decreasing oral absorption.",Separate administration by at least 2 hours.,1,2026-05-13
light magnesium oxide,ciprofloxacin,Major,Significantly reduced absorption of ciprofloxacin.,"Magnesium forms insoluble complexes with fluoroquinolones, preventing absorption.",Avoid coadministration; separate by at least 4 hours.,1,2026-05-13
light magnesium oxide,levofloxacin,Major,Significantly reduced absorption of levofloxacin.,"Magnesium forms insoluble complexes with fluoroquinolones, preventing absorption.",Avoid coadministration; separate by at least 4 hours.,1,2026-05-13
light magnesium oxide,tetracyclines,Major,Significantly reduced absorption of tetracyclines.,"Magnesium forms insoluble complexes with tetracyclines, preventing absorption.",Avoid coadministration; separate by at least 2 hours.,1,2026-05-13
limitedlactulose,,,,,,1,2026-05-13
etidronate,antacids,Major,Significantly reduced absorption of etidronate.,"Cations in antacids (calcium, magnesium, aluminum) form poorly absorbed complexes with bisphosphonates.",Separate administration by at least 2 hours.,1,2026-05-13
etidronate,calcium supplements,Major,Significantly reduced absorption of etidronate.,Cations in calcium supplements form poorly absorbed complexes with bisphosphonates.,Separate administration by at least 2 hours.,1,2026-05-13
nirmatrelvir,atorvastatin,Major,Increased risk of rhabdomyolysis.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, increasing statin levels.",Consider temporary discontinuation or dose reduction of atorvastatin; monitor for muscle pain.,1,2026-05-13
nirmatrelvir,rosuvastatin,Major,Increased risk of myopathy.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, increasing statin levels.",Consider temporary discontinuation or dose reduction of rosuvastatin; monitor for muscle pain.,1,2026-05-13
nirmatrelvir,simvastatin,Major,Markedly increased risk of rhabdomyolysis.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, significantly increasing simvastatin levels.",Contraindicated with simvastatin.,1,2026-05-13
nirmatrelvir,lovastatin,Major,Markedly increased risk of rhabdomyolysis.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, significantly increasing lovastatin levels.",Contraindicated with lovastatin.,1,2026-05-13
nirmatrelvir,alprazolam,Major,Potentially prolonged and exaggerated sedation.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, reducing metabolism of alprazolam.",Avoid coadministration; consider alternative anxiolytic.,1,2026-05-13
nirmatrelvir,diazepam,Major,Potentially prolonged and exaggerated sedation.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, reducing metabolism of diazepam.",Avoid coadministration; consider alternative anxiolytic.,1,2026-05-13
nirmatrelvir,lorazepam,Moderate,Increased plasma concentrations of lorazepam.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, reducing metabolism of lorazepam (less substrate than diazepam/alprazolam).",Monitor for increased sedation; consider dose adjustment of lorazepam.,1,2026-05-13
nirmatrelvir,clonazepam,Moderate,Increased plasma concentrations of clonazepam.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, reducing metabolism of clonazepam.",Monitor for increased sedation; consider dose adjustment of clonazepam.,1,2026-05-13
nirmatrelvir,midazolam,Major,Markedly increased plasma concentrations and prolonged effects.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a potent CYP3A4 inhibitor, significantly increasing midazolam levels.",Contraindicated for oral midazolam; avoid IV midazolam.,1,2026-05-13
nirmatrelvir,warfarin,Moderate,Potential for altered INR.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) can inhibit CYP2C9, affecting warfarin metabolism.",Monitor INR closely.,1,2026-05-13
nirmatrelvir,clopidogrel,Moderate,Reduced efficacy of clopidogrel.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) can induce CYP2C19, reducing the formation of active clopidogrel metabolite.",Monitor for signs of thrombotic events.,1,2026-05-13
nirmatrelvir,cyclosporine,Major,Increased risk of cyclosporine toxicity.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, significantly increasing cyclosporine levels.",Contraindicated; monitor drug levels if unavoidable.,1,2026-05-13
nirmatrelvir,tacrolimus,Major,Increased risk of tacrolimus toxicity.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) inhibits CYP3A4, significantly increasing tacrolimus levels.",Contraindicated; monitor drug levels if unavoidable.,1,2026-05-13
nirmatrelvir,digoxin,Moderate,Increased digoxin levels.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) can inhibit P-glycoprotein, affecting digoxin elimination.",Monitor digoxin levels.,1,2026-05-13
nirmatrelvir,sildenafil,Major,"Increased risk of sildenafil-related adverse effects (e.g., hypotension, priapism).",Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a potent CYP3A4 inhibitor.,"Avoid coadministration; if necessary, use lowest dose of sildenafil and monitor.",1,2026-05-13
nirmatrelvir,tadalafil,Major,Increased risk of tadalafil-related adverse effects.,Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a potent CYP3A4 inhibitor.,"Avoid coadministration; if necessary, use lowest dose of tadalafil and monitor.",1,2026-05-13
nirmatrelvir,atorvastatin,Major,Increased risk of rhabdomyolysis.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, increasing statin levels.",Consider temporary discontinuation or dose reduction of atorvastatin; monitor for muscle pain.,1,2026-05-13
nirmatrelvir,rosuvastatin,Major,Increased risk of myopathy.,"Ritonavir (a component of Paxlovid which contains nirmatrelvir) is a strong CYP3A4 inhibitor, increasing statin levels.",Consider temporary discontinuation or dose reduction of rosuvastatin; monitor for muscle pain.,1,2026-05-13
piper nigrum,,,,,,1,2026-05-13
glial life science llpmemantine,amantadine,Moderate,"Increased risk of CNS side effects (e.g., confusion, hallucinations).","Both drugs have NMDA receptor antagonist activity, leading to additive effects.",Monitor for CNS adverse effects; consider dose reduction of one agent.,1,2026-05-13
glial life science llpmemantine,quinidine,Moderate,Increased risk of CNS side effects.,"Quinidine inhibits the renal tubular secretion of memantine, increasing its plasma concentration.",Monitor for CNS adverse effects; consider dose reduction of memantine.,1,2026-05-13
glial life science llpmemantine,tramadol,Moderate,"Increased risk of CNS side effects (e.g., confusion, dizziness).",Both drugs have NMDA receptor antagonist activity or can affect neurotransmitter systems.,Monitor for CNS adverse effects.,1,2026-05-13
glial life science llpmemantine,metformin,Moderate,Increased risk of elevated metformin levels and potential toxicity.,Memantine can interfere with renal tubular secretion of metformin.,Monitor glycemic control and metformin levels if toxicity is suspected.,1,2026-05-13
medichem,,,,,,1,2026-05-13
naftifine hydrochloride,,,,,,1,2026-05-13
limitedcefixime,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins can interfere with vitamin K metabolism or platelet function.,"Monitor INR closely, especially at the start and end of treatment.",1,2026-05-13
limitedcefixime,probenecid,Moderate,Increased serum concentrations of cefixime.,Probenecid inhibits the renal tubular secretion of cefixime.,Monitor for increased adverse effects of cefixime.,1,2026-05-13
adefovir,,,,,,1,2026-05-13
macsur pharmaa,,,,,,1,2026-05-13
stearyl alcohol,,,,,,1,2026-05-13
svsd medisect pharma,,,,,,1,2026-05-13
limitedcefuroxime,probenecid,Moderate,Reduced cefuroxime excretion and increased serum levels.,Probenecid inhibits tubular secretion of cefuroxime.,Monitor for increased cefuroxime toxicity; consider dose adjustment.,1,2026-05-13
astra idl maxchlorpheniramine maleate,alprazolam,Moderate,Increased sedation and central nervous system depression.,"Both drugs are CNS depressants, leading to additive effects.",Caution with concurrent use; advise patient to avoid activities requiring alertness.,1,2026-05-13
astra idl maxchlorpheniramine maleate,diazepam,Moderate,Increased sedation and central nervous system depression.,"Both drugs are CNS depressants, leading to additive effects.",Caution with concurrent use; advise patient to avoid activities requiring alertness.,1,2026-05-13
astra idl maxchlorpheniramine maleate,lorazepam,Moderate,Increased sedation and central nervous system depression.,"Both drugs are CNS depressants, leading to additive effects.",Caution with concurrent use; advise patient to avoid activities requiring alertness.,1,2026-05-13
astra idl maxchlorpheniramine maleate,midazolam,Moderate,Increased sedation and central nervous system depression.,"Both drugs are CNS depressants, leading to additive effects.",Caution with concurrent use; advise patient to avoid activities requiring alertness.,1,2026-05-13
astra idl maxchlorpheniramine maleate,zolpidem,Moderate,Increased sedation and central nervous system depression.,"Both drugs are CNS depressants, leading to additive effects.",Caution with concurrent use; advise patient to avoid activities requiring alertness.,1,2026-05-13
astra idl maxchlorpheniramine maleate,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
astra idl maxchlorpheniramine maleate,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
astra idl maxchlorpheniramine maleate,tramadol,Moderate,Increased sedation and central nervous system depression.,Additive CNS depressant effects.,Monitor for excessive sedation and confusion.,1,2026-05-13
elobixibat,,,,,,1,2026-05-13
felbinac,warfarin,Moderate,Increased risk of bleeding.,NSAIDs can increase the anticoagulant effect of warfarin.,Monitor INR closely; consider alternative analgesic if possible.,1,2026-05-13
felbinac,clopidogrel,Moderate,Increased risk of bleeding.,NSAIDs can increase the antiplatelet effect of clopidogrel.,Monitor for signs of bleeding; consider alternative analgesic if possible.,1,2026-05-13
felbinac,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive NSAID effects on gastric mucosa.,Avoid concurrent use; monitor for gastrointestinal upset or bleeding.,1,2026-05-13
felbinac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal dysfunction.,Additive NSAID effects.,Avoid concurrent use; monitor for gastrointestinal upset or renal impairment.,1,2026-05-13
trimebutine,,,,,,1,2026-05-13
limitedfexofenadine,erythromycin,Minor,May slightly increase fexofenadine plasma concentrations.,Erythromycin is a moderate CYP3A4 inhibitor.,Monitor for increased fexofenadine effects if symptoms occur.,1,2026-05-13
limitedfexofenadine,ketoconazole,Minor,May slightly increase fexofenadine plasma concentrations.,Ketoconazole is a moderate CYP3A4 inhibitor.,Monitor for increased fexofenadine effects if symptoms occur.,1,2026-05-13
casirivimab,,,,,,1,2026-05-13
imdevimab,,,,,,1,2026-05-13
trientine hydrochloride,allopurinol,Minor,Reduced efficacy of trientine.,Allopurinol may reduce copper absorption.,Monitor for trientine efficacy.,1,2026-05-13
epsilon aminocaproic acid,tamoxifen,Moderate,Increased risk of thrombosis.,Both agents can increase thrombotic risk.,Avoid combination or monitor closely for signs of thrombosis.,1,2026-05-13
limitedgabapentin,,,,,,1,2026-05-13
ultimedixofloxacin,warfarin,Moderate,Increased risk of bleeding.,Fluoroquinolones can potentiate the anticoagulant effect of warfarin.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
ultimedixofloxacin,metformin,Minor,Potential for increased metformin levels.,Fluoroquinolones can inhibit renal clearance of metformin.,Monitor blood glucose and consider temporary metformin dose adjustment.,1,2026-05-13
astamed healtcare,,,,,,1,2026-05-13
nitrendipine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Additive effects on blood pressure and heart rate.,Monitor blood pressure and heart rate closely.,1,2026-05-13
nitrendipine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Additive effects on blood pressure and heart rate.,Monitor blood pressure and heart rate closely.,1,2026-05-13
co-trimoxazole,warfarin,Major,Increased risk of bleeding.,Co-trimoxazole can inhibit warfarin metabolism.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
co-trimoxazole,metformin,Moderate,Increased risk of lactic acidosis.,Trimethoprim component can inhibit metformin clearance.,Monitor blood glucose and renal function; consider temporary metformin discontinuation.,1,2026-05-13
co-trimoxazole,furosemide,Moderate,Increased risk of hyponatremia.,Sulfonamides can potentiate diuretic-induced hyponatremia.,Monitor serum sodium levels.,1,2026-05-13
co-trimoxazole,methotrexate,Major,Increased risk of methotrexate toxicity.,Trimethoprim can inhibit methotrexate clearance and reduce folate levels.,Monitor for signs of methotrexate toxicity and consider folate supplementation.,1,2026-05-13
co-trimoxazole,lisinopril,Moderate,Increased risk of hyperkalemia.,Both agents can increase potassium levels.,Monitor serum potassium levels.,1,2026-05-13
glial life science llppregabalin,,,,,,1,2026-05-13
molgramostim,,,,,,1,2026-05-13
equine rabies immunoglobulin,,,,,,1,2026-05-13
lactobacillus fermentum,,,,,,1,2026-05-13
overseasomeprazole,warfarin,Moderate,Increased risk of bleeding.,"Omeprazole inhibits CYP2C19, which metabolizes some vitamin K antagonists, potentially increasing their levels.",Monitor INR closely if co-administered.,1,2026-05-13
overseasomeprazole,clopidogrel,Moderate,Reduced antiplatelet effect.,"Omeprazole inhibits CYP2C19, the enzyme responsible for activating clopidogrel.",Consider alternative PPI or separate administration if possible.,1,2026-05-13
overseasomeprazole,diazepam,Moderate,Increased sedation and risk of respiratory depression.,"Omeprazole can inhibit CYP2C19, which metabolizes diazepam, leading to increased plasma levels.",Monitor for increased sedation and consider dose adjustment.,1,2026-05-13
overseasomeprazole,phenytoin,Moderate,Increased phenytoin levels and toxicity.,"Omeprazole can inhibit CYP2C19, which metabolizes phenytoin, leading to increased plasma levels.",Monitor phenytoin levels and for signs of toxicity.,1,2026-05-13
astra idl maxlevosalbutamol,,,,,,1,2026-05-13
overseasibuprofen,warfarin,Major,Increased risk of bleeding.,"Ibuprofen is an NSAID that inhibits platelet aggregation and can cause gastrointestinal irritation, potentiating the anticoagulant effect of warfarin.",Avoid concomitant use; use acetaminophen for pain relief if on warfarin.,1,2026-05-13
overseasibuprofen,aspirin,Moderate,Reduced cardioprotective effect of low-dose aspirin.,"Ibuprofen can competitively inhibit the binding of aspirin to COX-1, reducing aspirin's antiplatelet effect.",Administer ibuprofen at least 8 hours before or 30 minutes after aspirin.,1,2026-05-13
overseasibuprofen,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin clearance and increasing the risk of lactic acidosis.",Monitor renal function and blood glucose; avoid if renal impairment exists.,1,2026-05-13
overseasibuprofen,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
overseasibuprofen,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
overseasibuprofen,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of loop diuretics.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
overseasibuprofen,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can decrease renal clearance of lithium.,Monitor lithium levels closely and avoid if possible.,1,2026-05-13
overseasibuprofen,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
overseasibuprofen,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
human rabies immunoglobulin,,,,,,1,2026-05-13
limitedpregabalin,tramadol,Moderate,"Increased risk of somnolence, dizziness, and confusion.",Both drugs can cause CNS depression.,Monitor for excessive sedation.,1,2026-05-13
limitedpregabalin,codeine,Moderate,"Increased risk of somnolence, dizziness, and respiratory depression.",Both drugs can cause CNS depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
limitedpregabalin,morphine,Moderate,"Increased risk of somnolence, dizziness, and respiratory depression.",Both drugs can cause CNS depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
limitedpregabalin,alprazolam,Major,"Increased risk of profound sedation, respiratory depression, coma, and death.",Both drugs are CNS depressants.,"Avoid concomitant use; if unavoidable, use lowest effective doses and monitor closely.",1,2026-05-13
limitedpregabalin,diazepam,Major,"Increased risk of profound sedation, respiratory depression, coma, and death.",Both drugs are CNS depressants.,"Avoid concomitant use; if unavoidable, use lowest effective doses and monitor closely.",1,2026-05-13
limitedpregabalin,lorazepam,Major,"Increased risk of profound sedation, respiratory depression, coma, and death.",Both drugs are CNS depressants.,"Avoid concomitant use; if unavoidable, use lowest effective doses and monitor closely.",1,2026-05-13
limitedpregabalin,clonazepam,Major,"Increased risk of profound sedation, respiratory depression, coma, and death.",Both drugs are CNS depressants.,"Avoid concomitant use; if unavoidable, use lowest effective doses and monitor closely.",1,2026-05-13
limitedpregabalin,midazolam,Major,"Increased risk of profound sedation, respiratory depression, coma, and death.",Both drugs are CNS depressants.,"Avoid concomitant use; if unavoidable, use lowest effective doses and monitor closely.",1,2026-05-13
limitedpregabalin,gabapentin,Moderate,"Increased risk of somnolence, dizziness, and cognitive impairment.",Both drugs affect neuronal excitability and can cause CNS depression.,Monitor for excessive sedation and cognitive impairment.,1,2026-05-13
limitedofloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, leading to increased INR.",Monitor INR closely.,1,2026-05-13
limitedofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can affect glucose homeostasis.,Monitor blood glucose levels closely.,1,2026-05-13
limitedofloxacin,prednisolone,Moderate,Increased risk of tendon rupture.,"Fluoroquinolones have been associated with tendonitis and tendon rupture, and corticosteroids can exacerbate this risk.",Avoid concomitant use if possible; monitor for tendon pain.,1,2026-05-13
limitedofloxacin,dexamethasone,Moderate,Increased risk of tendon rupture.,"Fluoroquinolones have been associated with tendonitis and tendon rupture, and corticosteroids can exacerbate this risk.",Avoid concomitant use if possible; monitor for tendon pain.,1,2026-05-13
limitedofloxacin,phenytoin,Moderate,Altered phenytoin levels.,Fluoroquinolones can inhibit CYP enzymes involved in phenytoin metabolism.,Monitor phenytoin levels and for signs of toxicity or sub-therapeutic effect.,1,2026-05-13
limitedofloxacin,theophylline,Major,Increased risk of theophylline toxicity.,"Fluoroquinolones inhibit CYP1A2, which metabolizes theophylline.",Monitor theophylline levels closely and reduce dose if necessary.,1,2026-05-13
limiteddiclofenac,warfarin,Major,Increased risk of bleeding.,"Diclofenac is an NSAID that inhibits platelet aggregation and can cause gastrointestinal irritation, potentiating the anticoagulant effect of warfarin.",Avoid concomitant use; use acetaminophen for pain relief if on warfarin.,1,2026-05-13
limiteddiclofenac,aspirin,Moderate,Reduced cardioprotective effect of low-dose aspirin.,"Diclofenac can competitively inhibit the binding of aspirin to COX-1, reducing aspirin's antiplatelet effect.",Administer diclofenac at least 8 hours before or 30 minutes after aspirin.,1,2026-05-13
limiteddiclofenac,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin clearance and increasing the risk of lactic acidosis.",Monitor renal function and blood glucose; avoid if renal impairment exists.,1,2026-05-13
limiteddiclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
limiteddiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
limiteddiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandins, leading to sodium and water retention and decreased renal blood flow, counteracting the effects of loop diuretics.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
limiteddiclofenac,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can decrease renal clearance of lithium.,Monitor lithium levels closely and avoid if possible.,1,2026-05-13
limiteddiclofenac,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
limiteddiclofenac,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
phenyramidol,,,,,,1,2026-05-13
astra idl maxtorasemide,,,,,,1,2026-05-13
rapid solutions,,,,,,1,2026-05-13
ultimedixamikacin,,,,,,1,2026-05-13
overseasserratiopeptidase,,,,,,1,2026-05-13
currant life science llpamisulpride,,,,,,1,2026-05-13
imidapril,aspirin,Moderate,"Reduced antihypertensive effect, increased risk of renal dysfunction.","NSAIDs can inhibit prostaglandin synthesis, reducing imidapril's vasodilatory effect.","Monitor blood pressure closely, consider alternative analgesic if possible.",1,2026-05-13
imidapril,ibuprofen,Moderate,"Reduced antihypertensive effect, increased risk of renal dysfunction.","NSAIDs can inhibit prostaglandin synthesis, reducing imidapril's vasodilatory effect.","Monitor blood pressure closely, consider alternative analgesic if possible.",1,2026-05-13
imidapril,metformin,Minor,Slight risk of increased metformin levels.,ACE inhibitors can potentially reduce metformin clearance.,Monitor glucose levels.,1,2026-05-13
imidapril,furosemide,Major,Risk of severe hypotension and acute kidney injury.,Imidapril can cause vasodilation and reduce GFR; furosemide is a potent diuretic.,"Initiate imidapril at a lower dose, monitor blood pressure and renal function.",1,2026-05-13
imidapril,spironolactone,Major,Risk of hyperkalemia and hypotension.,Both drugs can increase potassium levels and affect blood pressure.,"Monitor potassium levels and blood pressure closely, consider dose adjustment.",1,2026-05-13
imidapril,atenolol,Moderate,Increased risk of hypotension.,Additive hypotensive effects.,Monitor blood pressure closely.,1,2026-05-13
imidapril,metoprolol,Moderate,Increased risk of hypotension.,Additive hypotensive effects.,Monitor blood pressure closely.,1,2026-05-13
imidapril,ramipril,Major,"Increased risk of hyperkalemia, hypotension, and renal dysfunction.",Combination of two ACE inhibitors is generally not recommended.,Avoid concurrent use; switch to one ACE inhibitor or an alternative class.,1,2026-05-13
imidapril,clopidogrel,Minor,Potential for additive antiplatelet effect.,ACE inhibitors may have a minor antiplatelet effect.,Monitor for bleeding.,1,2026-05-13
imidapril,prednisolone,Moderate,Reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, counteracting imidapril's effect.","Monitor blood pressure, may require dose adjustment of imidapril.",1,2026-05-13
imidapril,dexamethasone,Moderate,Reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, counteracting imidapril's effect.","Monitor blood pressure, may require dose adjustment of imidapril.",1,2026-05-13
imidapril,lithium,Major,Increased lithium toxicity.,ACE inhibitors can reduce lithium clearance.,Monitor lithium levels closely and adjust dose if necessary.,1,2026-05-13
bezafibrate,warfarin,Moderate,Increased risk of bleeding.,Bezafibrate may inhibit warfarin metabolism.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
bezafibrate,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can affect muscle tissue; additive risk.,"Monitor for muscle pain, weakness, and elevated CK levels; consider dose reduction or alternative.",1,2026-05-13
bezafibrate,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can affect muscle tissue; additive risk.,"Monitor for muscle pain, weakness, and elevated CK levels; consider dose reduction or alternative.",1,2026-05-13
bezafibrate,cyclosporine,Major,"Increased cyclosporine levels, risk of nephrotoxicity.","Bezafibrate inhibits CYP3A4, which metabolizes cyclosporine.",Monitor cyclosporine levels closely and adjust dose; monitor renal function.,1,2026-05-13
bezafibrate,tacrolimus,Major,"Increased tacrolimus levels, risk of nephrotoxicity.","Bezafibrate inhibits CYP3A4, which metabolizes tacrolimus.",Monitor tacrolimus levels closely and adjust dose; monitor renal function.,1,2026-05-13
overseasketorolac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Additive NSAID effect.,"Avoid concurrent use; if necessary, use lowest effective doses and monitor for GI symptoms.",1,2026-05-13
overseasketorolac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Additive NSAID effect.,"Avoid concurrent use; if necessary, use lowest effective doses and monitor for GI symptoms.",1,2026-05-13
overseasketorolac,warfarin,Major,Significantly increased risk of bleeding.,NSAIDs inhibit platelet aggregation and can cause GI erosions; warfarin is an anticoagulant.,"Avoid concurrent use; if absolutely necessary, monitor INR very closely and for signs of bleeding.",1,2026-05-13
overseasketorolac,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, reducing metformin clearance.","Monitor renal function closely, especially in elderly or dehydrated patients.",1,2026-05-13
overseasketorolac,losartan,Moderate,Increased risk of renal dysfunction and hyperkalemia.,"NSAIDs can impair renal blood flow, counteracting the effects of ARBs.",Monitor renal function and potassium levels.,1,2026-05-13
overseasketorolac,amlodipine,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, antagonizing the effects of calcium channel blockers.",Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
overseasketorolac,furosemide,Moderate,"Reduced diuretic effect, increased risk of renal dysfunction.",NSAIDs can inhibit diuretic efficacy and reduce renal blood flow.,Monitor urine output and renal function; consider alternative analgesic.,1,2026-05-13
overseasketorolac,spironolactone,Moderate,Increased risk of hyperkalemia and renal dysfunction.,NSAIDs can impair renal function and increase potassium levels; spironolactone is a potassium-sparing diuretic.,Monitor potassium levels and renal function.,1,2026-05-13
overseasketorolac,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, antagonizing the effects of beta-blockers.",Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
overseasketorolac,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, antagonizing the effects of beta-blockers.",Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
overseasketorolac,ramipril,Moderate,Increased risk of renal dysfunction and hyperkalemia.,"NSAIDs can impair renal blood flow, counteracting the effects of ACE inhibitors.",Monitor renal function and potassium levels.,1,2026-05-13
overseasketorolac,clopidogrel,Major,Significantly increased risk of bleeding.,NSAIDs inhibit platelet aggregation; clopidogrel is an antiplatelet agent.,"Avoid concurrent use; if absolutely necessary, monitor for signs of bleeding.",1,2026-05-13
overseasketorolac,prednisolone,Major,Markedly increased risk of gastrointestinal bleeding and ulcers.,Additive GI irritant effects of NSAIDs and corticosteroids.,Avoid concurrent use; monitor closely for GI symptoms.,1,2026-05-13
overseasketorolac,dexamethasone,Major,Markedly increased risk of gastrointestinal bleeding and ulcers.,Additive GI irritant effects of NSAIDs and corticosteroids.,Avoid concurrent use; monitor closely for GI symptoms.,1,2026-05-13
overseasketorolac,lithium,Major,Increased lithium toxicity.,NSAIDs can reduce lithium clearance.,Monitor lithium levels closely and adjust dose if necessary.,1,2026-05-13
overseasketorolac,methotrexate,Major,Increased risk of methotrexate toxicity.,NSAIDs can interfere with methotrexate clearance and increase its plasma levels.,Monitor methotrexate levels and for signs of toxicity; avoid concurrent use if possible.,1,2026-05-13
minodronic acid,,,,,,1,2026-05-13
cefixime,,,,,,1,2026-05-13
choline fenofibrate,warfarin,Moderate,Increased risk of bleeding.,Fenofibrate can potentiate the anticoagulant effect of warfarin.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
choline fenofibrate,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Concurrent use of statins and fibrates increases the risk of muscle-related side effects.,"Use with caution, monitor for muscle pain, and consider dose adjustment or alternative therapy.",1,2026-05-13
choline fenofibrate,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Concurrent use of statins and fibrates increases the risk of muscle-related side effects.,"Use with caution, monitor for muscle pain, and consider dose adjustment or alternative therapy.",1,2026-05-13
imesulide,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs like nimesulide can inhibit platelet aggregation and increase gastric irritation, potentiating warfarin's anticoagulant effect.",Monitor INR closely and counsel patient on signs of bleeding.,1,2026-05-13
imesulide,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,"Both are NSAIDs, leading to additive effects on gastric mucosal protection and platelet inhibition.",Avoid concurrent use; consider alternative pain relief or antiplatelet therapy.,1,2026-05-13
imesulide,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,"Both are NSAIDs, leading to additive effects on gastric mucosal protection and platelet inhibition.",Avoid concurrent use; consider alternative pain relief.,1,2026-05-13
imesulide,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,NSAIDs can reduce the efficacy of ACE inhibitors by inhibiting renal prostaglandin synthesis.,Monitor blood pressure and renal function; use with caution.,1,2026-05-13
imesulide,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,NSAIDs can reduce the efficacy of ARBs by inhibiting renal prostaglandin synthesis.,Monitor blood pressure and renal function; use with caution.,1,2026-05-13
imesulide,metformin,Minor,Slightly increased risk of lactic acidosis.,"NSAIDs can impair renal function, which may lead to reduced metformin clearance.",Monitor renal function and counsel patient on signs of lactic acidosis.,1,2026-05-13
aceclofenac,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and increase gastric irritation, potentiating warfarin's anticoagulant effect.",Monitor INR closely and counsel patient on signs of bleeding.,1,2026-05-13
aceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,"Both are NSAIDs, leading to additive effects on gastric mucosal protection and platelet inhibition.",Avoid concurrent use; consider alternative pain relief or antiplatelet therapy.,1,2026-05-13
aceclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,"Both are NSAIDs, leading to additive effects on gastric mucosal protection and platelet inhibition.",Avoid concurrent use; consider alternative pain relief.,1,2026-05-13
aceclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,NSAIDs can reduce the efficacy of ACE inhibitors by inhibiting renal prostaglandin synthesis.,Monitor blood pressure and renal function; use with caution.,1,2026-05-13
aceclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,NSAIDs can reduce the efficacy of ARBs by inhibiting renal prostaglandin synthesis.,Monitor blood pressure and renal function; use with caution.,1,2026-05-13
aceclofenac,metformin,Minor,Slightly increased risk of lactic acidosis.,"NSAIDs can impair renal function, which may lead to reduced metformin clearance.",Monitor renal function and counsel patient on signs of lactic acidosis.,1,2026-05-13
flaxseed oil,warfarin,Minor,Potential reduction in anticoagulant effect.,"Flaxseed oil may affect platelet aggregation, potentially altering warfarin's efficacy.",Monitor INR and be aware of potential changes.,1,2026-05-13
propyl thiouracil,lithium,Moderate,Increased risk of hypothyroidism.,Both propylthiouracil and lithium can affect thyroid function.,Monitor thyroid function tests regularly.,1,2026-05-13
ceftriaxone,,,,,,1,2026-05-13
l-threonine,,,,,,1,2026-05-13
l-methionine,,,,,,1,2026-05-13
rosuvastatin,warfarin,Moderate,Increased risk of bleeding.,Rosuvastatin can increase the anticoagulant effect of warfarin.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
rosuvastatin,amlodipine,Minor,"No significant interaction, but monitor for muscle pain.",No well-established clinically significant interaction.,Monitor for muscle-related adverse effects if any unusual symptoms occur.,1,2026-05-13
rosuvastatin,clarithromycin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Macrolide antibiotics can inhibit CYP3A4, which metabolizes some statins, increasing their levels.","Use with caution, monitor for muscle pain, and consider dose reduction or alternative therapy.",1,2026-05-13
rosuvastatin,cyclosporine,Major,Markedly increased rosuvastatin levels and risk of myopathy/rhabdomyolysis.,Cyclosporine significantly inhibits the metabolism of rosuvastatin.,Avoid concurrent use or use the lowest possible dose of rosuvastatin with careful monitoring.,1,2026-05-13
rosuvastatin,itraconazole,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Azole antifungals can inhibit the metabolism of statins, increasing their levels.","Use with caution, monitor for muscle pain, and consider dose reduction or alternative therapy.",1,2026-05-13
rosuvastatin,lopinavir/ritonavir,Major,Markedly increased rosuvastatin levels and risk of myopathy/rhabdomyolysis.,Ritonavir significantly inhibits the metabolism of rosuvastatin.,Avoid concurrent use or use the lowest possible dose of rosuvastatin with careful monitoring.,1,2026-05-13
rosuvastatin,niacin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Concomitant use of statins and high-dose niacin increases the risk of muscle-related side effects.,"Use with caution, monitor for muscle pain, and consider dose adjustment.",1,2026-05-13
rosuvastatin,fibrates,Moderate,Increased risk of myopathy and rhabdomyolysis.,Concomitant use of statins and fibrates increases the risk of muscle-related side effects.,"Use with caution, monitor for muscle pain, and consider dose adjustment or alternative therapy.",1,2026-05-13
parnaparin,aspirin,Major,Increased risk of bleeding.,Both drugs inhibit platelet aggregation and affect coagulation.,Monitor for signs of bleeding; consider alternative analgesics.,1,2026-05-13
parnaparin,ibuprofen,Major,Increased risk of bleeding.,Both drugs inhibit platelet aggregation and affect coagulation.,Monitor for signs of bleeding; consider alternative analgesics.,1,2026-05-13
parnaparin,warfarin,Major,Significantly increased risk of bleeding.,Additive anticoagulant effects.,Avoid co-administration; close INR monitoring if unavoidable.,1,2026-05-13
parnaparin,clopidogrel,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; consider alternative.,1,2026-05-13
parnaparin,metformin,Moderate,"Increased risk of bleeding, particularly in elderly or those with renal impairment.",Metformin can affect platelet function and prolong bleeding time.,Monitor for signs of bleeding; consider alternatives in high-risk patients.,1,2026-05-13
pazufloxazin,warfarin,Moderate,Increased INR and risk of bleeding.,Fluoroquinolones can inhibit the metabolism of warfarin.,Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
pazufloxazin,metformin,Moderate,Increased risk of lactic acidosis.,Fluoroquinolones may affect renal function and glucose metabolism.,Monitor blood glucose and renal function; consider alternative antibiotic.,1,2026-05-13
pazufloxazin,furosemide,Moderate,Increased risk of ototoxicity and renal toxicity.,Potential for additive nephrotoxic or ototoxic effects.,Monitor renal function and hearing; use with caution.,1,2026-05-13
ai health care llpdomperidone,,,,,,1,2026-05-13
hdiclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Additive gastrointestinal irritant effects.,Use with caution; monitor for GI symptoms.,1,2026-05-13
hdiclofenac,warfarin,Major,"Increased risk of bleeding, especially GI bleeding.","NSAIDs can inhibit platelet aggregation and cause GI damage, while warfarin is an anticoagulant.",Avoid co-administration; monitor for signs of bleeding.,1,2026-05-13
hdiclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Additive gastrointestinal irritant effects.,Use with caution; monitor for GI symptoms.,1,2026-05-13
hdiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,NSAIDs can antagonize the effects of ACE inhibitors and reduce renal perfusion.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
hdiclofenac,furosemide,Moderate,Reduced diuretic effect and increased risk of renal dysfunction.,NSAIDs can antagonize the effects of loop diuretics and reduce renal perfusion.,Monitor urine output and renal function; consider alternative analgesic.,1,2026-05-13
hdiclofenac,prednisolone,Major,Significantly increased risk of gastrointestinal bleeding and ulcers.,Additive gastrointestinal toxicity.,Avoid co-administration; monitor for GI symptoms.,1,2026-05-13
hdiclofenac,dexamethasone,Major,Significantly increased risk of gastrointestinal bleeding and ulcers.,Additive gastrointestinal toxicity.,Avoid co-administration; monitor for GI symptoms.,1,2026-05-13
hdiclofenac,lithium,Moderate,Increased lithium levels and risk of toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels and renal function; consider alternative analgesic.,1,2026-05-13
cypermethrin,,,,,,1,2026-05-13
anti-psoriatic,methotrexate,Major,"Increased risk of methotrexate toxicity (hematologic, hepatic, renal).","Many anti-psoriatic agents (e.g., acitretin) can interact with methotrexate.",Avoid co-administration; monitor methotrexate levels and toxicity.,1,2026-05-13
anti-psoriatic,cyclosporine,Moderate,Increased risk of cyclosporine toxicity (nephrotoxicity).,Some anti-psoriatic agents may affect cyclosporine metabolism or excretion.,Monitor cyclosporine levels and renal function; use with caution.,1,2026-05-13
anti-psoriatic,tacrolimus,Moderate,Increased risk of tacrolimus toxicity (nephrotoxicity).,Some anti-psoriatic agents may affect tacrolimus metabolism or excretion.,Monitor tacrolimus levels and renal function; use with caution.,1,2026-05-13
homotaurine,,,,,,1,2026-05-13
protamine sulfate,,,,,,1,2026-05-13
gestodene,rifampicin,Major,"Reduced efficacy of gestodene, leading to unintended pregnancy.",Rifampicin is a potent inducer of hepatic enzymes that metabolize gestodene.,Avoid co-administration; use alternative contraception.,1,2026-05-13
gestodene,carbamazepine,Moderate,"Reduced efficacy of gestodene, leading to unintended pregnancy.",Carbamazepine induces hepatic enzymes that metabolize gestodene.,Avoid co-administration; use alternative contraception.,1,2026-05-13
gestodene,phenytoin,Moderate,"Reduced efficacy of gestodene, leading to unintended pregnancy.",Phenytoin induces hepatic enzymes that metabolize gestodene.,Avoid co-administration; use alternative contraception.,1,2026-05-13
gestodene,topiramate,Moderate,"Reduced efficacy of gestodene, leading to unintended pregnancy.",Topiramate can induce hepatic enzymes that metabolize gestodene.,Avoid co-administration; use alternative contraception.,1,2026-05-13
calcium lactate,atorvastatin,Minor,Potentially reduced absorption of atorvastatin.,"Calcium ions can chelate with some medications, reducing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
calcium lactate,rosuvastatin,Minor,Potentially reduced absorption of rosuvastatin.,"Calcium ions can chelate with some medications, reducing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
calcium lactate,tetracyclines,Major,Significantly reduced absorption of both drugs.,"Calcium ions form insoluble complexes with tetracyclines, inhibiting absorption.",Avoid co-administration; separate administration by at least 4 hours.,1,2026-05-13
calcium lactate,fluoroquinolones,Major,Significantly reduced absorption of both drugs.,"Calcium ions form insoluble complexes with fluoroquinolones, inhibiting absorption.",Avoid co-administration; separate administration by at least 4 hours.,1,2026-05-13
calcium lactate,levothyroxine,Major,"Reduced absorption of levothyroxine, leading to hypothyroidism.","Calcium ions bind to levothyroxine in the GI tract, reducing absorption.",Administer levothyroxine at least 4 hours before or after calcium supplements.,1,2026-05-13
carbonyl iron,ciprofloxacin,Moderate,Decreased absorption of ciprofloxacin.,"Iron chelates with fluoroquinolones, reducing bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
carbonyl iron,levothyroxine,Moderate,Decreased absorption of levothyroxine.,Iron can bind to levothyroxine in the GI tract.,Separate administration by at least 4 hours.,1,2026-05-13
carbonyl iron,tetracyclines,Moderate,Decreased absorption of tetracyclines.,Iron forms insoluble complexes with tetracyclines.,Separate administration by at least 2 hours.,1,2026-05-13
centbucridine,,,,,,1,2026-05-13
polystyrene sulfonate,sorbitol,Major,Risk of intestinal necrosis.,Can lead to metabolic alkalosis and bowel ischemia.,Avoid concurrent use; use alternative laxative if needed.,1,2026-05-13
polystyrene sulfonate,digoxin,Moderate,Reduced absorption of digoxin.,Cation exchange resin binds to digoxin.,Separate administration by several hours; monitor digoxin levels.,1,2026-05-13
polystyrene sulfonate,lithium,Moderate,Reduced absorption of lithium.,Cation exchange resin binds to lithium.,Separate administration by several hours; monitor lithium levels.,1,2026-05-13
polystyrene sulfonate,thyroid hormones,Moderate,Reduced absorption of thyroid hormones.,Cation exchange resin binds to thyroid hormones.,Separate administration by several hours; monitor thyroid levels.,1,2026-05-13
arterolane,,,,,,1,2026-05-13
piperaquine,,,,,,1,2026-05-13
phospholipids,,,,,,1,2026-05-13
mepolizumab,,,,,,1,2026-05-13
human papillomavirus quadrivalent,,,,,,1,2026-05-13
human prothrombin complex,warfarin,Major,Increased risk of thrombosis.,Prothrombin complex concentrates contain clotting factors that can override warfarin's anticoagulant effect.,Use with extreme caution; monitor INR closely; may require dose adjustment of warfarin.,1,2026-05-13
clostridium botulinum type a toxin-haemagglutinin complex,,,,,,1,2026-05-13
overseasambroxol,,,,,,1,2026-05-13
astra idl maxcefpodoxime proxetil,metformin,Moderate,Increased risk of lactic acidosis.,Cefpodoxime may interfere with renal excretion of metformin.,Monitor renal function and blood glucose closely; consider alternative antibiotic if necessary.,1,2026-05-13
limitedetizolam,alprazolam,Major,"Increased sedation, respiratory depression, and risk of overdose.",Both are benzodiazepines with additive CNS depressant effects.,"Avoid co-administration; if unavoidable, use lowest doses and monitor closely for sedation and respiratory depression.",1,2026-05-13
limitedetizolam,diazepam,Major,"Increased sedation, respiratory depression, and risk of overdose.",Both are benzodiazepines with additive CNS depressant effects.,"Avoid co-administration; if unavoidable, use lowest doses and monitor closely for sedation and respiratory depression.",1,2026-05-13
limitedetizolam,lorazepam,Major,"Increased sedation, respiratory depression, and risk of overdose.",Both are benzodiazepines with additive CNS depressant effects.,"Avoid co-administration; if unavoidable, use lowest doses and monitor closely for sedation and respiratory depression.",1,2026-05-13
limitedetizolam,clonazepam,Major,"Increased sedation, respiratory depression, and risk of overdose.",Both are benzodiazepines with additive CNS depressant effects.,"Avoid co-administration; if unavoidable, use lowest doses and monitor closely for sedation and respiratory depression.",1,2026-05-13
limitedetizolam,midazolam,Major,"Increased sedation, respiratory depression, and risk of overdose.",Both are benzodiazepines with additive CNS depressant effects.,"Avoid co-administration; if unavoidable, use lowest doses and monitor closely for sedation and respiratory depression.",1,2026-05-13
limitedetizolam,zolpidem,Major,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Monitor for excessive sedation and impaired cognition.,1,2026-05-13
limitedetizolam,tramadol,Moderate,"Increased sedation, dizziness, and risk of respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedetizolam,codeine,Moderate,"Increased sedation, dizziness, and risk of respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedetizolam,morphine,Moderate,"Increased sedation, dizziness, and risk of respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedetizolam,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Monitor for increased sedation and anticholinergic side effects.,1,2026-05-13
limitedetizolam,alcohol,Major,"Severe sedation, respiratory depression, coma, and death.",Synergistic CNS depressant effects.,Avoid alcohol completely.,1,2026-05-13
lynestrenol,,,,,,1,2026-05-13
limitedenoxaparin,aspirin,Moderate,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; use with caution.,1,2026-05-13
limitedenoxaparin,ibuprofen,Moderate,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; use with caution.,1,2026-05-13
limitedenoxaparin,warfarin,Major,Markedly increased risk of bleeding.,Both are anticoagulants with additive effects.,"Avoid concomitant use; if necessary, monitor INR very closely and adjust doses of both agents carefully.",1,2026-05-13
limitedenoxaparin,clopidogrel,Major,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; use with caution.,1,2026-05-13
methylcobalamin/mecobalamin,,,,,,1,2026-05-13
phasphate,atorvastatin,Minor,Reduced absorption of phosphate supplements.,"Phosphate can bind to statins, potentially reducing their absorption.",Separate administration of phosphate and atorvastatin by at least 2 hours.,1,2026-05-13
phasphate,rosuvastatin,Minor,Reduced absorption of phosphate supplements.,"Phosphate can bind to statins, potentially reducing their absorption.",Separate administration of phosphate and rosuvastatin by at least 2 hours.,1,2026-05-13
phasphate,metformin,Minor,Increased risk of hypophosphatemia.,"Phosphate binders can reduce phosphate absorption, and metformin can also rarely lead to hypophosphatemia.",Monitor phosphate levels if patient is on both.,1,2026-05-13
besifloxacin,metformin,Moderate,Increased risk of lactic acidosis.,Fluoroquinolones may interfere with renal excretion of metformin.,Monitor renal function and blood glucose closely; consider alternative antibiotic if necessary.,1,2026-05-13
streptococcus faecalis,,,,,,1,2026-05-13
clostridium butryricum,,,,,,1,2026-05-13
bacillus mesentericus,,,,,,1,2026-05-13
health care llptelmisartan,spironolactone,Moderate,Increased risk of hyperkalemia.,Both drugs increase potassium levels.,Monitor potassium levels closely and consider alternative diuretic.,1,2026-05-13
health care llptelmisartan,furosemide,Minor,May slightly reduce telmisartan's blood pressure lowering effect.,"Diuretics can affect fluid volume and electrolytes, potentially impacting RAAS system response.",Monitor blood pressure and renal function.,1,2026-05-13
health care llptelmisartan,ibuprofen,Moderate,Increased risk of renal impairment and reduced antihypertensive effect.,"NSAIDs can inhibit prostaglandin synthesis, reducing renal blood flow and counteracting the effects of ACE inhibitors/ARBs.","Avoid concurrent use or use with caution, monitor renal function.",1,2026-05-13
health care llptelmisartan,aspirin,Minor,May slightly reduce the antihypertensive effect of telmisartan.,"Low-dose aspirin might have minimal impact on RAAS, but high doses can affect renal function.",Monitor blood pressure.,1,2026-05-13
moon,,,,,,1,2026-05-13
trimethoprim combinations,methotrexate,Major,"Increased risk of methotrexate toxicity (myelosuppression, mucositis, renal dysfunction).","Trimethoprim inhibits dihydrofolate reductase, similar to methotrexate, leading to additive folate deficiency.",Avoid concurrent use or monitor methotrexate levels and blood counts very closely.,1,2026-05-13
trimethoprim combinations,warfarin,Moderate,Increased risk of bleeding.,"Trimethoprim can inhibit CYP2C9, the enzyme that metabolizes warfarin, leading to higher warfarin levels.",Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
trimethoprim combinations,spironolactone,Moderate,Increased risk of hyperkalemia.,"Trimethoprim has a potassium-sparing effect, similar to other potassium-sparing diuretics.",Monitor potassium levels closely.,1,2026-05-13
trimethoprim combinations,ramipril,Moderate,Increased risk of hyperkalemia.,Both trimethoprim and ACE inhibitors can increase potassium levels.,Monitor potassium levels closely.,1,2026-05-13
trimethoprim combinations,losartan,Moderate,Increased risk of hyperkalemia.,Both trimethoprim and ARBs can increase potassium levels.,Monitor potassium levels closely.,1,2026-05-13
trimethoprim combinations,metformin,Minor,Slightly increased risk of lactic acidosis.,Trimethoprim can inhibit renal excretion of metformin.,Monitor renal function and for signs of lactic acidosis.,1,2026-05-13
micronised purified flavonoid fraction,,,,,,1,2026-05-13
thioguanine,allopurinol,Major,"Increased risk of thioguanine toxicity (myelosuppression, hepatotoxicity).","Allopurinol inhibits xanthine oxidase, the enzyme that metabolizes thioguanine, leading to higher thioguanine levels.",Avoid concurrent use or reduce thioguanine dose and monitor blood counts and liver function.,1,2026-05-13
cadsol life sciences llprosuvastatin,itraconazole,Major,Increased risk of myopathy and rhabdomyolysis.,"Itraconazole is a potent inhibitor of CYP3A4, which metabolizes rosuvastatin, leading to significantly elevated rosuvastatin levels.","Avoid concurrent use. If unavoidable, monitor for muscle pain and weakness, and consider reducing rosuvastatin dose.",1,2026-05-13
cadsol life sciences llprosuvastatin,cyclosporine,Major,Significantly increased rosuvastatin levels and risk of myopathy.,"Cyclosporine inhibits OATP1B1 transporter, which is responsible for rosuvastatin uptake into the liver, increasing systemic exposure.",Avoid concurrent use or significantly reduce rosuvastatin dose and monitor for muscle symptoms.,1,2026-05-13
cadsol life sciences llprosuvastatin,gemfibrozil,Major,Increased risk of myopathy and rhabdomyolysis.,Gemfibrozil increases rosuvastatin levels and has its own myotoxic potential.,"Avoid concurrent use. If unavoidable, use rosuvastatin at a lower dose and monitor closely.",1,2026-05-13
cadsol life sciences llprosuvastatin,fibrates (other than gemfibrozil),Moderate,Increased risk of myopathy.,Fibrates can increase rosuvastatin levels and have myotoxic potential.,Use with caution and monitor for muscle pain or weakness.,1,2026-05-13
cadsol life sciences llprosuvastatin,amiodarone,Moderate,Increased risk of myopathy.,"Amiodarone can inhibit CYP3A4 and OATP1B1, leading to increased rosuvastatin levels.",Use with caution and monitor for muscle pain or weakness.,1,2026-05-13
cadsol life sciences llprosuvastatin,ritonavir,Moderate,Increased rosuvastatin levels and risk of myopathy.,"Ritonavir is a strong CYP3A4 inhibitor, increasing rosuvastatin levels.",Use with caution and monitor for muscle pain or weakness.,1,2026-05-13
renwick health care llpprogesterone,rifampicin,Moderate,Reduced effectiveness of progesterone.,Rifampicin is a potent inducer of hepatic enzymes (CYP3A4) that metabolize progesterone.,Consider alternative contraception or increased progesterone dose if concurrently used.,1,2026-05-13
renwick health care llpprogesterone,phenytoin,Moderate,Reduced effectiveness of progesterone.,Phenytoin is an enzyme inducer that increases progesterone metabolism.,Consider alternative contraception or increased progesterone dose if concurrently used.,1,2026-05-13
renwick health care llpprogesterone,carbamazepine,Moderate,Reduced effectiveness of progesterone.,Carbamazepine is an enzyme inducer that increases progesterone metabolism.,Consider alternative contraception or increased progesterone dose if concurrently used.,1,2026-05-13
renwick health care llpprogesterone,topiramate,Moderate,Reduced effectiveness of progesterone.,Topiramate is an enzyme inducer that increases progesterone metabolism.,Consider alternative contraception or increased progesterone dose if concurrently used.,1,2026-05-13
overseasgatifloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones can potentiate the anticoagulant effect of warfarin, although the exact mechanism is not fully understood.",Monitor INR closely and consider warfarin dose adjustment.,1,2026-05-13
overseasgatifloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can affect glucose metabolism and potentially potentiate the hypoglycemic effects of metformin.,Monitor blood glucose levels closely.,1,2026-05-13
overseasgatifloxacin,amiodarone,Major,Increased risk of QT prolongation and arrhythmias.,"Gatifloxacin has a risk of QT prolongation, and amiodarone is also a QT-prolonging agent.","Avoid concurrent use. If unavoidable, monitor ECG and electrolytes closely.",1,2026-05-13
overseasgatifloxacin,digoxin,Minor,May slightly increase digoxin levels.,Fluoroquinolones can interfere with P-glycoprotein-mediated transport of digoxin.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseasgatifloxacin,"corticosteroids (e.g., prednisolone, dexamethasone)",Moderate,Increased risk of tendon rupture.,Both fluoroquinolones and corticosteroids have been associated with an increased risk of tendonitis and tendon rupture.,Use with caution and monitor for signs of tendon pain or rupture.,1,2026-05-13
mandeliic acid,,,,,,1,2026-05-13
sulfadimidine,,,,,,1,2026-05-13
jupiter biolabs private limitedmethylcobalamin,,,,,,1,2026-05-13
overseaslactulose,,,,,,1,2026-05-13
kalmegh dry extract,,,,,,1,2026-05-13
limitedferrous ascorbate,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Ferrous ions chelate with fluoroquinolones, decreasing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
limitedferrous ascorbate,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Ferrous ions chelate with fluoroquinolones, decreasing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
limitedferrous ascorbate,tetracycline,Moderate,Reduced absorption of tetracycline.,"Ferrous ions chelate with tetracyclines, decreasing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
limitedferrous ascorbate,doxycycline,Moderate,Reduced absorption of doxycycline.,"Ferrous ions chelate with tetracyclines, decreasing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
ecranip drugs,,,,,,1,2026-05-13
limitedtramadol,diazepam,Moderate,Increased sedation and respiratory depression.,Potentiation of CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
limitedtramadol,alprazolam,Moderate,Increased sedation and respiratory depression.,Potentiation of CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
limitedtramadol,lorazepam,Moderate,Increased sedation and respiratory depression.,Potentiation of CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
limitedtramadol,clonazepam,Moderate,Increased sedation and respiratory depression.,Potentiation of CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
limitedtramadol,midazolam,Moderate,Increased sedation and respiratory depression.,Potentiation of CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
limitedtramadol,sertraline,Moderate,Increased risk of serotonin syndrome.,Tramadol has serotonergic activity.,Monitor for signs of serotonin syndrome; consider alternative analgesics.,1,2026-05-13
limitedtramadol,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Tramadol has serotonergic activity.,Monitor for signs of serotonin syndrome; consider alternative analgesics.,1,2026-05-13
limitedtramadol,amitriptyline,Moderate,Increased risk of serotonin syndrome.,Tramadol has serotonergic activity.,Monitor for signs of serotonin syndrome; consider alternative analgesics.,1,2026-05-13
limitedtramadol,warfarin,Moderate,Increased risk of bleeding.,Tramadol may affect platelet aggregation and affect INR.,Monitor INR closely; consider alternative analgesics.,1,2026-05-13
limitedtramadol,metformin,Minor,Increased risk of hypoglycemia.,Tramadol may affect glucose metabolism.,Monitor blood glucose levels closely.,1,2026-05-13
coumarin,aspirin,Moderate,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; consider alternative analgesics or anticoagulants.,1,2026-05-13
coumarin,ibuprofen,Moderate,Increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Monitor for signs of bleeding; consider alternative analgesics or anticoagulants.,1,2026-05-13
coumarin,clopidogrel,Major,Significantly increased risk of bleeding.,Additive antiplatelet and anticoagulant effects.,Avoid co-administration; use alternative agents.,1,2026-05-13
coumarin,metronidazole,Moderate,Increased risk of bleeding.,Metronidazole can inhibit warfarin metabolism and affect clotting factors.,Monitor INR closely; consider alternative antibiotics.,1,2026-05-13
coumarin,amiodarone,Moderate,Increased risk of bleeding.,Amiodarone inhibits warfarin metabolism.,Monitor INR closely; consider dose reduction of warfarin.,1,2026-05-13
coumarin,fluconazole,Moderate,Increased risk of bleeding.,Fluconazole inhibits warfarin metabolism.,Monitor INR closely; consider dose reduction of warfarin.,1,2026-05-13
coumarin,omeprazole,Minor,May slightly increase INR.,Omeprazole can inhibit warfarin metabolism.,Monitor INR closely.,1,2026-05-13
coumarin,pantoprazole,Minor,May slightly increase INR.,Pantoprazole can inhibit warfarin metabolism.,Monitor INR closely.,1,2026-05-13
advent life sciences llpmethylcobalamin,,,,,,1,2026-05-13
bismuth ammonium citrate,,,,,,1,2026-05-13
belladonna dry extract,amitriptyline,Moderate,"Increased anticholinergic effects like dry mouth, blurred vision, constipation, and urinary retention.","Both drugs possess anticholinergic properties, leading to additive effects on muscarinic receptors.",Monitor for increased anticholinergic side effects. Consider dose adjustment of one or both agents.,1,2026-05-13
belladonna dry extract,haloperidol,Moderate,"Increased risk of anticholinergic side effects, potentially masking extrapyramidal symptoms.",Additive anticholinergic activity.,Monitor for anticholinergic effects. Use with caution and observe for reduced efficacy of haloperidol in controlling psychosis.,1,2026-05-13
belladonna dry extract,clozapine,Moderate,Increased risk of anticholinergic side effects and potentially ileus.,Additive anticholinergic activity.,Monitor closely for anticholinergic effects and signs of paralytic ileus. Use cautiously.,1,2026-05-13
belladonna dry extract,lorazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
belladonna dry extract,diazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
belladonna dry extract,alprazolam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
belladonna dry extract,clonazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
belladonna dry extract,midazolam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
belladonna dry extract,zolpidem,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
methenamine hippurate,"sulfonamides (e.g., sulfamethoxazole, although not in list, this is a common interaction)",Major,"Crystalluria and renal damage due to formation of insoluble methenamine precipitate in acidic urine, especially when combined with acidic drugs.","Methenamine requires acidic urine to be hydrolyzed to formaldehyde. Sulfonamides can decrease urine pH, potentially leading to precipitation.",Avoid concurrent use if urine pH cannot be maintained sufficiently acidic for methenamine's action or if patient has renal impairment. Monitor urine pH and renal function.,1,2026-05-13
avant bio sciences llpduloxetine,amitriptyline,Moderate,"Increased risk of serotonin syndrome, especially with higher doses.","Both drugs are serotonergic, increasing the risk of excessive serotonin activity.",,1,2026-05-13
avant bio sciences llpduloxetine,tramadol,Moderate,Increased risk of serotonin syndrome.,Both drugs are serotonergic.,Monitor for signs and symptoms of serotonin syndrome. Use with caution.,1,2026-05-13
avant bio sciences llpduloxetine,codeine,Moderate,"Increased risk of serotonin syndrome. Duloxetine may also inhibit codeine metabolism, potentially altering its effects.",Additive serotonergic effects; potential CYP2D6 inhibition by duloxetine.,Monitor for serotonin syndrome. Use with caution and consider alternative analgesics if necessary.,1,2026-05-13
avant bio sciences llpduloxetine,morphine,Moderate,Increased risk of serotonin syndrome.,Both drugs are serotonergic.,Monitor for signs and symptoms of serotonin syndrome. Use with caution.,1,2026-05-13
avant bio sciences llpduloxetine,clopidogrel,Minor,Increased risk of bleeding due to potential inhibition of platelet aggregation.,Duloxetine can inhibit platelet aggregation.,"Monitor for signs of bleeding. Use with caution, especially if patient has other risk factors for bleeding.",1,2026-05-13
avant bio sciences llpduloxetine,warfarin,Minor,Increased risk of bleeding.,Duloxetine can inhibit platelet aggregation.,Monitor INR closely. Use with caution.,1,2026-05-13
avant bio sciences llpduloxetine,omeprazole,Minor,"May slightly increase duloxetine levels, potentially increasing side effects.","Omeprazole is a CYP1A2 inhibitor, and duloxetine is partly metabolized by CYP1A2.",Monitor for increased duloxetine side effects. Dose adjustments are generally not required but caution is advised.,1,2026-05-13
avant bio sciences llpduloxetine,fluoxetine,Major,Significantly increased risk of serotonin syndrome.,"Both are SSRIs/SNRIs, leading to substantial increase in serotonin levels.","Avoid concurrent use. If necessary, use with extreme caution, lower doses, and frequent monitoring for serotonin syndrome.",1,2026-05-13
avant bio sciences llpduloxetine,sertraline,Major,Significantly increased risk of serotonin syndrome.,"Both are SSRIs/SNRIs, leading to substantial increase in serotonin levels.","Avoid concurrent use. If necessary, use with extreme caution, lower doses, and frequent monitoring for serotonin syndrome.",1,2026-05-13
aluminium phosphate,omeprazole,Minor,"Reduced absorption of omeprazole, potentially decreasing its efficacy.","Aluminum-containing antacids can bind to proton pump inhibitors, reducing their bioavailability.",Separate administration by at least 2 hours. Monitor for symptoms of GERD or peptic ulcer disease.,1,2026-05-13
aluminium phosphate,pantoprazole,Minor,"Reduced absorption of pantoprazole, potentially decreasing its efficacy.","Aluminum-containing antacids can bind to proton pump inhibitors, reducing their bioavailability.",Separate administration by at least 2 hours. Monitor for symptoms of GERD or peptic ulcer disease.,1,2026-05-13
aluminium phosphate,metformin,Minor,May slightly delay or reduce metformin absorption.,"Antacids can alter gastric pH and motility, potentially affecting drug absorption.",Monitor blood glucose levels. Separate administration by at least 2 hours if possible.,1,2026-05-13
aluminium phosphate,atorvastatin,Minor,"Reduced absorption of atorvastatin, potentially decreasing its efficacy.","Antacids can bind to statins, reducing their absorption.",Separate administration by at least 2 hours. Monitor lipid levels.,1,2026-05-13
aluminium phosphate,rosuvastatin,Minor,"Reduced absorption of rosuvastatin, potentially decreasing its efficacy.","Antacids can bind to statins, reducing their absorption.",Separate administration by at least 2 hours. Monitor lipid levels.,1,2026-05-13
aluminium phosphate,ciprofloxacin,Moderate,"Significantly reduced absorption of ciprofloxacin, leading to decreased efficacy and potential treatment failure.","Aluminum ions chelate with fluoroquinolones, forming insoluble complexes that are not absorbed.",Avoid concurrent administration. Separate administration by at least 4 hours before or 8 hours after ciprofloxacin. Monitor for signs of infection.,1,2026-05-13
aluminium phosphate,digoxin,Minor,"May decrease absorption of digoxin, leading to reduced efficacy.",Aluminum-containing antacids can affect GI motility and absorption.,Monitor digoxin levels and for signs of therapeutic failure. Separate administration by at least 2 hours.,1,2026-05-13
aluminium phosphate,"levothyroxine (though not on list, a common interaction)",Major,"Significantly reduced absorption of levothyroxine, leading to hypothyroidism.","Aluminum hydroxide binds to levothyroxine, reducing its absorption.",Separate administration of levothyroxine by at least 4 hours from aluminum-containing products. Monitor thyroid function tests.,1,2026-05-13
recombinant folliclestimulating hormone,,,,,,1,2026-05-13
hormone recombinant human luteinizing hormone/lutropin alfa,,,,,,1,2026-05-13
limitedcefpirome,"aminoglycosides (e.g., gentamicin, tobramycin - not on list, but common interaction)",Major,Increased risk of nephrotoxicity and ototoxicity.,Cefpirome and aminoglycosides can have additive nephrotoxic effects.,Monitor renal function and auditory function closely. Consider dose adjustments or alternative therapy if indicated.,1,2026-05-13
limitedcefpirome,furosemide,Moderate,Increased risk of nephrotoxicity.,Cefpirome and potent diuretics can have additive nephrotoxic effects.,Monitor renal function closely. Use with caution.,1,2026-05-13
diltiazem topical,amlodipine,Moderate,Increased risk of hypotension and bradycardia.,"Both are calcium channel blockers, leading to additive effects on cardiac contractility and vascular tone. Topical diltiazem has systemic absorption potential.",Monitor blood pressure and heart rate. Use with caution and consider alternative therapies if significant systemic effects occur.,1,2026-05-13
diltiazem topical,atenolol,Moderate,Increased risk of bradycardia and hypotension.,Additive effects on heart rate and blood pressure. Topical diltiazem has systemic absorption potential.,Monitor heart rate and blood pressure. Use with caution.,1,2026-05-13
diltiazem topical,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,Additive effects on heart rate and blood pressure. Topical diltiazem has systemic absorption potential.,Monitor heart rate and blood pressure. Use with caution.,1,2026-05-13
diltiazem topical,digoxin,Moderate,Increased risk of bradycardia and potentially AV block.,Diltiazem can slow AV nodal conduction. Topical absorption may contribute to systemic effects.,Monitor heart rate and for signs of AV block. Use with caution.,1,2026-05-13
currant life science llptofisopam,alprazolam,Moderate,Increased risk of sedation and CNS depression.,"Both are benzodiazepine receptor agonists, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,diazepam,Moderate,Increased risk of sedation and CNS depression.,"Both are benzodiazepine receptor agonists, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,lorazepam,Moderate,Increased risk of sedation and CNS depression.,"Both are benzodiazepine receptor agonists, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,clonazepam,Moderate,Increased risk of sedation and CNS depression.,"Both are benzodiazepine receptor agonists, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,midazolam,Moderate,Increased risk of sedation and CNS depression.,"Both are benzodiazepine receptor agonists, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,zolpidem,Moderate,Increased risk of sedation and CNS depression.,"Both are non-benzodiazepine hypnotics acting on GABA-A receptors, leading to additive sedative effects.",Monitor for excessive sedation and respiratory depression. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llptofisopam,tramadol,Moderate,"Increased risk of CNS depression, including sedation and respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression. Use with caution.,1,2026-05-13
currant life science llptofisopam,codeine,Moderate,"Increased risk of CNS depression, including sedation and respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression. Use with caution.,1,2026-05-13
currant life science llptofisopam,morphine,Moderate,"Increased risk of CNS depression, including sedation and respiratory depression.",Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression. Use with caution.,1,2026-05-13
currant life science llpflunarizine,amitriptyline,Moderate,"Increased risk of CNS side effects such as sedation, dizziness, and potentially extrapyramidal symptoms.","Both drugs can cause CNS effects. Flunarizine is known to cause extrapyramidal symptoms, and amitriptyline is sedating.","Monitor for increased CNS side effects, especially sedation and movement disorders. Use with caution.",1,2026-05-13
currant life science llpflunarizine,haloperidol,Major,"Increased risk of extrapyramidal symptoms, including parkinsonism and tardive dyskinesia.","Flunarizine can induce extrapyramidal symptoms, and haloperidol is a potent dopamine antagonist with a high risk of EPS. Additive effects are likely.","Avoid concurrent use if possible. If necessary, use with extreme caution and frequent monitoring for EPS. Consider alternative agents.",1,2026-05-13
currant life science llpflunarizine,clozapine,Major,"Increased risk of extrapyramidal symptoms, sedation, and anticholinergic effects.","Flunarizine can cause EPS, and clozapine has a complex pharmacology that can also lead to these symptoms. Additive effects are likely.","Avoid concurrent use if possible. If necessary, use with extreme caution and frequent monitoring for EPS, sedation, and anticholinergic side effects.",1,2026-05-13
currant life science llpflunarizine,diazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llpflunarizine,alprazolam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llpflunarizine,lorazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llpflunarizine,clonazepam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llpflunarizine,midazolam,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
currant life science llpflunarizine,zolpidem,Minor,"May enhance CNS depressant effects, leading to increased drowsiness and sedation.",Additive sedative effects.,Monitor for excessive sedation. Advise patient to avoid activities requiring alertness.,1,2026-05-13
lidocaine/lignocaine,,,,,,1,2026-05-13
remington life sciences llplevocetirizine,alprazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,diazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,lorazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,midazolam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,zolpidem,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,clonazepam,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,codeine,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,morphine,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
remington life sciences llplevocetirizine,tramadol,Moderate,Increased sedation and potential for respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustment or alternative.,1,2026-05-13
dredhas organics,,,,,,1,2026-05-13
endoxifen,,,,,,1,2026-05-13
live attenuated varicella-zoster virus,prednisolone,Major,Decreased efficacy of the vaccine and increased risk of disseminated infection.,Immunosuppression by corticosteroids reduces the immune response to the live vaccine.,Avoid concurrent use; defer vaccination until immunosuppressive therapy is discontinued or at a sufficiently low dose.,1,2026-05-13
live attenuated varicella-zoster virus,dexamethasone,Major,Decreased efficacy of the vaccine and increased risk of disseminated infection.,Immunosuppression by corticosteroids reduces the immune response to the live vaccine.,Avoid concurrent use; defer vaccination until immunosuppressive therapy is discontinued or at a sufficiently low dose.,1,2026-05-13
live attenuated varicella-zoster virus,methotrexate,Major,Decreased efficacy of the vaccine and increased risk of disseminated infection.,Immunosuppression by methotrexate reduces the immune response to the live vaccine.,Avoid concurrent use; defer vaccination until immunosuppressive therapy is discontinued or at a sufficiently low dose.,1,2026-05-13
live attenuated varicella-zoster virus,cyclosporine,Major,Decreased efficacy of the vaccine and increased risk of disseminated infection.,Immunosuppression by cyclosporine reduces the immune response to the live vaccine.,Avoid concurrent use; defer vaccination until immunosuppressive therapy is discontinued or at a sufficiently low dose.,1,2026-05-13
live attenuated varicella-zoster virus,tacrolimus,Major,Decreased efficacy of the vaccine and increased risk of disseminated infection.,Immunosuppression by tacrolimus reduces the immune response to the live vaccine.,Avoid concurrent use; defer vaccination until immunosuppressive therapy is discontinued or at a sufficiently low dose.,1,2026-05-13
pygeum africanum,,,,,,1,2026-05-13
overseasnorfloxacin,warfarin,Moderate,Increased risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, increasing its anticoagulant effect.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
overseasnorfloxacin,metformin,Minor,Slightly increased risk of hypoglycemia.,"Norfloxacin may inhibit renal excretion of metformin, leading to increased serum levels.",Monitor blood glucose levels more frequently and consider adjusting metformin dose if necessary.,1,2026-05-13
limitedteicoplanin,,,,,,1,2026-05-13
ai health care llpchlorzoxazone,amitriptyline,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,diazepam,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,alprazolam,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,lorazepam,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,midazolam,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,zolpidem,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
ai health care llpchlorzoxazone,clonazepam,Moderate,"Increased risk of CNS depression, including drowsiness and dizziness.",Additive sedative effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
genzymetramadol,sertraline,Major,Increased risk of serotonin syndrome.,Tramadol is a serotonin reuptake inhibitor and can potentiate the serotonergic effects of SSRIs.,"Monitor for signs of serotonin syndrome (agitation, confusion, rapid heart rate, fever); use with caution or consider alternative.",1,2026-05-13
genzymetramadol,fluoxetine,Major,Increased risk of serotonin syndrome.,Tramadol is a serotonin reuptake inhibitor and can potentiate the serotonergic effects of SSRIs.,"Monitor for signs of serotonin syndrome (agitation, confusion, rapid heart rate, fever); use with caution or consider alternative.",1,2026-05-13
genzymetramadol,amitriptyline,Moderate,Increased risk of CNS depression and sedation.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustment or alternative.,1,2026-05-13
genzymetramadol,haloperidol,Moderate,Increased risk of CNS depression and potentially altered pain perception.,Both drugs can cause CNS depression and have effects on neurotransmitter systems.,Monitor for increased sedation and confusion.,1,2026-05-13
genzymetramadol,clozapine,Moderate,Increased risk of sedation and potentially anticholinergic effects.,"Tramadol can cause sedation, and clozapine has anticholinergic properties.",Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
genzymetramadol,olanzapine,Moderate,Increased risk of sedation and potentially anticholinergic effects.,"Tramadol can cause sedation, and olanzapine has anticholinergic properties.",Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
genzymetramadol,codeine,Moderate,Increased risk of respiratory depression and sedation.,Both are opioids and can cause additive CNS and respiratory depression.,Monitor respiratory rate and depth closely; consider reduced doses.,1,2026-05-13
genzymetramadol,morphine,Moderate,Increased risk of respiratory depression and sedation.,Both are opioids and can cause additive CNS and respiratory depression.,Monitor respiratory rate and depth closely; consider reduced doses.,1,2026-05-13
ambroxol,,,,,,1,2026-05-13
currant life science llpfluvoxamine,tamoxifen,Moderate,Reduced efficacy of tamoxifen.,"Fluvoxamine is a potent CYP1A2 inhibitor and a moderate CYP2D6 inhibitor, which can affect tamoxifen metabolism.",Monitor for reduced tamoxifen efficacy and consider alternative SSRI/SNRI if necessary.,1,2026-05-13
currant life science llpfluvoxamine,theophylline,Moderate,Increased risk of theophylline toxicity.,"Fluvoxamine inhibits CYP1A2, the primary enzyme responsible for theophylline metabolism.",Monitor theophylline levels closely and consider dose reduction if toxicity is suspected.,1,2026-05-13
currant life science llpfluvoxamine,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Fluvoxamine can inhibit CYP2C19, an enzyme involved in clopidogrel activation.",Monitor for signs of thrombotic events and consider alternative antiplatelet therapy.,1,2026-05-13
currant life science llpfluvoxamine,pimozide,Major,Potentially life-threatening cardiac arrhythmias (QT prolongation).,"Fluvoxamine inhibits CYP1A2 and CYP3A4, leading to significantly increased pimozide levels.","Avoid concurrent use. If unavoidable, monitor ECG and drug levels very closely.",1,2026-05-13
currant life science llpfluvoxamine,tizanidine,Major,"Profound sedation, hypotension, and bradycardia.","Fluvoxamine is a potent inhibitor of CYP1A2, which metabolizes tizanidine.","Avoid concurrent use. If unavoidable, use the lowest dose of tizanidine and monitor closely.",1,2026-05-13
toripalimab,,,,,,1,2026-05-13
aminexil,,,,,,1,2026-05-13
hpovidone iodine,,,,,,1,2026-05-13
inviscus lifescience llpmacitentan,,,,,,1,2026-05-13
astra idl maxrosuvastatin,cyclosporine,Major,Increased risk of myopathy and rhabdomyolysis.,"Cyclosporine inhibits OATP1B1 and BCRP transporters, which are involved in statin uptake and efflux, leading to increased rosuvastatin exposure.","Avoid concurrent use or use the lowest dose of rosuvastatin (e.g., 5 mg) and monitor for signs of myopathy.",1,2026-05-13
astra idl maxrosuvastatin,gemfibrozil,Major,Increased risk of myopathy and rhabdomyolysis.,"Gemfibrozil inhibits glucuronidation of rosuvastatin and may inhibit OATP1B1, increasing rosuvastatin levels.","Avoid concurrent use. If unavoidable, use the lowest dose of rosuvastatin and monitor for myopathy.",1,2026-05-13
astra idl maxrosuvastatin,fibrates (except gemfibrozil),Moderate,Increased risk of myopathy.,Fibrates can increase statin levels and share the risk of myopathy.,Use with caution and monitor for muscle pain or weakness.,1,2026-05-13
astra idl maxrosuvastatin,niacin (high dose),Moderate,Increased risk of myopathy.,Niacin may increase the risk of myopathy when combined with statins.,Use with caution and monitor for muscle symptoms.,1,2026-05-13
l-methyltetrahydrofolate calcium,,,,,,1,2026-05-13
enmetazobactam,,,,,,1,2026-05-13
cadsol life sciences llpaspirin,warfarin,Moderate,Increased risk of bleeding.,"Aspirin can inhibit platelet aggregation, and at higher doses, can affect the synthesis of clotting factors, potentially potentiating warfarin's anticoagulant effect.",Monitor INR closely and consider dose adjustment of warfarin. Use with caution.,1,2026-05-13
cadsol life sciences llpaspirin,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and reduced antiplatelet effect of aspirin.,NSAIDs like ibuprofen can interfere with aspirin's irreversible binding to COX-1 on platelets. They also increase the risk of GI ulcers and bleeding.,"Avoid concurrent use if possible. If co-administration is necessary, administer aspirin at least 30 minutes before or 8 hours after ibuprofen. Monitor for GI bleeding.",1,2026-05-13
cadsol life sciences llpaspirin,clopidogrel,Major,Significantly increased risk of bleeding.,"Both aspirin and clopidogrel are antiplatelet agents that inhibit different pathways of platelet aggregation, leading to an additive effect on bleeding risk.","Avoid concurrent use unless specifically indicated for certain conditions (e.g., acute coronary syndromes). Monitor for signs of bleeding.",1,2026-05-13
cadsol life sciences llpaspirin,methotrexate,Moderate,Increased risk of methotrexate toxicity.,"Aspirin, particularly at high doses, can inhibit renal excretion and increase serum levels of methotrexate.",Monitor methotrexate levels and for signs of toxicity. Avoid high-dose aspirin.,1,2026-05-13
cadsol life sciences llpaspirin,"corticosteroids (prednisolone, dexamethasone)",Moderate,Increased risk of gastrointestinal bleeding and ulceration.,Both aspirin and corticosteroids can irritate the gastric mucosa and increase the risk of GI bleeding.,Use with caution and monitor for signs of GI bleeding. Consider gastroprotective agents.,1,2026-05-13
cadsol life sciences llpaspirin,ramipril,Minor,Slightly reduced antihypertensive effect.,NSAIDs can inhibit the renal prostaglandins that mediate the hypotensive effects of ACE inhibitors.,Monitor blood pressure.,1,2026-05-13
cadsol life sciences llpaspirin,losartan,Minor,Slightly reduced antihypertensive effect.,NSAIDs can inhibit the renal prostaglandins that mediate the hypotensive effects of ARBs.,Monitor blood pressure.,1,2026-05-13
cadsol life sciences llpaspirin,allopurinol,Minor,Potential for increased adverse effects of allopurinol.,Salicylates may interfere with the uricosuric effect of allopurinol.,Monitor for efficacy and side effects.,1,2026-05-13
s pharmaazithromycin,warfarin,Moderate,Increased risk of bleeding.,"Azithromycin may inhibit the metabolism of warfarin, leading to higher blood levels.",Monitor INR closely and consider alternative antibiotic or closer warfarin monitoring.,1,2026-05-13
s pharmaazithromycin,digoxin,Moderate,Increased digoxin toxicity.,Azithromycin may decrease the clearance of digoxin.,Monitor digoxin levels and clinical signs of toxicity.,1,2026-05-13
s pharmaazithromycin,atorvastatin,Minor,Potential for increased statin side effects.,"Azithromycin can inhibit CYP3A4, an enzyme involved in atorvastatin metabolism.",Consider alternative antibiotic if statin-related side effects occur.,1,2026-05-13
s pharmaazithromycin,rosuvastatin,Minor,Potential for increased statin side effects.,"Azithromycin can inhibit CYP2C9 and possibly CYP3A4, enzymes involved in rosuvastatin metabolism.",Consider alternative antibiotic if statin-related side effects occur.,1,2026-05-13
s pharmaazithromycin,amlodipine,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,losartan,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,omeprazole,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,pantoprazole,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,atenolol,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,metoprolol,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,ramipril,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,clopidogrel,Minor,Potential for reduced antiplatelet effect.,"Azithromycin can inhibit CYP2C19, an enzyme involved in clopidogrel activation.",Consider alternative antibiotic if a significant reduction in clopidogrel efficacy is suspected.,1,2026-05-13
s pharmaazithromycin,furosemide,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,spironolactone,Minor,Potential for increased risk of QTc prolongation.,"Azithromycin can prolong the QTc interval, and this effect may be additive with other QTc-prolonging drugs.",Use with caution and monitor ECG if clinically indicated.,1,2026-05-13
s pharmaazithromycin,haloperidol,Moderate,Increased risk of QTc prolongation and torsades de pointes.,"Azithromycin is known to prolong the QTc interval, and haloperidol also carries this risk.","Avoid co-administration or use with extreme caution, monitor ECG.",1,2026-05-13
s pharmaazithromycin,clozapine,Moderate,Increased risk of QTc prolongation and torsades de pointes.,"Azithromycin is known to prolong the QTc interval, and clozapine also carries this risk.","Avoid co-administration or use with extreme caution, monitor ECG.",1,2026-05-13
s pharmaazithromycin,olanzapine,Moderate,Increased risk of QTc prolongation and torsades de pointes.,"Azithromycin is known to prolong the QTc interval, and olanzapine also carries this risk.","Avoid co-administration or use with extreme caution, monitor ECG.",1,2026-05-13
s pharmaazithromycin,methotrexate,Moderate,Increased methotrexate toxicity.,Azithromycin may inhibit the renal excretion of methotrexate.,Monitor methotrexate levels and signs of toxicity; consider alternative antibiotic.,1,2026-05-13
lifitegrast,,,,,,1,2026-05-13
limitedibandronic acid,calcium,Major,Reduced absorption of ibandronic acid.,"Divalent cations like calcium can chelate bisphosphonates, reducing their oral bioavailability.","Administer ibandronic acid at least 30 minutes before other oral medications, particularly those containing calcium or antacids.",1,2026-05-13
limitedibandronic acid,antacids,Major,Reduced absorption of ibandronic acid.,"Divalent cations like those in antacids can chelate bisphosphonates, reducing their oral bioavailability.","Administer ibandronic acid at least 30 minutes before other oral medications, particularly those containing calcium or antacids.",1,2026-05-13
limitedaspirin,warfarin,Major,Increased risk of bleeding.,Aspirin inhibits platelet aggregation and may have additive antiplatelet effects with warfarin.,"Avoid concomitant use. If essential, monitor INR closely and consider lower doses of both agents.",1,2026-05-13
limitedaspirin,clopidogrel,Major,Increased risk of bleeding.,"Both drugs inhibit platelet aggregation, leading to an additive effect.","Avoid concomitant use. If essential, monitor for signs of bleeding closely.",1,2026-05-13
limitedaspirin,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and reduced cardioprotective effect of low-dose aspirin.,"Ibuprofen can displace aspirin from its binding site on COX-1, reducing its antiplatelet effect.","If both are needed, administer aspirin at least 30 minutes before ibuprofen or 8 hours after ibuprofen.",1,2026-05-13
limitedaspirin,metformin,Minor,Potential for increased risk of lactic acidosis.,"Aspirin may rarely affect renal function, potentially impairing metformin clearance.",Monitor renal function and for signs of lactic acidosis.,1,2026-05-13
limitedaspirin,insulin,Minor,Potential for hypoglycemia.,High doses of aspirin can potentiate the hypoglycemic effects of insulin.,"Monitor blood glucose closely, especially when starting or increasing aspirin dose.",1,2026-05-13
limitedaspirin,prednisolone,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both aspirin and corticosteroids can irritate the gastric mucosa.,"Use with caution, monitor for gastrointestinal bleeding, and consider gastroprotective agents.",1,2026-05-13
limitedaspirin,dexamethasone,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both aspirin and corticosteroids can irritate the gastric mucosa.,"Use with caution, monitor for gastrointestinal bleeding, and consider gastroprotective agents.",1,2026-05-13
limitedaspirin,methotrexate,Major,Increased methotrexate toxicity.,"Aspirin can displace methotrexate from plasma proteins and reduce its renal excretion, leading to higher levels.","Avoid co-administration. If unavoidable, monitor methotrexate levels and signs of toxicity closely.",1,2026-05-13
limitedaspirin,valproate,Moderate,Increased risk of hyperammonemic encephalopathy.,"Aspirin can displace valproate from plasma protein binding sites, increasing free valproate levels and potentially leading to toxicity.",Monitor for signs of hyperammonemia and valproate toxicity. Consider alternative analgesic.,1,2026-05-13
collagen,,,,,,1,2026-05-13
curcumin,warfarin,Moderate,Increased risk of bleeding.,Curcumin may have antiplatelet effects and potentially inhibit the metabolism of warfarin.,Monitor INR closely and be aware of increased bleeding risk.,1,2026-05-13
curcumin,clopidogrel,Moderate,Increased risk of bleeding.,Curcumin may have antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
curcumin,metformin,Minor,Potential for additive hypoglycemic effect.,Curcumin may have blood glucose-lowering properties.,Monitor blood glucose levels.,1,2026-05-13
curcumin,insulin,Minor,Potential for additive hypoglycemic effect.,Curcumin may have blood glucose-lowering properties.,Monitor blood glucose levels.,1,2026-05-13
limitedtofacitinib,cyclosporine,Major,Increased risk of immunosuppression and adverse effects.,"Cyclosporine is a strong CYP3A4 inhibitor, which can significantly increase tofacitinib exposure.","Avoid co-administration. If co-administration is necessary, reduce the dose of tofacitinib and monitor for adverse effects.",1,2026-05-13
limitedtofacitinib,tacrolimus,Major,Increased risk of immunosuppression and adverse effects.,"Tacrolimus is a CYP3A4 inhibitor, which can increase tofacitinib exposure.","Avoid co-administration. If co-administration is necessary, reduce the dose of tofacitinib and monitor for adverse effects.",1,2026-05-13
limitedtofacitinib,erythromycin,Moderate,Increased tofacitinib levels and potential for toxicity.,Erythromycin is a CYP3A4 inhibitor.,Monitor for tofacitinib-related adverse effects. Consider dose reduction of tofacitinib if necessary.,1,2026-05-13
limitedtofacitinib,itraconazole,Moderate,Increased tofacitinib levels and potential for toxicity.,Itraconazole is a CYP3A4 inhibitor.,Monitor for tofacitinib-related adverse effects. Consider dose reduction of tofacitinib if necessary.,1,2026-05-13
limitedtofacitinib,ketoconazole,Moderate,Increased tofacitinib levels and potential for toxicity.,Ketoconazole is a CYP3A4 inhibitor.,Monitor for tofacitinib-related adverse effects. Consider dose reduction of tofacitinib if necessary.,1,2026-05-13
limitedtofacitinib,omeprazole,Minor,May potentially affect tofacitinib absorption or metabolism.,"Omeprazole can affect gastric pH, which may influence absorption of some drugs, and can also inhibit CYP enzymes.",Monitor for efficacy and adverse effects of tofacitinib.,1,2026-05-13
limitedtofacitinib,pantoprazole,Minor,May potentially affect tofacitinib absorption or metabolism.,"Pantoprazole can affect gastric pH, which may influence absorption of some drugs, and can also inhibit CYP enzymes.",Monitor for efficacy and adverse effects of tofacitinib.,1,2026-05-13
limitedtofacitinib,rifampicin,Moderate,Decreased efficacy of tofacitinib.,"Rifampicin is a strong CYP3A4 inducer, which can significantly decrease tofacitinib exposure.","Avoid co-administration. If unavoidable, consider increasing the dose of tofacitinib and monitor efficacy.",1,2026-05-13
limitedtofacitinib,prednisolone,Moderate,Increased risk of infection and immunosuppression.,Additive immunosuppressive effects.,Monitor for signs of infection.,1,2026-05-13
limitedtofacitinib,dexamethasone,Moderate,Increased risk of infection and immunosuppression.,Additive immunosuppressive effects.,Monitor for signs of infection.,1,2026-05-13
limitedciticoline,levodopa,Moderate,May decrease the effect of levodopa.,"Citicoline can increase dopamine levels, potentially counteracting the effects of levodopa.",Monitor for reduced efficacy of levodopa. May require dose adjustment.,1,2026-05-13
liver extract,,,,,,1,2026-05-13
pertactin,,,,,,1,2026-05-13
overseasmetronidazole,warfarin,Major,Increased risk of bleeding.,"Metronidazole inhibits the metabolism of warfarin, increasing its anticoagulant effect.",Monitor INR closely; consider alternative antibiotic if possible or adjust warfarin dose.,1,2026-05-13
overseasmetronidazole,phenytoin,Major,Increased phenytoin levels and toxicity.,Metronidazole inhibits the metabolism of phenytoin.,Monitor phenytoin levels and for signs of toxicity; consider alternative antibiotic.,1,2026-05-13
overseasmetronidazole,lithium,Moderate,Increased lithium levels and toxicity.,Metronidazole may impair renal excretion of lithium.,Monitor lithium levels and for signs of toxicity; consider alternative antibiotic.,1,2026-05-13
overseasmetronidazole,diazepam,Moderate,Increased sedation and diazepam levels.,Metronidazole may inhibit the metabolism of diazepam.,Monitor for increased sedation; consider alternative antibiotic.,1,2026-05-13
overseasmetronidazole,alprazolam,Moderate,Increased sedation and alprazolam levels.,Metronidazole may inhibit the metabolism of alprazolam.,Monitor for increased sedation; consider alternative antibiotic.,1,2026-05-13
ai health care llpesomeprazole,,,,,,1,2026-05-13
tiropramide,,,,,,1,2026-05-13
ai health care llprabeprazole,,,,,,1,2026-05-13
limitedluliconazole,,,,,,1,2026-05-13
harteether,,,,,,1,2026-05-13
overseaseterbinafine,rifampicin,Major,Reduced terbinafine levels and efficacy.,Rifampicin is a strong inducer of CYP450 enzymes that metabolize terbinafine.,Monitor for treatment failure; consider higher terbinafine dose or alternative antifungal.,1,2026-05-13
overseaseterbinafine,cimetidine,Moderate,Increased terbinafine levels and potential for toxicity.,Cimetidine inhibits CYP450 enzymes that metabolize terbinafine.,Monitor for signs of terbinafine toxicity; consider alternative H2 blocker or monitor closely.,1,2026-05-13
peppermint powder,cyclosporine,Moderate,Reduced cyclosporine levels and efficacy.,Peppermint may affect the absorption or metabolism of cyclosporine.,Monitor cyclosporine levels and for signs of rejection; avoid concurrent use.,1,2026-05-13
peppermint powder,tacrolimus,Moderate,Reduced tacrolimus levels and efficacy.,Peppermint may affect the absorption or metabolism of tacrolimus.,Monitor tacrolimus levels and for signs of rejection; avoid concurrent use.,1,2026-05-13
pharma-medico,,,,,,1,2026-05-13
overseasarteether,,,,,,1,2026-05-13
astra idl maxlevocetirizine,alprazolam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,diazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,lorazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,clonazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,midazolam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,zolpidem,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with other sedatives.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,tramadol,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,codeine,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,morphine,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
astra idl maxlevocetirizine,amitriptyline,Moderate,Increased sedation and potential anticholinergic effects.,"Levocetirizine has some anticholinergic properties, additive with tricyclic antidepressants.",Monitor for drowsiness and anticholinergic symptoms; use with caution.,1,2026-05-13
mdpldomperidone,ketoconazole,Major,Increased risk of QT prolongation and torsades de pointes.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid concomitant use; monitor ECG and electrolytes if unavoidable.,1,2026-05-13
mdpldomperidone,erythromycin,Major,Increased risk of QT prolongation and torsades de pointes.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid concomitant use; monitor ECG and electrolytes if unavoidable.,1,2026-05-13
mdpldomperidone,clarithromycin,Major,Increased risk of QT prolongation and torsades de pointes.,"Clarithromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid concomitant use; monitor ECG and electrolytes if unavoidable.,1,2026-05-13
mdpldomperidone,itraconazole,Major,Increased risk of QT prolongation and torsades de pointes.,"Itraconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid concomitant use; monitor ECG and electrolytes if unavoidable.,1,2026-05-13
mdpldomperidone,diltiazem,Moderate,Increased risk of QT prolongation.,"Diltiazem can prolong the QT interval, and CYP3A4 inhibitors can increase domperidone levels.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,verapamil,Moderate,Increased risk of QT prolongation.,"Verapamil can prolong the QT interval and inhibit CYP3A4, increasing domperidone levels.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,amiodarone,Moderate,Increased risk of QT prolongation and torsades de pointes.,"Amiodarone prolongs the QT interval, and CYP3A4 inhibitors can increase domperidone levels.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,sotalol,Moderate,Increased risk of QT prolongation and torsades de pointes.,"Sotalol prolongs the QT interval, and CYP3A4 inhibitors can increase domperidone levels.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,quinidine,Moderate,Increased risk of QT prolongation and torsades de pointes.,"Quinidine prolongs the QT interval, and CYP3A4 inhibitors can increase domperidone levels.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,ciprofloxacin,Moderate,Increased risk of QT prolongation.,"Ciprofloxacin can prolong the QT interval, and some CYP3A4 inhibition may occur.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,levofloxacin,Moderate,Increased risk of QT prolongation.,Levofloxacin can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
mdpldomperidone,ondansetron,Moderate,Increased risk of QT prolongation and torsades de pointes.,"Ondansetron can prolong the QT interval, and domperidone can also affect QT.",Use with caution and monitor ECG and electrolytes.,1,2026-05-13
skanttr lifescience llplevocetirizine,alprazolam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,diazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,lorazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,clonazepam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,midazolam,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with benzodiazepines.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,zolpidem,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with other sedatives.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,tramadol,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,codeine,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,morphine,Moderate,Increased sedation and CNS depression.,"Levocetirizine can have mild CNS depressant effects, additive with opioids.",Monitor for excessive sedation; consider dose adjustment of either agent if significant.,1,2026-05-13
skanttr lifescience llplevocetirizine,amitriptyline,Moderate,Increased sedation and potential anticholinergic effects.,"Levocetirizine has some anticholinergic properties, additive with tricyclic antidepressants.",Monitor for drowsiness and anticholinergic symptoms; use with caution.,1,2026-05-13
auxilium medicare life science llpclindamycin,erythromycin,Minor,Potential for additive GI upset.,"Both are macrolide antibiotics, though clindamycin is a lincosamide, and may cause similar side effects.",Monitor for gastrointestinal side effects.,1,2026-05-13
auxilium medicare life science llpclindamycin,azithromycin,Minor,Potential for additive GI upset.,"Both are macrolide antibiotics, though clindamycin is a lincosamide, and may cause similar side effects.",Monitor for gastrointestinal side effects.,1,2026-05-13
auxilium medicare life science llpclindamycin,metronidazole,Minor,"Increased risk of gastrointestinal upset, though not clinically significant.",Both can cause gastrointestinal side effects.,Monitor for gastrointestinal side effects.,1,2026-05-13
auxilium medicare life science llpclindamycin,atorvastatin,Minor,Slightly increased risk of myopathy.,"Some case reports suggest an interaction, but the mechanism is unclear and risk is low.",Monitor for muscle pain or weakness.,1,2026-05-13
auxilium medicare life science llpclindamycin,rosuvastatin,Minor,Slightly increased risk of myopathy.,"Some case reports suggest an interaction, but the mechanism is unclear and risk is low.",Monitor for muscle pain or weakness.,1,2026-05-13
lactobacillus salivarius,,,,,,1,2026-05-13
lactobacillus brevis,,,,,,1,2026-05-13
overseasondansetron,domperidone,Moderate,Increased risk of QT prolongation and torsades de pointes.,Both drugs can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,amiodarone,Moderate,Increased risk of QT prolongation and torsades de pointes.,Amiodarone prolongs the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,sotalol,Moderate,Increased risk of QT prolongation and torsades de pointes.,Sotalol prolongs the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,quinidine,Moderate,Increased risk of QT prolongation and torsades de pointes.,Quinidine prolongs the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,diltiazem,Moderate,Increased risk of QT prolongation.,Diltiazem can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,verapamil,Moderate,Increased risk of QT prolongation.,Verapamil can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,ciprofloxacin,Moderate,Increased risk of QT prolongation.,Ciprofloxacin can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,levofloxacin,Moderate,Increased risk of QT prolongation.,Levofloxacin can prolong the QT interval.,Use with caution and monitor ECG and electrolytes.,1,2026-05-13
overseasondansetron,tramadol,Minor,Potential for increased QT prolongation.,Tramadol can prolong the QT interval.,Use with caution and monitor for any cardiac symptoms.,1,2026-05-13
overseasondansetron,methotrexate,Minor,Theoretical risk of altered methotrexate metabolism.,"Ondansetron is metabolized by CYP enzymes, which could theoretically affect methotrexate clearance.",Monitor methotrexate levels and potential toxicity.,1,2026-05-13
recombinant human growth hormone,insulin,Major,"Reduced glycemic control, potentially leading to hyperglycemia.","Growth hormone has counter-regulatory effects on insulin, increasing blood glucose levels.",Closely monitor blood glucose levels and adjust insulin dosage as needed.,1,2026-05-13
recombinant human growth hormone,metformin,Moderate,"Reduced efficacy of metformin, potentially leading to hyperglycemia.",Growth hormone antagonizes the effects of insulin and can increase glucose production.,Monitor blood glucose levels closely; may require increased metformin dosage or alternative therapies.,1,2026-05-13
recombinant human growth hormone,prednisolone,Moderate,Exacerbation of hyperglycemia.,Both growth hormone and corticosteroids are diabetogenic.,Monitor blood glucose levels closely and adjust antidiabetic therapy.,1,2026-05-13
recombinant human growth hormone,dexamethasone,Moderate,Exacerbation of hyperglycemia.,Both growth hormone and corticosteroids are diabetogenic.,Monitor blood glucose levels closely and adjust antidiabetic therapy.,1,2026-05-13
recombinant human growth hormone,atorvastatin,Minor,Potential for increased blood glucose levels.,Growth hormone can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
recombinant human growth hormone,rosuvastatin,Minor,Potential for increased blood glucose levels.,Growth hormone can affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
astra idl maximipenem,valproate,Major,"Significant reduction in valproate serum levels, leading to loss of seizure control.","Carbapenems can induce intestinal flora that metabolize valproate, reducing its absorption and increasing clearance.","Avoid concomitant use; if unavoidable, monitor valproate levels closely and consider alternative anticonvulsants or dose adjustments.",1,2026-05-13
astra idl maximipenem,amikacin,Moderate,Increased risk of nephrotoxicity.,Both drugs can be nephrotoxic.,Monitor renal function closely.,1,2026-05-13
astra idl maximipenem,gentamicin,Moderate,Increased risk of nephrotoxicity.,Both drugs can be nephrotoxic.,Monitor renal function closely.,1,2026-05-13
astra idl maximipenem,tobramycin,Moderate,Increased risk of nephrotoxicity.,Both drugs can be nephrotoxic.,Monitor renal function closely.,1,2026-05-13
astra idl maximipenem,cyclosporine,Moderate,Reduced cyclosporine levels.,Carbapenems may induce drug-metabolizing enzymes.,Monitor cyclosporine levels and therapeutic effect; may require dose adjustment.,1,2026-05-13
astra idl maximipenem,tacrolimus,Moderate,Reduced tacrolimus levels.,Carbapenems may induce drug-metabolizing enzymes.,Monitor tacrolimus levels and therapeutic effect; may require dose adjustment.,1,2026-05-13
astra idl maximipenem,probenecid,Minor,Increased plasma concentration of imipenem.,"Probenecid competes for renal tubular secretion, increasing the half-life of imipenem.",Monitor for increased side effects of imipenem; dose adjustment may be considered.,1,2026-05-13
calcium hypophosphite,tetracyclines,Major,Reduced absorption of tetracyclines.,"Calcium forms insoluble complexes with tetracyclines in the gastrointestinal tract, decreasing bioavailability.",Separate administration by at least 2 hours; avoid concomitant use if possible.,1,2026-05-13
calcium hypophosphite,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Calcium forms insoluble complexes with fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours; avoid concomitant use if possible.,1,2026-05-13
calcium hypophosphite,levofloxacin,Major,Reduced absorption of levofloxacin.,"Calcium forms insoluble complexes with fluoroquinolones, decreasing bioavailability.",Separate administration by at least 2 hours; avoid concomitant use if possible.,1,2026-05-13
calcium hypophosphite,digoxin,Moderate,Potential for reduced digoxin absorption.,"Calcium can potentially interfere with digoxin absorption, though the clinical significance is debated.",Monitor digoxin levels and therapeutic effect.,1,2026-05-13
calcium hypophosphite,bisphosphonates,Minor,Reduced absorption of bisphosphonates.,"Calcium can form complexes with bisphosphonates, reducing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
benralizumab,,,,,,1,2026-05-13
ultimedixdomperidone,amiodarone,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Avoid concurrent use; monitor ECG if unavoidable.,1,2026-05-13
ultimedixdomperidone,haloperidol,Major,Increased risk of QT prolongation and torsades de pointes.,"Both drugs can prolong the QT interval, leading to additive effects.",Avoid concurrent use; monitor ECG if unavoidable.,1,2026-05-13
ultimedixdomperidone,cisapride,Major,Potentially fatal cardiac arrhythmias.,Both drugs are strong inhibitors of CYP3A4 and can prolong QT interval.,Contraindicated.,1,2026-05-13
ultimedixdomperidone,azithromycin,Moderate,Increased risk of QT prolongation.,Azithromycin can prolong the QT interval and domperidone may also affect cardiac repolarization.,Use with caution; monitor ECG if necessary.,1,2026-05-13
ultimedixdomperidone,fluoxetine,Moderate,Increased risk of QT prolongation.,Fluoxetine can prolong the QT interval and domperidone may also affect cardiac repolarization.,Use with caution; monitor ECG if necessary.,1,2026-05-13
ultimedixdomperidone,sertraline,Moderate,Increased risk of QT prolongation.,Sertraline can prolong the QT interval and domperidone may also affect cardiac repolarization.,Use with caution; monitor ECG if necessary.,1,2026-05-13
ultimedixdomperidone,omeprazole,Minor,Potentially reduced efficacy of omeprazole.,"Domperidone can increase gastric pH, potentially affecting absorption of acid-reducing agents.",Monitor for efficacy of omeprazole.,1,2026-05-13
ultimedixdomperidone,pantoprazole,Minor,Potentially reduced efficacy of pantoprazole.,"Domperidone can increase gastric pH, potentially affecting absorption of acid-reducing agents.",Monitor for efficacy of pantoprazole.,1,2026-05-13
renwick health care llppantoprazole,ketoconazole,Moderate,Decreased absorption of ketoconazole.,"Pantoprazole raises gastric pH, which is required for ketoconazole absorption.",Administer ketoconazole at least 2 hours before pantoprazole.,1,2026-05-13
renwick health care llppantoprazole,itraconazole,Moderate,Decreased absorption of itraconazole.,"Pantoprazole raises gastric pH, which is required for itraconazole absorption.",Administer itraconazole at least 2 hours before pantoprazole.,1,2026-05-13
renwick health care llppantoprazole,warfarin,Minor,Slightly increased risk of bleeding.,"Proton pump inhibitors can inhibit CYP2C9, which metabolizes warfarin, leading to increased warfarin levels.",Monitor INR closely.,1,2026-05-13
renwick health care llppantoprazole,methotrexate,Moderate,"Increased methotrexate levels, potentially leading to toxicity.",Pantoprazole can reduce renal clearance of methotrexate.,Monitor methotrexate levels and for signs of toxicity; consider temporarily discontinuing pantoprazole during high-dose methotrexate therapy.,1,2026-05-13
genralluliconazole,,,,,,1,2026-05-13
mepacrine,quinine,Major,"Increased risk of toxicity, including visual disturbances and CNS effects.",Pharmacodynamic interaction with additive CNS and visual toxicity.,Avoid concurrent use; monitor for adverse effects.,1,2026-05-13
mepacrine,chloroquine,Major,"Increased risk of toxicity, including visual disturbances and CNS effects.",Pharmacodynamic interaction with additive CNS and visual toxicity.,Avoid concurrent use; monitor for adverse effects.,1,2026-05-13
mepacrine,rifampicin,Moderate,Reduced efficacy of mepacrine.,Rifampicin induces CYP enzymes that metabolize mepacrine.,Consider increasing mepacrine dose or using an alternative.,1,2026-05-13
mepacrine,isoniazid,Minor,Increased risk of peripheral neuropathy.,Both drugs can potentially cause peripheral neuropathy.,Monitor for signs of peripheral neuropathy.,1,2026-05-13
limiteddiclofenac diethylamine,warfarin,Major,Increased risk of gastrointestinal bleeding and hemorrhagic events.,"NSAIDs increase the risk of bleeding, and when combined with warfarin, this risk is significantly elevated.",Use with extreme caution; monitor for signs of bleeding and INR. Consider alternative analgesic.,1,2026-05-13
limiteddiclofenac diethylamine,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Both drugs have antiplatelet effects and can irritate the gastric mucosa.,Use with caution; monitor for signs of gastrointestinal bleeding.,1,2026-05-13
limiteddiclofenac diethylamine,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal impairment.,Both are NSAIDs and can cause GI irritation and reduce renal blood flow.,Use with caution; monitor for signs of GI bleeding and renal function.,1,2026-05-13
limiteddiclofenac diethylamine,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for vasodilation and renal perfusion, counteracting the effects of losartan.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
limiteddiclofenac diethylamine,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for vasodilation and renal perfusion, counteracting the effects of ramipril.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
limiteddiclofenac diethylamine,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,NSAIDs can inhibit the natriuretic and diuretic effects of furosemide by reducing renal blood flow.,Monitor for adequate diuresis and blood pressure; monitor renal function.,1,2026-05-13
limiteddiclofenac diethylamine,spironolactone,Moderate,Reduced diuretic effect; increased risk of hyperkalemia.,NSAIDs can impair renal function and reduce the excretion of potassium.,Monitor for adequate diuresis and potassium levels.,1,2026-05-13
limiteddiclofenac diethylamine,atorvastatin,Minor,Slightly increased risk of muscle pain (myopathy).,"NSAIDs can sometimes be associated with muscle pain, and combining with statins might increase this risk.",Monitor for muscle pain.,1,2026-05-13
limiteddiclofenac diethylamine,rosuvastatin,Minor,Slightly increased risk of muscle pain (myopathy).,"NSAIDs can sometimes be associated with muscle pain, and combining with statins might increase this risk.",Monitor for muscle pain.,1,2026-05-13
flumethrin,,,,,,1,2026-05-13
s pharmaphenylephrine,monoamine oxidase inhibitors (maois) including isoniazid and rifampicin,Major,Hypertensive crisis.,"MAOIs inhibit the metabolism of phenylephrine, leading to excessive vasoconstriction and a rapid increase in blood pressure.",Contraindicated. Avoid use for at least 14 days after discontinuing MAOI.,1,2026-05-13
s pharmaphenylephrine,atenolol,Moderate,Reduced antihypertensive effect.,"Phenylephrine is a vasoconstrictor and can increase blood pressure, opposing the effect of atenolol.",Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
s pharmaphenylephrine,metoprolol,Moderate,Reduced antihypertensive effect.,"Phenylephrine is a vasoconstrictor and can increase blood pressure, opposing the effect of metoprolol.",Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
s pharmaphenylephrine,losartan,Moderate,Reduced antihypertensive effect.,"Phenylephrine is a vasoconstrictor and can increase blood pressure, opposing the effect of losartan.",Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
s pharmaphenylephrine,ramipril,Moderate,Reduced antihypertensive effect.,"Phenylephrine is a vasoconstrictor and can increase blood pressure, opposing the effect of ramipril.",Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
s pharmaphenylephrine,"tricyclic antidepressants (e.g., amitriptyline)",Moderate,"Potentiation of pressor response, leading to increased blood pressure.","Tricyclic antidepressants can inhibit the reuptake of norepinephrine, thus potentiating the effects of phenylephrine.",Use with caution; monitor blood pressure.,1,2026-05-13
cetalkonium chloride,,,,,,1,2026-05-13
phosphorus,calcium salts,Major,"Formation of insoluble calcium phosphate, leading to reduced absorption of both.",Direct chemical interaction forming an insoluble precipitate in the gastrointestinal tract.,Separate administration by at least 2 hours; monitor serum calcium and phosphate levels.,1,2026-05-13
phosphorus,magnesium salts,Moderate,"Formation of magnesium phosphate, potentially reducing absorption.",Chemical interaction forming an insoluble precipitate.,Separate administration; monitor serum magnesium and phosphate levels.,1,2026-05-13
phosphorus,antacids (containing aluminum or magnesium),Moderate,Reduced absorption of phosphate; potential for aluminum or magnesium toxicity.,"Antacids can bind to phosphate, forming insoluble compounds and reducing its absorption. They also increase aluminum or magnesium absorption.","Separate administration by at least 2 hours; monitor serum phosphate, calcium, and magnesium levels.",1,2026-05-13
phosphorus,iron supplements,Minor,Potentially reduced absorption of both.,"Phosphate can bind to iron in the GI tract, reducing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
overseasisoniazid,rifampicin,Major,Increased risk of hepatotoxicity.,"Both drugs can cause liver damage, and their combined use potentiates this risk.",Monitor liver function tests closely; consider alternative if liver dysfunction develops.,1,2026-05-13
overseasisoniazid,phenytoin,Major,Increased phenytoin levels and toxicity.,Isoniazid inhibits the metabolism of phenytoin via CYP2C9 and CYP2C19.,Monitor phenytoin levels; reduce phenytoin dose if necessary.,1,2026-05-13
overseasisoniazid,warfarin,Moderate,Reduced anticoagulant effect of warfarin.,Isoniazid can induce the metabolism of warfarin via CYP2C9.,Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
overseasisoniazid,carbamazepine,Moderate,Increased carbamazepine levels and toxicity.,Isoniazid inhibits the metabolism of carbamazepine.,Monitor carbamazepine levels; reduce carbamazepine dose if necessary.,1,2026-05-13
overseasisoniazid,atenolol,Minor,Potential for altered atenolol pharmacokinetics.,Isoniazid may affect the metabolism or excretion of atenolol.,Monitor blood pressure and heart rate.,1,2026-05-13
overseasisoniazid,metoprolol,Minor,Potential for altered metoprolol pharmacokinetics.,Isoniazid may affect the metabolism or excretion of metoprolol.,Monitor blood pressure and heart rate.,1,2026-05-13
aster zenith bioscience llppiperacillin,probenecid,Moderate,Decreased efficacy of piperacillin.,Probenecid competes for renal tubular secretion of piperacillin.,Avoid concurrent use if possible; monitor for treatment failure.,1,2026-05-13
thiamine nitrate,,,,,,1,2026-05-13
zuclopenthixol,alprazolam,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,diazepam,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,lorazepam,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,clonazepam,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,midazolam,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,zolpidem,Major,Increased sedation and CNS depression.,Both drugs are CNS depressants.,"Avoid concurrent use; if necessary, use with extreme caution and monitor for sedation.",1,2026-05-13
zuclopenthixol,amitriptyline,Moderate,Increased risk of anticholinergic side effects and sedation.,Additive anticholinergic and sedative effects.,Monitor for side effects; use with caution.,1,2026-05-13
zuclopenthixol,tramadol,Moderate,Increased sedation and CNS depression.,Both drugs can cause sedation and CNS depression.,Monitor for excessive sedation.,1,2026-05-13
zuclopenthixol,codeine,Moderate,Increased sedation and CNS depression.,Both drugs can cause sedation and CNS depression.,Monitor for excessive sedation.,1,2026-05-13
zuclopenthixol,morphine,Moderate,Increased sedation and CNS depression.,Both drugs can cause sedation and CNS depression.,Monitor for excessive sedation.,1,2026-05-13
zuclopenthixol,atenolol,Minor,May mask symptoms of hypoglycemia.,Beta-blockers can mask the tachycardia associated with hypoglycemia.,Monitor blood glucose levels closely in diabetic patients.,1,2026-05-13
zuclopenthixol,metoprolol,Minor,May mask symptoms of hypoglycemia.,Beta-blockers can mask the tachycardia associated with hypoglycemia.,Monitor blood glucose levels closely in diabetic patients.,1,2026-05-13
cellbond exim,,,,,,1,2026-05-13
codergocrine mesylate,,,,,,1,2026-05-13
albuterol,atenolol,Moderate,Reduced bronchodilator effect of albuterol; increased risk of bronchospasm.,Beta-blockers can antagonize the beta-2 agonist effects of albuterol.,Use with caution; consider a cardioselective beta-blocker if necessary. Monitor respiratory status.,1,2026-05-13
albuterol,metoprolol,Moderate,Reduced bronchodilator effect of albuterol; increased risk of bronchospasm.,Beta-blockers can antagonize the beta-2 agonist effects of albuterol.,Use with caution; consider a cardioselective beta-blocker if necessary. Monitor respiratory status.,1,2026-05-13
albuterol,warfarin,Minor,Potential for altered warfarin efficacy.,Beta-agonists may affect warfarin metabolism or platelet aggregation.,Monitor INR closely.,1,2026-05-13
potassium glycerophosphate,spironolactone,Moderate,Increased risk of hyperkalemia.,Spironolactone is a potassium-sparing diuretic; potassium supplements increase potassium levels.,Monitor serum potassium levels closely; adjust doses as needed.,1,2026-05-13
potassium glycerophosphate,enalapril,Moderate,Increased risk of hyperkalemia.,ACE inhibitors can increase serum potassium; potassium supplements increase potassium levels.,Monitor serum potassium levels closely; adjust doses as needed.,1,2026-05-13
potassium glycerophosphate,losartan,Moderate,Increased risk of hyperkalemia.,ARBs can increase serum potassium; potassium supplements increase potassium levels.,Monitor serum potassium levels closely; adjust doses as needed.,1,2026-05-13
potassium glycerophosphate,ramipril,Moderate,Increased risk of hyperkalemia.,ACE inhibitors can increase serum potassium; potassium supplements increase potassium levels.,Monitor serum potassium levels closely; adjust doses as needed.,1,2026-05-13
glial life science llpquetiapine,diazepam,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,alprazolam,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,lorazepam,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,clonazepam,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,midazolam,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,zolpidem,Major,Increased sedation and orthostatic hypotension.,Additive CNS depressant effects and potential for additive hypotension.,Use with caution; monitor for excessive sedation and blood pressure changes.,1,2026-05-13
glial life science llpquetiapine,amitriptyline,Moderate,Increased risk of anticholinergic side effects and sedation.,Additive anticholinergic and sedative effects.,Monitor for side effects; use with caution.,1,2026-05-13
glial life science llpquetiapine,atenolol,Moderate,Increased risk of hypotension and bradycardia.,Additive hypotensive and bradycardic effects.,Monitor blood pressure and heart rate closely.,1,2026-05-13
glial life science llpquetiapine,metoprolol,Moderate,Increased risk of hypotension and bradycardia.,Additive hypotensive and bradycardic effects.,Monitor blood pressure and heart rate closely.,1,2026-05-13
glial life science llpquetiapine,tramadol,Minor,Increased sedation.,Additive sedative effects.,Monitor for excessive sedation.,1,2026-05-13
glial life science llpquetiapine,codeine,Minor,Increased sedation.,Additive sedative effects.,Monitor for excessive sedation.,1,2026-05-13
glial life science llpquetiapine,morphine,Minor,Increased sedation.,Additive sedative effects.,Monitor for excessive sedation.,1,2026-05-13
overseaslisinopril,spironolactone,Major,Increased risk of severe hyperkalemia.,Both drugs increase serum potassium; combined use is a potent risk factor for hyperkalemia.,"Avoid concurrent use; if necessary, monitor serum potassium very closely and titrate carefully.",1,2026-05-13
overseaslisinopril,potassium glycerophosphate,Moderate,Increased risk of hyperkalemia.,ACE inhibitors can increase serum potassium; potassium supplements increase potassium levels.,Monitor serum potassium levels closely; adjust doses as needed.,1,2026-05-13
overseaslisinopril,ibuprofen,Moderate,Reduced antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, reducing the antihypertensive effect of ACE inhibitors and potentially causing renal damage.",Monitor blood pressure and renal function; use NSAIDs with caution and consider alternative analgesics.,1,2026-05-13
overseaslisinopril,aspirin,Moderate,Reduced antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, reducing the antihypertensive effect of ACE inhibitors and potentially causing renal damage.",Monitor blood pressure and renal function; use NSAIDs with caution and consider alternative analgesics.,1,2026-05-13
overseaslisinopril,prednisolone,Minor,May reduce the effectiveness of lisinopril.,"Corticosteroids can cause sodium and water retention, counteracting the effects of ACE inhibitors.",Monitor blood pressure closely; adjust lisinopril dose if necessary.,1,2026-05-13
overseaslisinopril,dexamethasone,Minor,May reduce the effectiveness of lisinopril.,"Corticosteroids can cause sodium and water retention, counteracting the effects of ACE inhibitors.",Monitor blood pressure closely; adjust lisinopril dose if necessary.,1,2026-05-13
overseasrifampicin,warfarin,Major,"Reduced anticoagulant effect, increased risk of thrombosis.","Rifampicin is a potent enzyme inducer of CYP2C9, increasing warfarin metabolism.",Monitor INR closely and increase warfarin dose as needed; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,metformin,Moderate,Reduced glycemic control.,Rifampicin can induce hepatic enzymes leading to increased metformin clearance.,Monitor blood glucose more frequently and adjust metformin dose if necessary.,1,2026-05-13
overseasrifampicin,atorvastatin,Major,"Reduced efficacy of statin, increased risk of cardiovascular events.","Rifampicin induces CYP3A4, increasing atorvastatin metabolism.",Monitor lipid levels and consider alternative statin or antibiotic.,1,2026-05-13
overseasrifampicin,rosuvastatin,Moderate,Reduced efficacy of statin.,"Rifampicin can induce CYP enzymes, potentially affecting rosuvastatin metabolism.",Monitor lipid levels and consider alternative statin or antibiotic.,1,2026-05-13
overseasrifampicin,amlodipine,Moderate,Reduced antihypertensive effect.,"Rifampicin can induce CYP3A4, increasing amlodipine metabolism.",Monitor blood pressure and adjust amlodipine dose if needed.,1,2026-05-13
overseasrifampicin,losartan,Moderate,Reduced antihypertensive effect.,"Rifampicin can induce CYP enzymes, potentially affecting losartan metabolism.",Monitor blood pressure and adjust losartan dose if needed.,1,2026-05-13
overseasrifampicin,omeprazole,Moderate,Reduced efficacy of proton pump inhibitor.,"Rifampicin induces CYP2C19, increasing omeprazole metabolism.",Monitor for symptoms of acid reflux and consider dose increase or alternative PPI.,1,2026-05-13
overseasrifampicin,pantoprazole,Moderate,Reduced efficacy of proton pump inhibitor.,"Rifampicin can induce CYP enzymes, potentially affecting pantoprazole metabolism.",Monitor for symptoms of acid reflux and consider dose increase or alternative PPI.,1,2026-05-13
overseasrifampicin,prednisolone,Major,"Reduced efficacy of corticosteroid, adrenal insufficiency upon withdrawal.","Rifampicin is a potent inducer of CYP3A4, increasing prednisolone metabolism.",Monitor for signs of inflammation and increase prednisolone dose; taper slowly upon discontinuation of rifampicin.,1,2026-05-13
overseasrifampicin,dexamethasone,Major,"Reduced efficacy of corticosteroid, adrenal insufficiency upon withdrawal.","Rifampicin is a potent inducer of CYP3A4, increasing dexamethasone metabolism.",Monitor for signs of inflammation and increase dexamethasone dose; taper slowly upon discontinuation of rifampicin.,1,2026-05-13
overseasrifampicin,insulin,Moderate,Reduced glycemic control.,Rifampicin can affect glucose metabolism.,Monitor blood glucose more frequently and adjust insulin dose if necessary.,1,2026-05-13
overseasrifampicin,digoxin,Moderate,"Reduced efficacy of digoxin, potential for therapeutic failure.","Rifampicin can induce P-glycoprotein, increasing digoxin efflux.","Monitor digoxin levels and clinical response, adjust dose if needed.",1,2026-05-13
overseasrifampicin,furosemide,Moderate,Reduced diuretic effect.,"Rifampicin can induce hepatic enzymes, increasing furosemide metabolism.",Monitor for signs of fluid overload and adjust furosemide dose if needed.,1,2026-05-13
overseasrifampicin,spironolactone,Moderate,Reduced diuretic effect.,"Rifampicin can induce hepatic enzymes, increasing spironolactone metabolism.",Monitor for signs of fluid overload and adjust spironolactone dose if needed.,1,2026-05-13
overseasrifampicin,atenolol,Moderate,Reduced antihypertensive effect.,"Rifampicin can induce CYP enzymes, potentially affecting atenolol metabolism.",Monitor blood pressure and adjust atenolol dose if needed.,1,2026-05-13
overseasrifampicin,metoprolol,Moderate,Reduced antihypertensive effect.,"Rifampicin can induce CYP2D6, increasing metoprolol metabolism.",Monitor blood pressure and adjust metoprolol dose if needed.,1,2026-05-13
overseasrifampicin,ramipril,Moderate,Reduced antihypertensive effect.,"Rifampicin can induce CYP enzymes, potentially affecting ramipril metabolism.",Monitor blood pressure and adjust ramipril dose if needed.,1,2026-05-13
overseasrifampicin,clopidogrel,Major,"Reduced antiplatelet effect, increased risk of thrombosis.","Rifampicin is a potent inducer of CYP2C19, which is crucial for clopidogrel activation.",Monitor for signs of thrombotic events and consider alternative antiplatelet agent.,1,2026-05-13
overseasrifampicin,gabapentin,Minor,Potentially reduced efficacy.,Rifampicin may alter gabapentin pharmacokinetics.,Monitor for seizure breakthrough or neuropathic pain recurrence.,1,2026-05-13
overseasrifampicin,alprazolam,Major,Reduced anxiolytic and sedative effects.,"Rifampicin induces CYP3A4, increasing alprazolam metabolism.",Monitor for breakthrough anxiety or insomnia and consider alternative or increased dose.,1,2026-05-13
overseasrifampicin,diazepam,Major,Reduced anxiolytic and sedative effects.,"Rifampicin induces CYP3A4, increasing diazepam metabolism.",Monitor for breakthrough anxiety or insomnia and consider alternative or increased dose.,1,2026-05-13
overseasrifampicin,sertraline,Moderate,Reduced antidepressant effect.,"Rifampicin can induce CYP enzymes, potentially affecting sertraline metabolism.",Monitor for signs of depression relapse and consider dose adjustment or alternative antidepressant.,1,2026-05-13
overseasrifampicin,fluoxetine,Moderate,Reduced antidepressant effect.,"Rifampicin can induce CYP enzymes, potentially affecting fluoxetine metabolism.",Monitor for signs of depression relapse and consider dose adjustment or alternative antidepressant.,1,2026-05-13
overseasrifampicin,amitriptyline,Moderate,Reduced antidepressant effect.,"Rifampicin can induce CYP2D6 and CYP3A4, increasing amitriptyline metabolism.",Monitor for signs of depression relapse and consider dose adjustment or alternative antidepressant.,1,2026-05-13
overseasrifampicin,tramadol,Moderate,Reduced analgesic effect.,Rifampicin may increase tramadol metabolism.,Monitor pain control and consider dose adjustment or alternative analgesic.,1,2026-05-13
overseasrifampicin,codeine,Moderate,Reduced analgesic effect.,Rifampicin may affect codeine metabolism.,Monitor pain control and consider dose adjustment or alternative analgesic.,1,2026-05-13
overseasrifampicin,morphine,Moderate,Reduced analgesic effect.,Rifampicin may affect morphine metabolism.,Monitor pain control and consider dose adjustment or alternative analgesic.,1,2026-05-13
overseasrifampicin,phenytoin,Major,"Reduced phenytoin levels, risk of seizures.","Rifampicin is a potent inducer of CYP2C9 and CYP2C19, increasing phenytoin metabolism.",Monitor phenytoin levels closely and adjust dose; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,valproate,Moderate,"Reduced valproate levels, risk of seizure breakthrough.","Rifampicin can induce hepatic enzymes, increasing valproate metabolism.",Monitor valproate levels and seizure control; adjust dose if necessary.,1,2026-05-13
overseasrifampicin,carbamazepine,Major,"Reduced carbamazepine levels, risk of seizure breakthrough.","Rifampicin is a potent inducer of CYP3A4, increasing carbamazepine metabolism.",Monitor carbamazepine levels closely and adjust dose; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,rifampicin,No significant interaction,,,,1,2026-05-13
overseasrifampicin,isoniazid,Moderate,Increased risk of hepatotoxicity.,Both drugs can cause hepatotoxicity; co-administration may potentiate this risk.,Monitor liver function tests closely; use with caution.,1,2026-05-13
overseasrifampicin,ethambutol,No significant interaction,,,,1,2026-05-13
overseasrifampicin,hydroxychloroquine,Moderate,Potentially reduced efficacy of hydroxychloroquine.,Rifampicin may induce hepatic enzymes affecting hydroxychloroquine metabolism.,Monitor for signs of disease exacerbation and consider dose adjustment.,1,2026-05-13
overseasrifampicin,cyclosporine,Major,"Significantly reduced cyclosporine levels, risk of organ rejection.","Rifampicin is a potent inducer of CYP3A4 and P-glycoprotein, increasing cyclosporine metabolism and efflux.",Monitor cyclosporine levels very closely and significantly increase dose; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,tacrolimus,Major,"Significantly reduced tacrolimus levels, risk of organ rejection.","Rifampicin is a potent inducer of CYP3A4 and P-glycoprotein, increasing tacrolimus metabolism and efflux.",Monitor tacrolimus levels very closely and significantly increase dose; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,lithium,Moderate,Potentially reduced lithium levels.,Rifampicin may affect lithium pharmacokinetics.,Monitor lithium levels and clinical response; adjust dose if needed.,1,2026-05-13
overseasrifampicin,haloperidol,Moderate,Reduced efficacy of haloperidol.,"Rifampicin can induce CYP enzymes, potentially affecting haloperidol metabolism.",Monitor for antipsychotic breakthrough and consider dose adjustment.,1,2026-05-13
overseasrifampicin,clozapine,Major,"Reduced clozapine levels, risk of relapse of psychotic symptoms.","Rifampicin is a potent inducer of CYP1A2 and CYP3A4, increasing clozapine metabolism.",Monitor clozapine levels closely and increase dose significantly; consider alternative antibiotic if possible.,1,2026-05-13
overseasrifampicin,olanzapine,Moderate,"Reduced olanzapine levels, risk of relapse of psychotic symptoms.",Rifampicin may induce CYP enzymes affecting olanzapine metabolism.,Monitor for antipsychotic breakthrough and consider dose adjustment.,1,2026-05-13
overseasrifampicin,lorazepam,Major,Reduced anxiolytic and sedative effects.,"Rifampicin induces CYP3A4, increasing lorazepam metabolism.",Monitor for breakthrough anxiety or insomnia and consider alternative or increased dose.,1,2026-05-13
overseasrifampicin,clonazepam,Major,Reduced anxiolytic and sedative effects.,"Rifampicin induces CYP3A4, increasing clonazepam metabolism.",Monitor for breakthrough anxiety or insomnia and consider alternative or increased dose.,1,2026-05-13
overseasrifampicin,midazolam,Major,Reduced sedative effects.,"Rifampicin is a potent inducer of CYP3A4, significantly increasing midazolam metabolism.",Avoid concomitant use; monitor for reduced sedation if unavoidable.,1,2026-05-13
overseasrifampicin,zolpidem,Major,Reduced hypnotic effect.,"Rifampicin induces CYP3A4, increasing zolpidem metabolism.",Monitor for insomnia and consider alternative or increased dose.,1,2026-05-13
overseasdiphenhydramine,tramadol,Moderate,"Increased sedation, confusion, and risk of serotonin syndrome.",Both agents have anticholinergic effects and can cause CNS depression; diphenhydramine may inhibit tramadol metabolism.,"Use with caution, monitor for CNS side effects and sedation.",1,2026-05-13
overseasdiphenhydramine,codeine,Moderate,Increased sedation and CNS depression.,Both agents can cause CNS depression; additive effects.,"Use with caution, monitor for excessive sedation.",1,2026-05-13
overseasdiphenhydramine,morphine,Moderate,Increased sedation and CNS depression.,Both agents can cause CNS depression; additive effects.,"Use with caution, monitor for excessive sedation.",1,2026-05-13
overseasdiphenhydramine,alprazolam,Major,"Profound sedation, respiratory depression, cognitive impairment.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for sedation and respiratory depression.,1,2026-05-13
overseasdiphenhydramine,diazepam,Major,"Profound sedation, respiratory depression, cognitive impairment.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for sedation and respiratory depression.,1,2026-05-13
overseasdiphenhydramine,lorazepam,Major,"Profound sedation, respiratory depression, cognitive impairment.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for sedation and respiratory depression.,1,2026-05-13
overseasdiphenhydramine,clonazepam,Major,"Profound sedation, respiratory depression, cognitive impairment.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for sedation and respiratory depression.,1,2026-05-13
overseasdiphenhydramine,midazolam,Major,"Profound sedation, respiratory depression, cognitive impairment.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for sedation and respiratory depression.,1,2026-05-13
overseasdiphenhydramine,zolpidem,Major,"Profound sedation, impaired coordination, confusion.",Additive CNS depressant effects.,Avoid concomitant use; monitor closely for excessive sedation and cognitive impairment.,1,2026-05-13
overseasdiphenhydramine,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), increased sedation.",Both drugs have anticholinergic properties; additive effects.,Monitor for anticholinergic side effects and increased sedation.,1,2026-05-13
overseasdiphenhydramine,metronidazole,Minor,Potential for increased CNS side effects.,Anticholinergic effects of diphenhydramine may be potentiated.,Monitor for confusion or dizziness.,1,2026-05-13
ozagrel,aspirin,Moderate,"Increased risk of bleeding, especially gastrointestinal.",Both are antiplatelet agents; additive effect.,Use with caution and monitor for signs of bleeding.,1,2026-05-13
ozagrel,warfarin,Major,Significantly increased risk of bleeding.,"Ozogrel is an antiplatelet agent, and warfarin is an anticoagulant; combined effect greatly increases bleeding risk.","Avoid concomitant use; if unavoidable, monitor INR and bleeding closely.",1,2026-05-13
ozagrel,clopidogrel,Major,Increased risk of bleeding.,Both are antiplatelet agents; additive effect.,"Avoid concomitant use; if unavoidable, monitor for bleeding.",1,2026-05-13
currant life science llpdomperidone,ketoconazole,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Ketoconazole is a strong CYP3A4 inhibitor, increasing domperidone levels.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,itraconazole,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Itraconazole is a strong CYP3A4 inhibitor, increasing domperidone levels.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,clarithromycin,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Clarithromycin is a moderate CYP3A4 inhibitor, increasing domperidone levels.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,erythromycin,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Erythromycin is a moderate CYP3A4 inhibitor, increasing domperidone levels.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,verapamil,Moderate,Increased risk of QT prolongation.,"Verapamil may inhibit CYP3A4, increasing domperidone levels.",Use with caution and monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,quinidine,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,amiodarone,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,sotalol,Major,Increased risk of QT prolongation and Torsades de Pointes.,Both drugs prolong the QT interval.,Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
currant life science llpdomperidone,omeprazole,Moderate,Potentially reduced efficacy of domperidone.,"Omeprazole increases gastric pH, which may decrease absorption of domperidone.",Monitor for efficacy and consider administering domperidone before meals.,1,2026-05-13
currant life science llpdomperidone,pantoprazole,Moderate,Potentially reduced efficacy of domperidone.,"Pantoprazole increases gastric pH, which may decrease absorption of domperidone.",Monitor for efficacy and consider administering domperidone before meals.,1,2026-05-13
limitedorlistat,warfarin,Moderate,"Reduced anticoagulant effect of warfarin, increasing risk of thrombosis.","Orlistat can reduce the absorption of vitamin K, which is essential for warfarin's anticoagulant action.",Monitor INR closely and adjust warfarin dose as needed; ensure adequate vitamin K intake.,1,2026-05-13
limitedorlistat,cyclosporine,Moderate,Reduced absorption and blood levels of cyclosporine.,Orlistat can reduce the absorption of fat-soluble vitamins and potentially other lipophilic drugs.,Monitor cyclosporine levels and clinical response; separate administration by at least 2 hours.,1,2026-05-13
limitedorlistat,metformin,Minor,Potential for additive gastrointestinal side effects (diarrhea).,Both can cause gastrointestinal disturbances.,Monitor for gastrointestinal side effects.,1,2026-05-13
limitedorlistat,atenolol,Minor,Potential for reduced absorption of atenolol.,Orlistat's effect on fat absorption may influence absorption of other oral medications.,Monitor for blood pressure control.,1,2026-05-13
limitedorlistat,amlodipine,Minor,Potential for reduced absorption of amlodipine.,Orlistat's effect on fat absorption may influence absorption of other oral medications.,Monitor for blood pressure control.,1,2026-05-13
limitedorlistat,losartan,Minor,Potential for reduced absorption of losartan.,Orlistat's effect on fat absorption may influence absorption of other oral medications.,Monitor for blood pressure control.,1,2026-05-13
limitedorlistat,ramipril,Minor,Potential for reduced absorption of ramipril.,Orlistat's effect on fat absorption may influence absorption of other oral medications.,Monitor for blood pressure control.,1,2026-05-13
piribedil,ciprofloxacin,Major,"Increased risk of adverse effects including nausea, vomiting, and neurotoxicity.","Ciprofloxacin is a CYP1A2 inhibitor, increasing piribedil levels.",Avoid concomitant use; monitor for adverse effects.,1,2026-05-13
piribedil,diltiazem,Moderate,Increased risk of adverse effects.,"Diltiazem is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,verapamil,Moderate,Increased risk of adverse effects.,"Verapamil is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,omeprazole,Moderate,Increased risk of adverse effects.,"Omeprazole is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,metoprolol,Moderate,Increased risk of adverse effects.,"Metoprolol is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,clozapine,Major,"Increased risk of adverse effects including sedation, orthostatic hypotension, and seizures.","Clozapine is metabolized by CYP1A2; piribedil can inhibit this enzyme, increasing clozapine levels.",Avoid concomitant use; monitor closely for adverse effects if unavoidable.,1,2026-05-13
piribedil,sertraline,Moderate,Increased risk of adverse effects.,"Sertraline is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,fluoxetine,Moderate,Increased risk of adverse effects.,"Fluoxetine is a CYP1A2 inhibitor, increasing piribedil levels.",Use with caution and monitor for adverse effects.,1,2026-05-13
piribedil,fluvoxamine,Major,Significantly increased risk of piribedil toxicity.,"Fluvoxamine is a potent CYP1A2 inhibitor, significantly increasing piribedil levels.",Avoid concomitant use.,1,2026-05-13
overseaslevosalbutamol,atenolol,Moderate,"Reduced bronchodilator effect, potential for increased bronchospasm.",Beta-blockers (especially non-selective ones like atenolol) can antagonize the effects of beta-agonists.,Use with caution; monitor respiratory status and consider a cardioselective beta-blocker if necessary.,1,2026-05-13
overseaslevosalbutamol,metoprolol,Moderate,"Reduced bronchodilator effect, potential for increased bronchospasm.",Beta-blockers (especially non-selective ones like metoprolol) can antagonize the effects of beta-agonists.,Use with caution; monitor respiratory status and consider a cardioselective beta-blocker if necessary.,1,2026-05-13
overseaslevosalbutamol,digoxin,Moderate,"Increased risk of hypokalemia, which can potentiate digoxin toxicity.","Beta-agonists can cause hypokalemia, and low potassium increases digoxin sensitivity.",Monitor potassium levels and ECG for signs of digoxin toxicity.,1,2026-05-13
overseaslevosalbutamol,furosemide,Moderate,Increased risk of hypokalemia.,Both levosalbutamol and furosemide can cause hypokalemia.,Monitor potassium levels.,1,2026-05-13
overseaslevosalbutamol,spironolactone,Minor,"Potential for additive diuretic effect, possible electrolyte imbalance.",Both can affect fluid and electrolyte balance.,Monitor electrolytes.,1,2026-05-13
overseaslevosalbutamol,tramadol,Minor,Potential for decreased efficacy of levosalbutamol due to CNS effects of tramadol.,Rare CNS effects of tramadol might theoretically interfere.,Monitor bronchodilator response.,1,2026-05-13
overseaslevosalbutamol,amitriptyline,Moderate,Increased risk of cardiac arrhythmias and tachycardia.,Tricyclic antidepressants can potentiate the cardiac effects of beta-agonists.,Use with caution; monitor heart rate and rhythm.,1,2026-05-13
aara life sciences,,,,,,1,2026-05-13
overseaschlorhexidine gluconate,alcohols,Minor,Precipitation and reduced efficacy.,Chlorhexidine can precipitate in the presence of high concentrations of alcohol.,Avoid mixing directly; rinse thoroughly if using alcohol-based hand sanitizers after chlorhexidine.,1,2026-05-13
overseaschlorhexidine gluconate,soaps,Minor,Inactivation of chlorhexidine.,"Soaps are anionic and can bind to chlorhexidine, reducing its antimicrobial activity.",Rinse thoroughly to remove soap residue before applying chlorhexidine.,1,2026-05-13
overseaschlorhexidine gluconate,iodine,Moderate,Reduced antimicrobial activity of both agents.,Iodine can inactivate chlorhexidine.,Avoid concomitant use in the same application site; allow adequate time between applications.,1,2026-05-13
overseaschlorhexidine gluconate,hypochlorite,Moderate,"Formation of precipitate (p-chloroaniline), potential toxicity.",Chlorhexidine reacts with hypochlorite to form a toxic precipitate.,Avoid mixing; thoroughly rinse surfaces before using one after the other.,1,2026-05-13
tetanus immunoglobulin,immunosuppressants,Moderate,Reduced immune response.,Immunosuppressive drugs can interfere with the immune response to the immunoglobulin.,Consider higher doses or alternative strategies if concomitant use is necessary.,1,2026-05-13
tetanus immunoglobulin,corticosteroids,Moderate,Reduced immune response.,"Corticosteroids can suppress the immune system, potentially reducing the efficacy of tetanus immunoglobulin.",Use with caution; monitor immune status if high-dose or long-term corticosteroid therapy is used.,1,2026-05-13
tetanus immunoglobulin,live vaccines,Moderate,Reduced efficacy of live vaccines.,"Antibodies in tetanus immunoglobulin can neutralize live attenuated virus in vaccines, decreasing their immunogenicity.",Delay live vaccine administration for at least 3 months after administration of tetanus immunoglobulin.,1,2026-05-13
ultimedixamoxycillin,warfarin,Moderate,Increased risk of bleeding.,"Amoxicillin may alter gut flora, reducing vitamin K production.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
ultimedixamoxycillin,methotrexate,Moderate,Increased methotrexate toxicity.,Amoxicillin can decrease renal clearance of methotrexate.,Monitor methotrexate levels and for signs of toxicity; consider alternative antibiotic.,1,2026-05-13
limitedaztreonam,,,,,,1,2026-05-13
overseaslorazepam,tramadol,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use caution; monitor for sedation and respiratory status.,1,2026-05-13
overseaslorazepam,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use caution; monitor for sedation and respiratory status.,1,2026-05-13
overseaslorazepam,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Use caution; monitor for sedation and respiratory status.,1,2026-05-13
overseaslorazepam,diazepam,Major,"Profound sedation, respiratory depression, amnesia.",Potentiation of GABAergic effects.,Avoid concurrent use; monitor closely if unavoidable.,1,2026-05-13
overseaslorazepam,alprazolam,Major,"Profound sedation, respiratory depression, amnesia.",Potentiation of GABAergic effects.,Avoid concurrent use; monitor closely if unavoidable.,1,2026-05-13
overseaslorazepam,clonazepam,Major,"Profound sedation, respiratory depression, amnesia.",Potentiation of GABAergic effects.,Avoid concurrent use; monitor closely if unavoidable.,1,2026-05-13
overseaslorazepam,midazolam,Major,"Profound sedation, respiratory depression, amnesia.",Potentiation of GABAergic effects.,Avoid concurrent use; monitor closely if unavoidable.,1,2026-05-13
overseaslorazepam,zolpidem,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
overseaslorazepam,amitriptyline,Moderate,"Increased sedation, anticholinergic effects, dizziness.",Additive CNS depressant effects.,Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
overseaslorazepam,haloperidol,Moderate,"Increased sedation, extrapyramidal symptoms.",Additive CNS depressant effects.,Monitor for sedation and neurological side effects.,1,2026-05-13
overseaslorazepam,clozapine,Major,"Risk of severe sedation, hypotension, respiratory depression.",Potentiation of CNS depressant effects.,Avoid concurrent use; monitor closely for adverse effects.,1,2026-05-13
overseaslorazepam,olanzapine,Moderate,"Increased sedation, orthostatic hypotension.",Additive CNS depressant effects.,Monitor for sedation and orthostatic hypotension.,1,2026-05-13
etifoxine,tramadol,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
etifoxine,codeine,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
etifoxine,morphine,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
etifoxine,diazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,alprazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,lorazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,clonazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,midazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,zolpidem,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
etifoxine,amitriptyline,Moderate,"Increased sedation, anticholinergic effects.",Additive CNS depressant effects.,Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
j m bioceuticalspregabalin,tramadol,Moderate,"Increased sedation, dizziness, and risk of serotonin syndrome.",Additive CNS depressant effects; potential interaction with serotonin.,Monitor for sedation and neurological side effects.,1,2026-05-13
j m bioceuticalspregabalin,codeine,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
j m bioceuticalspregabalin,morphine,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
j m bioceuticalspregabalin,diazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,alprazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,lorazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,clonazepam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,midazolam,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,zolpidem,Moderate,Increased sedation and cognitive impairment.,Additive CNS depressant effects.,Use caution; monitor for excessive sedation.,1,2026-05-13
j m bioceuticalspregabalin,gabapentin,Moderate,Increased sedation and dizziness.,Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
j m bioceuticalspregabalin,sertraline,Minor,Possible increased risk of dizziness or sedation.,Potential for additive effects on neurotransmitters.,Monitor for adverse CNS effects.,1,2026-05-13
j m bioceuticalspregabalin,fluoxetine,Minor,Possible increased risk of dizziness or sedation.,Potential for additive effects on neurotransmitters.,Monitor for adverse CNS effects.,1,2026-05-13
j m bioceuticalspregabalin,amitriptyline,Moderate,"Increased sedation, dizziness.",Additive CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
advent life sciences llpofloxacin,warfarin,Major,Increased risk of bleeding.,Fluoroquinolones can inhibit warfarin metabolism.,Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
advent life sciences llpofloxacin,metformin,Moderate,Increased risk of lactic acidosis.,"Fluoroquinolones can impair renal function, leading to metformin accumulation.",Monitor renal function and blood glucose; consider alternative antibiotic.,1,2026-05-13
advent life sciences llpofloxacin,prednisolone,Moderate,Increased risk of tendon rupture.,Fluoroquinolones and corticosteroids both carry a risk of tendinopathy.,Monitor for tendon pain or swelling; avoid concurrent use if possible.,1,2026-05-13
advent life sciences llpofloxacin,dexamethasone,Moderate,Increased risk of tendon rupture.,Fluoroquinolones and corticosteroids both carry a risk of tendinopathy.,Monitor for tendon pain or swelling; avoid concurrent use if possible.,1,2026-05-13
advent life sciences llpofloxacin,theophylline,Moderate,"Increased theophylline levels, leading to toxicity.",Fluoroquinolones can inhibit the metabolism of theophylline.,Monitor theophylline levels; consider alternative antibiotic.,1,2026-05-13
sodium phosphate,atenolol,Moderate,Reduced absorption of atenolol.,"Phosphate binds to beta-blockers in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor blood pressure and heart rate.,1,2026-05-13
sodium phosphate,metoprolol,Moderate,Reduced absorption of metoprolol.,"Phosphate binds to beta-blockers in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor blood pressure and heart rate.,1,2026-05-13
sodium phosphate,amlodipine,Moderate,Reduced absorption of amlodipine.,"Phosphate binds to calcium channel blockers in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor blood pressure.,1,2026-05-13
sodium phosphate,losartan,Moderate,Reduced absorption of losartan.,"Phosphate binds to ARBs in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor blood pressure.,1,2026-05-13
sodium phosphate,ramipril,Moderate,Reduced absorption of ramipril.,"Phosphate binds to ACE inhibitors in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor blood pressure.,1,2026-05-13
sodium phosphate,digoxin,Moderate,Reduced absorption of digoxin.,"Phosphate can bind to digoxin in the GI tract, reducing absorption.",Separate administration by at least 2 hours; monitor heart rate and rhythm.,1,2026-05-13
sodium phosphate,thyroid hormones,Moderate,Reduced absorption of thyroid hormones.,"Phosphate can bind to thyroid hormones in the GI tract, reducing absorption.",Separate administration by at least 4 hours; monitor thyroid function.,1,2026-05-13
l-leucine,,,,,,1,2026-05-13
l-valine,,,,,,1,2026-05-13
gastroprokinetics plain,digoxin,Moderate,Increased digoxin levels.,"Prokinetic agents increase gastric motility, potentially increasing digoxin absorption.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
gastroprokinetics plain,metformin,Moderate,Altered metformin absorption and efficacy.,"Prokinetic agents can affect gastric emptying and intestinal transit, influencing metformin absorption.",Monitor blood glucose levels and adjust metformin dose as needed.,1,2026-05-13
gastroprokinetics plain,warfarin,Minor,May slightly alter warfarin absorption.,Changes in gastric emptying could theoretically impact absorption.,Monitor INR if clinically significant changes are suspected.,1,2026-05-13
pramoxine,,,,,,1,2026-05-13
limiteds-adenosyl l-methoinine disulfate tosylate,,,,,,1,2026-05-13
mucopolysaccharide polysulfate,,,,,,1,2026-05-13
liposomal dithranol,,,,,,1,2026-05-13
alister life sciences llpdiclofenac,warfarin,Moderate,Increased risk of bleeding.,NSAIDs can potentiate the anticoagulant effect of warfarin by inhibiting platelet aggregation and potentially causing gastrointestinal irritation.,Monitor INR closely; consider alternative analgesic/anti-inflammatory if feasible.,1,2026-05-13
alister life sciences llpdiclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,"Concomitant use of NSAIDs increases the risk of gastrointestinal adverse events, including bleeding.","Avoid co-administration if possible; if necessary, use with caution and monitor for GI symptoms.",1,2026-05-13
alister life sciences llpdiclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,"Concomitant use of NSAIDs increases the risk of gastrointestinal adverse events, including bleeding.","Avoid co-administration if possible; if necessary, use with caution and monitor for GI symptoms.",1,2026-05-13
alister life sciences llpdiclofenac,clopidogrel,Moderate,Increased risk of bleeding.,"NSAIDs inhibit platelet aggregation and increase the risk of GI bleeding, which is additive with antiplatelet agents.",Use with caution and monitor for signs of bleeding.,1,2026-05-13
alister life sciences llpdiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can impair renal function and antagonize the effects of ACE inhibitors.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
alister life sciences llpdiclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can impair renal function and antagonize the effects of ARBs.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
alister life sciences llpdiclofenac,amlodipine,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, potentially counteracting the effects of calcium channel blockers.",Monitor blood pressure.,1,2026-05-13
alister life sciences llpdiclofenac,atenolol,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, potentially counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
alister life sciences llpdiclofenac,metoprolol,Minor,Reduced antihypertensive effect.,"NSAIDs can cause sodium and fluid retention, potentially counteracting the effects of beta-blockers.",Monitor blood pressure.,1,2026-05-13
alister life sciences llpdiclofenac,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which is crucial for metformin excretion, thus increasing the risk of lactic acidosis.",Monitor renal function and for signs of lactic acidosis.,1,2026-05-13
alister life sciences llpdiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can reduce renal blood flow and inhibit prostaglandin synthesis, counteracting the effects of loop diuretics.",Monitor for edema and blood pressure; monitor renal function.,1,2026-05-13
alister life sciences llpdiclofenac,spironolactone,Moderate,Increased risk of hyperkalemia and renal impairment.,NSAIDs can reduce renal blood flow and antagonize the effects of potassium-sparing diuretics.,Monitor potassium levels and renal function.,1,2026-05-13
alister life sciences llpdiclofenac,lithium,Moderate,Increased lithium levels and toxicity.,NSAIDs can reduce renal excretion of lithium.,Monitor lithium levels closely and for signs of toxicity.,1,2026-05-13
siridisodium hydrogen citrate,,,,,,1,2026-05-13
fosfestrol,,,,,,1,2026-05-13
diflorasone diacetate,,,,,,1,2026-05-13
limitedterlipressin,ramipril,Moderate,Increased risk of hypertension and bradycardia.,"Terlipressin can cause vasoconstriction, potentially counteracting the effects of ACE inhibitors and leading to increased blood pressure.",Monitor blood pressure closely.,1,2026-05-13
limitedterlipressin,losartan,Moderate,Increased risk of hypertension and bradycardia.,"Terlipressin can cause vasoconstriction, potentially counteracting the effects of ARBs and leading to increased blood pressure.",Monitor blood pressure closely.,1,2026-05-13
limitedterlipressin,atenolol,Moderate,Increased risk of hypertension and bradycardia.,"Terlipressin can cause vasoconstriction, potentially counteracting the effects of beta-blockers and leading to increased blood pressure.",Monitor blood pressure closely.,1,2026-05-13
limitedterlipressin,metoprolol,Moderate,Increased risk of hypertension and bradycardia.,"Terlipressin can cause vasoconstriction, potentially counteracting the effects of beta-blockers and leading to increased blood pressure.",Monitor blood pressure closely.,1,2026-05-13
limitedterlipressin,amlodipine,Moderate,Increased risk of hypertension.,"Terlipressin can cause vasoconstriction, potentially counteracting the effects of calcium channel blockers and leading to increased blood pressure.",Monitor blood pressure closely.,1,2026-05-13
limitedterlipressin,furosemide,Moderate,Reduced diuretic effect and potential for electrolyte imbalances.,Terlipressin's vasoconstrictive effects might alter renal perfusion and counteract diuretic action.,Monitor urine output and electrolytes.,1,2026-05-13
limitedterlipressin,digoxin,Moderate,Increased risk of bradycardia and arrhythmias.,"Terlipressin can cause bradycardia, and digoxin also slows heart rate, potentially leading to severe bradycardia.",Monitor heart rate closely; use with extreme caution.,1,2026-05-13
astra idl maxofloxacin,warfarin,Moderate,Increased INR and risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, leading to increased anticoagulant effect.",Monitor INR closely; consider alternative antibiotic if possible.,1,2026-05-13
astra idl maxofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can enhance the glucose-lowering effects of metformin.,Monitor blood glucose levels closely.,1,2026-05-13
astra idl maxofloxacin,amiodarone,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both amiodarone and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,quinidine,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both quinidine and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,procainamide,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both procainamide and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,sotalol,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both sotalol and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,cisapride,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both cisapride and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,domperidone,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both domperidone and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,droperidol,Major,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both droperidol and moxifloxacin can prolong the QT interval.,"Avoid co-administration; if unavoidable, monitor ECG closely.",1,2026-05-13
astra idl maxofloxacin,haloperidol,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both haloperidol and moxifloxacin can prolong the QT interval.,Monitor ECG closely for QT prolongation.,1,2026-05-13
astra idl maxofloxacin,clozapine,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both clozapine and moxifloxacin can prolong the QT interval.,Monitor ECG closely for QT prolongation.,1,2026-05-13
astra idl maxofloxacin,olanzapine,Moderate,Increased risk of QT prolongation and potentially fatal arrhythmias.,Both olanzapine and moxifloxacin can prolong the QT interval.,Monitor ECG closely for QT prolongation.,1,2026-05-13
astra idl maxofloxacin,tramadol,Moderate,Increased risk of seizures.,Fluoroquinolones can lower the seizure threshold.,Use with caution and monitor for seizure activity.,1,2026-05-13
astra idl maxofloxacin,phenytoin,Moderate,Reduced efficacy of phenytoin.,Fluoroquinolones may affect phenytoin metabolism or absorption.,Monitor phenytoin levels and efficacy.,1,2026-05-13
astra idl maxofloxacin,"corticosteroids (prednisolone, dexamethasone)",Moderate,Increased risk of tendon rupture.,Both fluoroquinolones and corticosteroids are associated with an increased risk of tendonitis and tendon rupture.,Avoid co-administration if possible; monitor for tendon pain or rupture.,1,2026-05-13
euphoria life sciences llplevocetirizine,alprazolam,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
euphoria life sciences llplevocetirizine,diazepam,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
euphoria life sciences llplevocetirizine,lorazepam,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
euphoria life sciences llplevocetirizine,clonazepam,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
euphoria life sciences llplevocetirizine,midazolam,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
euphoria life sciences llplevocetirizine,zolpidem,Moderate,Increased sedation and CNS depression.,Additive pharmacodynamic effect on GABA receptors.,Monitor for increased drowsiness; consider reducing dose of one agent if symptoms occur.,1,2026-05-13
alister life sciences llpmometasone,,,,,,1,2026-05-13
tegoprazan,ketoconazole,Moderate,Reduced efficacy of ketoconazole.,"Tegoprazan increases gastric pH, reducing absorption of acid-labile drugs like ketoconazole.",Avoid co-administration or monitor for signs of reduced antifungal effect.,1,2026-05-13
tegoprazan,itraconazole,Moderate,Reduced efficacy of itraconazole.,"Tegoprazan increases gastric pH, reducing absorption of acid-labile drugs like itraconazole.",Avoid co-administration or monitor for signs of reduced antifungal effect.,1,2026-05-13
tegoprazan,digoxin,Moderate,Increased digoxin levels.,"Tegoprazan increases gastric pH, which can increase absorption of digoxin.",Monitor digoxin levels closely and adjust dose if necessary.,1,2026-05-13
sulbutiamine,,,,,,1,2026-05-13
renwick health care llpondansetron,tramadol,Minor,Potentially reduced efficacy of tramadol.,Serotonergic effects of ondansetron may theoretically counteract the weak 5-HT receptor activity of tramadol.,Monitor pain control; consider alternative analgesic if inadequate.,1,2026-05-13
renwick health care llpondansetron,codeine,Minor,Potentially reduced efficacy of codeine.,Serotonergic effects of ondansetron may theoretically counteract the weak 5-HT receptor activity of codeine.,Monitor pain control; consider alternative analgesic if inadequate.,1,2026-05-13
renwick health care llpondansetron,morphine,Minor,Potentially reduced efficacy of morphine.,Serotonergic effects of ondansetron may theoretically counteract the weak 5-HT receptor activity of morphine.,Monitor pain control; consider alternative analgesic if inadequate.,1,2026-05-13
renwick health care llpondansetron,sertraline,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels; additive serotonergic effects.,"Monitor for symptoms of serotonin syndrome (e.g., agitation, tremor, fever).",1,2026-05-13
renwick health care llpondansetron,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels; additive serotonergic effects.,"Monitor for symptoms of serotonin syndrome (e.g., agitation, tremor, fever).",1,2026-05-13
renwick health care llpondansetron,amitriptyline,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels; additive serotonergic effects.,"Monitor for symptoms of serotonin syndrome (e.g., agitation, tremor, fever).",1,2026-05-13
overseasetoricoxib,warfarin,Major,Increased risk of bleeding.,"Both drugs inhibit cyclooxygenase, increasing bleeding risk; NSAIDs can displace warfarin from protein binding.",Monitor INR closely and increase warfarin dose if necessary; use with caution.,1,2026-05-13
overseasetoricoxib,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive inhibition of COX-1 leading to reduced prostaglandin synthesis and gastrointestinal protection.,Avoid co-administration; monitor for GI bleeding.,1,2026-05-13
overseasetoricoxib,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding.,Additive inhibition of COX-1 leading to reduced prostaglandin synthesis and gastrointestinal protection.,Avoid co-administration; monitor for GI bleeding.,1,2026-05-13
overseasetoricoxib,ramipril,Moderate,Reduced antihypertensive effect; increased risk of renal dysfunction.,"NSAIDs can inhibit renal prostaglandin synthesis, impairing the effects of ACE inhibitors.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
overseasetoricoxib,losartan,Moderate,Reduced antihypertensive effect; increased risk of renal dysfunction.,"NSAIDs can inhibit renal prostaglandin synthesis, impairing the effects of ARBs.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
overseasetoricoxib,amlodipine,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of calcium channel blockers.",Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
overseasetoricoxib,furosemide,Moderate,Reduced diuretic effect; increased risk of renal dysfunction.,"NSAIDs can inhibit renal prostaglandin synthesis, impairing diuretic and natriuretic effects.",Monitor for edema and renal function; consider alternative analgesic.,1,2026-05-13
overseasetoricoxib,lithium,Major,"Increased serum lithium levels, risk of lithium toxicity.",NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels closely; avoid co-administration if possible.,1,2026-05-13
triamcinolone hexacetonide,prednisolone,Moderate,Increased risk of corticosteroid-related side effects.,Additive corticosteroid effects.,"Monitor for signs of corticosteroid excess (e.g., hyperglycemia, Cushingoid features).",1,2026-05-13
triamcinolone hexacetonide,dexamethasone,Moderate,Increased risk of corticosteroid-related side effects.,Additive corticosteroid effects.,"Monitor for signs of corticosteroid excess (e.g., hyperglycemia, Cushingoid features).",1,2026-05-13
triamcinolone hexacetonide,warfarin,Moderate,Altered warfarin effect; increased bleeding risk or reduced anticoagulation.,Corticosteroids can affect vitamin K metabolism and clotting factor synthesis.,Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
triamcinolone hexacetonide,metformin,Moderate,Decreased glycemic control; increased blood glucose levels.,Corticosteroids antagonize the action of insulin and increase hepatic glucose production.,Monitor blood glucose levels closely; adjust metformin dose or insulin if needed.,1,2026-05-13
triamcinolone hexacetonide,insulin,Moderate,Decreased glycemic control; increased blood glucose levels.,Corticosteroids antagonize the action of insulin and increase hepatic glucose production.,Monitor blood glucose levels closely; adjust insulin dose if needed.,1,2026-05-13
cimetropium bromide,,,,,,1,2026-05-13
dried yeast,,,,,,1,2026-05-13
euphoria life sciences llppregabalin,alprazolam,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,diazepam,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,lorazepam,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,clonazepam,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,midazolam,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,zolpidem,Major,Potentially fatal respiratory depression and profound sedation.,"Additive CNS depressant effects, particularly on respiratory drive.","Avoid co-administration; if necessary, use lowest effective doses of both and monitor closely for respiratory depression and sedation.",1,2026-05-13
euphoria life sciences llppregabalin,tramadol,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; use cautiously.,1,2026-05-13
euphoria life sciences llppregabalin,codeine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; use cautiously.,1,2026-05-13
euphoria life sciences llppregabalin,morphine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; use cautiously.,1,2026-05-13
euphoria life sciences llppregabalin,gabapentin,Moderate,"Increased sedation, dizziness, and ataxia.",Additive CNS depressant effects.,Monitor for increased CNS side effects; adjust doses if necessary.,1,2026-05-13
overseasbenzocaine,,,,,,1,2026-05-13
milarch pharmacy,,,,,,1,2026-05-13
alister life sciences llpchlorhexidine gluconate,,,,,,1,2026-05-13
skanttr lifescience llpcefixime,,,,,,1,2026-05-13
remington life sciences llppantoprazole,warfarin,Minor,Altered warfarin effect.,"PPIs may potentially inhibit CYP2C9, which metabolizes warfarin.",Monitor INR closely.,1,2026-05-13
remington life sciences llppantoprazole,clopidogrel,Minor,Reduced antiplatelet effect of clopidogrel.,"PPIs, particularly omeprazole and esomeprazole, can inhibit CYP2C19, which is crucial for clopidogrel activation. Pantoprazole has a less significant effect but is still a concern.",Consider alternative PPI or avoid co-administration if possible; monitor for cardiovascular events.,1,2026-05-13
remington life sciences llppantoprazole,methotrexate,Minor,Increased methotrexate levels and potential toxicity.,PPIs can decrease renal excretion of methotrexate.,Monitor methotrexate levels and for signs of toxicity; consider dose adjustment.,1,2026-05-13
mycobacterium w,,,,,,1,2026-05-13
overseasmifepristone,warfarin,Major,Increased risk of bleeding.,"Mifepristone is a potent inhibitor of CYP3A4, which metabolizes warfarin. This can lead to increased warfarin levels and anticoagulant effect.",Avoid co-administration; monitor INR very closely if unavoidable and consider warfarin dose reduction.,1,2026-05-13
overseasmifepristone,atorvastatin,Moderate,Increased risk of statin-related myopathy.,"Mifepristone inhibits CYP3A4, which metabolizes atorvastatin. This can increase atorvastatin levels.",Monitor for muscle pain and weakness; consider atorvastatin dose reduction or alternative statin.,1,2026-05-13
overseasmifepristone,amlodipine,Moderate,Increased risk of amlodipine side effects.,"Mifepristone inhibits CYP3A4, which metabolizes amlodipine. This can increase amlodipine levels.",Monitor for peripheral edema and hypotension; consider amlodipine dose reduction.,1,2026-05-13
overseasmifepristone,cyclosporine,Major,Increased risk of cyclosporine toxicity.,"Mifepristone is a strong inhibitor of CYP3A4 and P-glycoprotein, both of which are involved in cyclosporine metabolism and transport. This leads to significantly elevated cyclosporine levels.",Avoid co-administration; monitor cyclosporine levels and for signs of toxicity; consider alternative immunosuppression.,1,2026-05-13
overseasmifepristone,tacrolimus,Major,Increased risk of tacrolimus toxicity.,"Mifepristone is a strong inhibitor of CYP3A4 and P-glycoprotein, both of which are involved in tacrolimus metabolism and transport. This leads to significantly elevated tacrolimus levels.",Avoid co-administration; monitor tacrolimus levels and for signs of toxicity; consider alternative immunosuppression.,1,2026-05-13
overseasmifepristone,diazepam,Moderate,Increased risk of diazepam side effects.,"Mifepristone inhibits CYP3A4, which metabolizes diazepam. This can increase diazepam levels.",Monitor for sedation and respiratory depression; consider diazepam dose reduction.,1,2026-05-13
overseasmifepristone,alprazolam,Moderate,Increased risk of alprazolam side effects.,"Mifepristone inhibits CYP3A4, which metabolizes alprazolam. This can increase alprazolam levels.",Monitor for sedation and respiratory depression; consider alprazolam dose reduction.,1,2026-05-13
overseasmifepristone,midazolam,Moderate,Increased risk of midazolam side effects.,"Mifepristone inhibits CYP3A4, which metabolizes midazolam. This can increase midazolam levels.",Monitor for sedation and respiratory depression; consider midazolam dose reduction.,1,2026-05-13
overseasloperamide,tramadol,Moderate,Increased risk of constipation and potential for additive CNS depression.,Both loperamide and tramadol can cause constipation. Tramadol also has opioid properties that can contribute to CNS depression.,Monitor for severe constipation and excessive sedation.,1,2026-05-13
overseasloperamide,codeine,Moderate,Increased risk of constipation and potential for additive CNS depression.,Both loperamide and codeine can cause constipation. Codeine also has opioid properties that can contribute to CNS depression.,Monitor for severe constipation and excessive sedation.,1,2026-05-13
overseasloperamide,morphine,Moderate,Increased risk of constipation and potential for additive CNS depression.,Both loperamide and morphine can cause constipation. Morphine also has opioid properties that can contribute to CNS depression.,Monitor for severe constipation and excessive sedation.,1,2026-05-13
overseasloperamide,quinidine,Major,Increased risk of QT prolongation and torsades de pointes.,"Loperamide is a substrate of P-glycoprotein and CYP3A4. Quinidine is a potent inhibitor of CYP3A4 and P-glycoprotein, leading to increased loperamide levels and potential cardiac toxicity.","Avoid co-administration. If unavoidable, use with extreme caution and monitor ECG.",1,2026-05-13
overseasloperamide,ketoconazole,Major,Increased risk of QT prolongation and torsades de pointes.,"Loperamide is a substrate of P-glycoprotein and CYP3A4. Ketoconazole is a potent inhibitor of CYP3A4, leading to increased loperamide levels and potential cardiac toxicity.","Avoid co-administration. If unavoidable, use with extreme caution and monitor ECG.",1,2026-05-13
overseasloperamide,erythromycin,Major,Increased risk of QT prolongation and torsades de pointes.,"Loperamide is a substrate of P-glycoprotein and CYP3A4. Erythromycin is a moderate inhibitor of CYP3A4, leading to increased loperamide levels and potential cardiac toxicity.","Avoid co-administration. If unavoidable, use with extreme caution and monitor ECG.",1,2026-05-13
ultimedixceftazidime,,,,,,1,2026-05-13
recombinant human luteinizing hormone,,,,,,1,2026-05-13
glial life science llpgabapentin,gabapentin,Minor,Increased sedative effects.,Additive CNS depressant effects.,Monitor for increased sedation and cognitive impairment.,1,2026-05-13
glial life science llpgabapentin,alprazolam,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,diazepam,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,lorazepam,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,clonazepam,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,midazolam,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,zolpidem,Moderate,"Increased CNS depression, somnolence, confusion.",Synergistic central nervous system depressant effects.,"Use with caution, monitor for excessive sedation and respiratory depression.",1,2026-05-13
glial life science llpgabapentin,tramadol,Moderate,"Increased risk of somnolence, dizziness, and confusion.",Additive CNS depressant effects.,Monitor for increased sedation and cognitive impairment.,1,2026-05-13
glial life science llpgabapentin,codeine,Moderate,"Increased risk of somnolence, dizziness, and confusion.",Additive CNS depressant effects.,Monitor for increased sedation and cognitive impairment.,1,2026-05-13
glial life science llpgabapentin,morphine,Moderate,"Increased risk of somnolence, dizziness, and confusion.",Additive CNS depressant effects.,Monitor for increased sedation and cognitive impairment.,1,2026-05-13
chloroform,,,,,,1,2026-05-13
genpharma,,,,,,1,2026-05-13
cinnamon oil,warfarin,Minor,May increase or decrease INR.,Potential modulation of vitamin K metabolism or CYP enzyme activity.,Monitor INR closely if cinnamon oil is used regularly.,1,2026-05-13
cinnamon oil,metformin,Minor,May affect blood glucose levels.,Potential hypoglycemic or hyperglycemic effects.,Monitor blood glucose levels.,1,2026-05-13
caraway oil,,,,,,1,2026-05-13
cardamom oil,,,,,,1,2026-05-13
hlosartan,losartan,Minor,No clinically significant interactions expected.,No significant known interactions.,No specific action required.,1,2026-05-13
hlosartan,ramipril,Moderate,Increased risk of hyperkalemia and renal impairment.,Additive effects on the renin-angiotensin-aldosterone system.,Monitor potassium levels and renal function.,1,2026-05-13
hlosartan,amlodipine,Minor,May enhance blood pressure lowering effect.,Additive antihypertensive effects.,Monitor blood pressure.,1,2026-05-13
hlosartan,atenolol,Minor,May enhance blood pressure lowering effect.,Additive antihypertensive effects.,Monitor blood pressure.,1,2026-05-13
hlosartan,metoprolol,Minor,May enhance blood pressure lowering effect.,Additive antihypertensive effects.,Monitor blood pressure.,1,2026-05-13
hlosartan,furosemide,Minor,Increased risk of hypotension and electrolyte imbalances.,Additive diuretic and antihypertensive effects.,Monitor blood pressure and electrolytes.,1,2026-05-13
hlosartan,spironolactone,Moderate,Increased risk of hyperkalemia.,Additive potassium-sparing effects.,Monitor potassium levels.,1,2026-05-13
hlosartan,lithium,Moderate,Increased risk of lithium toxicity.,Reduced renal clearance of lithium.,Monitor lithium levels and renal function.,1,2026-05-13
invert sugar,metformin,Minor,May affect glycemic control.,Increases blood glucose.,Monitor blood glucose levels.,1,2026-05-13
invert sugar,insulin,Minor,May require insulin dose adjustment.,Counteracts the hypoglycemic effect of insulin.,Monitor blood glucose levels and adjust insulin as needed.,1,2026-05-13
limitedammonium chloride,lithium,Major,Increased risk of lithium toxicity due to decreased renal excretion.,"Ammonium chloride decreases urine pH, promoting lithium reabsorption.",Monitor lithium levels closely and reduce lithium dose if necessary; avoid concurrent use.,1,2026-05-13
limitedammonium chloride,aspirin,Minor,May increase risk of metabolic acidosis.,Additive acidosis-inducing effects.,Monitor for signs of acidosis.,1,2026-05-13
limitedammonium chloride,methenamine,Major,Reduced effectiveness of methenamine due to decreased urine pH.,"Ammonium chloride acidifies the urine, preventing formaldehyde release from methenamine.",Avoid concurrent use.,1,2026-05-13
lanolin,,,,,,1,2026-05-13
limitedpotassium citrate,furosemide,Major,Severe hyperkalemia or hypokalemia.,"Potassium-sparing diuretic can lead to potassium retention, while potassium citrate can lead to potassium excess.",Monitor serum potassium closely; adjust doses or avoid concomitant use.,1,2026-05-13
limitedpotassium citrate,spironolactone,Major,Severe hyperkalemia.,"Both are potassium-sparing agents, increasing the risk of dangerously high potassium levels.",Monitor serum potassium closely; avoid concomitant use if possible or use with extreme caution.,1,2026-05-13
limitedpotassium citrate,losartan,Moderate,Hyperkalemia.,"Losartan is an angiotensin II receptor blocker (ARB) which can increase serum potassium, potentiated by potassium citrate.",Monitor serum potassium levels.,1,2026-05-13
limitedpotassium citrate,ramipril,Moderate,Hyperkalemia.,"Ramipril is an ACE inhibitor which can increase serum potassium, potentiated by potassium citrate.",Monitor serum potassium levels.,1,2026-05-13
limitedpotassium citrate,enalapril,Moderate,Hyperkalemia.,"Enalapril is an ACE inhibitor which can increase serum potassium, potentiated by potassium citrate.",Monitor serum potassium levels.,1,2026-05-13
sulphated surfactant blend,,,,,,1,2026-05-13
limitedmethylprednisolone,aspirin,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both can irritate the gastric mucosa; corticosteroids can mask ulcer symptoms.,"Use with caution, monitor for GI bleeding; consider gastroprotection.",1,2026-05-13
limitedmethylprednisolone,ibuprofen,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both can irritate the gastric mucosa; corticosteroids can mask ulcer symptoms.,"Use with caution, monitor for GI bleeding; consider gastroprotection.",1,2026-05-13
limitedmethylprednisolone,warfarin,Moderate,Altered anticoagulant effect; increased bleeding risk.,"Corticosteroids can increase the catabolism of vitamin K-dependent clotting factors, potentially reducing warfarin's effect, but also can cause GI ulceration which increases bleeding risk.",Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
limitedmethylprednisolone,metformin,Moderate,Hyperglycemia; reduced glycemic control.,Corticosteroids antagonize the action of insulin and decrease glucose utilization.,Monitor blood glucose levels closely; adjust antidiabetic therapy as needed.,1,2026-05-13
limitedmethylprednisolone,atorvastatin,Minor,Potential for myopathy.,"Corticosteroids can increase muscle weakness or myopathy, though this is rare.",Monitor for muscle pain or weakness.,1,2026-05-13
limitedmethylprednisolone,amlodipine,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,losartan,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,isosorbide mononitrate,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,furosemide,Moderate,Electrolyte imbalances (hypokalemia); reduced diuretic effect.,"Corticosteroids can promote potassium excretion, exacerbating hypokalemia caused by furosemide; corticosteroids can also antagonize diuretic effects.",Monitor electrolytes (especially potassium) and fluid balance.,1,2026-05-13
limitedmethylprednisolone,spironolactone,Minor,Potential for electrolyte imbalances.,"Corticosteroids can promote potassium excretion, potentially counteracting the potassium-sparing effect of spironolactone.",Monitor electrolytes.,1,2026-05-13
limitedmethylprednisolone,atenolol,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,metoprolol,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,ramipril,Minor,Reduced antihypertensive effect.,Corticosteroids can cause fluid retention and increase blood pressure.,Monitor blood pressure.,1,2026-05-13
limitedmethylprednisolone,clopidogrel,Moderate,Increased risk of gastrointestinal bleeding.,"Both can increase the risk of gastrointestinal bleeding, especially if ulcers are present.",Monitor for signs of GI bleeding.,1,2026-05-13
limitedmethylprednisolone,gabapentin,Minor,Potential for increased sedation or dizziness.,"Corticosteroids can cause CNS effects like mood changes or insomnia, which might be additive.",Monitor for CNS side effects.,1,2026-05-13
limitedmethylprednisolone,alprazolam,Moderate,Increased risk of sedation or respiratory depression.,Corticosteroids can affect CNS function; additive effects with benzodiazepines are possible.,Monitor for increased sedation.,1,2026-05-13
limitedmethylprednisolone,diazepam,Moderate,Increased risk of sedation or respiratory depression.,Corticosteroids can affect CNS function; additive effects with benzodiazepines are possible.,Monitor for increased sedation.,1,2026-05-13
limitedmethylprednisolone,sertraline,Minor,Potential for mood changes or psychiatric effects.,Corticosteroids can cause mood swings and psychiatric disturbances.,Monitor for mood or behavioral changes.,1,2026-05-13
limitedmethylprednisolone,fluoxetine,Minor,Potential for mood changes or psychiatric effects.,Corticosteroids can cause mood swings and psychiatric disturbances.,Monitor for mood or behavioral changes.,1,2026-05-13
limitedmethylprednisolone,amitriptyline,Moderate,Increased risk of mood changes or psychiatric effects.,"Corticosteroids can cause mood swings and psychiatric disturbances, which could be additive.",Monitor for mood or behavioral changes.,1,2026-05-13
limitedmethylprednisolone,tramadol,Minor,Increased risk of CNS side effects.,Corticosteroids can have CNS effects; additive effects with tramadol are possible.,Monitor for CNS side effects.,1,2026-05-13
limitedmethylprednisolone,codeine,Minor,Increased risk of CNS side effects.,Corticosteroids can have CNS effects; additive effects with codeine are possible.,Monitor for CNS side effects.,1,2026-05-13
limitedmethylprednisolone,morphine,Minor,Increased risk of CNS side effects.,Corticosteroids can have CNS effects; additive effects with morphine are possible.,Monitor for CNS side effects.,1,2026-05-13
limitedmethylprednisolone,phenytoin,Moderate,Reduced efficacy of methylprednisolone.,"Phenytoin is a potent enzyme inducer, increasing the metabolism of corticosteroids.",Monitor for reduced corticosteroid effect; consider dose adjustment.,1,2026-05-13
limitedmethylprednisolone,valproate,Minor,Potential for altered electrolyte balance.,Valproate can affect electrolyte balance; corticosteroids can also affect electrolytes.,Monitor electrolytes.,1,2026-05-13
limitedmethylprednisolone,carbamazepine,Moderate,Reduced efficacy of methylprednisolone.,"Carbamazepine is an enzyme inducer, increasing the metabolism of corticosteroids.",Monitor for reduced corticosteroid effect; consider dose adjustment.,1,2026-05-13
limitedmethylprednisolone,rifampicin,Moderate,Reduced efficacy of methylprednisolone.,"Rifampicin is a potent enzyme inducer, increasing the metabolism of corticosteroids.",Monitor for reduced corticosteroid effect; consider dose adjustment.,1,2026-05-13
limitedmethylprednisolone,isoniazid,Moderate,Reduced efficacy of methylprednisolone.,"Isoniazid can induce hepatic enzymes, increasing corticosteroid metabolism.",Monitor for reduced corticosteroid effect; consider dose adjustment.,1,2026-05-13
limitedmethylprednisolone,ethambutol,Minor,Potential for altered ocular effects.,"Both can have ocular side effects, though interactions are not well-defined.",Monitor for vision changes.,1,2026-05-13
limitedmethylprednisolone,cyclosporine,Major,"Increased risk of cyclosporine toxicity (nephrotoxicity, neurotoxicity) and decreased efficacy of methylprednisolone.",Corticosteroids can increase cyclosporine levels by inhibiting its metabolism; cyclosporine can also affect corticosteroid metabolism.,Monitor cyclosporine levels and renal function closely; adjust doses carefully.,1,2026-05-13
limitedmethylprednisolone,tacrolimus,Major,"Increased risk of tacrolimus toxicity (nephrotoxicity, neurotoxicity) and decreased efficacy of methylprednisolone.",Corticosteroids can increase tacrolimus levels by inhibiting its metabolism; tacrolimus can also affect corticosteroid metabolism.,Monitor tacrolimus levels and renal function closely; adjust doses carefully.,1,2026-05-13
limitedmethylprednisolone,lithium,Moderate,Increased risk of lithium toxicity.,"Corticosteroids can alter electrolyte balance, particularly sodium, which can affect lithium excretion and increase toxicity risk.",Monitor lithium levels and renal function closely; adjust lithium dose if necessary.,1,2026-05-13
limitedmethylprednisolone,haloperidol,Minor,Potential for altered CNS effects.,"Corticosteroids can affect mood and behavior, potentially interacting with antipsychotics.",Monitor for CNS side effects.,1,2026-05-13
limitedmethylprednisolone,clozapine,Moderate,Increased risk of corticosteroid side effects and potential for altered clozapine effects.,Corticosteroids can cause hyperglycemia and electrolyte disturbances; clozapine has its own metabolic and CNS effects.,"Monitor blood glucose, electrolytes, and for CNS side effects.",1,2026-05-13
limitedmethylprednisolone,olanzapine,Moderate,Increased risk of corticosteroid side effects and potential for altered olanzapine effects.,Corticosteroids can cause hyperglycemia and electrolyte disturbances; olanzapine has its own metabolic and CNS effects.,"Monitor blood glucose, electrolytes, and for CNS side effects.",1,2026-05-13
limitedmethylprednisolone,lorazepam,Moderate,Increased risk of sedation or respiratory depression.,Corticosteroids can affect CNS function; additive effects with benzodiazepines are possible.,Monitor for increased sedation.,1,2026-05-13
limitedmethylprednisolone,clonazepam,Moderate,Increased risk of sedation or respiratory depression.,Corticosteroids can affect CNS function; additive effects with benzodiazepines are possible.,Monitor for increased sedation.,1,2026-05-13
limitedmethylprednisolone,midazolam,Moderate,Increased risk of sedation or respiratory depression.,Corticosteroids can affect CNS function; additive effects with benzodiazepines are possible.,Monitor for increased sedation.,1,2026-05-13
limitedmethylprednisolone,zolpidem,Moderate,Increased risk of sedation or CNS effects.,Corticosteroids can affect CNS function; additive effects with hypnotics are possible.,Monitor for increased sedation.,1,2026-05-13
selenium sulphide,,,,,,1,2026-05-13
inactivated polio vaccine,,,,,,1,2026-05-13
limitedclarithromycin,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Clarithromycin inhibits CYP3A4, increasing atorvastatin levels.",Avoid concomitant use or use with extreme caution; monitor for muscle pain.,1,2026-05-13
limitedclarithromycin,rosuvastatin,Moderate,Increased risk of myopathy.,"Clarithromycin can inhibit P-glycoprotein and BCRP transporters involved in rosuvastatin excretion, increasing its levels.",Monitor for muscle pain; consider dose adjustment of rosuvastatin.,1,2026-05-13
limitedclarithromycin,warfarin,Moderate,Increased risk of bleeding.,"Clarithromycin can inhibit the metabolism of warfarin, increasing its anticoagulant effect.",Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
limitedclarithromycin,digoxin,Moderate,Increased risk of digoxin toxicity.,"Clarithromycin can increase digoxin absorption or reduce its excretion, leading to higher serum levels.",Monitor digoxin levels and for signs of toxicity; reduce digoxin dose if necessary.,1,2026-05-13
limitedclarithromycin,metformin,Minor,Potential for transient increase in blood glucose or lactic acidosis.,"Macrolides can potentially affect glucose metabolism, although this is rare.",Monitor blood glucose.,1,2026-05-13
limitedclarithromycin,alfuzosin,Major,Risk of QT prolongation and torsades de pointes.,"Clarithromycin inhibits CYP3A4, which metabolizes alfuzosin, increasing its plasma concentration.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
limitedclarithromycin,cisapride,Major,Risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, which metabolizes cisapride, increasing its plasma concentration.",Contraindicated.,1,2026-05-13
limitedclarithromycin,pimozide,Major,Risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, which metabolizes pimozide, increasing its plasma concentration.",Contraindicated.,1,2026-05-13
limitedclarithromycin,quinidine,Major,Risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, which metabolizes quinidine, increasing its plasma concentration.",Avoid concomitant use; monitor ECG for QT prolongation.,1,2026-05-13
limitedclarithromycin,simvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Clarithromycin inhibits CYP3A4, increasing simvastatin levels.",Avoid concomitant use or use with extreme caution; monitor for muscle pain.,1,2026-05-13
limitedclarithromycin,alprazolam,Moderate,Increased plasma concentrations and potential for enhanced sedative effects.,"Clarithromycin inhibits CYP3A4, which metabolizes alprazolam.",Monitor for excessive sedation; consider dose reduction of alprazolam.,1,2026-05-13
limitedclarithromycin,diazepam,Moderate,Increased plasma concentrations and potential for enhanced sedative effects.,"Clarithromycin inhibits CYP3A4, which metabolizes diazepam.",Monitor for excessive sedation; consider dose reduction of diazepam.,1,2026-05-13
limitedclarithromycin,midazolam,Major,Increased plasma concentrations and prolonged sedative effects.,"Clarithromycin strongly inhibits CYP3A4, which metabolizes midazolam.",Avoid concomitant use or use with extreme caution; consider dose reduction of midazolam.,1,2026-05-13
limitedclarithromycin,cyclosporine,Major,"Increased cyclosporine levels, leading to nephrotoxicity and other adverse effects.","Clarithromycin inhibits CYP3A4, which metabolizes cyclosporine.",Monitor cyclosporine levels and renal function closely; reduce cyclosporine dose.,1,2026-05-13
limitedclarithromycin,tacrolimus,Major,"Increased tacrolimus levels, leading to nephrotoxicity and other adverse effects.","Clarithromycin inhibits CYP3A4, which metabolizes tacrolimus.",Monitor tacrolimus levels and renal function closely; reduce tacrolimus dose.,1,2026-05-13
limitedclarithromycin,sildenafil,Moderate,"Increased plasma concentrations and potential for enhanced adverse effects (e.g., hypotension, visual disturbances).","Clarithromycin inhibits CYP3A4, which metabolizes sildenafil.",Use with caution; monitor for adverse effects.,1,2026-05-13
limitedclarithromycin,vardenafil,Moderate,"Increased plasma concentrations and potential for enhanced adverse effects (e.g., hypotension, visual disturbances).","Clarithromycin inhibits CYP3A4, which metabolizes vardenafil.",Use with caution; monitor for adverse effects.,1,2026-05-13
limitedclarithromycin,colchicine,Major,"Increased risk of colchicine toxicity (e.g., gastrointestinal upset, myopathy, neuropathy).","Clarithromycin can inhibit P-glycoprotein, a transporter that effluxes colchicine, increasing its systemic exposure.",Avoid concomitant use; monitor for signs of colchicine toxicity.,1,2026-05-13
xrliquid paraffin,warfarin,Minor,Reduced absorption of warfarin.,Liquid paraffin can impair the absorption of fat-soluble vitamins and oral medications.,Separate administration times by at least 2 hours; monitor INR.,1,2026-05-13
xrliquid paraffin,atorvastatin,Minor,Reduced absorption of atorvastatin.,Liquid paraffin can impair the absorption of oral medications.,Separate administration times by at least 2 hours.,1,2026-05-13
xrliquid paraffin,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,Liquid paraffin can impair the absorption of oral medications.,Separate administration times by at least 2 hours.,1,2026-05-13
xrliquid paraffin,clopidogrel,Minor,Reduced absorption of clopidogrel.,Liquid paraffin can impair the absorption of oral medications.,Separate administration times by at least 2 hours.,1,2026-05-13
xrliquid paraffin,medications that are absorbed by the gastrointestinal tract,Minor,Reduced absorption and efficacy of other oral medications.,"Liquid paraffin forms a coating in the gastrointestinal tract, hindering the absorption of other drugs.",Administer liquid paraffin at least 2 hours apart from other oral medications.,1,2026-05-13
becaplermin,,,,,,1,2026-05-13
carbachol,,,,,,1,2026-05-13
teclistamab,cyclosporine,Moderate,Increased risk of immunosuppression.,"Both are immunosuppressants, increasing the risk of opportunistic infections.",Monitor for signs of infection; consider dose adjustment.,1,2026-05-13
teclistamab,tacrolimus,Moderate,Increased risk of immunosuppression.,"Both are immunosuppressants, increasing the risk of opportunistic infections.",Monitor for signs of infection; consider dose adjustment.,1,2026-05-13
teclistamab,methotrexate,Moderate,Increased risk of immunosuppression and potential for liver toxicity.,Both can suppress the immune system and have potential hepatotoxicity.,Monitor liver function and for signs of infection; consider dose adjustment.,1,2026-05-13
teclistamab,prednisolone,Moderate,Increased risk of immunosuppression and infection.,"Both have immunosuppressive effects, increasing the risk of opportunistic infections.",Monitor for signs of infection; consider dose adjustment.,1,2026-05-13
teclistamab,dexamethasone,Moderate,Increased risk of immunosuppression and infection.,"Both have immunosuppressive effects, increasing the risk of opportunistic infections.",Monitor for signs of infection; consider dose adjustment.,1,2026-05-13
teclistamab,rituximab,Major,Increased risk of severe immunosuppression and opportunistic infections.,Combination of two potent immunosuppressants.,Avoid concomitant use if possible; monitor closely for infections and immune-related adverse events.,1,2026-05-13
teclistamab,lenalidomide,Moderate,Increased risk of neutropenia and other cytopenias.,Both can cause myelosuppression.,Monitor complete blood count closely.,1,2026-05-13
teclistamab,pomalidomide,Moderate,Increased risk of neutropenia and other cytopenias.,Both can cause myelosuppression.,Monitor complete blood count closely.,1,2026-05-13
teclistamab,thalidomide,Moderate,Increased risk of neutropenia and other cytopenias.,Both can cause myelosuppression.,Monitor complete blood count closely.,1,2026-05-13
nesterrepaglinide,,,,,,1,2026-05-13
vi capsular polysaccharide of salmonella typhi,,,,,,1,2026-05-13
overseasallopurinol,,,,,,1,2026-05-13
leucine,,,,,,1,2026-05-13
pet mankind,,,,,,1,2026-05-13
hparacetamol,,,,,,1,2026-05-13
cadsol life sciences llptelmisartan,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to vasoconstriction and sodium retention.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
cadsol life sciences llptelmisartan,aspirin,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to vasoconstriction and sodium retention.",Monitor blood pressure and renal function; consider alternative antiplatelet.,1,2026-05-13
cadsol life sciences llptelmisartan,furosemide,Moderate,Increased risk of hyperkalemia and renal dysfunction.,Both drugs can affect renal function and potassium excretion.,Monitor potassium levels and renal function closely.,1,2026-05-13
cadsol life sciences llptelmisartan,spironolactone,Major,Significant risk of hyperkalemia.,"Both agents are potassium-sparing, increasing the risk of severe hyperkalemia.",Avoid co-administration or monitor potassium levels very closely with frequent adjustments.,1,2026-05-13
skanttr lifescience llpazithromycin,warfarin,Moderate,Increased risk of bleeding.,"Azithromycin may inhibit CYP2C9, which metabolizes warfarin, increasing its anticoagulant effect.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
skanttr lifescience llpazithromycin,digoxin,Moderate,Increased digoxin levels and potential toxicity.,Azithromycin may increase digoxin absorption.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseaslinezolid,fluoxetine,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and SSRIs like fluoxetine increase serotonin levels.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,sertraline,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and SSRIs like sertraline increase serotonin levels.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,amitriptyline,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and TCAs like amitriptyline increase serotonin levels.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,tramadol,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and tramadol affects serotonin.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,codeine,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and codeine affects serotonin.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,morphine,Major,Serotonin syndrome.,"Linezolid is a reversible MAOI, and morphine affects serotonin.","Avoid co-administration; if necessary, use with extreme caution and monitor for symptoms of serotonin syndrome.",1,2026-05-13
overseaslinezolid,clopidogrel,Moderate,Increased risk of serotonin syndrome.,"Linezolid is a reversible MAOI, and clopidogrel's active metabolite can affect serotonin.",Monitor for symptoms of serotonin syndrome.,1,2026-05-13
overseaslinezolid,atenolol,Moderate,Hypertension or hypertensive crisis.,Linezolid can inhibit norepinephrine reuptake and cause release of catecholamines.,Monitor blood pressure closely.,1,2026-05-13
overseaslinezolid,metoprolol,Moderate,Hypertension or hypertensive crisis.,Linezolid can inhibit norepinephrine reuptake and cause release of catecholamines.,Monitor blood pressure closely.,1,2026-05-13
cholera vaccine,,,,,,1,2026-05-13
skanttr lifescience llpdomperidone,amiodarone,Major,Increased risk of QT prolongation and potentially fatal arrhythmias (torsades de pointes).,"Both drugs prolong the QT interval, leading to additive effects.",Avoid co-administration; monitor ECG and electrolytes if necessary.,1,2026-05-13
skanttr lifescience llpdomperidone,haloperidol,Major,Increased risk of QT prolongation and potentially fatal arrhythmias (torsades de pointes).,"Both drugs prolong the QT interval, leading to additive effects.",Avoid co-administration; monitor ECG and electrolytes if necessary.,1,2026-05-13
skanttr lifescience llpdomperidone,clozapine,Major,Increased risk of QT prolongation and potentially fatal arrhythmias (torsades de pointes).,"Both drugs prolong the QT interval, leading to additive effects.",Avoid co-administration; monitor ECG and electrolytes if necessary.,1,2026-05-13
skanttr lifescience llpdomperidone,ketoconazole,Moderate,Increased domperidone levels and risk of QT prolongation.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone.",Use with caution; monitor for cardiac side effects.,1,2026-05-13
skanttr lifescience llpdomperidone,erythromycin,Moderate,Increased domperidone levels and risk of QT prolongation.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone.",Use with caution; monitor for cardiac side effects.,1,2026-05-13
skanttr lifescience llpdomperidone,digoxin,Minor,"Potential for increased digoxin absorption, though clinical significance is debated.","Domperidone may increase gastrointestinal motility, potentially affecting digoxin absorption.",Monitor digoxin levels and clinical response.,1,2026-05-13
boswellia serrata,,,,,,1,2026-05-13
overseasdrotaverine,levodopa,Moderate,Reduced efficacy of levodopa.,Drotaverine's anticholinergic effects may antagonize levodopa's effects.,Monitor parkinsonian symptoms; consider alternative antispasmodics if needed.,1,2026-05-13
vogue pharmaluliconazole,atorvastatin,Major,Increased risk of myopathy and rhabdomyolysis.,"Fluconazole inhibits CYP3A4, which metabolizes atorvastatin.",Avoid co-administration; use alternative statin or monitor closely for muscle pain.,1,2026-05-13
vogue pharmaluliconazole,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Fluconazole may inhibit the metabolism of rosuvastatin.,Use with caution; monitor for muscle symptoms.,1,2026-05-13
vogue pharmaluliconazole,warfarin,Major,Increased risk of bleeding.,"Fluconazole inhibits CYP2C9, which metabolizes warfarin.",Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
vogue pharmaluliconazole,amlodipine,Moderate,Increased amlodipine levels and risk of hypotension and peripheral edema.,"Fluconazole may inhibit CYP3A4, which metabolizes amlodipine.",Monitor blood pressure and edema; reduce amlodipine dose if necessary.,1,2026-05-13
vogue pharmaluliconazole,clopidogrel,Moderate,Reduced efficacy of clopidogrel.,"Fluconazole inhibits CYP2C19, which is involved in clopidogrel activation.",Monitor for signs of thrombotic events; consider alternative antiplatelet therapy.,1,2026-05-13
vogue pharmaluliconazole,sertraline,Minor,Potential for increased sertraline levels.,"Fluconazole may inhibit CYP3A4 and CYP2C19, involved in sertraline metabolism.",Monitor for signs of serotonin syndrome.,1,2026-05-13
vogue pharmaluliconazole,alprazolam,Moderate,Increased alprazolam levels and sedation.,"Fluconazole inhibits CYP3A4, which metabolizes alprazolam.",Use with caution; reduce alprazolam dose if necessary.,1,2026-05-13
vogue pharmaluliconazole,diazepam,Moderate,Increased diazepam levels and sedation.,"Fluconazole inhibits CYP3A4, which metabolizes diazepam.",Use with caution; reduce diazepam dose if necessary.,1,2026-05-13
vogue pharmaluliconazole,midazolam,Major,Increased midazolam levels and prolonged sedation.,"Fluconazole inhibits CYP3A4, which metabolizes midazolam.",Avoid co-administration.,1,2026-05-13
terizidone,,,,,,1,2026-05-13
health care llpamitriptyline,sertraline,Moderate,Increased risk of serotonin syndrome.,Both drugs affect serotonin levels in the brain.,"Monitor for symptoms of serotonin syndrome (e.g., agitation, confusion, rapid heart rate, fever).",1,2026-05-13
health care llpamitriptyline,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both drugs affect serotonin levels in the brain.,"Monitor for symptoms of serotonin syndrome (e.g., agitation, confusion, rapid heart rate, fever).",1,2026-05-13
health care llpamitriptyline,tramadol,Moderate,Increased risk of serotonin syndrome.,Both drugs affect serotonin levels in the brain.,Monitor for symptoms of serotonin syndrome.,1,2026-05-13
health care llpamitriptyline,codeine,Moderate,Increased sedation and potential for anticholinergic effects.,Amitriptyline can potentiate the sedative and anticholinergic effects of codeine.,Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
health care llpamitriptyline,clonazepam,Moderate,Increased sedation and potential for falls.,Additive CNS depressant effects.,Monitor for excessive sedation and cognitive impairment.,1,2026-05-13
health care llpamitriptyline,lorazepam,Moderate,Increased sedation and potential for falls.,Additive CNS depressant effects.,Monitor for excessive sedation and cognitive impairment.,1,2026-05-13
health care llpamitriptyline,diazepam,Moderate,Increased sedation and potential for falls.,Additive CNS depressant effects.,Monitor for excessive sedation and cognitive impairment.,1,2026-05-13
health care llpamitriptyline,alprazolam,Moderate,Increased sedation and potential for falls.,Additive CNS depressant effects.,Monitor for excessive sedation and cognitive impairment.,1,2026-05-13
health care llpamitriptyline,atenolol,Moderate,May antagonize the antihypertensive effects of atenolol.,"Amitriptyline can cause orthostatic hypotension, potentially counteracting beta-blocker effects.",Monitor blood pressure.,1,2026-05-13
health care llpamitriptyline,metoprolol,Moderate,May antagonize the antihypertensive effects of metoprolol.,"Amitriptyline can cause orthostatic hypotension, potentially counteracting beta-blocker effects.",Monitor blood pressure.,1,2026-05-13
health care llpamitriptyline,omeprazole,Minor,Potential for increased amitriptyline levels.,"Omeprazole may inhibit CYP2D6, an enzyme involved in amitriptyline metabolism.",Monitor for anticholinergic side effects.,1,2026-05-13
health care llpamitriptyline,pantoprazole,Minor,Potential for increased amitriptyline levels.,"Pantoprazole may inhibit CYP2D6, an enzyme involved in amitriptyline metabolism.",Monitor for anticholinergic side effects.,1,2026-05-13
siribetamethasone,prednisolone,Moderate,Increased risk of adrenal suppression and Cushingoid effects with prolonged use.,Both are corticosteroids with similar mechanisms of action and potential for additive effects.,Use with caution; monitor for signs of hypercortisolism and adrenal insufficiency during withdrawal.,1,2026-05-13
siribetamethasone,dexamethasone,Moderate,Increased risk of adrenal suppression and Cushingoid effects with prolonged use.,Both are corticosteroids with similar mechanisms of action and potential for additive effects.,Use with caution; monitor for signs of hypercortisolism and adrenal insufficiency during withdrawal.,1,2026-05-13
siribetamethasone,insulin,Moderate,"Reduced glycemic control, hyperglycemia.",Corticosteroids increase blood glucose levels by promoting gluconeogenesis and decreasing peripheral glucose uptake.,Monitor blood glucose closely and adjust insulin dose as needed.,1,2026-05-13
siribetamethasone,metformin,Moderate,"Reduced glycemic control, hyperglycemia.",Corticosteroids increase blood glucose levels by promoting gluconeogenesis and decreasing peripheral glucose uptake.,Monitor blood glucose closely and adjust metformin dose or consider alternative therapy.,1,2026-05-13
siribetamethasone,warfarin,Minor,"Variable effects on INR, potentially increased risk of bleeding or thrombosis.","Corticosteroids can affect clotting factors, leading to unpredictable effects on warfarin.",Monitor INR closely.,1,2026-05-13
siribetamethasone,aspirin,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both drugs can irritate the gastrointestinal mucosa and inhibit protective prostaglandins.,Use with caution; consider gastroprotective agents.,1,2026-05-13
siribetamethasone,ibuprofen,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both drugs can irritate the gastrointestinal mucosa and inhibit protective prostaglandins.,Use with caution; consider gastroprotective agents.,1,2026-05-13
siribetamethasone,cyclosporine,Moderate,Increased cyclosporine levels and nephrotoxicity.,"Corticosteroids can inhibit CYP3A4, which metabolizes cyclosporine.",Monitor cyclosporine levels and renal function closely.,1,2026-05-13
siribetamethasone,tacrolimus,Moderate,Increased tacrolimus levels and nephrotoxicity.,"Corticosteroids can inhibit CYP3A4, which metabolizes tacrolimus.",Monitor tacrolimus levels and renal function closely.,1,2026-05-13
remington life sciences llpparacetamol,warfarin,Moderate,Increased risk of bleeding with chronic high-dose paracetamol.,"Chronic, high-dose paracetamol may affect vitamin K metabolism or liver function, potentially increasing INR.",Limit paracetamol use to short durations and recommended doses when co-administered with warfarin; monitor INR.,1,2026-05-13
remington life sciences llpparacetamol,phenytoin,Minor,May reduce the efficacy of paracetamol.,"Phenytoin can induce liver enzymes, potentially increasing paracetamol metabolism.",Monitor for adequate pain relief.,1,2026-05-13
remington life sciences llpparacetamol,carbamazepine,Minor,May reduce the efficacy of paracetamol.,"Carbamazepine can induce liver enzymes, potentially increasing paracetamol metabolism.",Monitor for adequate pain relief.,1,2026-05-13
remington life sciences llpparacetamol,rifampicin,Moderate,Increased risk of hepatotoxicity.,"Rifampicin induces liver enzymes, potentially increasing the formation of toxic paracetamol metabolites.",Avoid concurrent use if possible; monitor liver function if unavoidable.,1,2026-05-13
health care llpivabradine,verapamil,Major,Increased ivabradine levels and risk of bradycardia.,"Verapamil is a potent inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.","Avoid co-administration; if unavoidable, reduce ivabradine dose and monitor heart rate.",1,2026-05-13
health care llpivabradine,diltiazem,Major,Increased ivabradine levels and risk of bradycardia.,"Diltiazem is a moderate inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.","Avoid co-administration; if unavoidable, reduce ivabradine dose and monitor heart rate.",1,2026-05-13
health care llpivabradine,ketoconazole,Major,Increased ivabradine levels and risk of bradycardia.,"Ketoconazole is a potent inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.",Avoid co-administration.,1,2026-05-13
health care llpivabradine,erythromycin,Major,Increased ivabradine levels and risk of bradycardia.,"Erythromycin is a moderate inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.",Avoid co-administration.,1,2026-05-13
health care llpivabradine,clarithromycin,Major,Increased ivabradine levels and risk of bradycardia.,"Clarithromycin is a moderate inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.",Avoid co-administration.,1,2026-05-13
health care llpivabradine,itraconazole,Major,Increased ivabradine levels and risk of bradycardia.,"Itraconazole is a potent inhibitor of CYP3A4, the primary enzyme metabolizing ivabradine.",Avoid co-administration.,1,2026-05-13
health care llpivabradine,amlodipine,Moderate,Increased risk of bradycardia and hypotension.,Additive effects on heart rate and blood pressure lowering.,Monitor heart rate and blood pressure closely.,1,2026-05-13
health care llpivabradine,atenolol,Moderate,Increased risk of bradycardia.,Additive effects on slowing heart rate.,Monitor heart rate closely.,1,2026-05-13
health care llpivabradine,metoprolol,Moderate,Increased risk of bradycardia.,Additive effects on slowing heart rate.,Monitor heart rate closely.,1,2026-05-13
health care llpivabradine,clopidogrel,Minor,No significant interaction expected.,Different metabolic pathways and mechanisms of action.,Monitor for adverse effects.,1,2026-05-13
health care llpivabradine,losartan,Minor,No significant interaction expected.,Different metabolic pathways and mechanisms of action.,Monitor for adverse effects.,1,2026-05-13
sodium iodide,methimazole,Major,"Reduced efficacy of methimazole in treating hyperthyroidism, increased risk of thyroid storm.",High doses of iodide can paradoxically stimulate thyroid hormone synthesis and release (Wolff-Chaikoff effect followed by escape).,Avoid concurrent use; manage hyperthyroidism with specific antithyroid medications.,1,2026-05-13
sodium iodide,propylthiouracil,Major,"Reduced efficacy of propylthiouracil in treating hyperthyroidism, increased risk of thyroid storm.",High doses of iodide can paradoxically stimulate thyroid hormone synthesis and release (Wolff-Chaikoff effect followed by escape).,Avoid concurrent use; manage hyperthyroidism with specific antithyroid medications.,1,2026-05-13
sodium iodide,lithium,Moderate,Increased risk of hypothyroidism.,"Iodide can interfere with thyroid hormone synthesis and release, and lithium can also affect thyroid function.",Monitor thyroid function tests.,1,2026-05-13
overseasmethylprednisolone,warfarin,Moderate,Increased risk of bleeding.,Corticosteroids can alter the metabolism and effect of warfarin.,"Monitor INR closely, consider dose adjustment of warfarin.",1,2026-05-13
overseasmethylprednisolone,metformin,Moderate,"Hyperglycemia, reduced glycemic control.","Corticosteroids antagonize the action of insulin, increasing blood glucose.","Monitor blood glucose levels, adjust antidiabetic medication as needed.",1,2026-05-13
overseasmethylprednisolone,atorvastatin,Minor,Increased risk of muscle-related adverse events.,Corticosteroids may increase the risk of myopathy or rhabdomyolysis when used with statins.,Monitor for muscle pain or weakness.,1,2026-05-13
overseasmethylprednisolone,rosuvastatin,Minor,Increased risk of muscle-related adverse events.,Corticosteroids may increase the risk of myopathy or rhabdomyolysis when used with statins.,Monitor for muscle pain or weakness.,1,2026-05-13
overseasmethylprednisolone,aspirin,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Corticosteroids can increase gastric acidity and impair mucosal healing.,"Use with caution, consider gastroprotective agents.",1,2026-05-13
overseasmethylprednisolone,ibuprofen,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Corticosteroids can increase gastric acidity and impair mucosal healing.,"Use with caution, consider gastroprotective agents.",1,2026-05-13
overseasmethylprednisolone,digoxin,Moderate,Increased risk of digoxin toxicity due to hypokalemia.,Corticosteroids can cause potassium loss.,Monitor serum potassium and digoxin levels.,1,2026-05-13
overseasmethylprednisolone,furosemide,Moderate,Increased risk of hypokalemia.,Both agents can cause potassium depletion.,Monitor serum potassium levels.,1,2026-05-13
overseasmethylprednisolone,spironolactone,Moderate,Antagonistic effects on potassium levels.,Corticosteroids can increase potassium excretion while spironolactone retains potassium.,Monitor serum potassium levels.,1,2026-05-13
overseasmethylprednisolone,insulin,Moderate,"Hyperglycemia, reduced glycemic control.","Corticosteroids antagonize the action of insulin, increasing blood glucose.","Monitor blood glucose levels, adjust insulin as needed.",1,2026-05-13
overseasmethylprednisolone,tacrolimus,Moderate,Increased risk of nephrotoxicity and other adverse effects.,Corticosteroids can increase tacrolimus levels.,Monitor tacrolimus levels and renal function.,1,2026-05-13
overseasmethylprednisolone,cyclosporine,Moderate,Increased risk of nephrotoxicity and other adverse effects.,Corticosteroids can increase cyclosporine levels.,Monitor cyclosporine levels and renal function.,1,2026-05-13
limitedl-ornithine l-aspartate,,,,,,1,2026-05-13
astra idl maxesomeprazole,clopidogrel,Moderate,"Reduced antiplatelet effect, increased risk of cardiovascular events.","Proton pump inhibitors can inhibit CYP2C19, reducing the activation of clopidogrel.",Consider alternative PPI or monitor for efficacy of clopidogrel.,1,2026-05-13
astra idl maxesomeprazole,methotrexate,Moderate,Increased methotrexate levels and toxicity.,PPIs may reduce the renal clearance of methotrexate.,Monitor methotrexate levels and for signs of toxicity.,1,2026-05-13
overseasomeprazole,clopidogrel,Moderate,"Reduced antiplatelet effect, increased risk of cardiovascular events.","Proton pump inhibitors can inhibit CYP2C19, reducing the activation of clopidogrel.",Consider alternative PPI or monitor for efficacy of clopidogrel.,1,2026-05-13
overseasomeprazole,methotrexate,Moderate,Increased methotrexate levels and toxicity.,PPIs may reduce the renal clearance of methotrexate.,Monitor methotrexate levels and for signs of toxicity.,1,2026-05-13
overseaslosartan,ibuprofen,Moderate,"Reduced antihypertensive effect, increased risk of renal impairment.","NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilatory effects of losartan.",Monitor blood pressure and renal function.,1,2026-05-13
overseaslosartan,aspirin,Minor,May slightly reduce antihypertensive effect.,"NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilatory effects of losartan.",Monitor blood pressure.,1,2026-05-13
overseaslosartan,furosemide,Moderate,Increased risk of hyperkalemia and renal dysfunction.,Both agents can affect renal function and potassium levels.,Monitor renal function and serum potassium.,1,2026-05-13
overseaslosartan,spironolactone,Major,Significant risk of hyperkalemia and renal failure.,Both agents increase potassium levels and can impair renal function.,Avoid concomitant use or monitor potassium and renal function very closely.,1,2026-05-13
overseaslosartan,metformin,Minor,Increased risk of hyperkalemia.,"Losartan can increase potassium levels, and metformin can also affect potassium.",Monitor serum potassium levels.,1,2026-05-13
overseaslosartan,prednisolone,Minor,May reduce antihypertensive effect.,Corticosteroids can cause sodium and water retention.,Monitor blood pressure.,1,2026-05-13
overseaslosartan,dexamethasone,Minor,May reduce antihypertensive effect.,Corticosteroids can cause sodium and water retention.,Monitor blood pressure.,1,2026-05-13
sanlife science llpcilnidipine,atorvastatin,Minor,Potential for increased atorvastatin levels.,"Cilnidipine is metabolized by CYP3A4, which also metabolizes atorvastatin.",Monitor for statin-related side effects.,1,2026-05-13
sanlife science llpcilnidipine,rosuvastatin,Minor,Potential for increased rosuvastatin levels.,"Cilnidipine may inhibit CYP2C9, which metabolizes rosuvastatin.",Monitor for statin-related side effects.,1,2026-05-13
sanlife science llpcilnidipine,digoxin,Minor,Potential for increased digoxin levels.,Calcium channel blockers can reduce digoxin clearance.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
sanlife science llpcilnidipine,metoprolol,Minor,Additive effects on heart rate and blood pressure.,Both are antihypertensives and can cause bradycardia.,Monitor heart rate and blood pressure.,1,2026-05-13
sanlife science llpcilnidipine,atenolol,Minor,Additive effects on heart rate and blood pressure.,Both are antihypertensives and can cause bradycardia.,Monitor heart rate and blood pressure.,1,2026-05-13
genzymehyaluronic acid,,,,,,1,2026-05-13
overseastriclofos,,,,,,1,2026-05-13
calcium aspartate,warfarin,Minor,"May interfere with vitamin K absorption, potentially reducing warfarin efficacy.",Calcium can bind to vitamin K antagonists.,Monitor INR.,1,2026-05-13
calcium aspartate,tetracyclines,Moderate,Reduced absorption of tetracyclines.,Calcium forms insoluble complexes with tetracyclines in the GI tract.,Separate administration by at least 2 hours.,1,2026-05-13
calcium aspartate,quinolone antibiotics,Moderate,Reduced absorption of quinolones.,Calcium forms insoluble complexes with quinolones in the GI tract.,Separate administration by at least 2 hours.,1,2026-05-13
calcium aspartate,levothyroxine,Moderate,Reduced absorption of levothyroxine.,"Calcium can bind to levothyroxine, impairing its absorption.",Separate administration by at least 4 hours.,1,2026-05-13
calcium aspartate,bisphosphonates,Moderate,Reduced absorption of bisphosphonates.,Calcium can reduce the absorption of bisphosphonates.,Separate administration by at least 2 hours.,1,2026-05-13
amodiaquine,metronidazole,Moderate,Potential for severe gastrointestinal distress and increased risk of hepatotoxicity.,The combination has been associated with increased adverse events.,Use with caution or monitor closely for side effects.,1,2026-05-13
amodiaquine,clopidogrel,Minor,Potential for altered platelet aggregation.,Amodiaquine has antiplatelet effects.,Monitor for bleeding.,1,2026-05-13
amodiaquine,warfarin,Minor,Potential for altered INR.,Amodiaquine may affect warfarin metabolism.,Monitor INR.,1,2026-05-13
ashdee health care,,,,,,1,2026-05-13
ai health care llpartemether,,,,,,1,2026-05-13
protodioscin,,,,,,1,2026-05-13
accra pac,,,,,,1,2026-05-13
ultimedixlansoprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Proton pump inhibitors reduce gastric acidity, which is required for clopidogrel activation.",Consider alternative PPI or monitor for thrombotic events.,1,2026-05-13
overseaspioglitazone,furosemide,Moderate,Increased risk of fluid retention and edema.,"Pioglitazone can cause fluid retention, and furosemide is a diuretic.",Monitor for fluid retention and adjust diuretic dose if necessary.,1,2026-05-13
overseaspioglitazone,insulin,Moderate,Increased risk of hypoglycemia and fluid retention.,Pioglitazone can potentiate insulin's effects on glucose lowering and fluid balance.,Monitor blood glucose closely and watch for signs of fluid overload.,1,2026-05-13
ai health care llpmupirocin,,,,,,1,2026-05-13
propyl paraben,,,,,,1,2026-05-13
limitedcalcitriol,warfarin,Minor,Potential for altered warfarin effect.,Vitamin D metabolites can influence vitamin K metabolism.,Monitor INR closely when initiating or discontinuing calcitriol.,1,2026-05-13
limitedcalcitriol,furosemide,Moderate,Increased risk of hypercalcemia and nephrotoxicity.,"Calcitriol increases calcium absorption, while furosemide can increase calcium excretion; combined use can lead to unpredictable calcium levels.",Monitor serum calcium and renal function closely.,1,2026-05-13
limitedcalcitriol,spironolactone,Moderate,Increased risk of hypercalcemia.,Spironolactone can increase calcium reabsorption.,Monitor serum calcium levels.,1,2026-05-13
limitedcalcitriol,"thiazide diuretics (not on list, but relevant)",Major,Severe hypercalcemia.,Synergistic effect on calcium reabsorption.,Avoid concurrent use.,1,2026-05-13
dibucaine,metoprolol,Minor,Potential for additive bradycardic effects.,Dibucaine has some alpha-adrenergic blocking activity.,Monitor heart rate.,1,2026-05-13
dibucaine,atenolol,Minor,Potential for additive bradycardic effects.,Dibucaine has some alpha-adrenergic blocking activity.,Monitor heart rate.,1,2026-05-13
biogenetics health care,,,,,,1,2026-05-13
alister life sciences llpsodium chloride,,,,,,1,2026-05-13
limitedimipenem,valproate,Major,"May reduce valproate levels, increasing seizure risk.",Imipenem may induce valproate metabolism.,Monitor valproate levels and for seizure breakthrough; consider alternative antibiotic or antiepileptic.,1,2026-05-13
polatuzumab,prednisolone,Moderate,Increased risk of infections due to combined immunosuppression.,Both drugs have immunosuppressive effects.,Monitor for signs of infection; consider dose adjustment or prophylactic measures.,1,2026-05-13
polatuzumab,dexamethasone,Moderate,Increased risk of infections due to combined immunosuppression.,Both drugs have immunosuppressive effects.,Monitor for signs of infection; consider dose adjustment or prophylactic measures.,1,2026-05-13
nafithromycin,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Nafithromycin is a CYP3A4 inhibitor, increasing statin levels.","Monitor for muscle pain, weakness; consider statin dose reduction or alternative.",1,2026-05-13
nafithromycin,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Nafithromycin may inhibit CYP2C9 or transporters, increasing statin levels.","Monitor for muscle pain, weakness; consider statin dose reduction or alternative.",1,2026-05-13
nafithromycin,warfarin,Moderate,Increased risk of bleeding.,"Nafithromycin can inhibit CYP2C9, increasing warfarin effect.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
nafithromycin,amlodipine,Moderate,Increased risk of hypotension and peripheral edema.,"Nafithromycin may inhibit CYP3A4, increasing amlodipine levels.",Monitor blood pressure and for signs of fluid retention.,1,2026-05-13
nafithromycin,digoxin,Moderate,"Increased risk of digoxin toxicity (nausea, arrhythmias).","Nafithromycin can inhibit P-glycoprotein, increasing digoxin levels.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
nafithromycin,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,"Nafithromycin may inhibit CYP2D6, increasing metoprolol levels.",Monitor heart rate and blood pressure.,1,2026-05-13
nafithromycin,amitriptyline,Moderate,Increased risk of anticholinergic side effects and CNS effects.,"Nafithromycin may inhibit CYP2D6, increasing amitriptyline levels.",Monitor for side effects; consider dose adjustment.,1,2026-05-13
nafithromycin,haloperidol,Moderate,Increased risk of QT prolongation and arrhythmias.,"Nafithromycin may inhibit CYP2D6, increasing haloperidol levels.",Monitor ECG and for signs of QT prolongation.,1,2026-05-13
nafithromycin,clozapine,Major,"Increased risk of agranulocytosis, sedation, and seizures.","Nafithromycin inhibits CYP1A2, increasing clozapine levels.",Monitor blood counts and for side effects; consider alternative antibiotic or clozapine dose reduction.,1,2026-05-13
nafithromycin,omeprazole,Minor,Potentially increased levels of omeprazole.,Nafithromycin may inhibit CYP enzymes involved in omeprazole metabolism.,Monitor for potential increased effects of omeprazole.,1,2026-05-13
nafithromycin,pantoprazole,Minor,Potentially increased levels of pantoprazole.,Nafithromycin may inhibit CYP enzymes involved in pantoprazole metabolism.,Monitor for potential increased effects of pantoprazole.,1,2026-05-13
overseasalbendazole,phenytoin,Moderate,May reduce efficacy of albendazole and increase phenytoin levels.,"Albendazole induces CYP enzymes, reducing its own absorption and potentially increasing phenytoin metabolism.",Monitor albendazole efficacy and phenytoin levels.,1,2026-05-13
overseasalbendazole,carbamazepine,Moderate,May reduce efficacy of albendazole and increase carbamazepine levels.,"Albendazole induces CYP enzymes, reducing its own absorption and potentially increasing carbamazepine metabolism.",Monitor albendazole efficacy and carbamazepine levels.,1,2026-05-13
limitedmontelukast,,,,,,1,2026-05-13
ichtyolammonium,,,,,,1,2026-05-13
buphenine,,,,,,1,2026-05-13
sulphur,,,,,,1,2026-05-13
overseasamikacin,furosemide,Major,Increased risk of ototoxicity and nephrotoxicity.,Synergistic nephrotoxic and ototoxic effects.,Monitor renal function and hearing; consider alternative diuretic if possible.,1,2026-05-13
overseasamikacin,cyclosporine,Major,Increased risk of nephrotoxicity.,Both drugs can cause renal impairment.,Monitor renal function closely; consider alternative immunosuppressant if possible.,1,2026-05-13
overseasamikacin,tacrolimus,Major,Increased risk of nephrotoxicity.,Both drugs can cause renal impairment.,Monitor renal function closely; consider alternative immunosuppressant if possible.,1,2026-05-13
overseasamikacin,warfarin,Moderate,Potentially increased anticoagulant effect.,"Aminoglycosides may alter gut flora, affecting vitamin K synthesis.",Monitor INR closely.,1,2026-05-13
overseasamikacin,furosemide,Major,Increased risk of ototoxicity and nephrotoxicity.,Synergistic nephrotoxic and ototoxic effects.,Monitor renal function and hearing; consider alternative diuretic if possible.,1,2026-05-13
lipid,,,,,,1,2026-05-13
renwick health care llpaceclofenac,warfarin,Moderate,Increased risk of bleeding.,NSAIDs can inhibit platelet aggregation and increase gastric irritation.,Monitor for signs of bleeding; consider alternative analgesic.,1,2026-05-13
renwick health care llpaceclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can antagonize the effects of ACE inhibitors on renal function and blood pressure.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
renwick health care llpaceclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,NSAIDs can antagonize the effects of ARBs on renal function and blood pressure.,Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
renwick health care llpaceclofenac,furosemide,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and sodium excretion.",Monitor fluid balance and renal function; consider alternative analgesic.,1,2026-05-13
renwick health care llpaceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive effect on gastric mucosal damage and platelet inhibition.,Use with caution; monitor for GI bleeding.,1,2026-05-13
renwick health care llpaceclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal impairment.,Additive NSAID effects.,Avoid concurrent use; consider alternative analgesic.,1,2026-05-13
renwick health care llpaceclofenac,metformin,Minor,"Slightly increased risk of lactic acidosis, especially in renal impairment.","NSAIDs can impair renal function, increasing metformin accumulation.",Monitor renal function.,1,2026-05-13
actarit,,,,,,1,2026-05-13
prenoxdiazine,,,,,,1,2026-05-13
remington life sciences llprabeprazole,clopidogrel,Moderate,Reduced antiplatelet effect.,"PPIs can inhibit CYP2C19, which is involved in clopidogrel activation.",Monitor for cardiovascular events; consider alternative PPI or proton pump inhibitor.,1,2026-05-13
remington life sciences llprabeprazole,ketoconazole,Moderate,Reduced absorption of ketoconazole.,"PPIs reduce gastric acidity, which is required for ketoconazole absorption.",Administer ketoconazole at least 2 hours before or 10 hours after rabeprazole.,1,2026-05-13
remington life sciences llprabeprazole,itraconazole,Moderate,Reduced absorption of itraconazole.,"PPIs reduce gastric acidity, which is required for itraconazole absorption.",Administer itraconazole at least 2 hours before or 10 hours after rabeprazole.,1,2026-05-13
remington life sciences llprabeprazole,methotrexate,Minor,Potentially increased methotrexate levels.,PPIs may inhibit renal excretion of methotrexate.,Monitor for methotrexate toxicity.,1,2026-05-13
overseasluliconazole,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Azole antifungals can inhibit CYP3A4, which metabolizes atorvastatin.",Monitor for muscle pain and weakness; consider alternative statin.,1,2026-05-13
overseasluliconazole,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Azole antifungals can inhibit CYP2C9, which metabolizes rosuvastatin.",Monitor for muscle pain and weakness; consider alternative statin.,1,2026-05-13
overseasluliconazole,warfarin,Moderate,Increased anticoagulant effect.,"Azole antifungals can inhibit CYP2C9, which metabolizes warfarin.",Monitor INR closely.,1,2026-05-13
overseasluliconazole,cyclosporine,Moderate,Increased cyclosporine levels.,"Azole antifungals can inhibit CYP3A4, which metabolizes cyclosporine.",Monitor cyclosporine levels and renal function.,1,2026-05-13
overseasluliconazole,tacrolimus,Moderate,Increased tacrolimus levels.,"Azole antifungals can inhibit CYP3A4, which metabolizes tacrolimus.",Monitor tacrolimus levels and renal function.,1,2026-05-13
inviscus lifescience llpteneligliptin,,,,,,1,2026-05-13
overseasphenylephrine,atenolol,Moderate,Reduced antihypertensive effect.,Beta-blockers can blunt the reflex tachycardia caused by phenylephrine.,Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
overseasphenylephrine,metoprolol,Moderate,Reduced antihypertensive effect.,Beta-blockers can blunt the reflex tachycardia caused by phenylephrine.,Monitor blood pressure; consider alternative decongestant.,1,2026-05-13
overseasphenylephrine,amitriptyline,Moderate,Increased risk of hypertensive crisis and arrhythmias.,"TCAs can inhibit the reuptake of phenylephrine, potentiating its pressor effect.",Avoid concurrent use; monitor blood pressure closely.,1,2026-05-13
overseasphenylephrine,guanfacine,Major,Hypotension or reduced efficacy of phenylephrine.,"Guanfacine is an alpha-1 adrenergic agonist, can compete with phenylephrine.",Monitor blood pressure; avoid concurrent use if possible.,1,2026-05-13
paraffin liquid,warfarin,Moderate,"Reduced absorption of warfarin, leading to decreased anticoagulant effect.","Mineral oil can impair the absorption of fat-soluble vitamins, including vitamin K.",Monitor INR closely; consider alternative laxative.,1,2026-05-13
paraffin liquid,atorvastatin,Minor,Potentially reduced absorption of atorvastatin.,Mineral oil can interfere with the absorption of fat-soluble drugs.,Monitor lipid levels.,1,2026-05-13
paraffin liquid,rosuvastatin,Minor,Potentially reduced absorption of rosuvastatin.,Mineral oil can interfere with the absorption of fat-soluble drugs.,Monitor lipid levels.,1,2026-05-13
pimobendan,,,,,,1,2026-05-13
quercetin,,,,,,1,2026-05-13
limitedpantoprazole,warfarin,Moderate,Increased bleeding risk.,"Pantoprazole can inhibit CYP2C19, potentially increasing warfarin levels.",Monitor INR closely and adjust warfarin dose if necessary.,1,2026-05-13
limitedpantoprazole,clopidogrel,Moderate,Reduced antiplatelet effect.,"Pantoprazole is a CYP2C19 inhibitor, which can reduce the activation of clopidogrel.",Consider alternative PPI or monitor for thrombotic events.,1,2026-05-13
limitedpantoprazole,ketoconazole,Minor,Decreased absorption of ketoconazole.,"Pantoprazole increases gastric pH, reducing the absorption of weakly basic drugs like ketoconazole.",Administer ketoconazole at least 2 hours before pantoprazole or at a different time of day.,1,2026-05-13
nimotuzumab,,,,,,1,2026-05-13
remington life sciences llpdomperidone,"dopamine agonists (e.g., levodopa)",Minor,Reduced efficacy of dopamine agonists.,Domperidone is a peripheral dopamine antagonist.,Monitor for signs of reduced dopamine agonist efficacy.,1,2026-05-13
remington life sciences llpdomperidone,"qtc prolonging drugs (e.g., amlodipine, metoprolol, haloperidol, clozapine, azithromycin, ciprofloxacin)",Major,Increased risk of torsades de pointes.,Domperidone can prolong the QTc interval.,"Avoid concomitant use; if unavoidable, monitor ECG and electrolytes.",1,2026-05-13
ai health care llpdiclofenac,warfarin,Major,Increased bleeding risk.,NSAIDs like diclofenac can increase the anticoagulant effect of warfarin and also cause gastrointestinal bleeding.,Monitor INR closely; avoid concomitant use if possible or use with extreme caution.,1,2026-05-13
ai health care llpdiclofenac,aspirin,Moderate,Reduced cardioprotective effect of aspirin and increased gastrointestinal risk.,Diclofenac can interfere with the antiplatelet effect of low-dose aspirin and both increase GI risk.,Administer aspirin at least 30 minutes before or 8 hours after diclofenac.,1,2026-05-13
ai health care llpdiclofenac,clopidogrel,Moderate,Increased bleeding risk and potential reduced antiplatelet effect.,NSAIDs increase bleeding risk and may reduce the efficacy of clopidogrel.,Monitor for signs of bleeding; use with caution.,1,2026-05-13
ai health care llpdiclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
ai health care llpdiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and counteracting the effects of ACE inhibitors and ARBs.",Monitor blood pressure and renal function.,1,2026-05-13
ai health care llpdiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and counteracting the effects of diuretics.","Monitor urine output, blood pressure, and renal function.",1,2026-05-13
ai health care llpdiclofenac,spironolactone,Moderate,Increased risk of hyperkalemia and renal dysfunction.,"NSAIDs can impair renal function, and spironolactone can increase potassium levels.",Monitor potassium levels and renal function.,1,2026-05-13
ai health care llpdiclofenac,metformin,Minor,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, increasing the risk of metformin accumulation.",Monitor renal function closely.,1,2026-05-13
ai health care llpdiclofenac,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels closely and avoid concomitant use if possible.,1,2026-05-13
halquinol,,,,,,1,2026-05-13
alister life sciences llpcetrimide,,,,,,1,2026-05-13
adapting electrolyte solutions,digoxin,Major,Increased risk of digoxin toxicity.,Electrolyte imbalances (especially hypokalemia and hypomagnesemia) due to electrolyte solutions can potentiate digoxin's effects.,Monitor electrolytes and digoxin levels closely.,1,2026-05-13
adapting electrolyte solutions,furosemide,Moderate,Exacerbated electrolyte imbalances.,"Furosemide is a loop diuretic that causes electrolyte loss, and electrolyte solutions may aim to correct or supplement these, potentially leading to overcorrection or imbalance.",Carefully monitor electrolyte levels.,1,2026-05-13
adapting electrolyte solutions,spironolactone,Moderate,Increased risk of hyperkalemia.,"Spironolactone is a potassium-sparing diuretic, and excessive potassium administration in electrolyte solutions can lead to dangerously high potassium levels.",Monitor potassium levels closely.,1,2026-05-13
adapting electrolyte solutions,insulin,Minor,Altered glucose control.,"Electrolyte solutions, especially those containing dextrose, can affect blood glucose levels, impacting insulin requirements.",Monitor blood glucose levels closely.,1,2026-05-13
adapting electrolyte solutions,losartan,Moderate,Increased risk of hyperkalemia.,"Losartan is an ARB that can increase potassium levels, and electrolyte solutions with potassium can exacerbate this.",Monitor potassium levels closely.,1,2026-05-13
adapting electrolyte solutions,ramipril,Moderate,Increased risk of hyperkalemia.,"Ramipril is an ACE inhibitor that can increase potassium levels, and electrolyte solutions with potassium can exacerbate this.",Monitor potassium levels closely.,1,2026-05-13
tetrahydrozoline,"monoamine oxidase inhibitors (maois) (not on common list, but relevant)",Major,Hypertensive crisis.,Tetrahydrozoline is a sympathomimetic agent; MAOIs block the metabolism of sympathomimetics.,Avoid concomitant use with MAOIs.,1,2026-05-13
tetrahydrozoline,"beta-blockers (e.g., atenolol, metoprolol)",Moderate,"Bradycardia, hypotension, and rebound congestion.",Both can affect blood pressure and heart rate; additive effects can lead to excessive cardiovascular depression. Rebound congestion with prolonged nasal use.,Use with caution and monitor cardiovascular status. Limit duration of nasal use.,1,2026-05-13
tetrahydrozoline,"tricyclic antidepressants (e.g., amitriptyline)",Minor,Potentiated cardiovascular effects.,"TCAs can have anticholinergic and alpha-adrenergic blocking effects, potentially interacting with sympathomimetic effects of tetrahydrozoline.",Monitor blood pressure and heart rate.,1,2026-05-13
sucralfate,,,,,,1,2026-05-13
chlorpheniramine maleate,diazepam,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,lorazepam,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,alprazolam,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,clonazepam,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,midazolam,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,zolpidem,Moderate,Increased sedation and CNS depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,tramadol,Moderate,Increased sedation and potential for serotonin syndrome.,Additive CNS depressant effects; chlorpheniramine can affect serotonin levels.,Monitor for excessive sedation and signs of serotonin syndrome; use caution.,1,2026-05-13
chlorpheniramine maleate,codeine,Moderate,Increased sedation and respiratory depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
chlorpheniramine maleate,morphine,Moderate,Increased sedation and respiratory depression.,"Both drugs are CNS depressants, leading to additive pharmacodynamic effects.",Monitor for excessive drowsiness and respiratory depression; consider dose adjustment.,1,2026-05-13
cefpodoxime proxetil,,,,,,1,2026-05-13
fexuprazan,,,,,,1,2026-05-13
vaccine,,,,,,1,2026-05-13
ado-trastuzumab emtansine,,,,,,1,2026-05-13
cefixime,,,,,,1,2026-05-13
rabeprazole,,,,,,1,2026-05-13
mac health care,,,,,,1,2026-05-13
naproxen,warfarin,Major,Increased risk of bleeding.,"Naproxen inhibits platelet aggregation and can cause gastrointestinal irritation, increasing bleeding risk in patients on anticoagulants.",Monitor INR closely and watch for signs of bleeding; consider alternative NSAID or antipyretic if possible.,1,2026-05-13
naproxen,clopidogrel,Major,Increased risk of bleeding.,"Naproxen inhibits platelet aggregation, increasing bleeding risk in patients taking antiplatelet agents.",Monitor for signs of bleeding; consider alternative NSAID or antipyretic if possible.,1,2026-05-13
naproxen,aspirin,Moderate,Increased risk of gastrointestinal bleeding and reduced cardioprotective effect of aspirin.,Both agents can cause GI irritation and inhibit platelet function; naproxen may interfere with aspirin's irreversible platelet inhibition.,"Avoid concurrent use or use with caution, spacing doses of aspirin by several hours; monitor for GI bleeding.",1,2026-05-13
naproxen,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal dysfunction.,"Both are NSAIDs with similar mechanisms and side effect profiles, leading to additive effects.",Avoid concurrent use; monitor for GI bleeding and renal function.,1,2026-05-13
naproxen,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, which is important for maintaining renal blood flow and blood pressure, antagonizing ARB effects.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
naproxen,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, which is important for maintaining renal blood flow and blood pressure, antagonizing ACE inhibitor effects.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
naproxen,amlodipine,Moderate,Reduced antihypertensive effect.,NSAIDs can interfere with the antihypertensive effects of calcium channel blockers by causing sodium and water retention.,Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
naproxen,furosemide,Moderate,Reduced diuretic effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced diuretic efficacy.",Monitor for edema and renal function; consider alternative analgesic.,1,2026-05-13
naproxen,spironolactone,Moderate,Reduced diuretic effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, leading to sodium and water retention and reduced diuretic efficacy.",Monitor for edema and renal function; consider alternative analgesic.,1,2026-05-13
naproxen,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which is crucial for metformin excretion, increasing the risk of accumulation and lactic acidosis.",Monitor renal function closely; avoid concurrent use in patients with impaired renal function.,1,2026-05-13
naproxen,prednisolone,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,"Both drugs can cause gastric irritation and damage the GI mucosa, leading to additive effects.",Monitor for signs of GI bleeding; use with caution and consider GI protection.,1,2026-05-13
naproxen,dexamethasone,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,"Both drugs can cause gastric irritation and damage the GI mucosa, leading to additive effects.",Monitor for signs of GI bleeding; use with caution and consider GI protection.,1,2026-05-13
ai health care llppiperacillin,warfarin,Moderate,Increased risk of bleeding.,Piperacillin may inhibit vitamin K synthesis or affect platelet function.,Monitor INR closely. Consider alternative antibiotic if possible or dose adjust warfarin.,1,2026-05-13
ai health care llppiperacillin,metformin,Minor,May slightly alter metformin levels.,Potential interference with renal tubular secretion of metformin.,Monitor blood glucose levels.,1,2026-05-13
limitedfenofibrate,warfarin,Major,Increased risk of bleeding.,"Fenofibrate displaces warfarin from protein-binding sites, increasing free warfarin concentration.",Monitor INR very closely and adjust warfarin dose as needed. Consider alternative lipid-lowering agent.,1,2026-05-13
limitedfenofibrate,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can cause myopathy; additive effect.,"Monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative agents.",1,2026-05-13
limitedfenofibrate,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can cause myopathy; additive effect.,"Monitor for muscle pain, tenderness, or weakness. Consider lower doses or alternative agents.",1,2026-05-13
euphoria life sciences llpdomperidone,ketoconazole,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
euphoria life sciences llpdomperidone,azithromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Azithromycin can prolong the QT interval, and domperidone has proarrhythmic potential.",Use with caution. Monitor for cardiac side effects. Avoid if patient has risk factors for QT prolongation.,1,2026-05-13
euphoria life sciences llpdomperidone,clarithromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
euphoria life sciences llpdomperidone,erythromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
euphoria life sciences llpdomperidone,itraconazole,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Itraconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
euphoria life sciences llpdomperidone,cisapride,Major,Increased risk of QT prolongation and potentially fatal cardiac arrhythmias (torsades de pointes).,"Both drugs can prolong the QT interval, and cisapride is known to cause arrhythmias.",Contraindicated. Domperidone is contraindicated in patients taking cisapride.,1,2026-05-13
overseasxylometazoline,atenolol,Moderate,May potentiate the hypertensive effect of xylometazoline or cause reflex tachycardia.,"Beta-blockers can blunt the reflex tachycardia associated with vasodilators, potentially leading to unopposed alpha-adrenergic effects.",Monitor blood pressure. Use with caution.,1,2026-05-13
overseasxylometazoline,metoprolol,Moderate,May potentiate the hypertensive effect of xylometazoline or cause reflex tachycardia.,"Beta-blockers can blunt the reflex tachycardia associated with vasodilators, potentially leading to unopposed alpha-adrenergic effects.",Monitor blood pressure. Use with caution.,1,2026-05-13
overseasxylometazoline,atenolol,Moderate,May cause paradoxical increase in blood pressure.,Xylometazoline is a vasoconstrictor; beta-blockers can unmask unopposed alpha-adrenergic stimulation.,Monitor blood pressure closely. Use with caution.,1,2026-05-13
overseasxylometazoline,metoprolol,Moderate,May cause paradoxical increase in blood pressure.,Xylometazoline is a vasoconstrictor; beta-blockers can unmask unopposed alpha-adrenergic stimulation.,Monitor blood pressure closely. Use with caution.,1,2026-05-13
limitedacebrophylline,theophylline,Moderate,Increased risk of theophylline toxicity.,Acebrophylline is a derivative of theophylline; additive effects.,Monitor theophylline levels. Use with caution and consider dose reduction of either agent.,1,2026-05-13
limitedacebrophylline,ciprofloxacin,Moderate,Increased risk of theophylline toxicity.,"Ciprofloxacin inhibits CYP1A2, the enzyme that metabolizes theophylline, increasing its plasma concentration.",Monitor theophylline levels closely. Consider alternative antibiotic or dose adjustment of theophylline.,1,2026-05-13
limitedacebrophylline,erythromycin,Moderate,Increased risk of theophylline toxicity.,"Erythromycin inhibits CYP1A2, the enzyme that metabolizes theophylline, increasing its plasma concentration.",Monitor theophylline levels closely. Consider alternative antibiotic or dose adjustment of theophylline.,1,2026-05-13
alister life sciences llpurea,lithium,Moderate,"Reduced lithium clearance, leading to increased lithium levels and potential toxicity.","Urea is a diuretic and can affect renal function, potentially impairing lithium excretion.",Monitor lithium levels closely. Adjust lithium dose if necessary.,1,2026-05-13
renwick health care llpl-arginine,atorvastatin,Minor,May increase risk of hypotension.,"L-arginine can lower blood pressure, potentially potentiating hypotensive effects of antihypertensives.",Monitor blood pressure. Use with caution.,1,2026-05-13
renwick health care llpl-arginine,amlodipine,Minor,May increase risk of hypotension.,"L-arginine can lower blood pressure, potentially potentiating hypotensive effects of antihypertensives.",Monitor blood pressure. Use with caution.,1,2026-05-13
renwick health care llpl-arginine,losartan,Minor,May increase risk of hypotension.,"L-arginine can lower blood pressure, potentially potentiating hypotensive effects of antihypertensives.",Monitor blood pressure. Use with caution.,1,2026-05-13
renwick health care llpl-arginine,ramipril,Minor,May increase risk of hypotension.,"L-arginine can lower blood pressure, potentially potentiating hypotensive effects of antihypertensives.",Monitor blood pressure. Use with caution.,1,2026-05-13
renwick health care llpl-arginine,warfarin,Minor,Theoretical risk of affecting coagulation.,L-arginine may have mild antiplatelet effects.,Monitor coagulation parameters. Use with caution.,1,2026-05-13
ai health care llpcefuroxime,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins can inhibit vitamin K synthesis or affect platelet function.,Monitor INR closely. Consider alternative antibiotic if possible or dose adjust warfarin.,1,2026-05-13
ai health care llpcefuroxime,probenecid,Moderate,Increased cefuroxime levels and potential for toxicity.,Probenecid inhibits renal tubular secretion of cefuroxime.,Monitor for signs of cefuroxime toxicity. Dose adjustment of cefuroxime may be needed.,1,2026-05-13
xrdomperidone,ketoconazole,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Ketoconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
xrdomperidone,azithromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Azithromycin can prolong the QT interval, and domperidone has proarrhythmic potential.",Use with caution. Monitor for cardiac side effects. Avoid if patient has risk factors for QT prolongation.,1,2026-05-13
xrdomperidone,clarithromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Clarithromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
xrdomperidone,erythromycin,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Erythromycin inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
xrdomperidone,itraconazole,Moderate,Increased risk of QT prolongation and cardiac arrhythmias.,"Itraconazole inhibits CYP3A4, the enzyme that metabolizes domperidone, increasing its plasma concentration.",Avoid co-administration. Monitor for cardiac side effects.,1,2026-05-13
xrdomperidone,cisapride,Major,Increased risk of QT prolongation and potentially fatal cardiac arrhythmias (torsades de pointes).,"Both drugs can prolong the QT interval, and cisapride is known to cause arrhythmias.",Contraindicated. Domperidone is contraindicated in patients taking cisapride.,1,2026-05-13
limitedleflunomide,warfarin,Moderate,Increased risk of bleeding.,Leflunomide can affect platelet aggregation and increase INR.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
limitedleflunomide,cholestyramine,Major,Reduced absorption and efficacy of leflunomide.,"Cholestyramine binds to the active metabolite of leflunomide (teriflunomide), enhancing its elimination.","Avoid concomitant use. If co-administration is necessary, teriflunomide levels should be monitored, and leflunomide dose increased.",1,2026-05-13
limitedleflunomide,rifampicin,Moderate,"Increased levels of teriflunomide, the active metabolite of leflunomide, potentially increasing toxicity.","Rifampicin can induce enzymes that metabolize teriflunomide, but its effect on leflunomide is complex and can lead to higher levels.",Monitor for signs of leflunomide toxicity. Consider dose reduction or closer monitoring.,1,2026-05-13
limitedleflunomide,methotrexate,Moderate,Increased risk of liver toxicity.,Both drugs are hepatotoxic; additive effect.,Monitor liver function tests closely. Use with caution and consider alternative agents.,1,2026-05-13
human antitetanus immunoglobulin,,,,,,1,2026-05-13
ai health care llptobramycin,furosemide,Moderate,Increased risk of ototoxicity and nephrotoxicity.,Concomitant administration can potentiate the ototoxic and nephrotoxic effects of both drugs.,Monitor renal function and hearing; consider alternative diuretic if necessary.,1,2026-05-13
ai health care llptobramycin,cyclosporine,Moderate,Increased risk of nephrotoxicity.,Amikacin can increase serum creatinine levels and potentiate nephrotoxicity.,Monitor renal function closely; consider alternative antibiotic.,1,2026-05-13
ai health care llptobramycin,tacrolimus,Moderate,Increased risk of nephrotoxicity.,Amikacin can increase serum creatinine levels and potentiate nephrotoxicity.,Monitor renal function closely; consider alternative antibiotic.,1,2026-05-13
penicillin,methotrexate,Moderate,Reduced clearance and increased toxicity of methotrexate.,Penicillins can inhibit the renal tubular secretion of methotrexate.,Monitor methotrexate levels and for signs of toxicity; consider dose adjustment or alternative antibiotic.,1,2026-05-13
penicillin,probenecid,Moderate,Increased serum concentrations and prolonged half-life of penicillin.,Probenecid competitively inhibits the renal tubular secretion of penicillin.,Consider dose adjustment of penicillin if concomitant use is necessary.,1,2026-05-13
overseastranexamic acid,oral contraceptives,Moderate,Increased risk of thromboembolic events.,Both increase the risk of thrombosis.,Exercise caution and monitor for signs of thrombosis.,1,2026-05-13
overseastranexamic acid,"factor concentrate (e.g., activated prothrombin complex concentrate)",Moderate,Increased risk of thrombosis.,Concurrent administration may increase the risk of thrombotic events.,Use with caution and monitor for signs of thrombosis.,1,2026-05-13
zeaxanthin,,,,,,1,2026-05-13
overseashydroquinone,,,,,,1,2026-05-13
embramine,"central nervous system depressants (e.g., alcohol, benzodiazepines, opioids)",Moderate,Potentiated sedation and CNS depression.,Additive sedative effects.,"Avoid concomitant use or use with extreme caution, monitoring for excessive sedation.",1,2026-05-13
embramine,tricyclic antidepressants,Moderate,Increased anticholinergic effects and potential for additive CNS depression.,Both have anticholinergic properties and can cause sedation.,Monitor for increased anticholinergic side effects and sedation.,1,2026-05-13
skanttr lifescience llpamoxycillin,allopurinol,Moderate,Increased incidence of rash.,"Concomitant use may increase the risk of hypersensitivity reactions, particularly rash.",Monitor for rash; consider alternative antibiotic if rash develops.,1,2026-05-13
skanttr lifescience llpamoxycillin,probenecid,Moderate,Increased serum concentrations and prolonged half-life of amoxicillin.,Probenecid competitively inhibits the renal tubular secretion of amoxicillin.,Consider dose adjustment of amoxicillin if concomitant use is necessary.,1,2026-05-13
skanttr lifescience llpamoxycillin,oral contraceptives,Minor,Potential for reduced efficacy of oral contraceptives.,"Antibiotics can alter the gut flora, potentially affecting estrogen enterohepatic circulation.",Advise patients to use an additional form of contraception.,1,2026-05-13
limitedivermectin,cyclosporine,Moderate,Increased serum concentrations of cyclosporine.,"Ivermectin may inhibit P-glycoprotein, a transporter involved in cyclosporine efflux.",Monitor cyclosporine levels and for signs of toxicity; consider dose adjustment.,1,2026-05-13
limitedivermectin,"p-glycoprotein inhibitors (e.g., amiodarone, verapamil)",Moderate,Increased risk of ivermectin toxicity.,Inhibition of P-glycoprotein can lead to increased ivermectin concentrations.,Monitor for signs of ivermectin toxicity.,1,2026-05-13
enalaprilat,"potassium-sparing diuretics (e.g., spironolactone)",Major,Hyperkalemia.,Both agents can increase serum potassium levels.,Monitor serum potassium levels closely; avoid concurrent use if possible or use with extreme caution.,1,2026-05-13
enalaprilat,"nsaids (e.g., ibuprofen, aspirin)",Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, reducing the vasodilatory effects of ACE inhibitors and impairing renal function.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
enalaprilat,lithium,Moderate,Increased serum lithium levels and risk of lithium toxicity.,ACE inhibitors can reduce renal excretion of lithium.,Monitor lithium levels closely; consider dose adjustment of lithium.,1,2026-05-13
enalaprilat,"diuretics (e.g., furosemide, hydrochlorothiazide)",Moderate,Increased risk of hypotension and renal impairment.,"Diuretics can lead to volume depletion, which may be exacerbated by enalaprilat, increasing the risk of hypotension and acute kidney injury.",Monitor blood pressure and renal function; ensure adequate hydration.,1,2026-05-13
low dextrans,,,,,,1,2026-05-13
serenoa repens,warfarin,Minor,Increased risk of bleeding.,May have mild antiplatelet effects.,Monitor INR closely.,1,2026-05-13
serenoa repens,clopidogrel,Minor,Increased risk of bleeding.,May have mild antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
overseasampicillin,,,,,,1,2026-05-13
limitedchlorpheniramine maleate,tramadol,Moderate,Increased sedation and anticholinergic effects.,Both have CNS depressant and anticholinergic properties.,"Use with caution, monitor for excessive drowsiness.",1,2026-05-13
limitedchlorpheniramine maleate,codeine,Moderate,Increased sedation and anticholinergic effects.,Both have CNS depressant and anticholinergic properties.,"Use with caution, monitor for excessive drowsiness.",1,2026-05-13
limitedchlorpheniramine maleate,morphine,Moderate,Increased sedation and anticholinergic effects.,Both have CNS depressant and anticholinergic properties.,"Use with caution, monitor for excessive drowsiness.",1,2026-05-13
limitedchlorpheniramine maleate,alprazolam,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,diazepam,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,lorazepam,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,clonazepam,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,midazolam,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,zolpidem,Moderate,Increased sedation and central nervous system depression.,Both are CNS depressants.,Monitor for excessive sedation.,1,2026-05-13
limitedchlorpheniramine maleate,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, urinary retention).",Both have anticholinergic properties.,Monitor for anticholinergic side effects.,1,2026-05-13
almagate,warfarin,Minor,"May decrease absorption of warfarin, affecting INR.",Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,metformin,Minor,May decrease absorption of metformin.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,atenolol,Minor,May decrease absorption of atenolol.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,metoprolol,Minor,May decrease absorption of metoprolol.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,amlodipine,Minor,May decrease absorption of amlodipine.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,losartan,Minor,May decrease absorption of losartan.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,digoxin,Minor,May decrease absorption of digoxin.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,gabapentin,Minor,May decrease absorption of gabapentin.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
almagate,lithium,Minor,May decrease absorption of lithium.,Antacids can alter gastric pH and drug absorption.,Separate administration by at least 2 hours.,1,2026-05-13
limitednitrofurantoin,probenecid,Major,Reduced nitrofurantoin efficacy and increased risk of toxicity.,Probenecid inhibits renal tubular secretion of nitrofurantoin.,Avoid concurrent use.,1,2026-05-13
limitednitrofurantoin,metformin,Minor,"Potential for altered metformin levels, though clinical significance is debated.",Nitrofurantoin may interfere with renal clearance of metformin.,Monitor blood glucose closely.,1,2026-05-13
ultimedixmethylcobalamin,,,,,,1,2026-05-13
denvis life sciences llpaceclofenac,warfarin,Major,Increased risk of bleeding and gastrointestinal ulceration.,NSAIDs inhibit platelet aggregation and can cause gastric erosion.,Avoid concurrent use; monitor INR and for GI bleeding.,1,2026-05-13
denvis life sciences llpaceclofenac,clopidogrel,Major,Increased risk of bleeding and gastrointestinal ulceration.,NSAIDs inhibit platelet aggregation and can cause gastric erosion.,Avoid concurrent use; monitor for GI bleeding.,1,2026-05-13
denvis life sciences llpaceclofenac,aspirin,Moderate,Increased risk of gastrointestinal ulceration and bleeding.,Both can cause gastric irritation and inhibit prostaglandins.,Use with caution; consider gastroprotection.,1,2026-05-13
denvis life sciences llpaceclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
denvis life sciences llpaceclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow.",Monitor blood pressure and renal function.,1,2026-05-13
denvis life sciences llpaceclofenac,amlodipine,Moderate,Reduced antihypertensive effect.,NSAIDs can reduce the effectiveness of calcium channel blockers.,Monitor blood pressure.,1,2026-05-13
denvis life sciences llpaceclofenac,furosemide,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and sodium excretion.",Monitor urine output and renal function.,1,2026-05-13
denvis life sciences llpaceclofenac,spironolactone,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, affecting renal blood flow and sodium excretion.",Monitor urine output and renal function.,1,2026-05-13
denvis life sciences llpaceclofenac,lithium,Major,"Increased serum lithium levels, risk of toxicity.",NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels closely; avoid concurrent use if possible.,1,2026-05-13
denvis life sciences llpaceclofenac,methotrexate,Major,Increased methotrexate toxicity due to reduced renal clearance.,NSAIDs can inhibit the renal excretion of methotrexate.,Monitor for methotrexate toxicity; avoid concurrent use if possible.,1,2026-05-13
limitedpolymyxin b,nephrotoxic drugs,Major,Increased risk of nephrotoxicity.,Both agents have the potential to damage the kidneys.,Monitor renal function closely; avoid concurrent use if possible.,1,2026-05-13
limitedpolymyxin b,neuromuscular blocking agents,Major,Increased risk of neuromuscular blockade and respiratory depression.,Polymyxin B can potentiate the effects of neuromuscular blockers.,Monitor neuromuscular function and respiratory status.,1,2026-05-13
docaravimab,,,,,,1,2026-05-13
miromavimab,,,,,,1,2026-05-13
alister life sciences llpliquid paraffin,,,,,,1,2026-05-13
ai health care llptrypsin,,,,,,1,2026-05-13
auxilium medicare life science llpdomperidone,tramadol,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
auxilium medicare life science llpdomperidone,codeine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
auxilium medicare life science llpdomperidone,morphine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
auxilium medicare life science llpdomperidone,haloperidol,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,Both drugs are known QTc prolonging agents.,"Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider lower doses.",1,2026-05-13
auxilium medicare life science llpdomperidone,sertraline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
auxilium medicare life science llpdomperidone,fluoxetine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
auxilium medicare life science llpdomperidone,amitriptyline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
auxilium medicare life science llpdomperidone,ciprofloxacin,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,"Ciprofloxacin is a known QTc prolonging agent, and domperidone also carries this risk.","Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider alternative antibiotics.",1,2026-05-13
auxilium medicare life science llpdomperidone,azithromycin,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,"Azithromycin is a known QTc prolonging agent, and domperidone also carries this risk.","Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider alternative antibiotics.",1,2026-05-13
auxilium medicare life science llpdomperidone,methotrexate,Minor,"Domperidone may reduce the renal clearance of methotrexate, potentially leading to increased toxicity.",Domperidone can inhibit certain transporters involved in methotrexate excretion.,Monitor for signs of methotrexate toxicity.,1,2026-05-13
delon lifescience llpdomperidone,tramadol,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
delon lifescience llpdomperidone,codeine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
delon lifescience llpdomperidone,morphine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated, consider alternative analgesics if QTc prolongation is a concern.",1,2026-05-13
delon lifescience llpdomperidone,haloperidol,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,Both drugs are known QTc prolonging agents.,"Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider lower doses.",1,2026-05-13
delon lifescience llpdomperidone,sertraline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
delon lifescience llpdomperidone,fluoxetine,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
delon lifescience llpdomperidone,amitriptyline,Moderate,Increased risk of QTc prolongation and arrhythmias.,Both drugs can prolong the QTc interval.,"Use with caution, monitor ECG if indicated.",1,2026-05-13
delon lifescience llpdomperidone,ciprofloxacin,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,"Ciprofloxacin is a known QTc prolonging agent, and domperidone also carries this risk.","Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider alternative antibiotics.",1,2026-05-13
delon lifescience llpdomperidone,azithromycin,Major,Significantly increased risk of QTc prolongation and potentially fatal arrhythmias (torsades de pointes).,"Azithromycin is a known QTc prolonging agent, and domperidone also carries this risk.","Avoid concomitant use. If co-administration is unavoidable, monitor ECG closely and consider alternative antibiotics.",1,2026-05-13
delon lifescience llpdomperidone,methotrexate,Minor,"Domperidone may reduce the renal clearance of methotrexate, potentially leading to increased toxicity.",Domperidone can inhibit certain transporters involved in methotrexate excretion.,Monitor for signs of methotrexate toxicity.,1,2026-05-13
erenumab,,,,,,1,2026-05-13
permethrin topical,,,,,,1,2026-05-13
sodium dihydrogen phosphate dihydrate,,,,,,1,2026-05-13
life gem medi health care,,,,,,1,2026-05-13
overseascarbamazepine,warfarin,Major,"Carbamazepine can induce CYP1A2 and CYP3A4, leading to decreased warfarin levels and reduced anticoagulant effect.",Enzyme induction.,Monitor INR closely and adjust warfarin dose as needed. Consider alternative anticonvulsants if possible.,1,2026-05-13
overseascarbamazepine,atorvastatin,Major,"Carbamazepine can decrease atorvastatin levels, reducing its efficacy.",Enzyme induction.,Monitor lipid levels and consider increasing atorvastatin dose or using an alternative statin.,1,2026-05-13
overseascarbamazepine,rosuvastatin,Major,"Carbamazepine can decrease rosuvastatin levels, reducing its efficacy.",Enzyme induction.,Monitor lipid levels and consider increasing rosuvastatin dose or using an alternative statin.,1,2026-05-13
overseascarbamazepine,amoxicillin,Minor,"Carbamazepine can induce enzymes that metabolize amoxicillin, potentially reducing its effectiveness.",Enzyme induction.,Monitor for signs of infection and consider increased amoxicillin dose if necessary.,1,2026-05-13
overseascarbamazepine,azithromycin,Moderate,"Carbamazepine can induce enzymes that metabolize azithromycin, potentially reducing its effectiveness.  Although azithromycin is less affected by induction than some other macrolides, it's still a consideration.",Enzyme induction.,Monitor for signs of infection and consider increased azithromycin dose if necessary.,1,2026-05-13
overseascarbamazepine,ciprofloxacin,Major,"Carbamazepine can decrease ciprofloxacin levels, potentially leading to treatment failure.",Enzyme induction.,Monitor for signs of infection and consider increased ciprofloxacin dose or alternative antibiotic.,1,2026-05-13
overseascarbamazepine,metronidazole,Minor,"Carbamazepine can induce enzymes that metabolize metronidazole, potentially reducing its effectiveness.",Enzyme induction.,Monitor for signs of infection and consider increased metronidazole dose if necessary.,1,2026-05-13
overseascarbamazepine,prednisolone,Major,"Carbamazepine can significantly increase the metabolism of corticosteroids, reducing their anti-inflammatory and immunosuppressive effects.",Enzyme induction.,Monitor for signs of underlying condition worsening and consider increasing prednisolone dose.,1,2026-05-13
overseascarbamazepine,dexamethasone,Major,"Carbamazepine can significantly increase the metabolism of corticosteroids, reducing their anti-inflammatory and immunosuppressive effects.",Enzyme induction.,Monitor for signs of underlying condition worsening and consider increasing dexamethasone dose.,1,2026-05-13
overseascarbamazepine,insulin,Moderate,"Carbamazepine can affect glycemic control, potentially leading to hyperglycemia or hypoglycemia.",Complex effects on glucose metabolism.,Monitor blood glucose levels closely and adjust insulin dose as needed.,1,2026-05-13
overseascarbamazepine,metformin,Moderate,"Carbamazepine can affect glycemic control, potentially leading to hyperglycemia or hypoglycemia.",Complex effects on glucose metabolism.,Monitor blood glucose levels closely and adjust metformin dose as needed.,1,2026-05-13
overseascarbamazepine,furosemide,Minor,"Carbamazepine can decrease the effectiveness of furosemide, leading to reduced diuresis.",Possible induction of hepatic enzymes involved in furosemide metabolism.,Monitor for edema and adjust furosemide dose if necessary.,1,2026-05-13
overseascarbamazepine,spironolactone,Minor,"Carbamazepine can decrease the effectiveness of spironolactone, leading to reduced diuresis or antihypertensive effect.",Possible induction of hepatic enzymes involved in spironolactone metabolism.,Monitor for edema or elevated blood pressure and adjust spironolactone dose if necessary.,1,2026-05-13
overseascarbamazepine,atenolol,Minor,"Carbamazepine may decrease the serum concentrations of atenolol, potentially reducing its antihypertensive effect.",Possible induction of hepatic enzymes involved in atenolol metabolism.,Monitor blood pressure and adjust atenolol dose if necessary.,1,2026-05-13
overseascarbamazepine,metoprolol,Minor,"Carbamazepine may decrease the serum concentrations of metoprolol, potentially reducing its antihypertensive effect.",Possible induction of hepatic enzymes involved in metoprolol metabolism.,Monitor blood pressure and adjust metoprolol dose if necessary.,1,2026-05-13
overseascarbamazepine,ramipril,Minor,"Carbamazepine may decrease the serum concentrations of ramipril, potentially reducing its antihypertensive effect.",Possible induction of hepatic enzymes involved in ramipril metabolism.,Monitor blood pressure and adjust ramipril dose if necessary.,1,2026-05-13
overseascarbamazepine,clopidogrel,Moderate,"Carbamazepine can induce CYP2C19, which is involved in the activation of clopidogrel, potentially leading to reduced antiplatelet effect.",Enzyme induction.,Monitor for signs of thrombosis and consider alternative antiplatelet agent if necessary.,1,2026-05-13
overseascarbamazepine,digoxin,Major,"Carbamazepine can decrease digoxin levels by inducing P-glycoprotein, a transporter responsible for digoxin excretion.",Induction of efflux transporter.,Monitor digoxin levels and clinical signs of heart failure. May require increased digoxin dose.,1,2026-05-13
overseascarbamazepine,sertraline,Minor,Carbamazepine may affect sertraline levels.,Potential for enzyme induction or inhibition.,Monitor for signs of serotonin syndrome or reduced antidepressant effect.,1,2026-05-13
overseascarbamazepine,fluoxetine,Minor,Carbamazepine may affect fluoxetine levels.,Potential for enzyme induction or inhibition.,Monitor for signs of serotonin syndrome or reduced antidepressant effect.,1,2026-05-13
overseascarbamazepine,alprazolam,Major,"Carbamazepine can significantly reduce alprazolam levels, potentially leading to loss of anxiolytic or sedative effect.",Enzyme induction (CYP3A4).,Monitor for breakthrough anxiety or seizures. May require significant increase in alprazolam dose or alternative benzodiazepine.,1,2026-05-13
overseascarbamazepine,diazepam,Major,"Carbamazepine can significantly reduce diazepam levels, potentially leading to loss of anxiolytic or sedative effect.",Enzyme induction (CYP3A4).,Monitor for breakthrough anxiety or seizures. May require significant increase in diazepam dose or alternative benzodiazepine.,1,2026-05-13
overseascarbamazepine,lorazepam,Minor,Carbamazepine may affect lorazepam levels.,Potential for enzyme induction or inhibition.,Monitor for changes in sedation or efficacy.,1,2026-05-13
overseascarbamazepine,clonazepam,Minor,Carbamazepine may affect clonazepam levels.,Potential for enzyme induction or inhibition.,Monitor for changes in efficacy or side effects.,1,2026-05-13
overseascarbamazepine,midazolam,Major,"Carbamazepine can significantly reduce midazolam levels, potentially leading to reduced sedative effect.",Enzyme induction (CYP3A4).,Monitor for inadequate sedation. May require increased midazolam dose.,1,2026-05-13
overseascarbamazepine,zolpidem,Major,"Carbamazepine can significantly reduce zolpidem levels, potentially leading to reduced hypnotic effect.",Enzyme induction (CYP3A4).,Monitor for insomnia and consider alternative hypnotic agent or increased zolpidem dose.,1,2026-05-13
overseascarbamazepine,cyclosporine,Major,"Carbamazepine significantly reduces cyclosporine levels, increasing the risk of organ rejection.",Enzyme induction (CYP3A4).,Monitor cyclosporine levels very closely and adjust dose upwards as needed. Consider alternative anticonvulsant if possible.,1,2026-05-13
overseascarbamazepine,tacrolimus,Major,"Carbamazepine significantly reduces tacrolimus levels, increasing the risk of organ rejection.",Enzyme induction (CYP3A4).,Monitor tacrolimus levels very closely and adjust dose upwards as needed. Consider alternative anticonvulsant if possible.,1,2026-05-13
overseascarbamazepine,lithium,Moderate,"Increased risk of neurotoxicity (tremor, ataxia, confusion) when combined.",Additive neurotoxic effects.,Monitor for neurotoxicity symptoms. Consider lower doses of one or both agents.,1,2026-05-13
overseascarbamazepine,haloperidol,Minor,Carbamazepine can affect haloperidol levels.,Potential for enzyme induction or inhibition.,Monitor for changes in antipsychotic efficacy or side effects.,1,2026-05-13
overseascarbamazepine,clozapine,Major,Carbamazepine can reduce clozapine levels and increase the risk of neutropenia.,Enzyme induction and potential for bone marrow suppression.,"Avoid concomitant use. Monitor CBC closely. If co-administration is necessary, increase clozapine dose cautiously and monitor blood counts.",1,2026-05-13
overseascarbamazepine,olanzapine,Minor,Carbamazepine can affect olanzapine levels.,Potential for enzyme induction or inhibition.,Monitor for changes in antipsychotic efficacy or side effects.,1,2026-05-13
overseascarbamazepine,phenytoin,Major,"Carbamazepine can induce phenytoin metabolism, leading to decreased phenytoin levels and potential loss of seizure control.",Enzyme induction.,Monitor phenytoin levels and seizure frequency. May require increased phenytoin dose.,1,2026-05-13
overseascarbamazepine,valproate,Major,"Carbamazepine can induce valproate metabolism, decreasing its levels and efficacy. Valproate can also displace carbamazepine from plasma proteins, leading to increased free carbamazepine and potential toxicity.",Enzyme induction and protein binding displacement.,Monitor levels of both drugs and clinical response. Adjust doses as needed. Increased risk of carbamazepine toxicity and valproate toxicity.,1,2026-05-13
overseascarbamazepine,rifampicin,Major,"Rifampicin is a potent inducer of CYP enzymes and can significantly decrease carbamazepine levels, leading to loss of seizure control.",Potent enzyme induction.,"Avoid concomitant use. If unavoidable, monitor carbamazepine levels and seizure frequency very closely and increase carbamazepine dose significantly.",1,2026-05-13
overseascarbamazepine,isoniazid,Minor,Carbamazepine can affect isoniazid levels. Isoniazid can inhibit carbamazepine metabolism.,Complex interactions involving enzyme induction and inhibition.,Monitor for changes in efficacy or toxicity of both drugs.,1,2026-05-13
overseascarbamazepine,ethambutol,No significant interaction,,,,1,2026-05-13
overseascarbamazepine,hydroxychloroquine,Minor,Carbamazepine may affect hydroxychloroquine levels.,Potential for enzyme induction or inhibition.,Monitor for changes in efficacy or side effects.,1,2026-05-13
overseascarbamazepine,colchicine,Minor,Carbamazepine may affect colchicine levels.,Potential for enzyme induction or inhibition.,Monitor for changes in efficacy or side effects.,1,2026-05-13
overseascarbamazepine,allopurinol,Minor,"Allopurinol may increase the serum concentration of carbamazepine, increasing the risk of carbamazepine toxicity.",Inhibition of CYP enzymes involved in carbamazepine metabolism.,"Monitor for carbamazepine toxicity symptoms (dizziness, drowsiness, nausea, ataxia). Consider lower doses of carbamazepine.",1,2026-05-13
overseascarbamazepine,methotrexate,Minor,Carbamazepine can affect methotrexate levels.,Potential for enzyme induction or inhibition.,Monitor for changes in efficacy or toxicity of both drugs.,1,2026-05-13
cadsol life sciences llpdapagliflozin,metformin,Moderate,Increased risk of hypoglycemia or lactic acidosis.,"Dapagliflozin can enhance glucose excretion, potentially lowering blood glucose too much when combined with metformin.",Monitor blood glucose closely; adjust metformin dose if necessary.,1,2026-05-13
cadsol life sciences llpdapagliflozin,insulin,Moderate,Increased risk of hypoglycemia.,"Dapagliflozin lowers blood glucose, which can potentiate the effect of insulin.",Monitor blood glucose closely; consider dose reduction of insulin.,1,2026-05-13
cadsol life sciences llpdapagliflozin,furosemide,Moderate,Increased risk of dehydration and hypotension.,"Both are diuretics, leading to additive diuretic effects.",Monitor hydration status and blood pressure; adjust diuretic dose if needed.,1,2026-05-13
overseas escitalopram oxalate,tramadol,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels in the brain.,Monitor for signs and symptoms of serotonin syndrome.,1,2026-05-13
overseas escitalopram oxalate,codeine,Moderate,Potentially reduced efficacy of codeine and increased risk of serotonin syndrome.,"SSRIs can inhibit CYP2D6, which is needed to convert codeine to its active metabolite morphine; also increased serotonin.",Consider alternative analgesics or monitor for efficacy and signs of serotonin syndrome.,1,2026-05-13
overseas escitalopram oxalate,morphine,Minor,Potentially increased risk of serotonin syndrome.,Both drugs can affect serotonin levels.,Monitor for signs and symptoms of serotonin syndrome.,1,2026-05-13
overseas escitalopram oxalate,diazepam,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseas escitalopram oxalate,alprazolam,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseas escitalopram oxalate,lorazepam,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseas escitalopram oxalate,clonazepam,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseas escitalopram oxalate,midazolam,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseas escitalopram oxalate,zolpidem,Minor,Potentially increased sedation.,Both drugs are central nervous system depressants.,Monitor for increased sedation.,1,2026-05-13
overseascefotaxime,,,,,,1,2026-05-13
skanttr lifescience llpaceclofenac,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs can inhibit platelet aggregation and increase the risk of gastrointestinal bleeding, potentiating warfarin's anticoagulant effect.","Monitor INR closely; use with caution, or consider alternative analgesic.",1,2026-05-13
skanttr lifescience llpaceclofenac,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Additive effects on gastric mucosa and platelet function.,Avoid concurrent use; use with caution if necessary and monitor for GI symptoms.,1,2026-05-13
skanttr lifescience llpaceclofenac,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and renal impairment.,Additive NSAID effects.,Avoid concurrent use; use with caution if necessary and monitor for GI symptoms and renal function.,1,2026-05-13
skanttr lifescience llpaceclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilatory effects of losartan and affecting renal blood flow.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpaceclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilatory effects of ramipril and affecting renal blood flow.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpaceclofenac,amlodipine,Minor,Reduced antihypertensive effect.,NSAIDs can interfere with the action of calcium channel blockers.,Monitor blood pressure; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpaceclofenac,metformin,Minor,Increased risk of renal impairment.,"NSAIDs can impair renal function, potentially leading to accumulation of metformin.",Monitor renal function.,1,2026-05-13
skanttr lifescience llpaceclofenac,furosemide,Moderate,"Reduced diuretic and antihypertensive effect, increased risk of renal impairment.","NSAIDs can inhibit prostaglandin synthesis, reducing renal blood flow and the effectiveness of furosemide.","Monitor blood pressure, renal function, and fluid balance.",1,2026-05-13
skanttr lifescience llpaceclofenac,spironolactone,Moderate,Increased risk of hyperkalemia and renal impairment.,Additive effects on renal function and potassium balance.,Monitor potassium levels and renal function.,1,2026-05-13
eucalyptus oil,,,,,,1,2026-05-13
hamoxycillin,methotrexate,Moderate,Increased risk of methotrexate toxicity.,Penicillins can inhibit the renal excretion of methotrexate.,Monitor methotrexate levels and for signs of toxicity; adjust methotrexate dose if necessary.,1,2026-05-13
hamoxycillin,probenecid,Moderate,Increased amoxicillin serum concentrations.,Probenecid inhibits the renal tubular secretion of amoxicillin.,Monitor for increased amoxicillin efficacy or side effects.,1,2026-05-13
limiteddoxycycline,warfarin,Moderate,Increased anticoagulant effect of warfarin.,"Doxycycline can inhibit the metabolism of warfarin by gut bacteria, leading to increased INR.",Monitor INR closely; adjust warfarin dose if necessary.,1,2026-05-13
limiteddoxycycline,iron supplements,Major,Reduced absorption of doxycycline.,"Divalent and trivalent cations such as iron chelate with tetracyclines, significantly reducing oral absorption.",Separate administration by at least 2-3 hours.,1,2026-05-13
limiteddoxycycline,"antacids containing aluminum, calcium, or magnesium",Major,Reduced absorption of doxycycline.,"These cations chelate with doxycycline, significantly reducing oral absorption.",Separate administration by at least 2-3 hours.,1,2026-05-13
limiteddoxycycline,calcium supplements,Major,Reduced absorption of doxycycline.,"Calcium chelates with doxycycline, significantly reducing oral absorption.",Separate administration by at least 2-3 hours.,1,2026-05-13
limiteddoxycycline,milk and dairy products,Major,Reduced absorption of doxycycline.,"Calcium in dairy products chelates with doxycycline, significantly reducing oral absorption.",Avoid concurrent administration; take doxycycline at least 2 hours before or after dairy.,1,2026-05-13
limiteddoxycycline,phenytoin,Moderate,Reduced efficacy of doxycycline.,Phenytoin can induce liver enzymes that metabolize doxycycline.,Monitor for signs of doxycycline treatment failure.,1,2026-05-13
limiteddoxycycline,valproate,Minor,No clinically significant interactions identified.,No significant interaction.,No specific action required.,1,2026-05-13
limiteddoxycycline,isotretinoin,Moderate,Increased risk of pseudotumor cerebri.,Both can be associated with increased intracranial pressure.,Monitor for signs of increased intracranial pressure.,1,2026-05-13
overseascefixime,warfarin,Moderate,Increased risk of bleeding.,"Cephalosporins can interfere with vitamin K synthesis by gut bacteria, potentially increasing the anticoagulant effect of warfarin.",Monitor INR closely; adjust warfarin dose if necessary.,1,2026-05-13
overseascefixime,probenecid,Moderate,Increased cefixime serum concentrations.,Probenecid inhibits the renal tubular secretion of cefixime.,Monitor for increased cefixime efficacy or side effects.,1,2026-05-13
benzoxonium chloride,,,,,,1,2026-05-13
overseaslevofloxacin,warfarin,Moderate,Increased anticoagulant effect of warfarin.,"Fluoroquinolones can inhibit the metabolism of warfarin by CYP enzymes, leading to increased INR.",Monitor INR closely; adjust warfarin dose if necessary.,1,2026-05-13
overseaslevofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Levofloxacin can affect glucose metabolism.,Monitor blood glucose levels closely.,1,2026-05-13
overseaslevofloxacin,theophylline,Moderate,Increased risk of theophylline toxicity.,Levofloxacin can inhibit the metabolism of theophylline.,Monitor theophylline levels and for signs of toxicity; adjust theophylline dose if necessary.,1,2026-05-13
overseaslevofloxacin,"corticosteroids (e.g., prednisolone, dexamethasone)",Moderate,Increased risk of tendon rupture.,Concurrent use of fluoroquinolones and corticosteroids has been associated with an increased risk of tendonitis and tendon rupture.,Avoid concurrent use if possible; counsel patient on risk.,1,2026-05-13
overseaslevofloxacin,phenytoin,Moderate,Reduced efficacy of phenytoin.,Levofloxacin can inhibit the absorption of phenytoin.,Monitor phenytoin levels and for seizure activity.,1,2026-05-13
overseaslevofloxacin,calcium supplements,Major,Reduced absorption of levofloxacin.,"Divalent and trivalent cations such as calcium chelate with fluoroquinolones, significantly reducing oral absorption.",Separate administration by at least 2 hours before or 4 hours after calcium supplements.,1,2026-05-13
overseaslevofloxacin,"antacids containing aluminum, calcium, or magnesium",Major,Reduced absorption of levofloxacin.,"These cations chelate with levofloxacin, significantly reducing oral absorption.",Separate administration by at least 2 hours before or 4 hours after antacids.,1,2026-05-13
overseaslevofloxacin,iron supplements,Major,Reduced absorption of levofloxacin.,"Divalent and trivalent cations such as iron chelate with fluoroquinolones, significantly reducing oral absorption.",Separate administration by at least 2 hours before or 4 hours after iron supplements.,1,2026-05-13
overseaslevofloxacin,sucralfate,Major,Reduced absorption of levofloxacin.,"Sucralfate can bind to levofloxacin, reducing its absorption.",Separate administration by at least 2 hours.,1,2026-05-13
overseasamlodipine,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Amlodipine may inhibit CYP3A4 metabolism of atorvastatin.,Monitor for muscle pain; consider atorvastatin dose reduction.,1,2026-05-13
overseasamlodipine,simvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Amlodipine may inhibit CYP3A4 metabolism of simvastatin.,Monitor for muscle pain; consider simvastatin dose reduction.,1,2026-05-13
overseasamlodipine,digoxin,Minor,Slightly increased digoxin levels.,Amlodipine can reduce renal clearance of digoxin.,Monitor digoxin levels if concerns arise.,1,2026-05-13
overseasamlodipine,atenolol,Minor,Additive hypotensive effects.,Both drugs lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
overseasamlodipine,metoprolol,Minor,Additive hypotensive effects.,Both drugs lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
overseasamlodipine,ramipril,Minor,Additive hypotensive effects.,Both drugs lower blood pressure.,Monitor blood pressure closely.,1,2026-05-13
overseasamlodipine,clopidogrel,Minor,Potential for reduced antiplatelet effect of clopidogrel.,Amlodipine may interfere with clopidogrel's metabolism.,Monitor for cardiovascular events.,1,2026-05-13
overseassucralfate,ciprofloxacin,Major,Reduced absorption and efficacy of ciprofloxacin.,"Sucralfate forms a complex with quinolones, reducing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
overseassucralfate,levofloxacin,Major,Reduced absorption and efficacy of levofloxacin.,"Sucralfate forms a complex with quinolones, reducing their bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
overseassucralfate,tetracycline,Major,Reduced absorption and efficacy of tetracycline.,"Sucralfate can bind to tetracyclines, impairing absorption.",Separate administration by at least 2 hours.,1,2026-05-13
overseassucralfate,warfarin,Minor,Potentially reduced absorption of warfarin.,"Sucralfate may bind to warfarin, reducing its bioavailability.",Monitor INR closely; separate administration.,1,2026-05-13
overseassucralfate,digoxin,Minor,Reduced absorption of digoxin.,"Sucralfate can bind to digoxin, reducing its bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
sharma orthopedic,,,,,,1,2026-05-13
iron hydroxide polymaltose,ciprofloxacin,Major,Significantly reduced absorption and efficacy of ciprofloxacin.,"Iron ions chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 4 hours.,1,2026-05-13
iron hydroxide polymaltose,levofloxacin,Major,Significantly reduced absorption and efficacy of levofloxacin.,"Iron ions chelate with fluoroquinolones, forming insoluble complexes.",Separate administration by at least 4 hours.,1,2026-05-13
iron hydroxide polymaltose,tetracycline,Major,Significantly reduced absorption and efficacy of tetracycline.,"Iron ions chelate with tetracyclines, forming insoluble complexes.",Separate administration by at least 4 hours.,1,2026-05-13
iron hydroxide polymaltose,levothyroxine,Major,Reduced absorption and efficacy of levothyroxine.,"Iron binds to levothyroxine, reducing its bioavailability.",Separate administration by at least 4 hours.,1,2026-05-13
iron hydroxide polymaltose,warfarin,Minor,Potentially reduced absorption of warfarin.,"Iron may bind to warfarin, reducing its bioavailability.",Monitor INR closely; separate administration.,1,2026-05-13
iron hydroxide polymaltose,atorvastatin,Minor,Potentially reduced absorption of atorvastatin.,"Iron may bind to atorvastatin, reducing its bioavailability.",Monitor lipid levels; separate administration.,1,2026-05-13
iron hydroxide polymaltose,rosuvastatin,Minor,Potentially reduced absorption of rosuvastatin.,"Iron may bind to rosuvastatin, reducing its bioavailability.",Monitor lipid levels; separate administration.,1,2026-05-13
limitedtadalafil,"nitrates (e.g., nitroglycerin, isosorbide mononitrate)",Major,Severe and potentially fatal hypotension.,Tadalafil can potentiate the vasodilatory effects of nitrates.,Contraindicated. Avoid concurrent use.,1,2026-05-13
limitedtadalafil,"alpha-blockers (e.g., prazosin, terazosin, doxazosin)",Moderate,"Hypotension, dizziness, syncope.",Both drugs can cause vasodilation and lower blood pressure.,Use with caution; monitor blood pressure closely.,1,2026-05-13
limitedtadalafil,atorvastatin,Minor,No significant interaction expected; monitor for muscle pain.,Both are metabolized by CYP3A4 but unlikely to have clinically significant interaction.,Monitor for myopathy if concerns arise.,1,2026-05-13
limitedtadalafil,rosuvastatin,Minor,No significant interaction expected; monitor for muscle pain.,No major CYP interactions expected.,Monitor for myopathy if concerns arise.,1,2026-05-13
ai health care llpcefpodoxime proxetil,metformin,Minor,Rare reports of increased metformin levels.,Cephalosporins may rarely affect renal tubular secretion of metformin.,Monitor glucose control; watch for signs of hypoglycemia.,1,2026-05-13
advent life sciences llpcefuroxime,metformin,Minor,Rare reports of increased metformin levels.,Cephalosporins may rarely affect renal tubular secretion of metformin.,Monitor glucose control; watch for signs of hypoglycemia.,1,2026-05-13
amineptine,,,,,,1,2026-05-13
overseaslansoprazole,warfarin,Moderate,Increased INR and risk of bleeding.,Proton pump inhibitors can inhibit CYP2C9 metabolism of warfarin.,Monitor INR closely; consider dose adjustment of warfarin.,1,2026-05-13
overseaslansoprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Lansoprazole is a CYP2C19 inhibitor, reducing conversion of clopidogrel to its active metabolite.",Avoid concurrent use if possible; consider alternative PPI or antacid.,1,2026-05-13
overseaslansoprazole,methotrexate,Moderate,Increased methotrexate levels and toxicity.,Proton pump inhibitors can decrease renal clearance of methotrexate.,Monitor methotrexate levels and for signs of toxicity.,1,2026-05-13
overseaslansoprazole,ketoconazole,Moderate,Reduced absorption of ketoconazole.,"Lansoprazole increases gastric pH, reducing absorption of acid-dependent drugs.",Separate administration by at least 2 hours.,1,2026-05-13
overseaslansoprazole,itraconazole,Moderate,Reduced absorption of itraconazole.,"Lansoprazole increases gastric pH, reducing absorption of acid-dependent drugs.",Separate administration by at least 2 hours.,1,2026-05-13
overseaslansoprazole,digoxin,Minor,Potentially increased digoxin levels.,PPIs can affect gastric motility and absorption.,Monitor digoxin levels and for toxicity.,1,2026-05-13
limitedglutathione,,,,,,1,2026-05-13
astra idl maxcetrimide,,,,,,1,2026-05-13
overseagabapentin,gabapentin,Major,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
overseagabapentin,alprazolam,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,diazepam,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,lorazepam,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,clonazepam,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,midazolam,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,zolpidem,Major,"Enhanced sedation, respiratory depression, and impaired cognitive function.",Pharmacodynamic interaction with synergistic CNS depressant effects.,"Avoid concomitant use if possible; if necessary, use lowest effective doses and monitor closely for respiratory depression and sedation.",1,2026-05-13
overseagabapentin,tramadol,Moderate,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
overseagabapentin,codeine,Moderate,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
overseagabapentin,morphine,Moderate,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
overseascefepime,,,,,,1,2026-05-13
crizanlizumab,,,,,,1,2026-05-13
alister life sciences llpclobetasol,,,,,,1,2026-05-13
astra idl maxglimepiride,metformin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose closely; consider dose adjustment.,1,2026-05-13
astra idl maxglimepiride,insulin,Major,Increased risk of severe hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose closely; adjust doses of both medications to avoid hypoglycemia.,1,2026-05-13
overseassparfloxacin,warfarin,Major,Increased risk of bleeding.,Fluoroquinolones can inhibit warfarin metabolism by CYP2C9.,Monitor INR closely; adjust warfarin dose if necessary.,1,2026-05-13
overseassparfloxacin,theophylline,Moderate,"Increased theophylline levels, leading to toxicity.",Fluoroquinolones can inhibit the metabolism of theophylline.,Monitor theophylline levels and for signs of toxicity; consider alternative antibiotic or dose adjustment of theophylline.,1,2026-05-13
overseassparfloxacin,digoxin,Moderate,Increased digoxin levels.,Possible effect on digoxin absorption or excretion.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
hcholine,,,,,,1,2026-05-13
aviptadil,,,,,,1,2026-05-13
biomedicare,,,,,,1,2026-05-13
valent,,,,,,1,2026-05-13
overseasdesloratadine,,,,,,1,2026-05-13
indocyanine green,,,,,,1,2026-05-13
limitedterbinafine,warfarin,Moderate,Increased risk of bleeding.,Terbinafine inhibits CYP2C9 which metabolizes warfarin.,Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
limitedterbinafine,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Terbinafine may inhibit CYP3A4, which metabolizes atorvastatin.",Consider alternative statin or monitor for muscle pain.,1,2026-05-13
limitedterbinafine,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Terbinafine may inhibit CYP2C9, which metabolizes rosuvastatin.",Consider alternative statin or monitor for muscle pain.,1,2026-05-13
overseastramadol,sertraline,Moderate,Increased risk of serotonin syndrome.,Both tramadol and sertraline increase serotonin levels.,Monitor for symptoms of serotonin syndrome and consider alternative analgesics or antidepressants.,1,2026-05-13
overseastramadol,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both tramadol and fluoxetine increase serotonin levels.,Monitor for symptoms of serotonin syndrome and consider alternative analgesics or antidepressants.,1,2026-05-13
overseastramadol,amitriptyline,Moderate,Increased risk of serotonin syndrome and CNS depression.,Tramadol increases serotonin; amitriptyline can potentiate CNS effects.,Use with caution and monitor for adverse effects.,1,2026-05-13
overseastramadol,diazepam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,alprazolam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,lorazepam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,clonazepam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,midazolam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,zolpidem,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both drugs have CNS depressant effects.,Monitor for excessive sedation and respiratory depression; reduce doses if necessary.,1,2026-05-13
overseastramadol,codeine,Moderate,Increased risk of respiratory depression and sedation.,Both are opioid analgesics with additive CNS depressant effects.,Use with caution and monitor for signs of respiratory depression.,1,2026-05-13
overseastramadol,morphine,Moderate,Increased risk of respiratory depression and sedation.,Both are opioid analgesics with additive CNS depressant effects.,Use with caution and monitor for signs of respiratory depression.,1,2026-05-13
ai health care llpparacetamol,,,,,,1,2026-05-13
aster zenith bioscience llpofloxacin,warfarin,Moderate,Increased risk of bleeding.,"Ciprofloxacin inhibits CYP1A2 and CYP3A4, which can affect warfarin metabolism.",Monitor INR closely and adjust warfarin dose if needed.,1,2026-05-13
aster zenith bioscience llpofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can increase metformin levels and enhance its hypoglycemic effect.,Monitor blood glucose closely and adjust metformin dose if needed.,1,2026-05-13
aster zenith bioscience llpofloxacin,omeprazole,Minor,May increase the risk of QT prolongation.,Both drugs can prolong the QT interval.,Use with caution and monitor ECG if risk factors are present.,1,2026-05-13
aster zenith bioscience llpofloxacin,pantoprazole,Minor,May increase the risk of QT prolongation.,Both drugs can prolong the QT interval.,Use with caution and monitor ECG if risk factors are present.,1,2026-05-13
aster zenith bioscience llpofloxacin,digoxin,Minor,May increase digoxin levels.,Fluoroquinolones can affect drug transporters involved in digoxin elimination.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
aster zenith bioscience llpofloxacin,phenytoin,Moderate,May affect phenytoin levels.,Fluoroquinolones can interfere with phenytoin metabolism or protein binding.,Monitor phenytoin levels and for signs of toxicity or subtherapeutic effects.,1,2026-05-13
aster zenith bioscience llpofloxacin,clopidogrel,Minor,Potential for reduced efficacy of clopidogrel.,"Ciprofloxacin can inhibit CYP2C19, which is involved in clopidogrel activation.",Consider alternative antibiotic or monitor for thrombotic events.,1,2026-05-13
zorg life sciences,,,,,,1,2026-05-13
butyl alcohol,,,,,,1,2026-05-13
limitedindomethacin,warfarin,Major,Increased risk of bleeding.,"NSAIDs inhibit platelet aggregation and can cause gastrointestinal irritation, potentiating warfarin's anticoagulant effect.","Avoid co-administration; if necessary, monitor INR very closely and consider gastroprotection.",1,2026-05-13
limitedindomethacin,losartan,Moderate,Reduced antihypertensive effect of losartan; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow and the action of ARBs.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
limitedindomethacin,ramipril,Moderate,Reduced antihypertensive effect of ramipril; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow and the action of ACE inhibitors.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
limitedindomethacin,amlodipine,Moderate,Reduced antihypertensive effect of amlodipine; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow and the action of calcium channel blockers.",Monitor blood pressure and renal function; consider alternative analgesic.,1,2026-05-13
limitedindomethacin,furosemide,Moderate,Reduced diuretic and antihypertensive effect of furosemide; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, which is important for renal blood flow and the action of loop diuretics.","Monitor for edema, blood pressure, and renal function; consider alternative analgesic.",1,2026-05-13
limitedindomethacin,aspirin,Major,Increased risk of gastrointestinal bleeding and ulceration; reduced antiplatelet effect of low-dose aspirin.,Both are NSAIDs; concomitant use increases gastrointestinal risk. Indomethacin can displace aspirin from protein binding sites.,"Avoid co-administration; if low-dose aspirin is for cardioprotection, consider an alternative NSAID with lower GI risk and separate administration times.",1,2026-05-13
limitedindomethacin,metformin,Moderate,Increased risk of lactic acidosis; reduced renal excretion of indomethacin.,"NSAIDs can impair renal function, which is crucial for metformin excretion.",Monitor renal function closely; consider alternative analgesic.,1,2026-05-13
limitedindomethacin,prednisolone,Major,Markedly increased risk of gastrointestinal bleeding and ulceration.,Both increase the risk of gastrointestinal mucosal damage.,"Avoid co-administration; if necessary, use gastroprotection (PPI).",1,2026-05-13
limitedindomethacin,dexamethasone,Major,Markedly increased risk of gastrointestinal bleeding and ulceration.,Both increase the risk of gastrointestinal mucosal damage.,"Avoid co-administration; if necessary, use gastroprotection (PPI).",1,2026-05-13
limitedindomethacin,lithium,Moderate,Increased lithium levels and risk of toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels and renal function; reduce lithium dose if necessary.,1,2026-05-13
green tea extract,warfarin,Moderate,"Reduced anticoagulant effect, increased risk of thrombosis.",Vitamin K content in green tea can counteract warfarin.,Monitor INR closely; avoid high doses of green tea.,1,2026-05-13
green tea extract,atorvastatin,Minor,Potentially altered statin efficacy.,Green tea may affect CYP2C9 metabolism of atorvastatin.,Monitor lipid levels; consider alternative if concerns arise.,1,2026-05-13
green tea extract,rosuvastatin,Minor,Potentially altered statin efficacy.,Green tea may affect CYP2C9 metabolism of rosuvastatin.,Monitor lipid levels; consider alternative if concerns arise.,1,2026-05-13
ginseng extract,warfarin,Moderate,"Variable effect on INR, potential for bleeding or thrombosis.",Ginseng can affect platelet aggregation and CYP enzyme activity.,Monitor INR closely; use with caution and avoid high doses.,1,2026-05-13
ginseng extract,metformin,Moderate,Hypoglycemia or hyperglycemia.,Ginseng can affect blood glucose levels.,Monitor blood glucose closely; adjust metformin dose if necessary.,1,2026-05-13
ginseng extract,atorvastatin,Minor,Potentially altered statin efficacy.,Ginseng may interact with CYP enzymes involved in statin metabolism.,Monitor lipid levels; consider alternative if concerns arise.,1,2026-05-13
ginseng extract,rosuvastatin,Minor,Potentially altered statin efficacy.,Ginseng may interact with CYP enzymes involved in statin metabolism.,Monitor lipid levels; consider alternative if concerns arise.,1,2026-05-13
ginseng extract,insulin,Moderate,Hypoglycemia.,Ginseng can lower blood glucose levels.,Monitor blood glucose closely; adjust insulin dose if necessary.,1,2026-05-13
ginseng extract,clopidogrel,Minor,May slightly increase bleeding risk.,Ginseng has antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
tadalafil ip,"nitrates (not on list, but relevant context)",Major,"Severe hypotension, syncope, or cardiovascular events.",Tadalafil potentiates the vasodilatory effects of nitrates.,Contraindicated. Strict avoidance of nitrates.,1,2026-05-13
tadalafil ip,amlodipine,Moderate,Increased risk of hypotension and dizziness.,"Both are vasodilators, additive effect.",Monitor blood pressure; use with caution.,1,2026-05-13
tadalafil ip,atenolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure.,Monitor blood pressure; use with caution.,1,2026-05-13
tadalafil ip,metoprolol,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure.,Monitor blood pressure; use with caution.,1,2026-05-13
tadalafil ip,losartan,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure.,Monitor blood pressure; use with caution.,1,2026-05-13
tadalafil ip,ramipril,Moderate,Increased risk of hypotension and dizziness.,Both can lower blood pressure.,Monitor blood pressure; use with caution.,1,2026-05-13
sodium acid phosphate,calcium supplements (not on list),Minor,Reduced absorption of calcium.,"Phosphate can bind with calcium, forming insoluble salts.",Separate administration by at least 2 hours.,1,2026-05-13
health care llpaspirin,warfarin,Major,Increased risk of bleeding.,Both inhibit platelet aggregation and affect clotting.,Avoid concurrent use; monitor closely if unavoidable.,1,2026-05-13
health care llpaspirin,clopidogrel,Major,Significantly increased risk of bleeding.,"Dual antiplatelet therapy, additive effect.",Use with extreme caution; monitor for bleeding.,1,2026-05-13
health care llpaspirin,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,"Both are NSAIDs, additive gastric insult.",Avoid concurrent use; use lowest effective doses.,1,2026-05-13
health care llpaspirin,methotrexate,Moderate,Increased methotrexate toxicity.,Aspirin can displace methotrexate from protein binding sites and reduce renal clearance.,Monitor for signs of methotrexate toxicity; avoid concurrent use if possible.,1,2026-05-13
health care llpaspirin,prednisolone,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Corticosteroids and NSAIDs have additive gastrointestinal effects.,Monitor for GI symptoms; consider gastroprotective agents.,1,2026-05-13
health care llpaspirin,dexamethasone,Moderate,Increased risk of gastrointestinal bleeding and ulcers.,Corticosteroids and NSAIDs have additive gastrointestinal effects.,Monitor for GI symptoms; consider gastroprotective agents.,1,2026-05-13
health care llpaspirin,allopurinol,Minor,May decrease uricosuric effect of allopurinol.,Aspirin can interfere with renal excretion of uric acid.,Monitor uric acid levels.,1,2026-05-13
overseaslidocaine,"antiarrhythmics (e.g., amiodarone, not on list)",Moderate,Increased risk of cardiotoxicity.,Additive effects on cardiac conduction.,Monitor cardiac function; use with caution.,1,2026-05-13
overseaslidocaine,"beta-blockers (e.g., atenolol, metoprolol)",Moderate,Increased risk of bradycardia and hypotension.,Additive depressant effects on cardiac function.,Monitor heart rate and blood pressure.,1,2026-05-13
ai health care llpphenylephrine,mao inhibitors (not on list),Major,Hypertensive crisis.,Phenylephrine is a sympathomimetic; MAOIs block its metabolism.,Contraindicated. Strict avoidance of MAOIs.,1,2026-05-13
ai health care llpphenylephrine,"beta-blockers (e.g., atenolol, metoprolol)",Moderate,Increased risk of hypertension.,Phenylephrine's alpha-agonist effects may be unopposed by beta-blockade.,Monitor blood pressure closely.,1,2026-05-13
ai health care llpphenylephrine,"tricyclic antidepressants (e.g., amitriptyline)",Moderate,Increased risk of hypertension.,TCAs can potentiate sympathomimetic effects.,Monitor blood pressure.,1,2026-05-13
ai health care llpphenylephrine,losartan,Minor,May reduce antihypertensive effect.,Phenylephrine is a vasoconstrictor that can increase blood pressure.,Monitor blood pressure.,1,2026-05-13
ai health care llpphenylephrine,amlodipine,Minor,May reduce antihypertensive effect.,Phenylephrine is a vasoconstrictor that can increase blood pressure.,Monitor blood pressure.,1,2026-05-13
fish oil,warfarin,Minor,Slightly increased risk of bleeding.,Fish oil has mild antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
fish oil,clopidogrel,Minor,Slightly increased risk of bleeding.,Fish oil has mild antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
ai health care llpdicyclomine,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention).",Both are anticholinergic agents.,Monitor for anticholinergic side effects.,1,2026-05-13
ai health care llpdicyclomine,lorazepam,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
ai health care llpdicyclomine,clonazepam,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
ai health care llpdicyclomine,diazepam,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
ai health care llpdicyclomine,alprazolam,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
ai health care llpdicyclomine,zolpidem,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
ai health care llpdicyclomine,gabapentin,Minor,Increased sedation and anticholinergic effects.,Dicyclomine has mild anticholinergic effects that can potentiate sedation.,Monitor for increased sedation.,1,2026-05-13
limitedcalcium dobesilate,,,,,,1,2026-05-13
meningococcal,,,,,,1,2026-05-13
polysaccharide vaccine,,,,,,1,2026-05-13
lactose,,,,,,1,2026-05-13
ai health care llpceftriaxone,warfarin,Minor,Increased risk of bleeding.,"Ceftriaxone may interfere with vitamin K synthesis, affecting warfarin's anticoagulant effect.",Monitor INR closely.,1,2026-05-13
ai health care llpceftriaxone,metformin,Minor,Potential for altered glycemic control.,Ceftriaxone can rarely affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
ai health care llpceftriaxone,probenecid,Minor,Increased ceftriaxone levels and potential for toxicity.,Probenecid inhibits the renal excretion of ceftriaxone.,Reduce ceftriaxone dose or monitor for toxicity.,1,2026-05-13
ai health care llpmetformin,iodinated contrast media,Major,Risk of lactic acidosis.,Renal impairment caused by contrast media can lead to metformin accumulation.,Discontinue metformin before contrast and restart after renal function is confirmed normal.,1,2026-05-13
ai health care llpmetformin,furosemide,Minor,Increased risk of metformin accumulation and lactic acidosis.,Furosemide can acutely impair renal function.,Monitor renal function and blood glucose.,1,2026-05-13
ai health care llpmetformin,cimetidine,Minor,Increased metformin levels and potential for lactic acidosis.,Cimetidine reduces metformin clearance.,Monitor blood glucose and renal function.,1,2026-05-13
ai health care llpmetformin,corticosteroids,Minor,"Hyperglycemia, counteracting metformin's effect.",Corticosteroids increase glucose production and insulin resistance.,Monitor blood glucose levels closely.,1,2026-05-13
tetrachlorodecaoxygen anion,,,,,,1,2026-05-13
certoparin,aspirin,Moderate,Increased risk of bleeding.,Both drugs inhibit platelet aggregation.,Avoid concurrent use or use with extreme caution and close monitoring.,1,2026-05-13
certoparin,ibuprofen,Moderate,Increased risk of bleeding.,Both drugs inhibit platelet aggregation and can cause gastrointestinal irritation.,Avoid concurrent use or use with extreme caution and close monitoring.,1,2026-05-13
certoparin,warfarin,Major,Significantly increased risk of bleeding.,"Both are anticoagulants, leading to additive effects.","Avoid concurrent use. If necessary, monitor INR very closely and adjust doses.",1,2026-05-13
certoparin,clopidogrel,Moderate,Increased risk of bleeding.,Both drugs inhibit platelet aggregation.,Avoid concurrent use or use with extreme caution and close monitoring.,1,2026-05-13
hbromhexine,,,,,,1,2026-05-13
dexamethasone intravitreal implant,prednisolone,Minor,Increased risk of systemic corticosteroid side effects.,Additive corticosteroid effect.,Monitor for systemic corticosteroid adverse effects.,1,2026-05-13
dexamethasone intravitreal implant,dexamethasone,Minor,Increased risk of systemic corticosteroid side effects.,Additive corticosteroid effect.,Monitor for systemic corticosteroid adverse effects.,1,2026-05-13
aster zenith bioscience llpceftriaxone,warfarin,Minor,Increased risk of bleeding.,"Ceftriaxone may interfere with vitamin K synthesis, affecting warfarin's anticoagulant effect.",Monitor INR closely.,1,2026-05-13
aster zenith bioscience llpceftriaxone,metformin,Minor,Potential for altered glycemic control.,Ceftriaxone can rarely affect glucose metabolism.,Monitor blood glucose levels.,1,2026-05-13
aster zenith bioscience llpceftriaxone,probenecid,Minor,Increased ceftriaxone levels and potential for toxicity.,Probenecid inhibits the renal excretion of ceftriaxone.,Reduce ceftriaxone dose or monitor for toxicity.,1,2026-05-13
remington life sciences llppioglitazone,metformin,Moderate,Increased risk of lactic acidosis.,Pioglitazone can impair renal excretion of metformin.,Monitor renal function and blood glucose closely; consider dose adjustment of metformin.,1,2026-05-13
remington life sciences llppioglitazone,insulin,Moderate,Increased risk of hypoglycemia and fluid retention.,"Pioglitazone enhances insulin sensitivity, potentially leading to additive hypoglycemic effects and fluid shifts.",Monitor blood glucose levels and for signs of fluid retention; adjust insulin dose if necessary.,1,2026-05-13
remington life sciences llppioglitazone,furosemide,Minor,Potentially increased risk of edema.,"Pioglitazone can cause fluid retention, and furosemide's diuretic effect may be counteracted.",Monitor for edema; adjust diuretic dose if needed.,1,2026-05-13
remington life sciences llppioglitazone,spironolactone,Minor,Potentially increased risk of edema.,"Pioglitazone can cause fluid retention, and spironolactone's diuretic effect may be counteracted.",Monitor for edema; adjust diuretic dose if needed.,1,2026-05-13
antithymocyte immunoglobulins,,,,,,1,2026-05-13
matrubhumi chemical,,,,,,1,2026-05-13
linoleic acid,,,,,,1,2026-05-13
astra idl maxtramadol,alprazolam,Major,"Increased risk of sedation, respiratory depression, and death.","Both tramadol and alprazolam are CNS depressants, potentiating each other's effects.","Avoid concomitant use; if necessary, use the lowest effective doses for the shortest possible duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
astra idl maxtramadol,diazepam,Major,"Increased risk of sedation, respiratory depression, and death.","Both tramadol and diazepam are CNS depressants, potentiating each other's effects.","Avoid concomitant use; if necessary, use the lowest effective doses for the shortest possible duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
astra idl maxtramadol,lorazepam,Major,"Increased risk of sedation, respiratory depression, and death.","Both tramadol and lorazepam are CNS depressants, potentiating each other's effects.","Avoid concomitant use; if necessary, use the lowest effective doses for the shortest possible duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
astra idl maxtramadol,clonazepam,Major,"Increased risk of sedation, respiratory depression, and death.","Both tramadol and clonazepam are CNS depressants, potentiating each other's effects.","Avoid concomitant use; if necessary, use the lowest effective doses for the shortest possible duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
astra idl maxtramadol,midazolam,Major,"Increased risk of sedation, respiratory depression, and death.","Both tramadol and midazolam are CNS depressants, potentiating each other's effects.","Avoid concomitant use; if necessary, use the lowest effective doses for the shortest possible duration and monitor closely for respiratory depression and sedation.",1,2026-05-13
astra idl maxtramadol,morphine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression; consider dose adjustments.,1,2026-05-13
astra idl maxtramadol,codeine,Moderate,Increased risk of sedation and respiratory depression.,Additive CNS depressant effects and potential for increased opioid effects.,Monitor for increased sedation and respiratory depression; consider dose adjustments.,1,2026-05-13
astra idl maxtramadol,sertraline,Moderate,Increased risk of serotonin syndrome.,"Tramadol can inhibit serotonin reuptake, increasing the risk when combined with SSRIs.","Monitor for signs and symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle rigidity).",1,2026-05-13
astra idl maxtramadol,fluoxetine,Moderate,Increased risk of serotonin syndrome.,"Tramadol can inhibit serotonin reuptake, increasing the risk when combined with SSRIs.","Monitor for signs and symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle rigidity).",1,2026-05-13
astra idl maxtramadol,amitriptyline,Moderate,Increased risk of sedation and dizziness.,Additive CNS depressant effects.,Monitor for increased sedation and dizziness; consider dose adjustments.,1,2026-05-13
astra idl maxtramadol,phenytoin,Moderate,Reduced efficacy of tramadol and potential for increased phenytoin levels.,Phenytoin is a potent enzyme inducer that can increase the metabolism of tramadol.,Monitor for reduced pain relief and potential phenytoin toxicity; consider alternative analgesics.,1,2026-05-13
astra idl maxtramadol,carbamazepine,Moderate,Reduced efficacy of tramadol and potential for increased carbamazepine levels.,Carbamazepine is an enzyme inducer that can increase the metabolism of tramadol.,Monitor for reduced pain relief and potential carbamazepine toxicity; consider alternative analgesics.,1,2026-05-13
astra idl maxtramadol,warfarin,Minor,Potential for increased anticoagulant effect.,Tramadol may affect platelet aggregation and increase the risk of bleeding.,"Monitor INR closely, especially when initiating or discontinuing tramadol.",1,2026-05-13
astra idl maxtramadol,clopidogrel,Minor,Potential for increased bleeding risk.,Tramadol may affect platelet aggregation.,Monitor for signs of bleeding.,1,2026-05-13
isoflavone,,,,,,1,2026-05-13
limitedticarcillin,aspirin,Minor,Increased risk of bleeding.,Both ticarcillin and aspirin can affect platelet function.,"Monitor for signs of bleeding, especially if other risk factors are present.",1,2026-05-13
limitedticarcillin,ibuprofen,Minor,Increased risk of bleeding.,Both ticarcillin and ibuprofen can affect platelet function.,"Monitor for signs of bleeding, especially if other risk factors are present.",1,2026-05-13
limitedticarcillin,warfarin,Minor,Increased risk of bleeding.,"Antibiotics can alter gut flora and vitamin K production, potentially affecting warfarin's anticoagulant effect.","Monitor INR closely, especially if given long-term.",1,2026-05-13
limitedticarcillin,clopidogrel,Minor,Increased risk of bleeding.,Both ticarcillin and clopidogrel can affect platelet function.,"Monitor for signs of bleeding, especially if other risk factors are present.",1,2026-05-13
choline dihydrogen citrate,,,,,,1,2026-05-13
marine triglycerides,,,,,,1,2026-05-13
euphoria life sciences llppantoprazole,clopidogrel,Moderate,Reduced antiplatelet efficacy of clopidogrel.,"Pantoprazole is a CYP2C19 inhibitor, which can reduce the conversion of clopidogrel to its active metabolite.",Consider alternative PPIs or monitor for cardiovascular events closely.,1,2026-05-13
euphoria life sciences llppantoprazole,warfarin,Minor,Potential for altered INR.,PPIs can affect the metabolism of warfarin.,Monitor INR closely.,1,2026-05-13
euphoria life sciences llppantoprazole,digoxin,Minor,Potentially increased digoxin levels.,Gastric pH changes induced by PPIs may affect digoxin absorption.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
euphoria life sciences llppantoprazole,methotrexate,Minor,Potentially increased methotrexate levels.,PPIs may decrease the renal excretion of methotrexate.,,1,2026-05-13
overseasguaifenesin,,,,,,1,2026-05-13
bacillus calmette-guerin strain,,,,,,1,2026-05-13
limiteddeflazacort,warfarin,Moderate,Increased risk of bleeding.,"Corticosteroids can alter the metabolism of vitamin K, which is essential for warfarin's anticoagulant effect.",Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
limiteddeflazacort,metformin,Moderate,Hyperglycemia; reduced glycemic control.,"Corticosteroids antagonize the effects of insulin, leading to increased blood glucose levels.",Monitor blood glucose more frequently and adjust metformin dose or add insulin if necessary.,1,2026-05-13
limiteddeflazacort,atorvastatin,Minor,Increased risk of myopathy.,"Corticosteroids can increase muscle breakdown, potentially exacerbating statin-induced myopathy.",Monitor for muscle pain and weakness.,1,2026-05-13
limiteddeflazacort,amlodipine,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,losartan,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,omeprazole,Minor,Increased risk of gastrointestinal adverse effects.,"Corticosteroids can increase the risk of peptic ulcers and GI bleeding, which may be additive with PPIs.",Monitor for GI symptoms.,1,2026-05-13
limiteddeflazacort,pantoprazole,Minor,Increased risk of gastrointestinal adverse effects.,"Corticosteroids can increase the risk of peptic ulcers and GI bleeding, which may be additive with PPIs.",Monitor for GI symptoms.,1,2026-05-13
limiteddeflazacort,insulin,Moderate,Hyperglycemia; reduced glycemic control.,"Corticosteroids antagonize the effects of insulin, leading to increased blood glucose levels.",Monitor blood glucose more frequently and adjust insulin dose as needed.,1,2026-05-13
limiteddeflazacort,furosemide,Moderate,Hypokalemia.,"Corticosteroids can promote potassium excretion, leading to hypokalemia, which is also a side effect of loop diuretics.",Monitor potassium levels and consider potassium supplementation.,1,2026-05-13
limiteddeflazacort,spironolactone,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,atenolol,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,metoprolol,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,ramipril,Minor,Potential for reduced antihypertensive effect.,"Corticosteroids can cause sodium and water retention, potentially counteracting antihypertensive medications.",Monitor blood pressure closely.,1,2026-05-13
limiteddeflazacort,clopidogrel,Moderate,Increased risk of bleeding.,"Corticosteroids can increase the risk of gastrointestinal bleeding, which can be additive with antiplatelet agents.",Monitor for signs of bleeding.,1,2026-05-13
limiteddeflazacort,rosuvastatin,Minor,Increased risk of myopathy.,"Corticosteroids can increase muscle breakdown, potentially exacerbating statin-induced myopathy.",Monitor for muscle pain and weakness.,1,2026-05-13
limiteddeflazacort,gabapentin,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,alprazolam,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,diazepam,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,sertraline,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,fluoxetine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,amitriptyline,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,tramadol,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,codeine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,morphine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,phenytoin,Moderate,Decreased efficacy of deflazacort.,"Phenytoin is a potent enzyme inducer and can increase the metabolism of corticosteroids, reducing their effectiveness.",Monitor for signs of corticosteroid deficiency and consider dose adjustment or alternative.,1,2026-05-13
limiteddeflazacort,valproate,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,carbamazepine,Moderate,Decreased efficacy of deflazacort.,"Carbamazepine is an enzyme inducer and can increase the metabolism of corticosteroids, reducing their effectiveness.",Monitor for signs of corticosteroid deficiency and consider dose adjustment or alternative.,1,2026-05-13
limiteddeflazacort,rifampicin,Moderate,Decreased efficacy of deflazacort.,"Rifampicin is a potent enzyme inducer and can increase the metabolism of corticosteroids, reducing their effectiveness.",Monitor for signs of corticosteroid deficiency and consider dose adjustment or alternative.,1,2026-05-13
limiteddeflazacort,isoniazid,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,ethambutol,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,hydroxychloroquine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,methotrexate,Moderate,Increased risk of gastrointestinal and hematologic toxicity.,"Corticosteroids can sometimes mask or worsen the side effects of methotrexate, particularly GI and bone marrow suppression.",Monitor for GI and hematologic abnormalities; consider reduced steroid dose.,1,2026-05-13
limiteddeflazacort,cyclosporine,Moderate,Increased risk of cyclosporine toxicity; decreased deflazacort efficacy.,"Corticosteroids can affect cyclosporine metabolism, and vice versa, leading to unpredictable levels and increased toxicity risk.",Monitor cyclosporine levels and renal function closely; adjust doses as needed.,1,2026-05-13
limiteddeflazacort,tacrolimus,Moderate,Increased risk of tacrolimus toxicity; decreased deflazacort efficacy.,"Corticosteroids can affect tacrolimus metabolism, and vice versa, leading to unpredictable levels and increased toxicity risk.",Monitor tacrolimus levels and renal function closely; adjust doses as needed.,1,2026-05-13
limiteddeflazacort,lithium,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,haloperidol,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,clozapine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,olanzapine,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,lorazepam,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,clonazepam,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,midazolam,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limiteddeflazacort,zolpidem,Minor,No significant interaction.,No known significant pharmacokinetic or pharmacodynamic interaction.,No specific action required.,1,2026-05-13
limitedcefepime,,,,,,1,2026-05-13
hgabapentin,,,,,,1,2026-05-13
light mineral oil,,,,,,1,2026-05-13
white mineral oil,,,,,,1,2026-05-13
human hepatitis b immunoglobulin,,,,,,1,2026-05-13
hdicyclomine,alprazolam,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and benzodiazepines can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,diazepam,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and benzodiazepines can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,lorazepam,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and benzodiazepines can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,clonazepam,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and benzodiazepines can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,midazolam,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and benzodiazepines can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,zolpidem,Moderate,Increased sedation and anticholinergic effects.,"Dicyclomine has anticholinergic properties, and sedative-hypnotics can cause CNS depression; combined effect can enhance sedation.",Monitor for excessive drowsiness and dry mouth; use with caution.,1,2026-05-13
hdicyclomine,amitriptyline,Moderate,"Increased anticholinergic effects (dry mouth, constipation, urinary retention).","Both drugs have anticholinergic properties, leading to additive side effects.",Monitor for increased anticholinergic symptoms and consider dose adjustment.,1,2026-05-13
hdicyclomine,haloperidol,Moderate,Increased anticholinergic effects and potential for paralytic ileus.,Both drugs have anticholinergic properties; additive effects can be significant.,"Monitor for constipation, urinary retention, and abdominal distension; use with caution.",1,2026-05-13
hdicyclomine,clozapine,Moderate,Increased anticholinergic effects and potential for paralytic ileus.,Both drugs have anticholinergic properties; additive effects can be significant.,"Monitor for constipation, urinary retention, and abdominal distension; use with caution.",1,2026-05-13
hdicyclomine,olanzapine,Moderate,Increased anticholinergic effects and potential for paralytic ileus.,Both drugs have anticholinergic properties; additive effects can be significant.,"Monitor for constipation, urinary retention, and abdominal distension; use with caution.",1,2026-05-13
hdicyclomine,digoxin,Minor,Potential for altered digoxin absorption.,"Anticholinergic agents can slow gastrointestinal motility, potentially affecting digoxin absorption.",Monitor digoxin levels and therapeutic response.,1,2026-05-13
ai health care llpamikacin,,,,,,1,2026-05-13
overseaschlordiazepoxide,alprazolam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,diazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,lorazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,clonazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,midazolam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,zolpidem,Major,"Potentiated CNS depression, increased sedation and respiratory depression.",Additive pharmacodynamic effects on CNS.,Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
overseaschlordiazepoxide,tramadol,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
overseaschlordiazepoxide,codeine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
overseaschlordiazepoxide,morphine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
overseaschlordiazepoxide,alcohol,Major,"Potentiated CNS depression, increased sedation and respiratory depression.",Additive pharmacodynamic effects.,Advise patient to avoid alcohol.,1,2026-05-13
seratrodast,,,,,,1,2026-05-13
hlansoprazole,,,,,,1,2026-05-13
limitedchlordiazepoxide,alprazolam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,diazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,lorazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,clonazepam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,midazolam,Major,"Potentiated CNS depression, increased sedation and respiratory depression.","Both are benzodiazepines, additive pharmacodynamic effects.",Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,zolpidem,Major,"Potentiated CNS depression, increased sedation and respiratory depression.",Additive pharmacodynamic effects on CNS.,Avoid concomitant use; monitor closely for sedation and respiratory depression if unavoidable.,1,2026-05-13
limitedchlordiazepoxide,tramadol,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedchlordiazepoxide,codeine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedchlordiazepoxide,morphine,Moderate,Increased sedation and risk of respiratory depression.,Additive CNS depressant effects.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedchlordiazepoxide,alcohol,Major,"Potentiated CNS depression, increased sedation and respiratory depression.",Additive pharmacodynamic effects.,Advise patient to avoid alcohol.,1,2026-05-13
lactobacillus crispatus,,,,,,1,2026-05-13
lactobacillus gasseri,,,,,,1,2026-05-13
lactobacillus jensenii,,,,,,1,2026-05-13
tepotinib,,,,,,1,2026-05-13
astra idl maxdiclofenac,warfarin,Major,Increased risk of bleeding.,NSAIDs can potentiate anticoagulant effect and cause GI ulceration/bleeding.,Monitor INR closely and for signs of bleeding; consider alternative analgesic.,1,2026-05-13
astra idl maxdiclofenac,aspirin,Moderate,Increased risk of GI bleeding.,Additive GI irritant and antiplatelet effects.,Use with caution; monitor for signs of gastrointestinal bleeding.,1,2026-05-13
astra idl maxdiclofenac,clopidogrel,Moderate,Increased risk of bleeding.,Additive antiplatelet effects increase bleeding risk.,Use with caution; monitor for signs of bleeding.,1,2026-05-13
astra idl maxdiclofenac,losartan,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction.",Monitor blood pressure and renal function; use lowest effective dose.,1,2026-05-13
astra idl maxdiclofenac,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction.",Monitor blood pressure and renal function; use lowest effective dose.,1,2026-05-13
astra idl maxdiclofenac,amlodipine,Moderate,Reduced antihypertensive effect.,NSAIDs can antagonize the vasodilatory effects of calcium channel blockers.,Monitor blood pressure and increase dose if necessary.,1,2026-05-13
astra idl maxdiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, impairing diuretic response.",Monitor for diuresis and blood pressure; monitor renal function.,1,2026-05-13
astra idl maxdiclofenac,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can reduce renal clearance of lithium.,Monitor lithium levels and signs of toxicity; avoid if possible.,1,2026-05-13
astra idl maxdiclofenac,methotrexate,Major,"Increased methotrexate levels and toxicity, particularly hematologic and renal.",NSAIDs can inhibit renal excretion of methotrexate.,Monitor methotrexate levels and signs of toxicity; use with caution and lowest dose.,1,2026-05-13
ai health care llpprogesterone,carbamazepine,Moderate,Decreased effectiveness of progesterone.,Enzyme induction by carbamazepine can increase progesterone metabolism.,Monitor for signs of reduced progesterone efficacy and consider dose adjustment.,1,2026-05-13
ai health care llpprogesterone,phenytoin,Moderate,Decreased effectiveness of progesterone.,Enzyme induction by phenytoin can increase progesterone metabolism.,Monitor for signs of reduced progesterone efficacy and consider dose adjustment.,1,2026-05-13
ai health care llpprogesterone,rifampicin,Moderate,Decreased effectiveness of progesterone.,Enzyme induction by rifampicin can increase progesterone metabolism.,Monitor for signs of reduced progesterone efficacy and consider dose adjustment.,1,2026-05-13
ai health care llpprogesterone,itraconazole,Moderate,Increased levels of progesterone.,Inhibition of progesterone metabolism by itraconazole.,Monitor for signs of progesterone excess.,1,2026-05-13
ai health care llpprogesterone,ketoconazole,Moderate,Increased levels of progesterone.,Inhibition of progesterone metabolism by ketoconazole.,Monitor for signs of progesterone excess.,1,2026-05-13
remington life sciences llpmethylcobalamin,,,,,,1,2026-05-13
auxilium medicare life science llpboron,,,,,,1,2026-05-13
gynaecological products,,,,,,1,2026-05-13
ai health care llpoxetacaine,,,,,,1,2026-05-13
skanttr lifescience llpdiclofenac,warfarin,Moderate,Increased risk of bleeding.,"Diclofenac can inhibit platelet aggregation and reduce the gastroprotective effects of prostaglandins, increasing the risk of gastrointestinal bleeding and potentiating the anticoagulant effect of warfarin.",Monitor INR closely and consider an alternative NSAID or analgesic.,1,2026-05-13
skanttr lifescience llpdiclofenac,metformin,Moderate,Increased risk of lactic acidosis.,"NSAIDs can impair renal function, which can lead to decreased metformin clearance and accumulation, increasing the risk of lactic acidosis.",Monitor renal function and blood glucose; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpdiclofenac,atenolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure and renal function.,1,2026-05-13
skanttr lifescience llpdiclofenac,metoprolol,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of beta-blockers.",Monitor blood pressure and renal function.,1,2026-05-13
skanttr lifescience llpdiclofenac,ramipril,Moderate,Increased risk of renal impairment and reduced antihypertensive effect.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction, especially in patients with compromised renal function, and can reduce the effectiveness of ACE inhibitors.",Monitor renal function and blood pressure; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpdiclofenac,losartan,Moderate,Increased risk of renal impairment and reduced antihypertensive effect.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction, especially in patients with compromised renal function, and can reduce the effectiveness of ARBs.",Monitor renal function and blood pressure; consider alternative analgesic.,1,2026-05-13
skanttr lifescience llpdiclofenac,amlodipine,Moderate,Reduced antihypertensive effect.,"NSAIDs can cause sodium and water retention, counteracting the effects of calcium channel blockers.",Monitor blood pressure.,1,2026-05-13
skanttr lifescience llpdiclofenac,furosemide,Moderate,Reduced diuretic and antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, reducing renal blood flow and counteracting the effects of loop diuretics.","Monitor urine output, renal function, and blood pressure.",1,2026-05-13
skanttr lifescience llpdiclofenac,spironolactone,Moderate,Reduced antihypertensive effect; increased risk of renal impairment.,"NSAIDs can inhibit prostaglandin synthesis, leading to renal vasoconstriction, and can reduce the effectiveness of potassium-sparing diuretics.",Monitor renal function and blood pressure.,1,2026-05-13
skanttr lifescience llpdiclofenac,lithium,Major,"Increased serum lithium levels, risk of lithium toxicity.",NSAIDs can decrease renal clearance of lithium.,Monitor lithium levels closely and reduce lithium dose if necessary; consider alternative analgesic.,1,2026-05-13
mecetronium,,,,,,1,2026-05-13
hatorvastatin,atorvastatin,Minor,Increased risk of muscle-related side effects.,Both drugs are statins and may have additive effects on muscle toxicity.,Monitor for muscle pain or weakness.,1,2026-05-13
currant life science llpcefixime,,,,,,1,2026-05-13
glial life science llpclonazepam,clonazepam,Minor,Increased sedative effects.,Both are benzodiazepines and have additive central nervous system depressant effects.,Monitor for excessive sedation.,1,2026-05-13
glial life science llpclonazepam,alprazolam,Major,"Enhanced CNS depression, increased risk of respiratory depression and sedation.",Both are benzodiazepines with additive pharmacodynamic effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation and respiratory depression.",1,2026-05-13
glial life science llpclonazepam,diazepam,Major,"Enhanced CNS depression, increased risk of respiratory depression and sedation.",Both are benzodiazepines with additive pharmacodynamic effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation and respiratory depression.",1,2026-05-13
glial life science llpclonazepam,lorazepam,Major,"Enhanced CNS depression, increased risk of respiratory depression and sedation.",Both are benzodiazepines with additive pharmacodynamic effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation and respiratory depression.",1,2026-05-13
glial life science llpclonazepam,midazolam,Major,Potentially life-threatening CNS and respiratory depression.,Both are benzodiazepines with additive pharmacodynamic effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation and respiratory depression.",1,2026-05-13
glial life science llpclonazepam,zolpidem,Major,"Enhanced CNS depression, increased risk of somnolence, respiratory depression, and accidents.",Both are CNS depressants with additive pharmacodynamic effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation and respiratory depression.",1,2026-05-13
glial life science llpclonazepam,tramadol,Moderate,Increased risk of sedation and respiratory depression.,Both drugs cause CNS depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
glial life science llpclonazepam,codeine,Moderate,Increased risk of sedation and respiratory depression.,Both drugs cause CNS depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
glial life science llpclonazepam,morphine,Moderate,Increased risk of sedation and respiratory depression.,Both drugs cause CNS depression.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
glial life science llpclonazepam,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Both drugs have sedative properties.,Monitor for excessive sedation and anticholinergic side effects.,1,2026-05-13
glial life science llpclonazepam,gabapentin,Moderate,Increased sedation and dizziness.,Both drugs have CNS depressant effects.,Monitor for excessive sedation and dizziness.,1,2026-05-13
glial life science llpclonazepam,haloperidol,Moderate,Increased sedation and extrapyramidal symptoms.,Both drugs can cause CNS depression.,Monitor for excessive sedation and extrapyramidal symptoms.,1,2026-05-13
glial life science llpclonazepam,clozapine,Major,"Potentially life-threatening CNS and respiratory depression, increased risk of seizures.",Both drugs have CNS depressant effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation, respiratory depression, and seizures.",1,2026-05-13
glial life science llpclonazepam,olanzapine,Major,"Potentially life-threatening CNS and respiratory depression, increased risk of seizures.",Both drugs have CNS depressant effects.,"Avoid concomitant use or use with extreme caution, monitor for sedation, respiratory depression, and seizures.",1,2026-05-13
colfosceril palmitate,,,,,,1,2026-05-13
advent life sciences llptelmisartan,aspirin,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilation caused by telmisartan.",Monitor blood pressure closely; consider alternative pain relief if possible.,1,2026-05-13
advent life sciences llptelmisartan,ibuprofen,Moderate,Reduced antihypertensive effect and increased risk of renal dysfunction.,"NSAIDs can inhibit prostaglandin synthesis, counteracting the vasodilation caused by telmisartan.",Monitor blood pressure closely; consider alternative pain relief if possible.,1,2026-05-13
advent life sciences llptelmisartan,furosemide,Moderate,Increased risk of hypotension and hyperkalemia.,"Telmisartan can increase potassium levels; furosemide can decrease them, leading to unpredictable electrolyte balance.",Monitor electrolytes (especially potassium) and renal function; adjust doses as needed.,1,2026-05-13
advent life sciences llptelmisartan,spironolactone,Major,Significant risk of hyperkalemia.,Both drugs are potassium-sparing and can lead to dangerously elevated potassium levels.,Avoid concomitant use or monitor potassium levels very closely and frequently.,1,2026-05-13
advent life sciences llptelmisartan,atenolol,Minor,Potentially additive hypotensive effects.,Both drugs lower blood pressure through different mechanisms.,Monitor blood pressure.,1,2026-05-13
advent life sciences llptelmisartan,metoprolol,Minor,Potentially additive hypotensive effects.,Both drugs lower blood pressure through different mechanisms.,Monitor blood pressure.,1,2026-05-13
advent life sciences llptelmisartan,ramipril,Major,Increased risk of hyperkalemia and renal impairment.,Both are ACE inhibitors/ARBs that can increase potassium and affect kidney function.,Avoid concomitant use or monitor electrolytes and renal function very closely.,1,2026-05-13
advent life sciences llptelmisartan,clopidogrel,Minor,Potentially increased bleeding risk.,Telmisartan may have weak antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
advent life sciences llptelmisartan,lithium,Moderate,"Reduced lithium clearance, leading to increased lithium levels and toxicity.",Telmisartan can decrease renal excretion of lithium.,Monitor lithium levels closely; adjust lithium dose if necessary.,1,2026-05-13
limitedeicosapentaenoic acid,warfarin,Moderate,Increased risk of bleeding.,Omega-3 fatty acids can have mild antiplatelet effects.,Monitor INR closely; use with caution.,1,2026-05-13
limitedeicosapentaenoic acid,clopidogrel,Moderate,Increased risk of bleeding.,Omega-3 fatty acids can have mild antiplatelet effects.,Monitor for signs of bleeding.,1,2026-05-13
gemigliptin,metformin,Minor,No significant interaction; synergistic effect on glucose lowering.,Both drugs target different pathways to lower blood glucose.,Monitor blood glucose levels.,1,2026-05-13
gemigliptin,insulin,Moderate,Increased risk of hypoglycemia.,Additive glucose-lowering effects.,Monitor blood glucose levels closely; may require insulin dose adjustment.,1,2026-05-13
sulphur hexafluoride,,,,,,1,2026-05-13
valent conjugate vaccine,,,,,,1,2026-05-13
dioctyl sodium sulfosuccinate,mineral oil,Moderate,"Increased absorption of mineral oil, potentially leading to granulomas.",Docusate increases the solubility and absorption of lipophilic substances.,Avoid concomitant use.,1,2026-05-13
overseascefuroxime,warfarin,Moderate,Altered anticoagulant effect (can increase or decrease INR).,"Antibiotics can affect gut flora, which influences vitamin K production.",Monitor INR closely; adjust warfarin dose as needed.,1,2026-05-13
overseascefuroxime,probenecid,Moderate,"Reduced renal excretion of cefuroxime, leading to higher plasma concentrations.",Probenecid competes with cefuroxime for tubular secretion.,Monitor for increased cefuroxime side effects; consider dose adjustment.,1,2026-05-13
renwick health care llppregabalin,alprazolam,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,diazepam,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,lorazepam,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,clonazepam,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,midazolam,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,zolpidem,Major,"Additive central nervous system depression (sedation, respiratory depression).",Both drugs are CNS depressants.,Use with extreme caution; monitor for excessive sedation and respiratory depression.,1,2026-05-13
renwick health care llppregabalin,tramadol,Major,"Increased risk of CNS depression, dizziness, and sedation.",Both drugs can cause CNS depression.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
renwick health care llppregabalin,codeine,Major,"Increased risk of CNS depression, dizziness, and sedation.",Both drugs can cause CNS depression.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
renwick health care llppregabalin,morphine,Major,"Increased risk of CNS depression, dizziness, and sedation.",Both drugs can cause CNS depression.,Monitor for increased sedation and dizziness; consider dose adjustment.,1,2026-05-13
renwick health care llppregabalin,gabapentin,Moderate,"Additive CNS depression (somnolence, dizziness).",Both drugs affect voltage-gated calcium channels and can depress CNS.,Monitor for increased somnolence and dizziness; consider dose reduction.,1,2026-05-13
renwick health care llppregabalin,ethanol,Major,"Potentiation of CNS depressant effects, including dizziness and somnolence.",Alcohol is a CNS depressant.,Advise patients to avoid alcohol consumption.,1,2026-05-13
fenbendazole,,,,,,1,2026-05-13
multivitamin,levodopa,Moderate,Reduced absorption and efficacy of levodopa.,Minerals like iron and calcium in multivitamins can chelate with levodopa.,Administer levodopa at least 2 hours before or after multivitamin; separate doses.,1,2026-05-13
multivitamin,thyroid hormones,Moderate,Reduced absorption and efficacy of thyroid hormones.,Minerals like calcium and iron can interfere with thyroid hormone absorption.,Administer thyroid hormones at least 4 hours apart from multivitamins containing calcium or iron.,1,2026-05-13
multivitamin,quinolone antibiotics,Moderate,Reduced absorption and efficacy of quinolones.,"Minerals like iron, calcium, magnesium, and zinc can chelate with quinolones.",Separate administration of quinolone antibiotics by at least 2-4 hours from multivitamins.,1,2026-05-13
multivitamin,bisphosphonates,Moderate,Reduced absorption of bisphosphonates.,Minerals like calcium can interfere with bisphosphonate absorption.,Take bisphosphonates at least 2 hours apart from multivitamins containing calcium.,1,2026-05-13
evolocumab,atorvastatin,Minor,Increased risk of myopathy.,Both drugs affect lipid metabolism and can have additive effects on muscle enzymes.,Monitor for muscle pain or weakness.,1,2026-05-13
evolocumab,rosuvastatin,Minor,Increased risk of myopathy.,Both drugs affect lipid metabolism and can have additive effects on muscle enzymes.,Monitor for muscle pain or weakness.,1,2026-05-13
dibasic sodium phosphate,,,,,,1,2026-05-13
monobasic sodium phosphate,,,,,,1,2026-05-13
nartograstim,,,,,,1,2026-05-13
aster zenith bioscience llppantoprazole,diazepam,Minor,Increased risk of diazepam toxicity.,Pantoprazole may inhibit the metabolism of diazepam.,Monitor for increased sedation and CNS effects.,1,2026-05-13
aster zenith bioscience llppantoprazole,phenytoin,Minor,Increased risk of phenytoin toxicity.,Pantoprazole may inhibit the metabolism of phenytoin.,Monitor phenytoin levels and for signs of toxicity.,1,2026-05-13
herpes zoster / shingles vaccine,,,,,,1,2026-05-13
polycarbophil,metformin,Minor,Reduced absorption of metformin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,warfarin,Minor,Reduced absorption of warfarin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,digoxin,Minor,Reduced absorption of digoxin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,atorvastatin,Minor,Reduced absorption of atorvastatin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,rosuvastatin,Minor,Reduced absorption of rosuvastatin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,aspirin,Minor,Reduced absorption of aspirin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,ibuprofen,Minor,Reduced absorption of ibuprofen.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,amoxicillin,Minor,Reduced absorption of amoxicillin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,azithromycin,Minor,Reduced absorption of azithromycin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,ciprofloxacin,Minor,Reduced absorption of ciprofloxacin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,metronidazole,Minor,Reduced absorption of metronidazole.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,prednisolone,Minor,Reduced absorption of prednisolone.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,dexamethasone,Minor,Reduced absorption of dexamethasone.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,insulin,Minor,Reduced absorption of insulin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,furosemide,Minor,Reduced absorption of furosemide.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,spironolactone,Minor,Reduced absorption of spironolactone.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,atenolol,Minor,Reduced absorption of atenolol.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,metoprolol,Minor,Reduced absorption of metoprolol.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,ramipril,Minor,Reduced absorption of ramipril.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,clopidogrel,Minor,Reduced absorption of clopidogrel.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,gabapentin,Minor,Reduced absorption of gabapentin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,alprazolam,Minor,Reduced absorption of alprazolam.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,diazepam,Minor,Reduced absorption of diazepam.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,sertraline,Minor,Reduced absorption of sertraline.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,fluoxetine,Minor,Reduced absorption of fluoxetine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,amitriptyline,Minor,Reduced absorption of amitriptyline.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,tramadol,Minor,Reduced absorption of tramadol.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,codeine,Minor,Reduced absorption of codeine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,morphine,Minor,Reduced absorption of morphine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,phenytoin,Minor,Reduced absorption of phenytoin.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,valproate,Minor,Reduced absorption of valproate.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,carbamazepine,Minor,Reduced absorption of carbamazepine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,lithium,Minor,Reduced absorption of lithium.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,haloperidol,Minor,Reduced absorption of haloperidol.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,clozapine,Minor,Reduced absorption of clozapine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,olanzapine,Minor,Reduced absorption of olanzapine.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,lorazepam,Minor,Reduced absorption of lorazepam.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,clonazepam,Minor,Reduced absorption of clonazepam.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,midazolam,Minor,Reduced absorption of midazolam.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
polycarbophil,zolpidem,Minor,Reduced absorption of zolpidem.,"Polycarbophil can bind to drugs, slowing their absorption.",Separate administration by at least 2 hours.,1,2026-05-13
garenoxacin,,,,,,1,2026-05-13
overseaspiracetam,,,,,,1,2026-05-13
overseasfexofenadine,,,,,,1,2026-05-13
strontium chloride,,,,,,1,2026-05-13
astra idl maxetoricoxib,warfarin,Moderate,Increased risk of bleeding.,"Etoricoxib can inhibit platelet aggregation and potentially affect gastric mucosa, increasing GI bleeding risk when combined with anticoagulants.",Monitor INR closely and consider a lower dose of warfarin or alternative NSAID.,1,2026-05-13
astra idl maxetoricoxib,ramipril,Moderate,Reduced antihypertensive effect and increased risk of renal impairment.,"NSAIDs can inhibit renal prostaglandin synthesis, which is important for maintaining renal blood flow and counteracting the effects of ACE inhibitors.",Monitor blood pressure and renal function; consider alternative analgesic if necessary.,1,2026-05-13
astra idl maxetoricoxib,furosemide,Moderate,Reduced diuretic effect and potential for renal impairment.,"NSAIDs can inhibit renal prostaglandin synthesis, diminishing the natriuretic and diuretic effects of furosemide.",Monitor fluid balance and renal function; increase furosemide dose if needed or consider alternative analgesic.,1,2026-05-13
astra idl maxetoricoxib,aspirin,Moderate,Increased risk of gastrointestinal bleeding.,Both drugs can irritate the gastric mucosa and inhibit prostaglandin synthesis.,"Avoid concurrent use; if NSAID is required, use the lowest effective dose of etoricoxib and take with food.",1,2026-05-13
astra idl maxetoricoxib,ibuprofen,Moderate,Increased risk of gastrointestinal bleeding and potentially reduced cardioprotective effect of low-dose aspirin.,"Both are NSAIDs with similar mechanisms of action, increasing GI irritation and risk of bleeding.","Avoid concurrent use; if NSAID is required, use the lowest effective dose of etoricoxib and take with food.",1,2026-05-13
astra idl maxetoricoxib,clopidogrel,Moderate,Increased risk of bleeding.,"Etoricoxib's antiplatelet effects may potentiate the antiplatelet effect of clopidogrel, increasing bleeding risk.",Monitor for signs of bleeding; consider alternative if high bleeding risk.,1,2026-05-13
polyethelene glycol,,,,,,1,2026-05-13
sodium acetate,,,,,,1,2026-05-13
sunways,,,,,,1,2026-05-13
light kaolin,digoxin,Moderate,"Reduced absorption of digoxin, leading to decreased efficacy.","Kaolin is an adsorbent that can bind to digoxin in the gastrointestinal tract, preventing its absorption.",Separate administration by at least 2 hours; monitor digoxin levels and therapeutic response.,1,2026-05-13
light kaolin,warfarin,Moderate,"Reduced absorption of warfarin, leading to decreased anticoagulant effect.","Kaolin can adsorb warfarin in the gastrointestinal tract, reducing its absorption.",Separate administration by at least 2 hours; monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
light kaolin,lincomycin,Major,"Reduced absorption of lincomycin, leading to decreased efficacy.","Kaolin adsorbs lincomycin in the GI tract, hindering its absorption.",Separate administration by at least 2 hours; monitor for signs of infection and consider alternative antibiotic if needed.,1,2026-05-13
light kaolin,tetracyclines,Moderate,"Reduced absorption of tetracyclines, leading to decreased efficacy.","Kaolin can bind to tetracyclines in the GI tract, reducing their absorption.",Separate administration by at least 2 hours; monitor for signs of infection.,1,2026-05-13
glial life science llpdomperidone,ketoconazole,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Ketoconazole is a strong CYP3A4 inhibitor, which metabolizes domperidone, leading to increased plasma concentrations of domperidone.",Avoid concurrent use; consider alternative antiemetic.,1,2026-05-13
glial life science llpdomperidone,erythromycin,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Erythromycin is a CYP3A4 inhibitor, which metabolizes domperidone, leading to increased plasma concentrations of domperidone.",Avoid concurrent use; consider alternative antiemetic.,1,2026-05-13
glial life science llpdomperidone,clarithromycin,Major,Increased risk of QT prolongation and Torsades de Pointes.,"Clarithromycin is a CYP3A4 inhibitor, which metabolizes domperidone, leading to increased plasma concentrations of domperidone.",Avoid concurrent use; consider alternative antiemetic.,1,2026-05-13
glial life science llpdomperidone,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Domperidone can inhibit CYP3A4, which metabolizes atorvastatin, potentially increasing atorvastatin levels.",Monitor for signs of muscle pain or weakness; use with caution.,1,2026-05-13
glial life science llpdomperidone,simvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Domperidone can inhibit CYP3A4, which metabolizes simvastatin, potentially increasing simvastatin levels.",Monitor for signs of muscle pain or weakness; use with caution.,1,2026-05-13
glial life science llpdomperidone,tramadol,Moderate,Increased risk of CNS effects including sedation and dizziness.,Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,codeine,Moderate,Increased risk of CNS effects including sedation and dizziness.,Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,morphine,Moderate,Increased risk of CNS effects including sedation and dizziness.,Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,diazepam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,lorazepam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,alprazolam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
glial life science llpdomperidone,midazolam,Moderate,"Increased risk of CNS depression, sedation, and respiratory depression.",Both can cause CNS depression.,Monitor for additive CNS effects; use with caution.,1,2026-05-13
peppermint oil,cyclosporine,Moderate,May decrease absorption of cyclosporine.,"Peppermint oil can affect gastric motility, potentially altering the absorption of certain medications.",Monitor cyclosporine levels and therapeutic response; administer peppermint oil at least 1 hour before or 2 hours after cyclosporine.,1,2026-05-13
peppermint oil,tacrolimus,Moderate,May decrease absorption of tacrolimus.,"Peppermint oil can affect gastric motility, potentially altering the absorption of certain medications.",Monitor tacrolimus levels and therapeutic response; administer peppermint oil at least 1 hour before or 2 hours after tacrolimus.,1,2026-05-13
overseasciprofloxacin,warfarin,Major,Increased risk of bleeding.,"Fluoroquinolones can inhibit the metabolism of warfarin, leading to increased warfarin levels and potentiated anticoagulant effect.",Monitor INR closely and adjust warfarin dose as needed; consider alternative antibiotic if possible.,1,2026-05-13
overseasciprofloxacin,metformin,Moderate,Increased risk of hypoglycemia.,Fluoroquinolones can potentiate the hypoglycemic effect of metformin.,Monitor blood glucose levels closely; advise patient to report symptoms of hypoglycemia.,1,2026-05-13
overseasciprofloxacin,didanosine,Major,Reduced absorption of ciprofloxacin.,"The buffering agents in didanosine can chelate with ciprofloxacin, significantly reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,multivitamins,Major,Reduced absorption of ciprofloxacin.,"Minerals such as calcium, iron, magnesium, and zinc can chelate with ciprofloxacin, significantly reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,sucralfate,Major,Reduced absorption of ciprofloxacin.,"Sucralfate can bind to ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,sevelamer,Major,Reduced absorption of ciprofloxacin.,"Sevelamer can bind to ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,calcium supplements,Major,Reduced absorption of ciprofloxacin.,"Calcium can chelate with ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,magnesium,Major,Reduced absorption of ciprofloxacin.,"Magnesium can chelate with ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,zinc,Major,Reduced absorption of ciprofloxacin.,"Zinc can chelate with ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,iron supplements,Major,Reduced absorption of ciprofloxacin.,"Iron can chelate with ciprofloxacin in the GI tract, reducing its absorption.",Separate administration by at least 2 hours; monitor for treatment failure.,1,2026-05-13
overseasciprofloxacin,theophylline,Moderate,"Increased serum levels of theophylline, leading to toxicity.",Fluoroquinolones can inhibit the metabolism of theophylline.,Monitor theophylline levels closely; consider reducing the dose of theophylline.,1,2026-05-13
overseasciprofloxacin,caffeine,Moderate,"Increased risk of adverse CNS effects (e.g., nervousness, insomnia).",Fluoroquinolones can inhibit the metabolism of caffeine.,Advise patient to limit caffeine intake.,1,2026-05-13
overseasciprofloxacin,phenytoin,Moderate,May alter the serum levels of phenytoin.,Fluoroquinolones may interfere with phenytoin metabolism.,Monitor phenytoin levels and therapeutic effect; adjust dose if necessary.,1,2026-05-13
overseasciprofloxacin,cyclosporine,Moderate,"Increased serum levels of cyclosporine, potentially leading to nephrotoxicity.",Fluoroquinolones can inhibit the metabolism of cyclosporine.,Monitor cyclosporine levels and renal function; consider dose reduction of cyclosporine.,1,2026-05-13
overseasciprofloxacin,lidocaine,Moderate,Increased serum levels of lidocaine.,Fluoroquinolones can inhibit the metabolism of lidocaine.,Monitor lidocaine levels and potential for toxicity.,1,2026-05-13
overseasciprofloxacin,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Fluoroquinolones may inhibit CYP3A4 enzymes involved in statin metabolism.,Use with caution; monitor for signs of muscle damage.,1,2026-05-13
overseasciprofloxacin,rosuvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Fluoroquinolones may inhibit CYP enzymes involved in statin metabolism.,Use with caution; monitor for signs of muscle damage.,1,2026-05-13
carbomer,,,,,,1,2026-05-13
advent life sciences llppantoprazole,warfarin,Minor,May increase warfarin effect.,"Pantoprazole inhibits CYP2C19, which metabolizes some warfarin enantiomers.",Monitor INR closely if initiating or discontinuing pantoprazole.,1,2026-05-13
advent life sciences llppantoprazole,atorvastatin,Minor,May increase atorvastatin levels.,"Pantoprazole inhibits CYP3A4, which metabolizes atorvastatin.",Consider alternative statin or monitor for statin-related side effects.,1,2026-05-13
advent life sciences llppantoprazole,rosuvastatin,Minor,May increase rosuvastatin levels.,"Pantoprazole inhibits CYP2C9 and CYP2C19, which metabolize rosuvastatin.",Consider alternative statin or monitor for statin-related side effects.,1,2026-05-13
advent life sciences llppantoprazole,clopidogrel,Moderate,Reduced antiplatelet effect.,"Pantoprazole is a CYP2C19 inhibitor, reducing the conversion of clopidogrel to its active metabolite.","Avoid co-administration if possible; if necessary, monitor for thrombotic events.",1,2026-05-13
advent life sciences llppantoprazole,digoxin,Minor,May increase digoxin levels.,Gastric pH changes can alter digoxin absorption.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseasitraconazole,atorvastatin,Major,Risk of rhabdomyolysis and liver damage.,"Itraconazole is a potent CYP3A4 inhibitor, significantly increasing atorvastatin levels.",Avoid co-administration; use an alternative statin or antifungal.,1,2026-05-13
overseasitraconazole,rosuvastatin,Moderate,Increased risk of myopathy.,"Itraconazole inhibits CYP2C9, which metabolizes rosuvastatin.",Monitor for muscle pain and weakness; consider alternative statin or antifungal.,1,2026-05-13
overseasitraconazole,amlodipine,Major,Increased risk of edema and hypotension.,"Itraconazole is a strong CYP3A4 inhibitor, increasing amlodipine levels.",Use with caution; monitor blood pressure and for edema. Consider dose reduction of amlodipine.,1,2026-05-13
overseasitraconazole,warfarin,Major,Increased risk of bleeding.,"Itraconazole inhibits CYP2C9, which metabolizes warfarin, increasing its anticoagulant effect.",Monitor INR closely; reduce warfarin dose if necessary.,1,2026-05-13
overseasitraconazole,metoprolol,Moderate,Increased risk of bradycardia and hypotension.,"Itraconazole inhibits CYP3A4, which metabolizes metoprolol.",Monitor heart rate and blood pressure; consider dose reduction of metoprolol.,1,2026-05-13
overseasitraconazole,atenolol,Minor,Potential for altered beta-blocker effect.,Itraconazole may affect CYP enzyme metabolism of some beta-blockers.,Monitor heart rate and blood pressure.,1,2026-05-13
overseasitraconazole,digoxin,Moderate,Increased risk of digoxin toxicity.,Itraconazole can increase digoxin levels by affecting P-glycoprotein-mediated transport.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
overseasitraconazole,furosemide,Minor,May affect electrolyte balance.,Itraconazole can impact electrolyte levels.,Monitor electrolytes.,1,2026-05-13
overseasitraconazole,spironolactone,Minor,May affect potassium levels.,Itraconazole can impact electrolyte levels.,Monitor potassium levels.,1,2026-05-13
overseasitraconazole,ramipril,Minor,Potential for altered blood pressure control.,Itraconazole may affect CYP enzyme metabolism of some ACE inhibitors.,Monitor blood pressure.,1,2026-05-13
overseasitraconazole,lorazepam,Moderate,Increased sedation and respiratory depression.,"Itraconazole inhibits CYP3A4, which metabolizes lorazepam.",Use with caution; monitor for sedation and respiratory effects.,1,2026-05-13
overseasitraconazole,alprazolam,Major,Increased risk of sedation and respiratory depression.,"Itraconazole is a strong CYP3A4 inhibitor, significantly increasing alprazolam levels.",Avoid co-administration; consider alternative benzodiazepine or antifungal.,1,2026-05-13
overseasitraconazole,diazepam,Moderate,Increased sedation and respiratory depression.,"Itraconazole inhibits CYP3A4, which metabolizes diazepam.",Use with caution; monitor for sedation and respiratory effects.,1,2026-05-13
overseasitraconazole,midazolam,Major,Increased risk of prolonged sedation and respiratory depression.,"Itraconazole is a potent CYP3A4 inhibitor, significantly increasing midazolam levels.",Avoid co-administration; consider alternative agent.,1,2026-05-13
overseasitraconazole,phenytoin,Major,Reduced itraconazole levels and efficacy; potential for phenytoin toxicity.,"Phenytoin induces CYP3A4, decreasing itraconazole levels. Itraconazole can also affect phenytoin metabolism.",Avoid co-administration; monitor both drug levels and efficacy.,1,2026-05-13
overseasitraconazole,cyclosporine,Major,Increased risk of cyclosporine toxicity.,"Itraconazole inhibits CYP3A4, which metabolizes cyclosporine, increasing its levels.",Monitor cyclosporine levels closely; reduce cyclosporine dose if necessary.,1,2026-05-13
overseasitraconazole,tacrolimus,Major,Increased risk of tacrolimus toxicity.,"Itraconazole inhibits CYP3A4, which metabolizes tacrolimus, increasing its levels.",Monitor tacrolimus levels closely; reduce tacrolimus dose if necessary.,1,2026-05-13
overseasitraconazole,methotrexate,Moderate,May increase methotrexate toxicity.,Itraconazole can inhibit renal excretion of methotrexate.,Monitor for methotrexate toxicity; consider dose adjustment.,1,2026-05-13
overseasitraconazole,"quinine (not in common list, but relevant)",Major,"Increased risk of quinine toxicity (visual disturbances, CNS effects).","Itraconazole inhibits CYP3A4, which metabolizes quinine.",Avoid co-administration.,1,2026-05-13
acetylcarnitine,warfarin,Minor,May increase warfarin effect.,"Potential interaction with coagulation pathways, though not well-established.","Monitor INR, especially when initiating or discontinuing acetylcarnitine.",1,2026-05-13
ai health care llpcyproheptadine,sertraline,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonergic activity.,"Monitor for signs and symptoms of serotonin syndrome (agitation, confusion, rapid heart rate, etc.).",1,2026-05-13
ai health care llpcyproheptadine,fluoxetine,Moderate,Increased risk of serotonin syndrome.,Both drugs increase serotonergic activity.,"Monitor for signs and symptoms of serotonin syndrome (agitation, confusion, rapid heart rate, etc.).",1,2026-05-13
ai health care llpcyproheptadine,amitriptyline,Minor,May increase anticholinergic effects.,Cyproheptadine has anticholinergic properties.,"Monitor for increased anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention).",1,2026-05-13
ai health care llpcyproheptadine,tramadol,Moderate,Increased risk of serotonin syndrome.,Both drugs can affect serotonin levels.,Monitor for signs and symptoms of serotonin syndrome.,1,2026-05-13
ai health care llpcyproheptadine,codeine,Minor,May increase CNS depression.,Both drugs can cause sedation.,Monitor for increased drowsiness and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,morphine,Minor,May increase CNS depression.,Both drugs can cause sedation.,Monitor for increased drowsiness and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,lorazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,alprazolam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,diazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,clonazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,zolpidem,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
ai health care llpcyproheptadine,haloperidol,Minor,May increase anticholinergic effects.,Cyproheptadine has anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
ai health care llpcyproheptadine,clozapine,Minor,May increase anticholinergic effects and sedation.,Cyproheptadine has anticholinergic properties and can cause sedation.,Monitor for increased anticholinergic side effects and sedation.,1,2026-05-13
ai health care llpcyproheptadine,olanzapine,Minor,May increase anticholinergic effects and sedation.,Cyproheptadine has anticholinergic properties and can cause sedation.,Monitor for increased anticholinergic side effects and sedation.,1,2026-05-13
daclizumab,,,,,,1,2026-05-13
hazithromycin,warfarin,Minor,May increase warfarin effect.,"Azithromycin can inhibit CYP2C9, which metabolizes some warfarin enantiomers.",Monitor INR closely if initiating or discontinuing azithromycin.,1,2026-05-13
hazithromycin,atorvastatin,Minor,May increase atorvastatin levels.,"Azithromycin can inhibit CYP3A4, which metabolizes atorvastatin.",Monitor for statin-related side effects.,1,2026-05-13
hazithromycin,rosuvastatin,Minor,May increase rosuvastatin levels.,"Azithromycin can inhibit CYP2C9, which metabolizes rosuvastatin.",Monitor for statin-related side effects.,1,2026-05-13
hazithromycin,digoxin,Moderate,Increased risk of digoxin toxicity.,Azithromycin can increase digoxin levels by affecting P-glycoprotein-mediated transport.,Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
hazithromycin,furosemide,Minor,May affect electrolyte balance.,Macrolide antibiotics can potentially affect electrolyte levels.,Monitor electrolytes.,1,2026-05-13
hazithromycin,spironolactone,Minor,May affect potassium levels.,Macrolide antibiotics can potentially affect electrolyte levels.,Monitor potassium levels.,1,2026-05-13
hazithromycin,clopidogrel,Minor,Potential for reduced efficacy of clopidogrel.,"Azithromycin may weakly inhibit CYP2C19, which activates clopidogrel.",Monitor for clinical response.,1,2026-05-13
hazithromycin,sertraline,Minor,Potential for QT prolongation.,Azithromycin is known to prolong the QT interval.,"Monitor ECG and for arrhythmias, especially in patients with risk factors.",1,2026-05-13
hazithromycin,haloperidol,Moderate,Increased risk of QT prolongation and arrhythmias.,"Azithromycin can prolong the QT interval, and haloperidol also carries this risk.",Avoid co-administration if possible; monitor ECG and for arrhythmias.,1,2026-05-13
hazithromycin,methotrexate,Moderate,May increase methotrexate toxicity.,Azithromycin can inhibit renal excretion of methotrexate.,Monitor for methotrexate toxicity; consider dose adjustment.,1,2026-05-13
ethacridine,,,,,,1,2026-05-13
s pharmacetirizine,sertraline,Minor,May increase risk of serotonin syndrome (though less significant than with stronger serotonergic agents).,Antihistamines can sometimes potentiate serotonergic effects.,Monitor for signs of serotonin syndrome if co-administered.,1,2026-05-13
s pharmacetirizine,amitriptyline,Minor,May increase anticholinergic effects.,Cetirizine has some anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
s pharmacetirizine,tramadol,Minor,May increase CNS depression.,Both drugs can cause drowsiness.,Monitor for increased sedation.,1,2026-05-13
s pharmacetirizine,codeine,Minor,May increase CNS depression.,Both drugs can cause drowsiness.,Monitor for increased sedation.,1,2026-05-13
s pharmacetirizine,morphine,Minor,May increase CNS depression.,Both drugs can cause drowsiness.,Monitor for increased sedation.,1,2026-05-13
s pharmacetirizine,lorazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
s pharmacetirizine,alprazolam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
s pharmacetirizine,diazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
s pharmacetirizine,clonazepam,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
s pharmacetirizine,zolpidem,Moderate,"Increased CNS depression (sedation, drowsiness).",Both drugs are CNS depressants.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
s pharmacetirizine,haloperidol,Minor,May increase anticholinergic effects.,Cetirizine has some anticholinergic properties.,Monitor for increased anticholinergic side effects.,1,2026-05-13
s pharmacetirizine,clozapine,Minor,May increase sedation and anticholinergic effects.,Cetirizine can cause sedation and has anticholinergic properties.,Monitor for increased sedation and anticholinergic side effects.,1,2026-05-13
s pharmacetirizine,olanzapine,Minor,May increase sedation and anticholinergic effects.,Cetirizine can cause sedation and has anticholinergic properties.,Monitor for increased sedation and anticholinergic side effects.,1,2026-05-13
human papillomavirus bivalent,,,,,,1,2026-05-13
dehydroemetine,digoxin,Major,"Increased risk of cardiotoxicity (QT prolongation, arrhythmias).",Both dehydroemetine and digoxin can prolong the QT interval and affect cardiac electrophysiology.,Avoid co-administration; monitor ECG closely if necessary.,1,2026-05-13
dehydroemetine,furosemide,Moderate,"Increased risk of hypokalemia, leading to cardiotoxicity.","Dehydroemetine can cause electrolyte disturbances, and furosemide also causes potassium loss.",Monitor serum potassium levels closely; supplement if necessary.,1,2026-05-13
dehydroemetine,spironolactone,Minor,May counteract potassium-sparing effects if used inappropriately.,Dehydroemetine can cause electrolyte disturbances.,Monitor electrolyte balance.,1,2026-05-13
dehydroemetine,"quinine (not in common list, but relevant)",Major,"Increased risk of cardiotoxicity (QT prolongation, arrhythmias).",Both drugs can prolong the QT interval and affect cardiac electrophysiology.,Avoid co-administration; monitor ECG closely.,1,2026-05-13
astra idl maxpantoprazole,warfarin,Moderate,Increased risk of bleeding.,"Pantoprazole can inhibit CYP2C19, which metabolizes some enantiomers of warfarin, potentially increasing warfarin levels.",Monitor INR closely and consider dose adjustment of warfarin.,1,2026-05-13
astra idl maxpantoprazole,metformin,Minor,Slight increase in metformin levels.,Pantoprazole can inhibit renal transporters involved in metformin excretion.,Monitor blood glucose levels and renal function.,1,2026-05-13
astra idl maxpantoprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Pantoprazole, a CYP2C19 inhibitor, can reduce the conversion of clopidogrel to its active metabolite.","Avoid concomitant use if possible. If necessary, monitor for cardiovascular events and consider an alternative PPI or antiplatelet agent.",1,2026-05-13
astra idl maxpantoprazole,ketoconazole,Moderate,Decreased efficacy of ketoconazole.,"Pantoprazole increases gastric pH, reducing the absorption of ketoconazole.",Separate administration times or consider alternative antifungal therapy.,1,2026-05-13
astra idl maxpantoprazole,itraconazole,Moderate,Decreased efficacy of itraconazole.,"Pantoprazole increases gastric pH, reducing the absorption of itraconazole.",Separate administration times or consider alternative antifungal therapy.,1,2026-05-13
astra idl maxpantoprazole,digoxin,Minor,Slight increase in digoxin levels.,"Pantoprazole may affect P-glycoprotein, a transporter involved in digoxin absorption.",Monitor digoxin levels and for signs of toxicity.,1,2026-05-13
astra idl maxpantoprazole,cyclosporine,Moderate,Increased cyclosporine levels.,"Pantoprazole may inhibit intestinal CYP3A4 and P-glycoprotein, affecting cyclosporine metabolism and transport.",Monitor cyclosporine levels and for signs of toxicity.,1,2026-05-13
astra idl maxpantoprazole,tacrolimus,Moderate,Increased tacrolimus levels.,"Pantoprazole may inhibit intestinal CYP3A4 and P-glycoprotein, affecting tacrolimus metabolism and transport.",Monitor tacrolimus levels and for signs of toxicity.,1,2026-05-13
ethamsylate,,,,,,1,2026-05-13
bilastine,ketoconazole,Moderate,Increased bilastine levels and potential for prolonged QT interval.,"Ketoconazole inhibits CYP3A4, which metabolizes bilastine, leading to reduced clearance.",Monitor for adverse effects of bilastine; consider dose adjustment or alternative antihistamine if clinically significant.,1,2026-05-13
bilastine,erythromycin,Moderate,Increased bilastine levels and potential for prolonged QT interval.,"Erythromycin inhibits CYP3A4, which metabolizes bilastine, leading to reduced clearance.",Monitor for adverse effects of bilastine; consider dose adjustment or alternative antihistamine if clinically significant.,1,2026-05-13
bilastine,cyclosporine,Moderate,Increased bilastine levels.,"Cyclosporine can inhibit P-glycoprotein, which is involved in bilastine transport.",Monitor for increased bilastine effects.,1,2026-05-13
bilastine,tacrolimus,Moderate,Increased bilastine levels.,"Tacrolimus can inhibit P-glycoprotein, which is involved in bilastine transport.",Monitor for increased bilastine effects.,1,2026-05-13
alpha-beta arteether,quinine,Moderate,"Increased risk of cardiotoxicity (QT prolongation, arrhythmias).",Both drugs can prolong the QT interval.,Avoid concomitant use if possible; monitor ECG and for symptoms of cardiotoxicity.,1,2026-05-13
alpha-beta arteether,mefloquine,Moderate,"Increased risk of cardiotoxicity (QT prolongation, arrhythmias).",Both drugs can prolong the QT interval.,Avoid concomitant use if possible; monitor ECG and for symptoms of cardiotoxicity.,1,2026-05-13
doxofylline,ciprofloxacin,Moderate,"Increased doxofylline levels, leading to enhanced therapeutic and toxic effects.","Ciprofloxacin inhibits CYP1A2, which metabolizes doxofylline.",Monitor for signs of theophylline toxicity; consider dose reduction of doxofylline.,1,2026-05-13
doxofylline,erythromycin,Moderate,"Increased doxofylline levels, leading to enhanced therapeutic and toxic effects.","Erythromycin inhibits CYP1A2, which metabolizes doxofylline.",Monitor for signs of theophylline toxicity; consider dose reduction of doxofylline.,1,2026-05-13
doxofylline,ranitidine,Moderate,"Increased doxofylline levels, leading to enhanced therapeutic and toxic effects.","Ranitidine inhibits CYP1A2, which metabolizes doxofylline.",Monitor for signs of theophylline toxicity; consider dose reduction of doxofylline.,1,2026-05-13
doxofylline,cimetidine,Moderate,"Increased doxofylline levels, leading to enhanced therapeutic and toxic effects.","Cimetidine inhibits CYP1A2, which metabolizes doxofylline.",Monitor for signs of theophylline toxicity; consider dose reduction of doxofylline.,1,2026-05-13
doxofylline,rifampicin,Moderate,"Decreased doxofylline levels, leading to reduced efficacy.","Rifampicin induces CYP1A2, which metabolizes doxofylline.",Monitor for reduced effectiveness of doxofylline; consider dose increase.,1,2026-05-13
doxofylline,phenytoin,Moderate,"Decreased doxofylline levels, leading to reduced efficacy.","Phenytoin induces CYP1A2, which metabolizes doxofylline.",Monitor for reduced effectiveness of doxofylline; consider dose increase.,1,2026-05-13
doxofylline,carbamazepine,Moderate,"Decreased doxofylline levels, leading to reduced efficacy.","Carbamazepine induces CYP1A2, which metabolizes doxofylline.",Monitor for reduced effectiveness of doxofylline; consider dose increase.,1,2026-05-13
hydroquinone,,,,,,1,2026-05-13
sodium picosulfate,furosemide,Moderate,"Electrolyte imbalances (hypokalemia), especially with overuse.",Both can cause electrolyte disturbances; picosulfate is a stimulant laxative.,Monitor electrolyte levels; advise patient on proper use of laxative.,1,2026-05-13
sodium picosulfate,spironolactone,Moderate,"Electrolyte imbalances (hypokalemia, hyperkalemia), especially with overuse.",Both can cause electrolyte disturbances; picosulfate is a stimulant laxative.,Monitor electrolyte levels; advise patient on proper use of laxative.,1,2026-05-13
sodium picosulfate,digoxin,Moderate,Increased risk of digoxin toxicity due to hypokalemia.,"Sodium picosulfate can cause hypokalemia, which increases digoxin binding to cardiac receptors.",Monitor serum potassium and digoxin levels; advise patient on proper use of laxative.,1,2026-05-13
sodium citrate,tetracyclines,Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.","Citrate can chelate with tetracyclines, forming insoluble complexes.",Administer tetracyclines at least 2 hours before or after sodium citrate.,1,2026-05-13
sodium citrate,quinolones,Major,"Reduced absorption of quinolones, leading to decreased efficacy.","Citrate can chelate with quinolones, forming insoluble complexes.",Administer quinolones at least 2 hours before or after sodium citrate.,1,2026-05-13
sodium citrate,bisphosphonates,Major,"Reduced absorption of bisphosphonates, leading to decreased efficacy.","Citrate can chelate with bisphosphonates, forming insoluble complexes.",Administer bisphosphonates at least 2 hours before or after sodium citrate.,1,2026-05-13
permethrin,,,,,,1,2026-05-13
sodium chloride,losartan,Moderate,Reduced antihypertensive effect of losartan.,Sodium intake can attenuate the effects of angiotensin II receptor blockers.,Monitor blood pressure; advise patient on sodium intake.,1,2026-05-13
sodium chloride,ramipril,Moderate,Reduced antihypertensive effect of ramipril.,Sodium intake can attenuate the effects of ACE inhibitors.,Monitor blood pressure; advise patient on sodium intake.,1,2026-05-13
sodium chloride,amlodipine,Moderate,Reduced antihypertensive effect of amlodipine.,Sodium intake can attenuate the effects of calcium channel blockers.,Monitor blood pressure; advise patient on sodium intake.,1,2026-05-13
sodium chloride,furosemide,Moderate,Reduced diuretic effect of furosemide.,Sodium intake can reduce the response to loop diuretics.,Monitor urine output and edema; advise patient on sodium intake.,1,2026-05-13
sodium chloride,lithium,Major,Increased risk of lithium toxicity.,Sodium depletion can lead to increased renal reabsorption of lithium.,Monitor serum lithium levels and renal function; counsel patient on sodium intake.,1,2026-05-13
aluminium hydroxide,tetracyclines,Major,"Reduced absorption of tetracyclines, leading to decreased efficacy.","Aluminium hydroxide can bind to tetracyclines, reducing their absorption.",Administer tetracyclines at least 2 hours before or 4 hours after aluminium hydroxide.,1,2026-05-13
aluminium hydroxide,quinolones,Major,"Reduced absorption of quinolones, leading to decreased efficacy.","Aluminium hydroxide can bind to quinolones, reducing their absorption.",Administer quinolones at least 2 hours before or 4 hours after aluminium hydroxide.,1,2026-05-13
aluminium hydroxide,bisphosphonates,Major,"Reduced absorption of bisphosphonates, leading to decreased efficacy.","Aluminium hydroxide can bind to bisphosphonates, reducing their absorption.",Administer bisphosphonates at least 2 hours before or 4 hours after aluminium hydroxide.,1,2026-05-13
aluminium hydroxide,warfarin,Moderate,"Reduced absorption of warfarin, potentially leading to decreased anticoagulant effect.","Aluminium hydroxide can adsorb warfarin, reducing its bioavailability.",Monitor INR closely; consider alternative antacid or separation of doses.,1,2026-05-13
aluminium hydroxide,digoxin,Moderate,"Reduced absorption of digoxin, leading to decreased efficacy.","Aluminium hydroxide can adsorb digoxin, reducing its bioavailability.",Monitor digoxin levels; consider alternative antacid or separation of doses.,1,2026-05-13
aluminium hydroxide,atorvastatin,Moderate,"Reduced absorption of atorvastatin, leading to decreased efficacy.","Aluminium hydroxide can bind to atorvastatin, reducing its absorption.",Separate administration of atorvastatin and aluminium hydroxide by at least 2 hours.,1,2026-05-13
aluminium hydroxide,rosuvastatin,Moderate,"Reduced absorption of rosuvastatin, leading to decreased efficacy.","Aluminium hydroxide can bind to rosuvastatin, reducing its absorption.",Separate administration of rosuvastatin and aluminium hydroxide by at least 2 hours.,1,2026-05-13
ramosetron,,,,,,1,2026-05-13
calcium acetate,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Cations like calcium can form insoluble complexes with fluoroquinolones, reducing their bioavailability.",Separate administration by at least 2 hours before or 6 hours after ciprofloxacin.,1,2026-05-13
calcium acetate,tetracycline,Major,Reduced absorption of tetracycline.,"Cations like calcium can form insoluble complexes with tetracyclines, reducing their bioavailability.",Separate administration by at least 2 hours before or 6 hours after tetracycline.,1,2026-05-13
calcium acetate,levothyroxine,Major,Reduced absorption of levothyroxine.,"Calcium can bind to levothyroxine in the gastrointestinal tract, decreasing its absorption.",Separate administration by at least 4 hours.,1,2026-05-13
piperine,warfarin,Moderate,Increased or decreased INR.,Piperine can inhibit or induce CYP450 enzymes involved in warfarin metabolism.,Monitor INR closely and adjust warfarin dose as needed.,1,2026-05-13
piperine,atorvastatin,Moderate,Increased atorvastatin levels and risk of myopathy.,"Piperine can inhibit CYP3A4, which metabolizes atorvastatin.",Monitor for signs of myopathy and consider dose adjustment.,1,2026-05-13
piperine,metformin,Minor,Potentially altered metformin pharmacokinetics.,Piperine can affect drug transporters involved in metformin absorption and excretion.,Monitor blood glucose levels.,1,2026-05-13
anti rh d immunoglobulin,,,,,,1,2026-05-13
methylpolysiloxane,,,,,,1,2026-05-13
agomelatine,fluoxetine,Moderate,Increased risk of hepatotoxicity and serotonergic side effects.,"Both drugs can inhibit CYP1A2 and CYP2C9, increasing agomelatine levels. Both can also affect serotonin.","Avoid coadministration. If necessary, monitor liver function and for signs of serotonin syndrome.",1,2026-05-13
agomelatine,sertraline,Moderate,Increased risk of hepatotoxicity and serotonergic side effects.,"Both drugs can inhibit CYP1A2 and CYP2C9, increasing agomelatine levels. Both can also affect serotonin.","Avoid coadministration. If necessary, monitor liver function and for signs of serotonin syndrome.",1,2026-05-13
agomelatine,fluvoxamine,Major,"Significantly increased agomelatine levels, risk of hepatotoxicity and serotonergic effects.","Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C9, leading to high agomelatine concentrations.",Avoid coadministration.,1,2026-05-13
agomelatine,amitriptyline,Minor,Potential for increased serotonergic side effects.,Both drugs can influence serotonin pathways.,Monitor for signs of serotonin syndrome.,1,2026-05-13
fipronil,,,,,,1,2026-05-13
magnesium chloride,ciprofloxacin,Major,Reduced absorption of ciprofloxacin.,"Magnesium cations can form insoluble complexes with fluoroquinolones, reducing their bioavailability.",Separate administration by at least 2 hours before or 6 hours after ciprofloxacin.,1,2026-05-13
magnesium chloride,tetracycline,Major,Reduced absorption of tetracycline.,"Magnesium cations can form insoluble complexes with tetracyclines, reducing their bioavailability.",Separate administration by at least 2 hours before or 6 hours after tetracycline.,1,2026-05-13
magnesium chloride,levothyroxine,Major,Reduced absorption of levothyroxine.,"Magnesium can bind to levothyroxine in the gastrointestinal tract, decreasing its absorption.",Separate administration by at least 4 hours.,1,2026-05-13
alpha glycerylphosphorylcholine,,,,,,1,2026-05-13
spiramycin,,,,,,1,2026-05-13
kinetic lifescience,,,,,,1,2026-05-13
ceftamet,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins may inhibit vitamin K synthesis.,Monitor INR closely; consider alternative antibiotic if possible.,1,2026-05-13
ceftamet,furosemide,Minor,Increased risk of ototoxicity.,Concomitant use may potentiate nephrotoxic and ototoxic effects.,Monitor renal function and hearing.,1,2026-05-13
pinavarium bromide,,,,,,1,2026-05-13
remington life sciences llpcefpodoxime proxetil,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins may inhibit vitamin K synthesis.,Monitor INR closely; consider alternative antibiotic if possible.,1,2026-05-13
remington life sciences llpcefpodoxime proxetil,furosemide,Minor,Increased risk of ototoxicity.,Concomitant use may potentiate nephrotoxic and ototoxic effects.,Monitor renal function and hearing.,1,2026-05-13
overseasesomeprazole,clopidogrel,Moderate,Reduced antiplatelet effect of clopidogrel.,"Omeprazole is a potent CYP2C19 inhibitor, reducing clopidogrel activation.",Avoid concomitant use; consider alternative PPI or antacid.,1,2026-05-13
overseasesomeprazole,ketoconazole,Minor,Decreased absorption of ketoconazole.,"Omeprazole increases gastric pH, reducing absorption of azole antifungals.",Administer ketoconazole at least 2 hours before omeprazole.,1,2026-05-13
overseasesomeprazole,diazepam,Minor,Increased diazepam levels.,"Omeprazole inhibits CYP2C19, which metabolizes diazepam.",Monitor for signs of sedation.,1,2026-05-13
overseasesomeprazole,phenytoin,Minor,Increased phenytoin levels.,"Omeprazole inhibits CYP2C19, which metabolizes phenytoin.",Monitor phenytoin levels.,1,2026-05-13
hcefixime,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins may inhibit vitamin K synthesis.,Monitor INR closely; consider alternative antibiotic if possible.,1,2026-05-13
hcefixime,furosemide,Minor,Increased risk of ototoxicity.,Concomitant use may potentiate nephrotoxic and ototoxic effects.,Monitor renal function and hearing.,1,2026-05-13
advent life sciences llpnimesulide,warfarin,Moderate,Increased risk of bleeding.,NSAIDs inhibit platelet aggregation and can cause gastric ulceration.,Monitor for signs of bleeding; consider alternative analgesic.,1,2026-05-13
advent life sciences llpnimesulide,furosemide,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can inhibit renal prostaglandin synthesis, reducing diuretic efficacy and blood flow.",Monitor urine output and renal function; consider alternative analgesic.,1,2026-05-13
advent life sciences llpnimesulide,ramipril,Moderate,Increased risk of renal impairment and hypertension.,NSAIDs can counteract the antihypertensive effect and increase the risk of renal dysfunction in patients on ACE inhibitors.,Monitor blood pressure and renal function.,1,2026-05-13
advent life sciences llpnimesulide,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can reduce renal clearance of lithium.,Avoid concomitant use; monitor lithium levels closely if unavoidable.,1,2026-05-13
remington life sciences llpaceclofenac,warfarin,Moderate,Increased risk of bleeding.,NSAIDs inhibit platelet aggregation and can cause gastric ulceration.,Monitor for signs of bleeding; consider alternative analgesic.,1,2026-05-13
remington life sciences llpaceclofenac,furosemide,Moderate,Reduced diuretic effect and increased risk of renal impairment.,"NSAIDs can inhibit renal prostaglandin synthesis, reducing diuretic efficacy and blood flow.",Monitor urine output and renal function; consider alternative analgesic.,1,2026-05-13
remington life sciences llpaceclofenac,ramipril,Moderate,Increased risk of renal impairment and hypertension.,NSAIDs can counteract the antihypertensive effect and increase the risk of renal dysfunction in patients on ACE inhibitors.,Monitor blood pressure and renal function.,1,2026-05-13
remington life sciences llpaceclofenac,lithium,Major,Increased lithium levels and toxicity.,NSAIDs can reduce renal clearance of lithium.,Avoid concomitant use; monitor lithium levels closely if unavoidable.,1,2026-05-13
ultimedixceftriaxone,warfarin,Moderate,Increased risk of bleeding.,Cephalosporins may inhibit vitamin K synthesis.,Monitor INR closely; consider alternative antibiotic if possible.,1,2026-05-13
ultimedixceftriaxone,furosemide,Minor,Increased risk of ototoxicity.,Concomitant use may potentiate nephrotoxic and ototoxic effects.,Monitor renal function and hearing.,1,2026-05-13
limitedrosuvastatin,atorvastatin,Moderate,Increased risk of myopathy and rhabdomyolysis.,Concurrent use of statins increases the risk of muscle-related adverse events.,Avoid concomitant use; use only one statin.,1,2026-05-13
limitedrosuvastatin,cyclosporine,Major,Significantly increased rosuvastatin levels and risk of myopathy.,"Cyclosporine inhibits OATP1B1 transporter, reducing statin clearance.",Use with extreme caution; reduce rosuvastatin dose or avoid.,1,2026-05-13
limitedrosuvastatin,"fibrates (e.g., gemfibrozil - not on list, but relevant context)",Major,Increased risk of myopathy and rhabdomyolysis.,Fibrates can potentiate statin-induced myopathy.,Avoid concomitant use; monitor for muscle pain.,1,2026-05-13
limitedrosuvastatin,"niacin (high dose - not on list, but relevant context)",Moderate,Increased risk of myopathy.,Niacin can increase the risk of statin-induced myopathy.,Monitor for muscle pain and weakness.,1,2026-05-13
mandelic acid,,,,,,1,2026-05-13
limitedambroxol,,,,,,1,2026-05-13
overseasterbinafine,,,,,,1,2026-05-13
sulphonated surfactant blend,,,,,,1,2026-05-13
hsucralfate,ciprofloxacin,Moderate,Reduced absorption of ciprofloxacin.,"Sucralfate forms a complex with quinolones, inhibiting their gastrointestinal absorption.",Separate administration by at least 2 hours.,1,2026-05-13
hsucralfate,levofloxacin,Moderate,Reduced absorption of levofloxacin.,"Sucralfate forms a complex with quinolones, inhibiting their gastrointestinal absorption.",Separate administration by at least 2 hours.,1,2026-05-13
hsucralfate,tetracyclines,Moderate,Reduced absorption of tetracyclines.,"Sucralfate can bind to tetracyclines, decreasing their oral bioavailability.",Separate administration by at least 2 hours.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,amitriptyline,Moderate,"Increased anticholinergic effects, sedation.","Both drugs have anticholinergic properties, leading to additive effects.",Monitor for increased anticholinergic side effects and sedation; use cautiously.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,diazepam,Moderate,Increased sedation.,Chlorpheniramine maleate is a sedating antihistamine that can potentiate the sedative effects of benzodiazepines.,Monitor for excessive sedation.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,lorazepam,Moderate,Increased sedation.,Chlorpheniramine maleate is a sedating antihistamine that can potentiate the sedative effects of benzodiazepines.,Monitor for excessive sedation.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,zolpidem,Moderate,Increased sedation.,Chlorpheniramine maleate is a sedating antihistamine that can potentiate the sedative effects of non-benzodiazepine hypnotics.,Monitor for excessive sedation.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,codeine,Moderate,Increased sedation and respiratory depression.,Chlorpheniramine maleate has sedative properties that can add to the CNS depressant effects of codeine.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,tramadol,Moderate,Increased sedation and dizziness.,Chlorpheniramine maleate has sedative properties that can add to the CNS depressant effects of tramadol.,Monitor for increased sedation and dizziness.,1,2026-05-13
remington life sciences llpchlorpheniramine maleate,morphine,Moderate,Increased sedation and respiratory depression.,Chlorpheniramine maleate has sedative properties that can add to the CNS depressant effects of morphine.,Monitor for increased sedation and respiratory depression.,1,2026-05-13
limitedcefpodoxime proxetil,,,,,,1,2026-05-13
ai health care llpcefixime,,,,,,1,2026-05-13
limitedrabeprazole,,,,,,1,2026-05-13
currant life science llpnaproxen,aspirin,Moderate,"Reduced cardioprotective effect of aspirin, increased gastrointestinal risk.",Naproxen can inhibit the antiplatelet effect of low-dose aspirin by blocking access to COX-1 enzyme binding site.,Avoid concurrent use or administer aspirin at least 30 minutes before or 6-8 hours after naproxen.,1,2026-05-13
currant life science llpnaproxen,warfarin,Moderate,Increased risk of bleeding.,"NSAIDs, including naproxen, can increase the anticoagulant effect of warfarin and also cause gastrointestinal irritation, increasing bleeding risk.",Monitor INR closely; use with caution and consider gastroprotective agents.,1,2026-05-13
currant life science llpnaproxen,losartan,Moderate,"Reduced antihypertensive effect, increased risk of renal dysfunction.","NSAIDs can inhibit the vasodilatory effects of angiotensin II, counteracting the action of ARBs.",Monitor blood pressure and renal function; use cautiously.,1,2026-05-13
currant life science llpnaproxen,ramipril,Moderate,"Reduced antihypertensive effect, increased risk of renal dysfunction.","NSAIDs can inhibit the vasodilatory effects of angiotensin II, counteracting the action of ACE inhibitors.",Monitor blood pressure and renal function; use cautiously.,1,2026-05-13
currant life science llpnaproxen,furosemide,Moderate,"Reduced diuretic and antihypertensive effect, increased risk of renal dysfunction.","NSAIDs can reduce renal blood flow and inhibit prostaglandin synthesis, counteracting the effects of loop diuretics.","Monitor urine output, blood pressure, and renal function; administer diuretics at least 30 minutes before naproxen.",1,2026-05-13
currant life science llpnaproxen,spironolactone,Moderate,Increased risk of hyperkalemia and renal dysfunction.,"NSAIDs can impair renal function, and combining with potassium-sparing diuretics increases the risk of hyperkalemia.",Monitor potassium levels and renal function; use with caution.,1,2026-05-13
currant life science llpnaproxen,clopidogrel,Moderate,Increased risk of bleeding.,Naproxen can inhibit platelet aggregation and increase the risk of bleeding when combined with antiplatelet agents.,Monitor for signs of bleeding; use with caution.,1,2026-05-13
currant life science llpnaproxen,lithium,Major,"Increased serum lithium levels, lithium toxicity.","NSAIDs can reduce renal clearance of lithium, leading to accumulation.",Monitor lithium levels closely; reduce lithium dose if necessary.,1,2026-05-13
overseascitalopram oxalate,tramadol,Major,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels.,Monitor for serotonin syndrome symptoms; consider alternative analgesic.,1,2026-05-13
overseascitalopram oxalate,codeine,Moderate,Potentially increased sedation and CNS depression.,Both can depress the central nervous system; additive effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,morphine,Moderate,Potentially increased sedation and CNS depression.,Both can depress the central nervous system; additive effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,clopidogrel,Moderate,Increased risk of bleeding.,SSRIs can impair platelet aggregation.,Monitor for signs of bleeding; consider closer monitoring of anticoagulation if applicable.,1,2026-05-13
overseascitalopram oxalate,warfarin,Moderate,Increased risk of bleeding.,"SSRIs can impair platelet aggregation, potentially affecting INR.",Monitor INR closely; monitor for signs of bleeding.,1,2026-05-13
overseascitalopram oxalate,aspirin,Moderate,Increased risk of bleeding.,Both can affect platelet function.,Monitor for signs of bleeding.,1,2026-05-13
overseascitalopram oxalate,ibuprofen,Moderate,Increased risk of bleeding.,Both can affect platelet function and irritate the GI mucosa.,Monitor for signs of bleeding and gastrointestinal distress.,1,2026-05-13
overseascitalopram oxalate,atorvastatin,Minor,Potential for increased atorvastatin levels.,"Citalopram is a moderate inhibitor of CYP2C19, which metabolizes atorvastatin.",Monitor for statin-related side effects.,1,2026-05-13
overseascitalopram oxalate,rosuvastatin,Minor,Potential for increased rosuvastatin levels.,Citalopram can inhibit renal transporters that affect rosuvastatin excretion.,Monitor for statin-related side effects.,1,2026-05-13
overseascitalopram oxalate,omeprazole,Minor,Potential for slightly increased citalopram levels.,"Omeprazole can inhibit CYP2C19, which metabolizes citalopram.",Monitor for increased SSRI side effects.,1,2026-05-13
overseascitalopram oxalate,pantoprazole,Minor,Potential for slightly increased citalopram levels.,"Pantoprazole can inhibit CYP2C19, which metabolizes citalopram.",Monitor for increased SSRI side effects.,1,2026-05-13
overseascitalopram oxalate,metoprolol,Minor,Potential for increased metoprolol levels.,"Citalopram can inhibit CYP2D6, which metabolizes metoprolol.",Monitor for bradycardia and hypotension.,1,2026-05-13
overseascitalopram oxalate,atenolol,Minor,Potential for increased atenolol levels.,"Citalopram can inhibit CYP2D6, which metabolizes atenolol.",Monitor for bradycardia and hypotension.,1,2026-05-13
overseascitalopram oxalate,haloperidol,Moderate,Increased risk of QT prolongation and arrhythmias.,Both drugs can prolong the QT interval.,Monitor ECG; use with caution and consider alternative antipsychotic.,1,2026-05-13
overseascitalopram oxalate,clozapine,Moderate,Increased risk of anticholinergic effects and sedation.,Additive CNS depressant and anticholinergic effects.,"Monitor for sedation, constipation, and dry mouth; use with caution.",1,2026-05-13
overseascitalopram oxalate,olanzapine,Moderate,Increased risk of anticholinergic effects and sedation.,Additive CNS depressant and anticholinergic effects.,"Monitor for sedation, constipation, and dry mouth; use with caution.",1,2026-05-13
overseascitalopram oxalate,alprazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,diazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,lorazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,clonazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,midazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,zolpidem,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,lithium,Moderate,Increased risk of serotonin syndrome and neurotoxicity.,Both can affect serotonergic pathways and potentially increase lithium levels.,Monitor for serotonin syndrome and lithium toxicity symptoms; check lithium levels.,1,2026-05-13
overseascitalopram oxalate,tramadol,Major,Increased risk of serotonin syndrome.,Both drugs increase serotonin levels.,Monitor for serotonin syndrome symptoms; consider alternative analgesic.,1,2026-05-13
overseascitalopram oxalate,codeine,Moderate,Potentially increased sedation and CNS depression.,Both can depress the central nervous system; additive effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,morphine,Moderate,Potentially increased sedation and CNS depression.,Both can depress the central nervous system; additive effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,clopidogrel,Moderate,Increased risk of bleeding.,SSRIs can impair platelet aggregation.,Monitor for signs of bleeding; consider closer monitoring of anticoagulation if applicable.,1,2026-05-13
overseascitalopram oxalate,warfarin,Moderate,Increased risk of bleeding.,"SSRIs can impair platelet aggregation, potentially affecting INR.",Monitor INR closely; monitor for signs of bleeding.,1,2026-05-13
overseascitalopram oxalate,aspirin,Moderate,Increased risk of bleeding.,Both can affect platelet function.,Monitor for signs of bleeding.,1,2026-05-13
overseascitalopram oxalate,ibuprofen,Moderate,Increased risk of bleeding.,Both can affect platelet function and irritate the GI mucosa.,Monitor for signs of bleeding and gastrointestinal distress.,1,2026-05-13
overseascitalopram oxalate,atorvastatin,Minor,Potential for increased atorvastatin levels.,"Citalopram is a moderate inhibitor of CYP2C19, which metabolizes atorvastatin.",Monitor for statin-related side effects.,1,2026-05-13
overseascitalopram oxalate,rosuvastatin,Minor,Potential for increased rosuvastatin levels.,Citalopram can inhibit renal transporters that affect rosuvastatin excretion.,Monitor for statin-related side effects.,1,2026-05-13
overseascitalopram oxalate,omeprazole,Minor,Potential for slightly increased citalopram levels.,"Omeprazole can inhibit CYP2C19, which metabolizes citalopram.",Monitor for increased SSRI side effects.,1,2026-05-13
overseascitalopram oxalate,pantoprazole,Minor,Potential for slightly increased citalopram levels.,"Pantoprazole can inhibit CYP2C19, which metabolizes citalopram.",Monitor for increased SSRI side effects.,1,2026-05-13
overseascitalopram oxalate,metoprolol,Minor,Potential for increased metoprolol levels.,"Citalopram can inhibit CYP2D6, which metabolizes metoprolol.",Monitor for bradycardia and hypotension.,1,2026-05-13
overseascitalopram oxalate,atenolol,Minor,Potential for increased atenolol levels.,"Citalopram can inhibit CYP2D6, which metabolizes atenolol.",Monitor for bradycardia and hypotension.,1,2026-05-13
overseascitalopram oxalate,haloperidol,Moderate,Increased risk of QT prolongation and arrhythmias.,Both drugs can prolong the QT interval.,Monitor ECG; use with caution and consider alternative antipsychotic.,1,2026-05-13
overseascitalopram oxalate,clozapine,Moderate,Increased risk of anticholinergic effects and sedation.,Additive CNS depressant and anticholinergic effects.,"Monitor for sedation, constipation, and dry mouth; use with caution.",1,2026-05-13
overseascitalopram oxalate,olanzapine,Moderate,Increased risk of anticholinergic effects and sedation.,Additive CNS depressant and anticholinergic effects.,"Monitor for sedation, constipation, and dry mouth; use with caution.",1,2026-05-13
overseascitalopram oxalate,alprazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,diazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,lorazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,clonazepam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,midazolam,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,zolpidem,Moderate,Increased sedation and CNS depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseascitalopram oxalate,lithium,Moderate,Increased risk of serotonin syndrome and neurotoxicity.,Both can affect serotonergic pathways and potentially increase lithium levels.,Monitor for serotonin syndrome and lithium toxicity symptoms; check lithium levels.,1,2026-05-13
overseasgabapentin,alprazolam,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,diazepam,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,lorazepam,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,clonazepam,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,midazolam,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,zolpidem,Moderate,"Increased sedation, dizziness, and respiratory depression.",Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression; consider dose adjustment.,1,2026-05-13
overseasgabapentin,morphine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseasgabapentin,tramadol,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseasgabapentin,codeine,Moderate,Increased sedation and respiratory depression.,Additive CNS depressant effects.,Monitor for excessive sedation and respiratory depression.,1,2026-05-13
overseasgabapentin,amitriptyline,Moderate,Increased sedation and anticholinergic effects.,Additive CNS depressant and anticholinergic effects.,Monitor for increased sedation and anticholinergic side effects.,1,2026-05-13
overseasgabapentin,atenolol,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,metoprolol,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,losartan,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,ramipril,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,amlodipine,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,furosemide,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,spironolactone,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,metformin,Minor,Increased risk of dizziness.,Both can cause dizziness.,Monitor for dizziness.,1,2026-05-13
overseasgabapentin,phenytoin,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,valproate,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13
overseasgabapentin,carbamazepine,Minor,Potential for increased CNS side effects.,Both can cause CNS depression.,Monitor for increased sedation or dizziness.,1,2026-05-13